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ABSTRACT 
The prevalence of obesity and related comorbidities, such as type 2 diabetes mellitus (T2DM) have 
reached epidemic proportions globally.  Weight loss improves morbidity and mortality in people with 
obesity and T2DM.  However, effective long-term obesity treatments are limited.   
Lifestyle modification is the first line treatment, but long-term data suggest a return to baseline weight 
after successful weight loss.  In contrast, bariatric surgery causes permanent anatomical changes in 
the gastrointestinal tract (GIT) to facilitate weight loss.  This is the most effective long-term treatment 
for obesity and T2DM.  However, compared to the large number of eligible individuals, very few 
patients undergo bariatric surgery. 
Minimally invasive treatment options have been developed to fill the treatment gap between 
conservative and surgical measures.  One treatment option is the duodenal-jejunal bypass sleeve 
(DJBS; EndoBarrier®; GI Dynamics, Lexington, MA, USA).  This is a 60 cm impermeable sleeve 
device, which is placed endoscopically into the duodenal bulb, extending to the jejunum and left in 
place for up to 48 weeks.  The device separates bile and pancreatic secretions from chyme, reducing 
the contact of ingested food with the small intestinal mucosa.  Significant weight loss and 
improvements in glycaemic control have been reported after DJBS treatment, but little is known about 
the mechanisms of action of the device.  The device dwells in the GIT, but the impact of implantation 
on gastrointestinal function has undergone limited investigation.  Obesity and T2DM are associated 
with derangements in normal physiology.  We currently have a poor understanding of the impact of 
DJBS treatment on these parameters, and how this might be linked to device mechanisms of action.  
The effect of DJBS implantation on the upper GIT microbiota or the local or systemic immune 
response is unknown.  Therefore, this thesis addresses the mechanisms of action of the DJBS in terms 
of clinical response, gastrointestinal function and microbial and immune parameters. 
The clinical effects of DJBS treatment, in addition to dietary intake, lifestyle factors and long-term 
outcomes after device removal were assessed.  DJBS treatment for up to 48 weeks resulted in 
significant improvements in anthropometric and metabolic measures.  In parallel, reductions in 
dietary intake were observed.  One year after device removal, the majority of patients were unable to 
sustain clinically significant weight loss.  Despite this, some beneficial metabolic effects remained. 
Investigation of the effect of DJBS treatment on gastrointestinal function revealed no significant 
impact of DJBS treatment on gastric emptying or intraluminal lipolytic activity.   
However, gastrointestinal symptoms were significantly increased following DJBS implantation.   
In particular, there was a significant increase in epigastric pain symptoms after device placement.   
When considered in combination with the dietary intake results, a key mechanism of action of the 
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device for inducing weight loss appears to be the induction of gastrointestinal symptoms.  This occurs 
primarily in relation to meals and may facilitate weight loss by reducing dietary intake. 
Changes to patients’ gastrointestinal microbiota during DJBS treatment was investigated using 16S 
rRNA gene sequencing technology.  The gastric and duodenal mucosa-associated microbiota 
(MAM), stool microbiota and the device biofilm microbial community were characterised.   
DJBS treatment induced significant changes in the gastric and duodenal MAM, such as decreases in 
organisms typical of the proximal GIT and increases in organisms typical of the distal intestine.   
A distinct microbial community was formed on the device, characterised largely by organisms typical 
of the distal intestine.  DJBS treatment induced transient changes in the stool microbiota.  This was 
mirrored by changes in the predicted functional capacity of the microbiota, suggesting an alteration 
in energy metabolism, with a preference for carbohydrate metabolism. 
Finally, the systemic and local immune response to DJBS treatment was assessed.  There was no 
significant change in circulating pro-inflammatory cytokines following DJBS treatment.  There were 
changes in T cell phenotype that were broadly suggestive of an increase in immune activation.  In the 
duodenum, modest changes in morphology occurred following DJBS treatment, with villous blunting 
observed in a number of patients.  In parallel, there was a significant increase in eosinophils and 
intraepithelial lymphocytes.  This suggest the DJBS, a foreign body in the duodenum that is colonised 
by microbes typical of the distal intestine, induces a local immune response. 
In summary, this thesis has demonstrated the DJBS was clinically effective in the study population, 
resulting in weight loss and broad metabolic improvements.  The DJBS induces significant 
gastrointestinal symptoms (including meal-related symptoms) in parallel with a significant reduction 
in dietary intake that may facilitate weight loss.  There was no evidence of change in gastric emptying 
or altered absorption of fat.  There were significant changes in the gastrointestinal microbiota 
following DJBS treatment, with a proliferation of more distal bowel organisms compared to those 
typically observed in the duodenum.  In concert, a local immune response was observed, with 
potential implications for device safety.  These results may provide insight into DJBS efficacy and 
tolerability and provide avenues of future research. 
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1.1 OBESITY AND RELATED COMORBIDITIES 
1.1.1 Obesity – Definitions and Prevalence 
Obesity is defined as abnormal or excessive fat accumulation that impairs health1.  The World Obesity 
Federation has defined obesity as a “chronic, relapsing, progressive disease process”2.  In clinical 
practice, Body Mass Index (BMI), is most commonly used to assess weight status3.  For Caucasian 
individuals, a BMI of ≥ 30 kg/m2 is the threshold for the diagnosis of obesity.  This common definition 
of obesity makes no distinction in adipose tissue distribution.  Central adiposity is the accumulation 
of adipose tissue in the abdominal region.  As opposed to a gynoid obesity distribution, where adipose 
tissue accumulates on the lower body, central adiposity is more strongly associated with negative 
health outcomes4. 
The prevalence of obesity has reached epidemic proportions in both developed and developing 
nations.  The World Health Organization estimated that 13% of the global adult population suffered 
from obesity in 20161.  The most recent Australian National Health Survey estimated that obesity 
impacted 28% of the Australian population5.  Nearly 25% of the Australian adult population had a 
waist circumference that predisposed them to an increase risk of metabolic disease5.  Recent estimates 
suggest future disease burden due to overweight and obesity could be reduced by 14% with a modest 
degree of weight loss (3kg)5.  Socioeconomic status is a relevant co-factor in the development of 
obesity.  In Australia, those in the lowest socioeconomic grouping were more likely to have obesity 
(34%), as compared to those in the highest socioeconomic group (22%)5. 
The costs of obesity are significant.  In Australia, the estimated total cost in 2011-12 was $8.6 billion, 
including $3.8 billion in direct costs (health-care related costs) and $4.8 billion in indirect costs  
(lost productivity of the individual and carers, welfare costs and reduced taxation revenue)6.   
Without targeted action to reduce the rise in obesity prevalence, these costs are predicted to contribute 
an additional $87.7 billion dollars over the ten year period up to 20256. 
1.1.2 Obesity-related Comorbidities 
The comorbidities of obesity are extensive and carry additional health risks.  Obesity impacts all 
organ systems in the body, with significant cardiovascular, endocrine, gastrointestinal (GI), 
hepatobiliary, haematological, musculoskeletal, psychological, pulmonary and reproductive 
outcomes7.  Overweight and obesity have also been linked to the development of colon, kidney, liver, 
pancreatic, gallbladder, stomach, oesophageal, breast, prostate, endometrial and ovarian cancers8. 
One of the most common comorbidities of obesity is type 2 diabetes mellitus (T2DM)9.   
T2DM results from the body’s inability to appropriately respond to insulin10.  This is referred to as 
insulin resistance, and primarily impacts the liver, muscle and adipose tissue11.  Whilst insulin 
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resistance is pronounced in T2DM, insulin secretion is also reduced due to islet cell dysfunction12.  
This leads to the requirement for exogenous insulin to adequately control blood glucose levels, similar 
to in type 1 diabetes mellitus (T1DM).  In Australia, approximately one million adults with T2DM 
are registered on the National Diabetes Service Scheme13.  This is likely an underrepresentation of 
true prevalence, as it is estimated that 50% of individuals with T2DM globally have not received a 
formal diagnosis14. 
Impaired glucose control is a key component of the metabolic syndrome.  In 2009, a consensus 
definition was released15.  The diagnostic criteria for the metabolic syndrome are the presence and/or 
treatment of any three of five the following parameters: elevated waist circumference; elevated 
triglycerides of ≥ 1.7 mmol/L; reduced high-density lipoprotein (HDL) cholesterol below 1.3 mmol/L 
for females and 1.0 mmol/L for males; elevated blood pressure of ≥130 mmHg and/or ≥ 85 mmHg 
for systolic and diastolic pressure respectively; and elevated fasting blood glucose of 5.6 mmol/L or 
greater.  All parameters except elevated waist circumference are applicable to all ethnic populations.  
Elevated waist circumference, an indicator of abdominal adiposity, has population specific targets.  
In Australia, current population guidelines classify a waist measurement >80 cm for Caucasian 
women and >94 cm for Caucasian men as increasing the risk of chronic disease, including the 
metabolic syndrome3.  For those of Asian heritage, the thresholds are >80 cm and >90 cm for women 
and men respectively.  These guidelines report that specific targets for Aboriginals, Pacific Islanders 
and African Americans are yet to be determined. 
Non-Alcoholic Fatty Liver Disease (NAFLD) is a condition where fat accumulates in the liver in the 
absence of alcohol abuse16.  NAFLD is strongly associated with obesity and insulin resistance17, and 
leads to changes in glucose, lipid and lipoprotein metabolism in the liver18, 19.  NAFLD is the most 
common cause of chronic liver disease in Australia and refers to a spectrum of disorders that can be 
histologically classified20.  Non-alcoholic fatty liver refers to hepatic steatosis, without evidence of 
hepatocellular injury.  Non-alcoholic steatohepatitis (NASH) refers to the presence of hepatic 
steatosis with evidence of inflammation and hepatocellular injury16.  The two disorders differ in their 
likelihood of progression to cirrhosis and hepatocellular carcinoma21, 22. 
1.1.3 The Aetiology of Obesity 
Obesity develops due to a long-term imbalance between energy intake and expenditure.  This positive 
energy balance leads to storage of excess energy as triglyceride, primary in the adipose tissue.   
The aetiology and pathophysiology of obesity are complex, with an interplay of genetic, 
environmental and behavioural factors that alter either energy intake or energy expenditure. 
Monogenic defects leading to obesity are rare, and are more relevant in the aetiology of obesity in 
childhood.  A number of these single gene defects act within the leptin-melanocortin pathway, a key 
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pathway in the regulation of energy balance23.  Chromosomal abnormalities can also lead to 
conditions with an obese phenotype24. 
In the majority of individuals, the genetic determinants of obesity are polygenic.  Both genetic and 
epigenetic mechanisms have been identified25.  Hundreds of genetic susceptibility loci have been 
linked to obesity through genome wide association studies26.  The gene most strongly associated with 
obesity is the fat mass and obesity-associated (FTO) gene27.  Overall, the genetic contribution to the 
development of obesity is estimated to be low with a conglomerate of 97 loci only representing 2.7% 
of variation in BMI, highlighting the multifactorial nature of obesity pathogenesis26. 
The “set-point hypothesis” refers to a theory of homeostatic defence of a certain body weight that is 
regulated by neuronal and hormonal mechanisms28.  After major weight loss, induced by  
lifestyle-based means29 or bariatric surgery30, weight recidivism is common.  Metabolic adaptations 
such as a reduction in metabolic rate29 and an increase in appetite stimulating hormones31 observed 
after weight loss support this theory. 
Environmental factors have contributed to both an increase in energy intake and a decrease in energy 
expenditure.  There has been widespread change in the food supply over recent decades, to the point 
our food environment is now described as being “obesogenic”.  This refers to the increase in 
availability (both convenience and quantity) and accessibility to food, in addition to the marketing 
environment surrounding food32.  This large shift in our food supply has included massive increases 
in the availability of low cost, energy-dense, nutrient-poor food and drinks.  Financial and living 
environments have also been linked with obesity, likely due to relationships with food accessibility 
and availability.  In Australia, those in lower socioeconomic groups have a higher likelihood of 
developing obesity5.  This may be associated with perceptions surrounding food availability and 
affordability, which may impact food consumption patterns33.  Those in regional locations are also 
more likely to have obesity than those in metropolitan areas5.  This may be associated with either 
restricted availability or higher cost of ‘healthy’ foods in rural and remote areas34, 35. 
In parallel to changes in dietary intake, changes in the built environment have precipitated a reduction 
in physical activity.  Environmental factors such as increased sedentary transport time due to 
increased travelling distance in urban areas, lack of physical activity infrastructure (such as walking 
paths or recreational facilities) and land use patterns may contribute to a reduction in physical 
activity36.  Other environmental factors that have been linked to obesity and are under further 
investigation include the impact of exposure to environmental chemicals on the endocrine system37. 
Behavioural factors, such as the choice of foods consumed, are also a strong determinant of obesity.  
Consumption of a “Western diet” is typified by an increased consumption of refined carbohydrates, 
5 
 
sugars and fats.  Broadly, the majority of Australians consume a Western style diet, with up to 35% 
of energy intake estimated to be derived from high fat, high sugar discretionary foods and drinks38.  
Nearly 10% of adult Australians consume sugar sweetened beverages daily39.  This shift in diet 
composition has occurred in parallel with increasing portion size, particularly in discretionary foods 
and drinks.  Between 1995 and 2012, there was a 66% increase in the energy content (per portion) of 
discretionary food items5.  This highlights how dietary choices, and therefore consumption patterns, 
are changing to facilitate weight gain. 
Over recent decades, physical activity has also reduced.  In 2017-18, it was estimated that only 15% 
of Australian adults met population guidelines for physical activity39.  Behavioural determinants of 
physical activity include sedentary behaviours such as screen time, the use of energy-sparing 
equipment at home and work and the reduction in leisure time physical activity by choice, increased 
work hours or other factors40. 
The contribution of neurobiological mechanisms to weight gain has also been investigated, primarily 
in animal models.  Concepts such as environmental stimuli (such as food marketing images), hedonic 
hunger, and neurological changes in food reward systems linking addiction-like behaviours to food 
consumption have been explored41.  Further work is required in humans but cumulatively, these 
suggest both conscious and subconscious neurological modulation of food intake. 
Treatment of comorbid conditions can also have a negative impact on weight.  Some anti-convulsant, 
anti-psychotic and anti-depressant medications are associated with weight gain42.  In the context of 
T2DM, insulin and insulin secretagogue medications are also associated with weight gain42.  
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1.2 OBESITY INDUCED PERTURBATIONS OF NORMAL PHYSIOLOGY 
1.2.1 Gastrointestinal Function 
The gastrointestinal tract (GIT) is a critical component in the aetiology of obesity, as it is the site 
where all ingested nutrients are absorbed.  The enteric nervous system is involved in the regulation 
of GI motor function, regulation of fluid secretion (including exocrine secretion) and GI blood flow.  
Gastric emptying, pancreatic exocrine function and GI sensory function will be discussed below as 
relevant components of GI function that are altered in obesity and T2DM. 
1.2.1.1 Gastric Emptying 
Functionally, the stomach can be divided into the proximal stomach, responsible for generating a 
phasic basal pressure; the distal stomach, responsible for generating a tonic pressure to grind ingested 
food; and the pylorus, responsible for emptying of gastric contents into the duodenum. 
Gastric smooth muscle contractions are generated in the pacemaker region of the stomach, located 
between the fundus and the proximal body.  These slow waves originate in the interstitial cells of 
Cajal.  Slow waves are propagated both circumferentially and distally from the pacemaker region 
with a frequency of three cycles per minute. 
When food is swallowed, the lower oesophageal sphincter and proximal stomach relax to allow entry 
of food into the stomach.  This vagovagal reflex is called receptive relaxation.  The result of this 
process is an increase in intragastric volume without an increase in intragastric pressure.  In response 
to food contents within the stomach, a process of gastric accommodation occurs, whereby a sustained 
decrease in gastric tone allows sustained expansion of intragastric volume.  This process is mediated 
by the vagal nerve. 
Stomach contents are emptied into the duodenum in a pulsatile fashion43, 44.  The regulation of gastric 
emptying is multifactorial with gastric neuromuscular coordination45, intragastric volume46, caloric 
content47, macronutrient composition48, viscosity49, particle size50, glycaemic control51, 52 and 
hormone-mediated feedback signalling from the small intestine53-58 all influencing the rate of gastric 
emptying.  The pattern of gastric emptying also differs depending on the type of meal ingested. 
Liquids  
Non-nutritive liquids, such as water, exit the stomach rapidly, initially in an exponential pattern 
followed by a slower linear pattern47.  The liquids disperse in the stomach and are emptied without a 
lag phase47. 
Gastric emptying of nutritive liquids is regulated by both intragastric volume59 and caloric content47.  
The emptying of nutritive liquids occurs in an approximately linear pattern60.  Nutritive liquid gastric 
emptying is also mediated by duodenal feedback in response to nutrient stimulation60. 
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Solids 
Gastric emptying of solids is biphasic, with a lag phase followed by a linear emptying phase.   
When solids are ingested, they are initially stored in the proximal stomach.  They are slowly moved 
to the antrum, where food particles are ground against the closed pylorus, reducing particle size to  
<2 mm61.  This is reflective of the lag phase of gastric emptying.  Following the lag phase, the pattern 
of gastric emptying becomes linear.  Particles are propelled towards the pyloric sphincter by 
contractions in the proximal antrum.  The pyloric sphincter will only allow particles of <1-2 mm to 
pass into the duodenum62.  Particles that are too large are propelled to the proximal antrum for further 
grinding.  Larger meal volumes and greater caloric density of meals delays gastric emptying63. 
When a mixed meal of liquids and solids are consumed together, gastric emptying is delayed, 
compared to a solid meal consumed alone64.  When a mixed meal is consumed, gastric emptying of 
solids is delayed until 80% of the liquid component has been emptied, and then is emptied in a linear 
fashion65. 
Gastrointestinal Regulation of Gastric Emptying 
In the small intestine, mechanical66 or chemical stimulation67 has been demonstrated to delay gastric 
emptying via relaxation of the proximal stomach.  GI peptide hormones produced by small intestinal 
mucosal cells in response to nutrient stimulation such as cholecystokinin (CCK)53, 54, peptide YY 
(PYY)55, 56 and glucagon-like peptide (GLP)-157, 58 have been demonstrated to delay gastric emptying.  
Conversely, ghrelin, which is secreted primarily in the stomach, has been demonstrated to accelerate 
gastric emptying68. 
Assessment of Gastric Emptying 
Direct Assessment 
The “gold standard” for the assessment of gastric emptying is scintigraphy69.  The test involves 
ingesting a meal that has been labelled with a radioisotope, the most common being 99mTc-sulfur 
colloid for solid meals.  For mixed or liquid meals, the liquid component is most commonly labelled 
with 111In-diethylenetriaminepentaacetic acid.  Images are then taken by a gamma camera at defined 
time-points for between one and four hours.  It is recommended that scintigraphy should be performed 
for a minimum of four hours to adequately capture gastric emptying rate70.  The key reporting 
outcomes are gastric emptying lag time (tlag), half time (t1/2) and percent of gastric retention. 
Indirect Assessments 
A common indirect measure of gastric emptying utilises a stable, non-radioactive 13C isotope.   
13C can be bound to either a medium chain triglyceride (octanoic acid for solids or acetate for liquids) 
or a protein-rich algae (spirulina) which is added to a test meal.  The 13C substrate is absorbed in the 
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small intestine and carried to the liver by the vena portae, where it is oxidised to 13CO2.  The ratio of 
13CO2 compared to atmospheric CO2 (12CO2) can then be detected in breath samples, which are 
analysed via isotope ratio mass spectrometry or infrared spectroscopy.  The kinetics of 13CO2 
appearance in the breath is indicative of gastric emptying rate.  The key reporting outcomes are tlag 
and t1/2.  This test has been validated against scintigraphy for assessing the gastric emptying kinetics 
of solid71, 72 and liquid meals73. 
The absorption kinetics of paracetamol have also been used to assess gastric emptying.   
Gastric emptying measured by paracetamol absorption correlates well with scintigraphic measures of 
liquid gastric emptying74. 
Impact of Obesity and T2DM on Gastric Emptying 
Data on gastric emptying rates in obesity have largely been drawn from small studies, producing 
contradictory results.  Normal75-77, accelerated78-81 and delayed82-84 gastric emptying of solids has 
been reported.  In a large prospective study, obesity was significantly associated with accelerated 
gastric emptying of solids and liquids85.  This is the largest documented cohort of patients with obesity 
(n=201) where gastric emptying has been assessed, using the gold standard gastric scintigraphy 
method. 
Acutely, the relationship between gastric emptying and glycaemia is bidirectional and is mediated via 
small intestinal feedback mechanisms86.  Acute hyperglycaemia has been demonstrated to delay 
gastric emptying in patients with T1DM52 and T2DM87.  In a study of patients with T1DM and healthy 
controls, administration of insulin accelerated gastric emptying51.  Blood glucose concentration at the 
time of a gastric emptying investigation has also been shown to be important in those with diabetes88.  
In patients with blood glucose concentrations of ≤ 15 mmol/L, retention at 10 minutes was 
significantly less than those with blood glucose concentrations > 15 mmol/L. 
The prevalence of delayed gastric emptying in small studies of patients with long-standing T2DM 
has been reported to be between 30 and 56%87, 89, 90.  The prevalence of diabetic gastroparesis, a 
clinical condition where delayed gastric emptying occurs in the absence of a mechanical obstruction, 
and in the presence of GI symptoms such as nausea, postprandial fullness and early satiety is low91.  
In the context of T2DM, a 1.0% incidence of developing diabetic gastroparesis over a 10 year period 
has been reported92. 
1.2.1.2 Pancreatic Exocrine Function 
Exocrine function of the pancreas includes the secretion of pancreatic juice into the duodenum.  
Pancreatic juice contains acid-neutralising bicarbonate and digestive enzymes.  Pancreatic secretion 
is modulated by three phases: the cephalic phase, the gastric phase and the intestinal phase.   
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The intestinal phase is responsible for 60-70% of secretion93.  Secretion of bicarbonate and fluid is 
mediated by secretin, which is secreted by S cells in the duodenal mucosa in response to acidification.  
Bile acids and lipids also stimulate secretin secretion. Pancreatic acinar cells secrete proteases, 
amylases, lipases and nucleases to facilitate breakdown and absorption.  Secretion of these enzymes 
in the postprandial state is stimulated by CCK, which in turn is stimulated by lipids and proteins in 
the duodenal lumen.  The presence of carbohydrate or fat in the distal small intestine inhibits 
pancreatic secretion94.  Pancreatic exocrine insufficiency (PEI) refers to the insufficient production 
of digestive enzymes following a meal to allow for the normal digestive process to occur93.  
Approximately 90% of exocrine function must be lost before severe PEI is evident95. 
Assessment of Pancreatic Exocrine Function 
The “gold standard” for assessment of pancreatic exocrine function are direct tests that involve the 
measurement of luminal enzyme activity (adjusted by flow markers) such as the secretin-CCK test.  
This test involves the placement of a duodenal tube and assessment of enzymatic output following 
intravenous administration of CCK96.  This test is infrequently performed as it is invasive and costly. 
A number of indirect measures have been utilised to assess pancreatic exocrine function.  The  
“gold standard” for the indirect assessment of steatorrhoea is the 72 hour faecal fat test.  Stool is 
collected over a 72 hour period, while the patient consumes a specified diet with at least  
100 g fat/day97.  This test is also an indirect measure for the assessment of PEI.  Sensitivity for PEI 
is high, but specificity is low98 since this test does not discriminate between pancreatic and  
non-pancreatic causes of fat malabsorption. 
Faecal elastase-1 is a proteolytic enzyme produced by pancreatic acinar cells.  Faecal elastase 
concentrations have been shown to correlate well with the output of other pancreatic enzymes99.   
This test is commonly used in clinical practice as it is non-invasive and cost effective.  This test has 
also has a high sensitivity; however, sensitivity varies depending on the population measured, with a 
high false positive rate in low risk patients100. 
Another indirect measure of pancreatic function uses a 13C labelled isotope administered in a test 
meal.  This test relies on intraluminal metabolism of lipids in the small intestine.  The most commonly 
used substrate is 13C mixed triglyceride.  This molecule is hydrolysed by pancreatic lipase to a 
medium chain fatty acid (13C octanoic acid) which can be absorbed directly, and labelled 
monoglycerides which are incorporated into chylomicrons for absorption101.  The labelled substrate 
is then transported to the liver and metabolised to carbon dioxide.  This travels in the circulation and 
can be detected as 13CO2 in the breath.  This test is only appropriate in those without liver disease, 
and cannot discriminate between pancreatic and non-pancreatic origins of malabsorption. 
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Impact of Obesity and T2DM on Pancreatic Exocrine Function 
In pre-clinical models, the exocrine response to CCK administration is reduced in obese rats and 
mice102.  In humans, there is limited evidence to suggest obesity is associated with alterations in 
pancreatic enzyme output103, 104.  However, the endocrine and exocrine functions of the pancreas are 
intrinsically linked, implying metabolic dysfunction leads to alterations in pancreatic function.  
Endocrine products secreted in the islets of Langerhans, such as insulin, travel through the exocrine 
pancreas in the portal circulation.  Insulin has been demonstrated to have a trophic effect on the 
exocrine pancreas, with a reduction in exocrine pancreas volume reported in diabetes105.  PEI has 
been associated with both T1DM and T2DM106.  The prevalence of PEI, as evidence by faecal elastase 
concentration, has been estimated to be 27% in T2DM107.  Faecal elastase concentrations have also 
been shown to correlate with glycated haemoglobin (HbA1c) levels, as a marker of endocrine 
dysfunction in T2DM108. 
1.2.1.3 Gastrointestinal Sensory Function 
Stimulation of GI mechano-and chemo-sensors (e.g. via ingestion of a meal or contractions) results 
in visceral sensation.  The majority of afferent sensory information is perceived unconsciously and 
serves key homeostatic functions.  However, sensations such as fullness, nausea, satiety and pain 
occur with conscious awareness. 
In the stomach, sensory function is mediated by vagal and splanchnic afferent nerves.  These nerves 
respond to both mechanical and chemical stimuli.  Mechanoreceptors respond to distension and can 
signal satiety and fullness109.  High threshold mechanoreceptors are typically involved in the pain 
response, and are thus termed mechanonociceptors110.  Mucosal receptors (particularly in the 
oesophagus) respond to chemical stimuli and are involved in the sensations of nausea and vomiting, 
as well as satiety110, 111.  Mucosal receptors can respond to local factors such as CCK112 and 
serotonin113, leading to sensitisation to perception.  Afferent responses can also be stimulated by 
tissue damage and inflammation110. 
Assessment of Gastrointestinal Sensory Function 
The “gold standard” for the assessment of GI sensory function uses a barostat to measure the 
mechanosensory response to stimulus (increasing pressure of the balloon dwelling in the stomach).  
Patients are asked to report upper GI symptoms on a visual analogue scale during stimulation114.  
Brain imaging techniques such as positron emission tomography, single photon emission computer 
tomography and functional magnetic resonance imaging have also been used to assess brain activity 
as a result of visceral stimulation115.  However, these techniques are invasive, expensive and require 
specialised equipment and thus less invasive techniques have been developed. 
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A nutrient drink test can be used to assess gastric accommodation and sensation as components of GI 
sensory function.  In the literature, a variety of protocols have been used, with different drinks, 
maximum volumes and speed of consumption116-123.  These tests have been conducted in healthy 
controls and patients with functional GI disorders (FGIDs).  A standardised nutrient challenge test 
using a commercially available nutrient drink (Fresubin; Fresenius, Germany) has been used to assess 
symptom response following administration of three 200 mL boluses across 15 minutes.  This was 
validated in 48 blood donors with GI symptoms, 20 healthy controls, and 40 FGID patients124.   
In symptomatic blood donors and FGID patients, there was a significant difference in upper GI 
symptoms reported on a visual analogue scale, compared with healthy controls.  This protocol has 
been adopted within the Princess Alexandra Hospital (PAH) Department of Gastroenterology and 
Hepatology using a locally available nutrient drink (Resource Plus; Nestlé, Vevey, Switzerland). 
Gastrointestinal Sensory Function in Obesity and T2DM 
Kim et al. conducted a study of 13 individuals with obesity and 19 lean controls, finding no difference 
in fasting and postprandial total gastric volumes in those with obesity as compared controls125.   
The fasting volume of the distal stomach was greater in those with obesity.  This difference did not 
impact the maximum tolerated volume or symptom response (nausea, pain, bloating and fullness) to 
a nutrient drink test, suggesting functionally relevant changes in gastric accommodation may not 
occur in obesity. 
In a study by Acosta et al., obesity was associated with a higher volume to reach fullness in a nutrient 
drink test85.  There was no correlation with maximal tolerated volume, corroborating the findings of 
Kim and colleagues.  In this study, obesity was associated with a higher fasting gastric volume, 
conflicting the findings of Kim and colleagues85.  Instead, acceleration of gastric emptying was 
observed, suggesting alterations in GI motor function may be relevant to changes in sensory function 
in obesity. 
T2DM has been associated with an increased prevalence of upper GI symptoms compared to matched 
community controls126.  In this study, self-reported poor glycaemic control was independently 
associated with upper GI dysmotility symptoms.  In healthy adults, supraphysiological 
hyperglycaemia has also been associated with an increase in nausea and fullness symptoms during 
duodenal lipid infusion127.  In healthy adults, glucose infusion reduced both the threshold for detection 
of pain and pain tolerance following electric stimulation of the hand128.  Investigation into neuronal 
pathways that may be related have been limited to animal models129, 130.  Together, these findings 
suggest a link between glycaemia and perception of upper GI symptoms. 
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1.2.2 The Gastrointestinal Microbiota 
The human GIT is colonised by a variety of bacteria, archaea, viruses and unicellular eukaryotes.   
The number of microbial cells dwelling within the human GIT has been estimated to be in the order 
of 1014 131.  Despite the identification of over 500 species, the number of phyla within the GIT are 
relatively limited.  The predominant phyla are Bacteroidetes and Firmicutes, but Synergistetes, 
Proteobacteria, TM7, Spirochaetes, Tenericutes, Lentisphaerae, Verrucomicrobia, Actinobacteria, 
Fusobacteria and Cyanobacteria may also be present132, 133. 
The GI microbiota develops rapidly after birth and by one year of age resembles that of a mature adult 
microbiota134.  The adult GI microbiota is relatively stable, and although diverse, a large portion of 
an individual’s microbiota tends to be represented by approximately 40 core species135, which are 
characteristic of each individual.  Despite this relative stability, a number of factors can alter the 
microbiota, including static factors such as host genetics, and modifiable factors such as 
environment136.  Recent evidence from a large human study has suggested environment plays the 
most critical role in shaping the microbiota.  In this study, differences in diet and anthropometric 
measures were associated with the inter-individual variability in microbiota profiles137.   
This highlights the potential for modification of the microbiota through lifestyle-based approaches. 
1.2.2.1 Assessment of the Gastrointestinal Microbiota 
Over the last two decades, there have been significant advances in the understanding of the 
composition of the human GI microbiota.  This has been driven by advances in technology, with 
culture independent methods allowing us to harness the genetic content of the microbial community.  
This is preferable as culture-based techniques are impractical in this context, in part due to the high 
prevalence of anaerobic taxa.  The explosion in knowledge of the microbiota, driven by the Human 
Microbiome Project132, has fostered the interest of clinicians, researchers and consumers alike. 
To date, the most common molecular technique for the assessment of the microbiota uses a common 
marker gene, 16S ribosomal ribonucleic acid (16S rRNA), that is highly conserved in bacteria and 
archaea.  The 16S rRNA gene contains nine hypervariable regions that can be selected to maximise 
resolution for taxonomic classification.  Sample sequences are compared to reference genome 
databases such as Greengenes138 and SILVA139 based on similarity to the 16S rRNA marker gene.  
Often, this results in classification to the Operational Taxonomic Unit (OTU) level, which is usually 
determined on the basis of 97% similarity and is a proxy marker for species level for a taxon that 
appears in the database. 
Metagenomic sequencing refers to the sequencing of the entire genome of a sample.  This technique 
is more powerful as compared to amplicon based techniques, as it allows a more detailed 
characterisation at both a taxonomic and functional level.  To date, the use of this technique has been 
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limited by cost, but is becoming more affordable and thus more common.  Sample sequences are 
compared to databases such as MEGAN140 and MetaPhlAn141. 
Sequencing data can also provide information about the functional profiles of the bacteria.   
This information is inherently valuable as ultimately it is the function of microbial communities, such 
as metabolic outputs, that drive impacts on health.  In the case of 16S rRNA sequencing, the functional 
outputs of bacteria can be inferred using bioinformatics software that maps samples to existing 
reference genomes142.  Metagenomic sequencing provides a more accurate representation, as the 
entirety of the microbial genome in each sample is sequenced, and thus the metabolic activity can be 
directly inferred based on the genes present. 
1.2.2.2 Regional Variation in the Gastrointestinal Microbiota 
Colonisation across the length of the GIT varies, with the number of microbes and diversity of taxa 
present increasing from the proximal to the distal GIT.  The biological niche that exists at each 
location varies, and this shapes the community formed.  In the proximal GIT, transit is rapid and the 
environment is more acidic, has a higher presence of antimicrobial peptides and bile acids and has a 
higher presence of oxygen than in the distal GIT143.  The functional profiles of bacteria in these 
regions are different as well, driven by their exposure to nutrients.  For example, in the proximal GIT, 
genes involved in simple sugar metabolism are enriched144, while in the distal GIT, pathways for the 
fermentation of non-digestible carbohydrates are enriched145. 
The composition of the GI microbiota also differs at the same anatomical site, with different 
communities of microorganisms colonising the mucosa as compared to the luminal contents.   
The mucosa-associated microbiota (MAM) refers to the microbial community adhered to the mucosa.  
This is an important population, as it represents the microbial community that is in direct contact with 
the host.  The colonic MAM has been demonstrated to be different to that recovered in faeces, which 
is more representative of the luminal microbiota146-148.  Significant differences in the MAM between 
the proximal and distal GIT have also been reported149.  Due to the inherent difficulty of sampling 
the mucosa, the majority of reports on GI microbiota refer to stool microbiota. 
1.2.2.3 Impact of Diet on the Gastrointestinal Microbiota 
Diet is a key modulator of the GI microbiota as it is a key source of nutrients, and the availability of 
these nutrients influences the community of GI microbes and the metabolites they produce.   
Cross-sectional data from two diverse communities has suggested that long-term dietary patterns 
modulate an individual’s microbiota profile150.  In this study, children from Burkina Faso, who 
typically consume a diet high in fibre, had a high abundance of Bacteroidetes and a low abundance 
of Firmicutes.  Conversely, Italian children, who typically consume a lower fibre diet, were enriched 
in Firmicutes and in particular members of the Enterobacteriaceae family. 
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Whilst long-term dietary patterns determine the microbiota profile, and this profile may be stable in 
an individual over a long period of time, major dietary change can rapidly alter the GI microbiota.   
In particular, a shift to an animal-based diet resulted in an increase in bile tolerant organisms such as 
Bacteroides and a decrease in the abundance of non-digestible carbohydrate fermenting taxa such as 
Roseburia151.  When this profound dietary change was ceased, the microbiota profiles rapidly returned 
to their baseline state.  This finding is supported by the seasonal cyclic changes in the microbiota in 
the Hadza hunter-gatherer population in Tanzania, associated with seasonal changes in the food 
environment across the year152. 
Gut microbes produce beneficial metabolites that have relevant impacts on human health.   
Short-chain fatty acids (SCFAs) are a major product of microbial fermentation of indigestible 
carbohydrates in the colon153.  They are also a minor product of protein fermentation154.  The most 
common SCFAs produced in the human colon are acetate, propionate and butyrate155.  Production of 
SCFAs is modulated by dietary fibre subtype intake and GI transit time156.  SCFAs are an important 
energy source for colonocytes157.  With the exception of acetate, which is found in the circulation, 
the majority of absorbed SCFAs are metabolised in the liver158.  Acetate and butyrate are metabolised 
to acetyl-co enzyme A, whilst propionate enters the citric acid cycle and can be used to produce 
glucose via gluconeogenesis156. As such SCFAs are an additional energy source, accounting for  
5-15% of total caloric intake159.  In patients with T2DM, an increase is circulating acetate levels has 
been reported160.  This was correlated with fasting glucose and HbA1c levels.  The most well studied 
SCFA is butyrate, which has been demonstrated to be associated with maintaining colonic health156. 
Non-dietary derived substrates are also important for microbial metabolism.  Some microbes can 
metabolise host glycans, and cross-feeding of host glycans also occurs161.  The mucus secreted in the 
GIT is glycan rich, providing an endogenous energy source162.  Proximity to the glycan layer, which 
may include adhesion, is important for metabolism of host glycans.  Microbes must also possess genes 
encoding the relevant enzymes for glycan degradation162.  In particular, members of the genera 
Bacteroides and Bifidobacterium and Akkermansia muciniphilia have been demonstrated to be 
capable of metabolising mucus163.  Fermentation products can also be used as substrates for other 
organisms.  For example, hydrogen gas produced as part of carbohydrate fermentation, can be utilised 
by sulfate-reducing bacteria such as Desulfovibrio and methanogenic archaea such as 
Methanobrevibacter164.  These relationships highlight the complexity of measuring the impact of diet 
on the GI microbiota. 
Of particular relevance to this thesis is the response to a Western diet, typified by high fat and sugar 
intake and low fibre intake.  In a murine model, a Western diet was associated with a significant 
increase in the relative abundance (RA) of Firmicutes and Verrucomicrobia and a significant decrease 
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in Bacteroidetes, compared to mice consuming a high fibre diet165.  A Western diet was also 
associated with a bloom of bacteria that are capable of metabolising simple sugars in the distal GIT 
of mice166.  In humans, long-term consumption of a high fat diet was positively associated with the 
RA of Bacteroidetes and Actinobacteria, and was negatively associated with the RA of Firmicutes 
and Proteobacteria167.  The influence of fat on the microbiota appears to be dependent on the type of 
fat consumed.  Saturated fat intake appears to be associated with deleterious impacts on the 
microbiota, in particular alterations in the ratio of Bacteroidetes to Firmicutes168. 
1.2.2.4 Links between Obesity and the Gastrointestinal Microbiota 
The most pervasive evidence of the role of the GI microbiota in weight status comes from a study of 
germ-free mice.  Germ-free mice had lower body fat than those colonised with a normal microbiota169.  
In these germ-free mice, subsequent re-colonisation with a normal microbiota resulted in an increase 
in body fat and insulin resistance despite an overall reduction in food intake.  This was the first 
evidence suggesting a role of the microbiota in the regulation of body weight and metabolic health.  
In another study, germ-free mice colonised with faecal microbes from obese mice had significantly 
greater body fat than mice colonised with faecal microbes from lean littermates170.  Metagenomic 
analysis revealed these animals to be enriched in Firmicutes, with an increased capacity for dietary 
energy harvest, evidenced by an increase in caecal SCFAs and a decrease in calories recovered in the 
stool. 
In humans, obesity has been associated with an altered microbiota profile171 and alterations in colonic 
energy harvesting172.  Broadly, it has been suggested there is an increase in the ratio of Firmicutes to 
Bacteroidetes in obesity171, 173; however, findings are inconsistent.  Some studies have shown change 
in the Bacteroidetes to Firmicutes ratio174, 175.  More specifically, members of the Clostridium cluster 
XIVa, Lactobacillus and Bacteroides have been reported to be enriched, whilst Bifidobacterium, 
Faecalibacterium and Oscillospira have been reported to be depleted176. 
1.2.2.5 Links between T2DM and the Gastrointestinal Microbiota 
TD2M has been associated with distinct changes in the GI microbiota.  In a study of 345 Chinese 
individuals, T2DM was characterised by alterations in taxonomic profile, but not alpha diversity.  
Specifically, there was an enrichment in opportunistic pathogens such as Escherichia coli and a 
reduction in butyrate-producing bacteria such as Roseburia intestinalis177.  The key mucin degrading 
bacterium, Akkermansia muciniphilia, was also enriched.  Functional analyses revealed an 
enrichment of membrane transport pathways, and specifically for transport of sugars and  
branched-chain amino acids.  In the context of T2DM, these would be highly available substrates to 
GI microbes178.  T2DM has previously been associated with oxidative stress179.  This study also 
identified an enrichment of oxidative stress resistance genes, suggesting a stimulation of microbial 
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defence against TD2M-related oxidative stress.  These functional findings have been confirmed in a 
study of European women180, where a significant increases in four Lactobacillus species and 
significant decreases in five Clostridium species was also reported in the TD2M cohort. 
Changes in the GI microbiota also appear to be related to glucose control independently of markers 
of adiposity.  In a study of 36 European males, 18 of whom had T2DM, the ratio of  
Bacteroidetes: Firmicutes and the ratio of Prevotella: Clostridia (C. coccoides-E. rectale) were 
significantly positively correlated with plasma glucose concentration, but not BMI181.  There was also 
a higher abundance of Betaproteobacteria in T2DM subjects compared to controls, and this was 
positively correlated with plasma glucose. 
The abundance of particular microbes at genus or species level has also been investigated.   
Both Bifidobacterium174 and Faecalibacterium prausnitzii177, 182 are reported to be reduced in T2DM.  
This is notable, as these bacteria are associated with anti-inflammatory properties183, 184. These data 
indicate possible changes in the microbiota associated with T2DM that may be distinct from the 
impacts of obesity; however, more research is required. 
An important consideration in the effect of T2DM on the microbiota is the pharmacological treatment 
protocol.  Metformin is the most commonly prescribed medication for T2DM, and has been 
associated with alterations in the microbiota.  The relationship is unclear with metformin usage 
associated with both an enrichment185 and a depletion186 in butyrate-producing bacteria. 
1.2.2.6 Impact of Weight Loss on the Gastrointestinal Microbiota 
Dietary weight loss interventions have been associated with variable changes in the stool microbiota 
in humans.  Following hypercaloric dietary intervention, bacterial diversity was increased in two 
studies187, 188, with no significant change in two studies189, 190.  The majority of studies have reported 
no significant impact of hypercaloric diet intervention on taxonomy at the phylum  
level175, 189-192.  Two studies reported an increase in Bacteroidetes and a decrease in Firmicutes171, 193, 
whilst one study reported an increase in Firmicutes and a decrease in Bacteroidetes194.  In studies 
using a hypercaloric, but also high protein and low carbohydrate diet, a number of consistent 
observations were reported at species level.  Specifically, a reduction in butyrate producers such as 
Roseburia spp, Clostridium cluster XIVa, Eubacterium rectale and Bifidobacterium spp were  
observed175, 188, 190, 192, 194.  There was a high level of inter-individual variation across these studies 
and considerable heterogeneity in microbiota assessment methodologies.  Bariatric surgery has also 
been associated with changes in the stool microbiota in humans.  Further details can be found in 
Chapter 1 Section 1.3.3.4. 
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1.2.3 Inflammation 
1.2.3.1 Inflammation and Obesity 
Obesity is associated with inflammation in the skeletal muscle, liver, pancreas, brain, GIT and adipose 
tissue195.  Systemic markers of inflammation have been positively associated with increased 
adiposity196.  As such, obesity is considered a chronic, low grade inflammatory state.   
Systemic markers of inflammation have also been associated with the pathogenesis of obesity-related 
comorbidities such as T2DM197, 198 and cardiovascular disease199.  
In obesity, the adipose tissue is a key site of the inflammatory response, with the accumulation of 
macrophages playing a key role in the secretion of pro-inflammatory cytokines200, 201.   
Activated macrophages exist as either “classically activated” M1 macrophages, or “alternatively 
activated” M2 macrophages.  M1 macrophages are activated by interferon gamma and 
lipopolysaccharide (LPS).  M2 macrophages are a heterogeneous population and are activated by 
interleukin (IL)-4, IL-13, LPS, apoptotic cells, IL-10, transforming growth factor-β and 
glucocorticoids202.  M1 macrophages are considered pro-inflammatory and secrete tumour necrosis 
factor (TNF), IL-6 and IL-1β in addition to producing reactive oxygen (ROS) and nitrogen species.  
M2 macrophages produce anti-inflammatory cytokines such as IL-10 and transforming growth  
factor-β and produce arginase-1, preventing nitric oxide production.  M2 macrophages are associated 
with tissue remodelling203.  In addition to the increased infiltration of macrophages into the adipose 
tissue in obesity, a phenotypic shift from M2 to pro-inflammatory M1 macrophages is reported204. 
In the inflammatory process, neutrophils and lymphocytes are recruited into the adipose tissue prior 
to macrophage infiltration205.  Obesity has been linked to alterations in neutrophil activity and 
function in the adipose tissue and systemically206, 207.  Neutrophil infiltration in the adipose tissue 
appears to drive the polarisation of M1 macrophages206.  In the circulation, neutrophils from patients 
with severe obesity had higher levels of chemotactic and random migration207.  They also released 
significantly more basal superoxides.  Phagocytosis and adherence were not significantly different to 
controls.  Cumulatively, these results suggest the neutrophils are primed, which increase the response 
of the neutrophils when exposed to an activating stimulus208.  However, in the context of T2DM, 
deficits in all of these functions have been demonstrated209-211, suggesting mechanisms could be 
different in these two closely related conditions.  Other components of the innate immune system 
such as natural killer cells and dendritic cells have also been shown to have altered function in obesity 
and T2DM212. 
Adaptive immunity is also altered in patients with obesity and T2DM.  Adipose tissue and systemic 
T cell populations display altered activation states213, 214.  Both cluster of differentiation (CD) 4+ and  
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CD 8+ effector T cells have been implicated in the initiation of adipose tissue inflammation and the 
ongoing inflammatory response215, 216.  A recent murine study has demonstrated CD4+ effector  
T cells are implicated in weight regain following successful weight loss217.  Infiltration of  
CD4+ effector T cells in the adipose tissue preceded weight regain, suggesting an ‘obesity memory’ 
response after introduction of a high fat diet.  Deficits in regulatory and γδ T cell populations and 
compromised function have been reported in obesity218. 
Despite strong links between obesity and adipose tissue T cell populations, derangements in leukocyte 
cell phenotype or function in the circulation provide a more clinically accessible marker of systemic 
inflammation and cardiometabolic risk.  Overall monocyte, neutrophil and lymphocyte counts have 
been reported to be higher in obesity than lean controls, have been associated with metabolic 
dysregulations such at the metabolic syndrome219-221 and can be altered by weight loss222.   
Similarly, circulating cytokines provide another clinically accessible measure of inflammation.   
A recent systematic review assessed the impact of lifestyle-based or surgical weight loss interventions 
on circulating markers of inflammation.  In the majority of included studies, a significant reduction 
in pro-inflammatory biomarkers, and in particular IL-6 and TNF was reported223.  
1.2.3.2 Inflammation and Insulin Resistance 
In obesity, the key sites of insulin resistance are the adipose tissue, skeletal muscle and liver.   
TNF has been strongly linked to skeletal muscle and adipocyte insulin resistance224.  TNF stimulates 
phosphorylation of the insulin receptor substrate-1 protein, disturbing signalling224.  TNF also reduces 
the expression of glucose transporter type 4, a key transporter for glucose uptake in the adipose tissue, 
muscle and liver.  TNF can also activate nuclear factor kappa B (NF- κB) and c-Jun N-terminal kinase 
signalling pathways224, increasing the concentration of pro-inflammatory cytokines and perpetuating 
the immune response.  In the adipose tissue, TNF also inhibits peroxisome proliferator-activated 
receptor γ (PPARγ), a key driver of lipid synthesis and storage225.  
Weight loss has been demonstrated to improve insulin sensitivity226.  A modest degree of weight loss 
(5%) has been associated with improvements in improved adipose tissue, muscle and hepatic insulin 
sensitivity227.  However, in this study there was no improvement in adipose tissue or systemic immune 
markers.  This highlights the complexity of the relationship between insulin resistance and 
inflammation. 
1.2.3.3 Relationship between the Gastrointestinal Microbiota and Inflammation 
The GI microbiota is a relevant modulator of inflammation in the human body.  The relevance of the 
interaction between the immune system and the microbiota is best illustrated by perturbations in the 
microbiota observed in a number of intestinal and extra-intestinal inflammatory disease states228-231.  
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To date, human studies have provided only limited evidence as to whether these perturbations are a 
cause or consequence of the disease state. 
Commensal microbes in the GIT are in close contact with the gut epithelium.  The mucus layer 
separating the epithelium and gut microbes acts as both a physical and immunological barrier232.  
When intestinal permeability is compromised, microbes and other particles can cross this epithelial 
layer into the lamina propria.  In the lamina propria, antigen presenting cells such as macrophages 
and dendritic cells present antigens to T helper cells233.  Antigen presentation activates the effector 
function of T lymphocytes in the lamina propria; however, effector T lymphocytes are also found 
within the healthy intestinal epithelium. 
Intestinal permeability increases in parallel with BMI and is associated with insulin sensitivity234.   
Evidence from animal studies suggest intestinal permeability may be associated with changes in the 
microbiota induced by the consumption of a high-fat diet235.  Other factors that may contribute to 
intestinal permeability include nutrient deficiencies, high fructose intake and systemic 
inflammation236.  Regardless of the pathogenic process involved, increased intestinal permeability 
can lead to metabolic endotoxaemia.  This refers to the translocation of bacterial LPS across the 
epithelial membrane, into the lamina propria and ultimately into the circulation.  This is the key 
pathway by which the microbiota and inflammation are linked in obesity.  LPS binds to an activation 
complex containing the Toll-like receptor-4 (TLR-4)237.  These activation complexes are highly 
expressed on liver, adipose tissue and muscle cells and activate NF- κB238.  NF- κB activation leads 
to the production of pro-inflammatory cytokines and ROS.  The increase in pro-inflammatory 
cytokines, including TNF, can lead to a signalling cascade that blocks the activity of insulin on its 
receptor239.  Thus, LPS can perpetuate insulin resistance in patients with obesity.  LPS has been 
demonstrated to trigger adipose tissue macrophage recruitment240, facilitating the phenotypic shift 
from M2 to M1 macrophages observed in obesity. 
1.2.3.4 Diet-Immune and Diet-Immune-Microbiota Interactions 
Dietary constituents are also associated with the immune response.  In brief, saturated fat is associated 
with a pro-inflammatory response via activation of the TLR-4 containing activation complex241.   
Saturated fats can also increase the production of atherogenic lipids which trigger an inflammatory 
response.  Conversely, polyunsaturated fatty acids have anti-inflammatory effects via inhibition of 
the pro-inflammatory TLR-4 and NF- κB pathways and activation of the anti-inflammatory nuclear 
receptor PPARγ242. 
Cross-talk between the microbiota and the immune system can be partly mediated by dietary 
constituents.  For example, diets high in animal protein result in an increase in production of 
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trimethylamine N-oxide (TMAO) by the microbiota243.  Physiological concentrations of TMAO  
in vitro have been demonstrated to increase pro-inflammatory cytokine gene expression, in part via 
activation of the NF- κB pathway244.  In a rodent model, a high milk protein diet was associated with 
a reduction in NF- κB expression245.  Thus, the source of dietary protein appears critical in the 
inflammatory response.  
The microbiota are key to the relationship between carbohydrate intake and inflammation.   
In particular, SCFAs, a product of microbial fermentation, have been implicated in a variety of 
immunomodulatory roles.  Butyrate activates the inflammasome by binding to G-protein coupled 
receptors, helping to maintain the integrity of the epithelial barrier246.  Butyrate also appears to 
regulate the expression of tight junction proteins, improving barrier function247.  Acetate has also 
been suggested to modulate barrier function in a murine model248.  In mice, lethal colitis developed 
following a low fibre diet249.  This was attributed to an increase in taxa capable of mucus degradation 
secondary to dietary fibre restriction.  The erosion of the mucus barrier was linked to reduced barrier 
function, thus permitting lethal infection. 
SCFAs can modulate both innate and adaptive immune responses.  Butyrate inhibits NF- κB 
signalling and histone deacetylase function250, 251.  Through these pathways, the pro-inflammatory 
macrophage and neutrophil response is reduced252, 253.  Butyrate reduces dendritic cell activity in the 
lamina propria promoting immunotolerance254, 255.  SCFAs also modulate T cell populations, resulting 
in expansion of regulatory T cell populations and have also been implicated in T cell  
differentiation250, 256.  SCFAs can also act as signalling molecules, acting on G-protein coupled 
receptors, with relevant impacts on metabolic health via modulation of hormonal secretion, energy 
expenditure and insulin sensitivity257.  
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1.3 OBESITY TREATMENT STRATEGIES 
Obesity management is complex and individualised; however, algorithm-based approaches to 
treatment have recently been developed to aid primary care physicians.  These approaches escalate 
through various treatment strategies on the basis of BMI and comorbidities, with a BMI of ≥40 kg/m2 
or a BMI of ≥35 kg/m2 with significant comorbidities typically resulting in a faster escalation to 
bariatric surgery.  Lifestyle modification intervention and pharmacotherapy are first line treatments.  
These are generally delivered in the primary care setting; however, tertiary medical obesity 
management services may also utilise these methods.  Clinically significant weight loss  
(≥ 5% of baseline weight)258, as a result of lifestyle modification intervention or bariatric surgery is 
beneficial, leading to improvements in obesity-related comorbidities and cancer risk259-261.   
Similarly, in patients with obesity-related metabolic complications, lifestyle and pharmacotherapeutic 
management of deranged metabolic parameters are first line therapies. 
Failure of conservative treatment measures is generally required before escalation to bariatric surgery.  
Recently, a paradigm shift in treatment has suggested bariatric surgery be considered in patients with 
a BMI 35.0-39.9 kg/m2 with inadequate glycaemic control despite medical and lifestyle therapy 
optimisation and in those with BMI ≥40 kg/m2 regardless of medical optimisation of glycaemic 
control262.  Bariatric surgery has been demonstrated to improve glycaemic outcomes in a manner that 
is distinct from the weight loss benefits of surgery263, 264. 
1.3.1 Lifestyle Modification Intervention 
Lifestyle modification intervention is the cornerstone of obesity treatment, either as a primary therapy 
or as an adjunctive therapy to pharmacotherapy or bariatric surgery.  Lifestyle modification 
intervention for obesity management induces weight loss via a reduction in overall energy intake.  
Strategies used may include the modification of dietary intake via calorie restriction, macronutrient 
manipulation or cognitive behavioural therapy.  Exercise may also be utilised to increase energy 
expenditure.  Very low calorie diets (VLCDs) which aim to reduce energy intake to <3300 kJ/day 
(<800 kcal/day) by replacement of meals with formulated shakes, soups and bars can also be used.  
Typically, these are recommended for short-term interventions of approximately 12 weeks, but can 
be continued for up to 12 months under medical or allied health supervision265, 266.  VLCDs have also 
been demonstrated to improve metabolic outcomes in patients with impaired glucose tolerance or 
T2DM265, 266.  Medical nutrition therapy for T2DM aims to reduce body weight and independently 
improve glycaemic control through modification of carbohydrate intake, with a particular focus on 
dietary fibre intake and glycaemic index/load267. 
22 
 
Lifestyle modification intervention to facilitate weight loss has been demonstrated to be efficacious 
in the short-term, with maximum efficacy at six to 12 months268, 269.  In severe obesity  
(BMI > 35 kg/m2), lifestyle modification intervention induces modest weight loss; however, there is 
limited evidence of a concurrent reduction in cardiometabolic risk270.  Moreover, there is a lack of 
long-term efficacy for lifestyle modification intervention with the majority of individuals regaining 
all weight lost within two to five years, regardless of the magnitude of weight loss initially 
achieved271-273. 
1.3.2 Pharmacotherapy 
Pharmacological agents are often used as an adjunctive therapy to lifestyle modifications in the 
obesity treatment paradigm.  Globally, the number of pharmacotherapeutic obesity treatments is 
limited.  Approval and usage status varies by country.  In Australia, phentermine (monotherapy only), 
a naltrexone/bupropion combination, orlistat and liraglutide are approved for obesity management.  
Phentermine and naltrexone/bupropion act on the central nervous system274, 275, whilst orlistat acts in 
the GIT276.  Liraglutide has both local and central activity277.  Topiramate, an anticonvulsant, and 
phentermine/topiramate combinations may also be prescribed off-label. 
Key issues with pharmacological weight loss treatments are the duration of administration and the 
impact on long-term weight status.  The majority of studies do not extend beyond approximately one 
year of follow-up and as such the long-term efficacy and safety implications are unknown.   
In long-term studies of orlistat, the weight loss benefits were relatively limited, with an approximately 
3 kg greater weight loss than placebo at 2-4 years278, 279.  Cost may also be a prohibitive factor.   
In Australia, these medications cost between AUD$100 and AUD$400 per month, and are not 
subsidised under the Pharmaceutical Benefits Scheme for obesity treatment. 
1.3.3 Bariatric Surgery 
The American Society for Metabolic and Bariatric Surgery (ASMBS) define bariatric surgery as 
surgical procedures which “cause weight loss by restricting the amount of food the stomach can hold, 
causing malabsorption of nutrients, or by a combination of both gastric restriction and 
malabsorption”280.  The history of bariatric surgery is extensive, with the first bariatric surgical 
procedure, the jejunoileal bypass, performed in the United States in 1953.  In the following decades, 
numerous procedures were introduced and discontinued.  Currently, there are four commonly 
performed bariatric surgical procedures, described below. 
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1.3.3.1 Procedures 
Laparoscopic Adjustable Gastric Band (LAGB; Lap-Band®) 
An inflatable gastric band is laparoscopically inserted below the level of the gastroesophageal 
junction to create a gastric pouch.  The band is connected to a subcutaneous infusion port to allow for 
infusion of saline to tighten or loosen the band, regulating the flow of ingested foods from the gastric 
pouch into the remainder of the stomach.  This is the only reversible bariatric surgical procedure.  
This procedure has progressively become less common, due to a poorer long-term efficacy profile281 
and a higher rate of revisions281, compared to other surgical techniques.  LAGB procedures now 
represent less than 20% of surgeries performed in Australia282.  
Laparoscopic Sleeve Gastrectomy (LSG) 
A tubular stomach is created by resecting the greater curvature of the stomach, preserving the pylorus 
and part of the antrum.  This resection removes the fundus, which is the primary location of ghrelin 
production, leading to a marked reduction in circulating plasma ghrelin concentrations283.   
Typically, the stomach volume is reduced to approximately 100-150 mL.  This is now the most 
commonly performed bariatric surgical procedure in Australia282. 
Gastric Bypass Procedures 
The Roux-en-Y gastric bypass (RYGB) creates a small pouch of stomach (~30 mL), which is 
anastomosed to the jejunum, referred to as the Roux or alimentary limb.  The remaining portion of 
the stomach produces digestive juices, and bile and pancreatic juices are secreted from the ampulla 
of Vater into the second part of the duodenum.  This biliopancreatic limb transports these secretions 
to the jejunojejunostomy, which is formed by anastomosing the biliopancreatic limb to a more distal 
part of the jejunum.  At the jejunojejunostomy, the alimentary and biliopancreatic limbs form a 
common channel, allowing ingested nutrients to come into contact with the digestive juices to 
facilitate breakdown and absorption.  If both limbs are at their maximal length, then approximately 
one third of the small intestine is bypassed.  The length of jejunum in the biliopancreatic limb has 
been demonstrated to be associated with fat malabsorption in patients that have undergone RYGB, 
with a significant reduction in fat absorption occurring at a length of 70 cm284.  The RYGB is 
considered to be the “gold standard” of bariatric surgery280.  Globally, gastric bypass is the most 
commonly performed procedure285.  In Australia, its utilisation is more limited, representing less than 
10% of procedures reported in the voluntary Bariatric Surgery Registry in 2017-18286. 
The one-anastomosis gastric bypass (OAGB) creates a tubular stomach pouch, similar to LSG, which 
is anastomosed to a jejunal loop.  The length of the afferent limb is typically 150-200 cm from the 
ligament of Treitz287.  Adjustment of the limb length dependent on baseline BMI has been shown to 
result in better weight loss outcomes, with afferent limbs of up to 350 cm used in those with a BMI 
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>50 kg/m2 288.  Of the 82% of bypass procedures billed to Medicare captured in the Bariatric Surgery 
Registry in 2017-18, approximately 40% were OAGB286.  This indicates the growing popularity of 
this procedure in Australia. 
Biliopancreatic Diversion with Duodenal Switch  
The biliopancreatic diversion with duodenal switch (BPD-DS) involves a partial sleeve gastrectomy, 
with the pylorus retained to prevent dumping.  Like in the RYGB, both an alimentary limb and a 
biliopancreatic limb are created.  In this procedure, there is a shorter common channel.  In the 
alimentary limb, the terminal ileum is anastomosed just below the level of the pylorus.  In the 
biliopancreatic limb, the duodenum is anastomosed at the level of the terminal ileum.  This procedure 
is associated with the greatest degree of weight loss289; however, is rarely performed in Australia 
(<0.5% of all primary procedures)282. 
1.3.3.2 Safety of Bariatric Surgical Procedures 
Safety outcomes are typically reported as early (<30 days) or late (>30 days) complications and 
further stratified as major or minor.  The ASMBS defines major complications as any complication 
leading to ≥7 day hospital stay, requirement for anticoagulant administration, reintervention or 
reoperation290.  In 2014, a large systemic review and meta-analyses reported outcomes from 161,756 
patients who underwent bariatric surgery between 2003 and 2012291.  Early (≤30 days) mortality was 
estimated at 0.08% (n=1,803) in Randomised Controlled Trials (RCTs) and 0.22% (n=136,903) in 
observational studies.  Late (>30 days) mortality was estimated at 0.31% (n=1,703) in RCTs and 
0.35% (n=66,897) in observational studies.  In RCTs, sleeve gastrectomy (including open procedures) 
was associated with the highest early and late mortality rate, whilst in observational studies, gastric 
bypass (including both open and laparoscopic RYGB, laparoscopic BPD-DS and BPD-RYGB) was 
associated with the highest mortality rate.  Due to heterogeneity in outcome reporting, only an overall 
complication rate was reported.  Complication rate was estimated at 17.0% (n=1,778) in RCTs and 
9.8% (n=113,002) in observational studies.  Gastric bypass procedures were associated with the 
highest rate of complications in both RCTs (21.0%) and observational studies (12.0%).  Thus, these 
results suggest that while the mortality rate is appreciably low, the overall complication rate is 
significant. 
1.3.3.3 Clinical Efficacy of Bariatric Surgical Procedures 
Weight loss outcome reporting is variable after bariatric surgery.  The ASMBS recommend reporting 
of mean baseline BMI, change in BMI, total body weight loss (TBWL) and percent excess weight 
loss (EWL) and/or percent excess BMI loss290.  EWL refers to any weight carried over a BMI of  
25.0 kg/m2 (in a Caucasian population).  Duration of clinical outcome reporting is specified as  
short-term (<3 years post-operative), medium-term (>3 but <5 years post-operative) and long-term 
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(>5 years post-operative)290.  In a systematic review and meta-analyses, mean EWL at one year was 
59.8% across nine RCTs and 46.2% across 39 observational studies291.  Gastric bypass procedures 
were associated with the greatest magnitude of early weight loss. 
Long-term maintenance of weight loss is variable, with weight regain typically beginning between 
one and two years after surgery292.  A number of factors have been linked to this weight recidivism, 
broadly classified as patient-related factors and procedure-related factors.  Patient-related factors 
include non-compliance with post-surgery nutrition and physical activity recommendations293, 294 and 
the presence of mental health comorbidities295-297.  Negative metabolic adaptations such as an increase 
in appetite stimulating hormones such as ghrelin298, 299 and a reduction in resting energy expenditure 
have also been reported300, 301.  Long-term weight maintenance also appears to be linked to the 
surgical procedure the patient underwent.  At five years, EWL was greater after OAGB as compared 
to LSG and RYGB302, 303.  At 10 years, weight loss has been reported to be greatest after BPD-DS 
(71.0% EWL) followed by RYGB (60.1% EWL) and LAGB (48.8% EWL), although LSG was not 
included in this meta-analysis304. 
Bariatric surgery is also an effective treatment for T2DM.  Outcome reporting for improvement in 
diabetes is recommended to be stratified as total remission, partial remission, improvement, 
unchanged or recurrence290.  Complete remission refers to normal glycaemia  
(HbA1c <6%; fasting glucose <5.6 mmol/L) in the absence of anti-hyperglycaemic agents.  Partial 
remission refers to subdiabetic glycaemia (HbA1c 6.0-6.4%; fasting glucose 5.6-5.9 mmol/L) in the 
absence of anti-hyperglycaemic agents.  Improvement refers to a statistically significant improvement 
in either HbA1c or fasting glucose without meeting remission criteria or a reduction in anti-
hyperglycaemic agents (discontinuation or 50% dose reduction of insulin or one oral agent).   
Using these definitions, a 2006 systematic review and meta-analysis reported on diabetes outcomes 
from 621 studies289.  Across these studies, complete remission was reported in 78.1% of patients.   
The proportion of patients who had complete remission was highest for BPD with/without duodenal 
switch followed by gastric bypass.  Sleeve gastrectomy was not reported on.  A more recent network 
meta-analysis of 25 RCTs reports at least partial remission in 94.6% of BPD patients, 86.1% of 
OAGB patients, 73.9% of BPD-DS patients, 64.1% of RYGB patients, 52.4% of LSG patients and 
30.3% of LAGB patients305. 
1.3.3.4 Mechanisms of Action of Bariatric Surgical Procedures 
Historically, bariatric surgery procedures have been described as either primarily restrictive or 
primarily malabsorptive procedures.  LAGB and LSG have been classified as primarily restrictive, 
whilst RYGB and BPD have been classified as primarily malabsorptive.  Whilst these classifications 
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are intuitive, evidence suggests a more complex regulation of the weight loss response following 
surgery.  These will be discussed as individual themes below. 
Energy Expenditure 
A number of studies have assessed resting energy expenditure after RYGB.  The majority of studies 
report a reduction in resting energy expenditure300, 306-308.  However, when adjusted for predicted 
metabolic rate, an increase in energy expenditure has been reported in some studies309, 310.   
Other studies have reported that energy expenditure did not differ from lean controls when adjusted 
for fat mass or loss of fat-free mass308. 
The contribution of diet-induced thermogenesis to weight loss after RYGB has also been assessed.  
A significant increase in diet-induced thermogenesis has been observed311, 312.  Weight regain after 
RYGB has also been associated with a reduction in both diet-induced thermogenesis and resting 
energy expenditure313, 314.  The effects of bariatric surgery, and in particular LSG, on energy 
expenditure require further investigation. 
Modulation of Food Intake 
Whilst both LSG and RYGB have a mechanically restrictive component, this is unlikely to be a major 
mechanism by which weight loss is induced.  In a large review including 5,000 LSG patients, there 
was no significant difference in EWL on the basis of larger versus smaller bougie size315.  A small 
prospective study has identified antral volume, as opposed to overall bougie size, as a possible 
contributor to weight loss efficacy after LSG316.  Following RYGB, weight loss at one317 and three 
years318 post-procedure was not correlated with the size of the gastric pouch. 
Behavioural change and nutrition counselling are a key component of post-bariatric surgery care 
recommendations for weight loss and improvements in glycaemic control319.  Lifestyle modification 
intervention alone is ineffective in producing long-term weight loss due to the difficulty of sustained 
behaviour change271-273.  Animal models have provided evidence for a biologically, rather than 
behaviourally-driven change in food preference after bariatric surgery.  Following LSG or RYGB, 
there is a shift towards a preference for a lower energy carbohydrate rich diet, as opposed to a higher 
fat diet320, 321.  After LSG, this was associated with an aversion to intragastric oil320.  In humans, 
alterations in self-reported dietary intake support these findings with a reduction in high calorie foods 
or dietary fat after RYGB306, 322, 323.  After LSG, changes in taste intensity and decreased enjoyment 
of high calorie foods have been reported324, 325.  Changes in the smell of food have also been reported 
after both LSG and RYGB326, 327.  Functional imaging studies have also reported a reduction in brain 
reward pathways to high calorie foods following RYGB328.  Further work is needed to assess the 
neurobiological determinants of alterations in food preference after bariatric surgery in humans. 
27 
 
Bariatric surgery has been demonstrated to modulate visceral sensation in response to nutrient 
stimulation, with an increase in satiety scores following a standardised nutrient drink329.  Further, a 
higher baseline maximum tolerated volume was found to be independently negatively predictive of 
weight loss at one year after bariatric surgery in a cohort of 14 females with severe obesity330. 
Satiety responses may be associated with changes in the hormonal regulation of appetite after bariatric 
surgery.  The incretin effect refers to the ability of oral glucose to stimulate a greater insulin response 
than intravenously administered glucose331.  After both LSG and RYGB, the incretin effect is 
substantially increased.  The evidence of the effect of bariatric surgery on glucose-dependent 
insulinotropic peptide (GIP) is conflicting.  Both an increase332, 333 and a decrease334, 335 in GIP has 
been reported after RYGB.  An increase in GLP-1 has been reported following both RYGB and 
LSG333, 336-339.  Evidence from animal models suggests the mechanism via which this occurs is 
different between the two procedures.  Following LSG, the density of GLP-1 producing L cells is 
increased, whilst after RYGB there is intestinal hyperplasia and an increase in the number of  
L cells340.  The physiological relevance of the observed increase in GLP-1 is poorly defined.   
Data from knockout animal models suggest that GLP-1 acting on its receptor is not critical for either 
the weight loss response or global improvements in glycaemic control after both LSG and  
RYGB341, 342.  Further research is required to determine the role of incretin peptides in the weight loss 
and glycaemic control response to bariatric surgery. 
Alterations in other gut derived hormones have been reported after bariatric surgery.  PYY is a central 
modulator of satiety, acting in the hypothalamus343.  An increase in the post-prandial PYY response 
has been reported after both LSG and RYGB344-347. Higher PYY levels have been correlated with 
lower appetite scores346, 348.  GLP-2, a gut-derived peptide implicated in in mucosal homeostasis and 
proliferation349, has also been reported to increase after RYGB in rodents and humans350, 351. 
Some of these hormonal changes may be linked with intestinal proliferation and hypertrophy.  
Following RYGB, intestinal hypertrophy has been observed in animal models350, 352.  These changes 
have not been reported following LSG353.  Morphological changes such as increased villus height and 
crypt depth have also been reported after RYGB in animal models, which may provide a mechanism 
via which malabsorption is limited350, 354.  These changes have been linked to increases in GLP-2350.  
Pancreatic hyperplasia has also been reported following RYGB in animal models355.  It has been 
proposed that this may be mediated by the parallel increase in GLP-1 or GIP following RYGB356.  
This contributes to the improvement in glucose control seen after RYGB. 
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Gastrointestinal Function 
In addition to morphological changes in the GIT, changes in GI function have been reported following 
bariatric surgery.  Bowel habits in patients with severe obesity are altered357.  However, following 
RYGB, constipation is significantly increased358, suggesting malabsorption may be limited.   
A limited number of studies of RYGB have reported fat malabsorption following RYGB284, 359, with 
clinically significant malabsorption likely associated with the length of the alimentary limb284.   
This may be a minor mechanism via which weight loss is facilitated.  
Gastric emptying has also been assessed following bariatric surgery.  Aa significant acceleration of 
gastric emptying has been reported after both LSG360-362 and RYGB363-366.  However, more rapid 
pouch emptying has been associated with both better and poorer weight loss outcomes364, 365.   
The relevance of changes in GI motor function for weight loss outcomes requires further 
investigation. 
The Gastrointestinal Microbiota and Bile Acids 
A number of taxonomic changes in the GI microbiota have been reported after bariatric surgery.  
These may be associated with alterations in dietary intake and physiological impacts of the anatomical 
changes caused by surgery, such as alterations in gastric emptying, intestinal pH and exposure to bile.  
At the phylum level, a decrease in the ratio of Firmicutes: Bacteroidetes has been reported in a number 
of studies following RYGB367-371.  Conversely, one study has reported an increase in the ratio of 
Firmicutes: Bacteroidetes372.  An increase in Proteobacteria368, 370, 371, 373 and more specifically 
Gammaproteobacteria has also been reported374, 375.  Other phyla reported to be increased following 
RYGB include Fusobacteria373, Actinobacteria372 and Bacteroidetes .  At the genus level, a significant 
increase in common taxa such as Bacteroides, Streptococcus, Prevotella, Enterobacter, Citrobacter 
and Veillonella has been reported367, 368, 370, 371, 373, 376.  Bifidobacterium has been reported both to 
increase377 and decrease367.  Similarly, conflicting evidence also exists about change in abundance of 
Escherichia (including E.coli) and Faecalibacterium (including F.prausnitzii)367, 368, 377.   
Significant reductions in the RA of common taxa such as Lactobacillus, Coprococcus and 
Anaerostipes have been reported after RYGB367, 368. 
Following LSG, a significant decrease in the ratio of Firmicutes: Bacteroidetes has been reported in 
four studies371, 378-380.  One study has reported no significant change in the ratio of Firmicutes: 
Bacteroidetes370.  Studies have also reported either an increase in Bacteroidetes372, 379 or a decrease in 
Bacteroidetes371.  One study has reported a decrease in Firmicutes380.  Similarly, both a significant 
increase371 and a significant decrease370 in Proteobacteria has been reported following LSG.  
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In humans, these results do not define whether weight loss is a cause or consequence of changes in 
the microbiota, as weight loss does not occur in isolation from other metabolic changes which may 
precipitate changes in the microbiota, such as reduced systemic inflammation.  However, murine 
models have provided a more causative link, with faecal transplant from both RYGB-treated mice 
and humans resulting in a reduction in fat mass in inoculated germ-free mice375, 381. 
Following RYGB, three studies have reported an increase in bacterial richness369, 372, 373, whilst one 
study has reported no significant change in diversity370.  In two studies assessing outcomes following 
LSG or LAGB, no change in diversity was reported380, 382.  
Bile acids are produced and conjugated in the liver for secretion in bile into the duodenum at the 
ampulla of Vater.  Bile acids facilitate the digestion of fat and ultimately the absorption of 
triglycerides, cholesterol and fat soluble vitamins.  The majority of bile acids are reabsorbed in the 
ileum via the enterohepatic circulation.  Bile acid composition is modulated by the composition of 
the GI microbiota.  Specifically, the microbiota are critical for the formation of secondary bile acids, 
which are the product of microbial transformation of primary bile acids.  Total bile acid concentration 
has been shown to be increased after RYGB383-386.  Conflicting data exist on the impact of LSG on 
circulating bile acid concentrations.  Both significant increases384, 387 and no change388, 389 in total or 
conjugated bile acid concentration has been reported after LSG. 
Bile acids also act as a signalling molecule and are an important modulator of energy and glucose 
metabolism.  A larger increase in circulating bile acid concentration has been associated with T2DM 
remission after RYGB385, 390.  This may be associated with bile acid activity on both the Takeda  
G-protein coupled receptor 5 (TGR5), which increases GLP-1 secretion391, or on the farnesoid X 
receptor (FXR), which increases insulin secretion by pancreatic β-cells392.  Murine models have 
demonstrated a key role of FXR in improvement in glycaemia, as knockout mice showed a reduction 
in improvement in glycaemia after LSG, as well as impaired weight loss393.  Bile acids may also act 
on the TGR5 receptor in adipose and skeletal muscle tissue, increasing energy expenditure by 
increasing thyroid hormone activation394. 
Glycaemic Control 
In addition to the aforementioned effects of changes in incretin peptides and bile acids on glycaemic 
control, distinct improvements in insulin sensitivity have also been reported.  In animal models, 
intraperitoneal administered glucose loads are cleared faster after both LSG and RYGB, compared to 
obese rats but not body weight matched rats395.  As intraperitoneal administration bypasses the 
intestine, this is more reflective of improvements in overall insulin sensitivity that are weight loss 
dependent395.  However, it appears that improvements in hepatic insulin sensitivity occur following 
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RYGB in a weight loss-independent manner395.  Enhanced insulin signalling in adipose tissue and 
skeletal muscle has also been reported in humans396. 
Inflammation 
Bariatric surgery is effective is reducing inflammation in the adipose tissue.  This is driven by a 
reduction in macrophage infiltration in subcutaneous adipose tissue397.  In turn, this reduced 
infiltration is likely driven by a reduction in chemoattractant proteins and an increase in  
anti-inflammatory IL-10 production397.  Changes in adipose tissue macrophage polarisation have also 
been observed, with a return to a predominantly M2 macrophage phenotype204.  A murine study has 
suggested this phenotypic shift is weight loss independent398.  Cytokine expression in the liver and 
adipose tissue is also reduced, whilst adiponectin expression is increased399, 400.  Successful weight 
loss (>20%) has also been associated with a reduction in pro-inflammatory cytokine, chemokine and 
macrophage cell surface marker expression in subcutaneous adipose tissue401.  In the colon, a 
reduction in pro-inflammatory cytokine expression and macrophage and T cell populations have also 
been reported402. 
Following bariatric surgery, there are also alterations in circulating markers of inflammation.   
A significant increase in adiponectin has been reported after both RYGB and LSG403-406.   
A significant decrease in circulating leptin concentrations has also been reported after RYGB and 
LSG407-410.  Investigation into the impact of bariatric surgery on circulating cytokines has produced 
inconsistent findings.  The majority of studies report no significant effect on TNF in over one to 24 
months post-surgery406, 411, 412.  In the short-term, the effects on IL-6 are variable with either a decrease 
or no change reported406, 411, 413.  Long-term studies suggest a reduction in IL-6406, 411, 413.   
These results could be impacted by heterogeneity in comorbidity burden within study cohorts, as 
patients without diabetes appear to have a larger change in adipokines after surgery414. 
1.3.3.5 Clinical Utilisation of Bariatric Surgery 
In Australia, the majority of surgeries are currently performed primarily in private patients or patients 
with private health insurance.  In 2014-15, 79% of weight loss surgeries were principally funded by 
private health funds, whilst 12% were self-funded282.  Publicly funded weight loss surgeries 
represented less than 10% of all surgeries performed.  
Medicare, the universal health care system in Australia, subsidises a fixed fee for a particular service.  
If a practitioner charges more than the scheduled fee, the patient (or healthcare fund) is required to 
fund the remaining cost.  In 2014-15, approximately 25,000 weight loss procedures were billed via 
the Medicare system5.  The total cost of these procedures was estimated at $62.8 million, with 
Medicare funding $25.7 million of costs and patients or insurance companies paying $37.1 million 
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dollars282.  Primary bariatric procedures were estimated to constitute 79.4% of all procedures.   
More recent data from the voluntary Bariatric Surgery Registry suggest similar trends.  In the  
2017-18 financial year, the registry captured 64.9% of all bariatric surgeries billed to Medicare.   
Of these procedures, 77% were primary procedures.  However, less than 5% were primary procedures 
performed in a public hospital. 
The number of procedures performed is clearly disproportionate to the number of eligible patients.  
Indeed, on the basis of T2DM as an indication for surgery, it is estimated that 1.3% of eligible patients 
are treated with bariatric surgery each year in Australia415.  The reasons for the underutilisation of 
surgery are multifactorial but include financial limitations416, patient417 and physician418 attitudes and 
beliefs surrounding obesity and surgery and fear of complications or negative side effects417. 
1.3.4 Endoscopic Bariatric Therapies 
Endoscopic bariatric therapies utilise endoscopic techniques to mimic bariatric surgery.  Like bariatric 
surgery, these devices are used in conjunction with lifestyle modification therapy.  The first of these 
techniques, the intragastric balloon, became commercially available in the 1980s419.  Whilst the 
clinical effects of the more established techniques are well defined, the mechanisms of action are 
largely unknown. 
The American Society for Gastrointestinal Endoscopy (ASGE) and ASMBS Joint Bariatric 
Endoscopy Task Force have defined targets for the determination of clinical efficacy and safety 
profiles for endoscopic bariatric therapies420.  For the primary treatment of obesity, clinical efficacy 
is determined as a minimum of 25% of EWL after 12 months of treatment.  If a control group is used, 
the difference in EWL between the treatment and control group should be ≥ 15% and be statistically 
significant.  Additionally, the risk of a serious adverse event (SAE) must be ≤ 5% to be endorsed by 
the Task Force.  Broadly, endoscopic bariatric therapies can be divided into gastric therapies and 
small intestinal therapies, and will be presented as such below. 
1.3.4.1 Gastric Procedures 
Intragastric Balloons 
Intragastric balloons are filled with fluid or gas and may dwell for a period of six to12 months.   
A volume of 400 mL is needed to produce greater weight loss than a control group421 and thus the 
majority of balloons have an inflated volume of 400-900 mL.  The most widely utilised intragastric 
balloon is the Orbera® balloon (Apollo Endosurgery, TX, USA), which was previously sold as the 
BioEnterics Intragastric Balloon (Allergan, CA, USA).  In Australia, there are two commercially 
available options: the Orbera® balloon and the Spatz3® balloon (Spatz Medical, NY, USA).   
The Orbera® balloon is filled with up 400-700 mL of saline, is endoscopically implanted and 
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removed and is approved for placement for up to six months.  The Spatz3® balloon has an adjustable 
volume, is endoscopically implanted and removed and is approved for placement for up to 12 months.  
A recent consensus statement from Brazil reports a mean weight loss of 18.4±2.9% from a total of 
41,863 implants422.  Treatment with the Orbera® balloon dominated, representing 78.2% of these 
procedures.  In this same cohort, the SAE rate was 2.5% overall and 2% for the Orbera® balloon.  
The ASGE has endorsed the use of the Orbera® balloon for primary weight loss therapy, following 
a systematic review and meta-analysis of 17 studies reporting mean EWL of 25.44% at 12 months423.  
This meta-analysis also reported an acceptable safety profile, with less than 5% SAEs.  Despite these 
safety data, to date this is the only endoscopic bariatric therapy that has been associated with 
mortality424.  In Australia, there have been three reports of death following intragastric balloon use425. 
A small number of studies have assessed mechanisms of action of intragastric balloon devices.  
Delayed gastric emptying has been reported in a number of studies426-428, and has been both positively 
associated426 or not associated428 with weight loss.  The impact of intragastric balloon placement on 
circulating appetite control biomarkers has been studied in a limited number of small studies with 
conflicting findings428-432. 
Endoscopic Suturing/Plication Techniques 
A variety of endoscopic suturing or plication techniques exist, with the purpose of reducing 
intragastric volume.  In Australia, the only available technique is endoscopic sleeve gastroplasty 
performed using the OverStitch platform (Apollo Endosurgery).  Endoscopic sleeve gastroplasty 
creates a tubular stomach, similar to that created by LSG.  This is performed by using full thickness 
sutures to stitch along the greater curvature from the distal stomach to the proximal stomach.   
This reduces both the diameter of the lumen, and also the length of the stomach.  Unlike LSG the 
fundus is preserved. 
The largest single centre cohort comes from 1,000 consecutive patients in Saudi Arabia433.  In this 
cohort, mean weight loss at 12 months was 15.0±7.7% (n=216).  At 18 months post procedure, weight 
loss had stabilised at 14.8±8.5% (n=85).  A total of 24 patients were readmitted due to SAEs.  In a 
large multicentre study, mean weight loss at 24 months post-procedure was 18.6%  
(95% confidence interval: 15.7-21.5)434.  In this cohort, there were five (2%) SAEs.  To date, there 
are no published reports of weight loss outcomes beyond 24 months post-procedure.  One study has 
reported on mechanisms of action, with a reduction in calories required to reach fullness on a nutrient 
drink test and a delay in gastric emptying post-procedure435.  
Other endoscopic gastroplasty techniques include Primary Obesity Surgery Endolumenal (POSE) 
which is performed using the Incisionless Operating Platform (USGI Medical, CA, USA), the 
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Transoral gastric volume Reduction as an Intervention for weight Management (TRIM) procedure 
which is performed using the RESTORe suturing system (C.R. Bard, NJ, USA) and Transoral 
Endscopic Vertical Gastroplasty (TOGa®) which is performed using the TOGa® Sleeve Stapler and 
the TOGa® Restrictor.  In a meta-analysis of two studies using the POSE procedure, mean weight 
loss was 5.8±7.1% (n=376), with a total of five SAEs436. 
Aspiration Therapy 
The AspireAssist® system (Aspire Bariatrics, PA, USA) uses a percutaneous endoscopic gastrostomy 
to facilitate the aspiration of approximately 30% of ingested gastric contents.  The gastrostomy tube 
is attached to a skin port.  The skin port attaches to a proprietary connector device, which has an 
inbuilt counter.  This counter allows for 115 aspiration cycles before it locks, preventing access to the 
skin port for further aspiration.  This is designed as a safety feature to prevent misuse of the 
technology.  At the connecter, a siphon, 600 mL reservoir and drain tube are connected to allow for 
drainage and flushing of gastric contents directly into the toilet.  This procedure is commercially 
available in Australia. 
In a four year study, TBWL was 18.2±9.4% (n=155) after one year and 19.2±13.1% (n=12) after four 
years437.  The mean reduction in HbA1c at one year was 1.0%.  Seven cases of buried bumpers occurred 
and one case of peritonitis were reported.  The pivotal USA-based trial reported similar results with 
a mean weight loss of 12.1±9.6% over one year and five SAEs438.  There was one case each of 
peritonitis, pre-pyloric ulcer and skin-port malfunction (leading to A-tube replacement) and two cases 
of severe abdominal pain (in one patient).  The mechanisms of action of this device have received 
limited investigation.  However, weight loss results exceed what would be expected by maximal 
compliance with a 30% reduction in caloric intake, achieved by aspirating gastric contents 20 minutes 
after a meal439. 
1.3.4.2 Small Intestinal Procedures 
Whilst a number of gastric procedures are commercially available, the majority of small intestinal 
procedures are only approved for investigational use and have undergone very limited human 
investigation to date. 
Self-Assembling Magnets for Incisionless Anastomosis 
This procedure uses simultaneous gastroscopy and colonoscopy to deploy self-assembling magnets 
using the Incisionless Anastomosis System (GI Windows, MA, USA).  Once connected, these 
magnets apply compressive pressure to the tissue trapped within the magnets.  Over a number of days, 
this tissues undergoes necrosis, creating a fully patent anastomosis.  The anastomosis creates a dual 
path for transport of nutrients.  To date, one clinical study has been reported in a cohort of 10 patients 
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with obesity and T2DM440.  In this cohort, a jejunoileostomy was performed.  One year after the 
procedure, mean weight loss was 14.6% and the mean reduction in HbA1c was 1.9%. 
Duodenal Mucosal Resurfacing 
Duodenal Mucosal Resurfacing is performed using the Revita™ device (Fractyl Laboratories Inc., 
MA, USA).  This procedure hydrothermally ablates the superficial duodenal mucosa.  It is 
hypothesised that this alters enteroendocrine signalling and increases incretin activity to improve 
T2DM parameters441.  To date one clinical study has been published, but pivotal trials are underway 
in Europe and the United States.  In this study of 44 patients with T2DM, HbA1c was reduced by 
1.2±0.03% after six months442.  Improvements in glycaemic control were greater in those that had a 
larger section (>9 cm) of mucosa ablated (mean reduction in HbA1c of 2.5%), as compared to those 
who had a shorter section (<6 cm) of mucosa ablated (mean reduction in HbA1c 1.2%).  In a subgroup 
of patients with a larger mucosal ablation, screening baseline HbA1c between 7.5 and 10% and stable 
medication usage, there was a modest weight loss of 2.5±0.1 kg six months after the procedure. 
Duodenal-Jejunal Bypass Sleeve (EndoBarrier®) 
The duodenal-jejunal bypass sleeve (DJBS; EndoBarrier®; GI Dynamics, MA, USA) is a 60 cm 
fluoropolymer sleeve that is endoscopically-placed and anchored in the proximal duodenum.   
The self-expanding metal ring at the base diverts ingested food contents down the internal surface of 
the sleeve, whilst bile and pancreatic secretions travel down the external surface of the sleeve.   
The nutrients and digestive juices meet in the mid jejunum for absorption.  The DJBS was approved 
for use in the Australian market in 2011.  In October 2016, the device was removed from the 
Australian Register of Therapeutic Goods (ARTG) and is no longer commercially available in 
Australia. 
The safety profile of the DJBS has received significant attention recently.  SAEs leading to early 
explant include device migration, upper GI bleeding, and sleeve obstruction443-464.   
Common mild-moderate adverse events include abdominal pain, nausea and vomiting.  There have 
been a limited number of cases of hepatic abscess reported in the literature450, 452, 454, 458, 459, 461-465.  
There was a 3.2% prevalence of hepatic abscess in the United States-based pivotal ENDO Trial.   
This lead to the early termination of the study as it exceeded the predetermined safety threshold of 
2%466.  A number of other trials have also reported SAE rates that exceed the 5% threshold considered 
acceptable by the ASGE423.  The adverse event rate between studies is variable, ranging between  
0 and 69%449, 461.  A 2018 systematic review of 1,056 patients reported a SAE rate of 3.7%.   
Further research is required to determine the modulators of device-related SAEs. 
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Since the emergence of the DJBS in 2007, numerous studies assessing clinical efficacy have been 
published.  Early studies of the DJBS ran for a 12 week duration in small populations, without an 
emphasis on T2DM.  More recently, studies have been conducted for 24-144 weeks, with variable 
post-explant follow-up, up to four years post-explant.  Weight loss efficacy and improvements in 
glycaemic control are well established after DJBS treatment.  The majority of studies do not include 
a control population, which may introduce bias and reduce the confidence of conclusion drawn from 
the data.  The Joint Bariatric Taskforce guidelines define ≥25% EWL at 12 months as demonstrating 
efficacy420; however, EWL is not always reported.  Differing study populations, durations and lack 
of reporting on impact of lifestyle modification intervention compliance further complicates 
interpretation of results.  To date, no study has reported in detail on dietary compliance, despite the 
majority of studies prescribing a calorie-controlled diet that in itself would initiate significant weight 
loss. 
The impact of DJBS implantation on body composition has been poorly studied.  Four studies have 
found a decrease in fat mass.  One study of 12 patients with obesity and T2DM reported a significant 
reduction in fat mass at 24 weeks467.  In a 52 week study reporting outcomes on 16 patients, significant 
reductions in fat mass were observed, despite no change in body fat percentage, indicating a 
concurrent loss of lean body mass451.  Conversely, in 30 patients with obesity and T2DM, a significant 
reduction in fat mass without a reduction in lean body mass was observed after 10 months of DJBS 
dwell.  In a 26 week study of 11 patients with obesity and T2DM and 13 patients with obesity and 
normal glucose tolerance, no significant weight loss occurred in either group; however, there were 
significant losses in total body fat mass and visceral fat mass456.  In these studies, there was no report 
on compliance with an exercise regimen, which may prevent lean body mass loss in the context of 
weight loss468.  Further research is needed to clarify these findings. 
A smaller number of studies have also assessed cardiovascular, hepatic and inflammation-related 
outcomes, and baseline predictors of intervention success.  Improvements in blood pressure and either 
an improvement or no overall change in lipid profile have been reported449, 454, 457, 461, 464, 469.  de Jonge 
and colleagues have assessed the impact of DJBS implantation on serum markers of NAFLD.   
Significant improvements (p<0.05) in alanine aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma-glutamyl transferase (GGT), caspase-cleaved cytokeratin-18 and liver-type fatty acid 
binding protein (L-FABP) were reported within three months of DJBS implantation470.  At six 
months, serum ALT and GGT continued to improve, with other parameters stabilising.  At six months 
post-explant, ALT, GGT and caspase-cleaved cytokeratin-18 were still significantly improved 
(p<0.05) compared to baseline; however, AST and L-FABP had returned to near baseline levels.  
These findings have been supported by Stratmann et al., in a cohort of 18 patients with obesity and 
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T2DM, serum ALT, AST and GGT were significantly reduced451.  In an Australian cohort of 114 
individuals (38 with T2DM), a significant reduction in GGT was observed, whilst a significant 
increase in ALP occurred454.  A trend toward a reduction in ALT (p=0.059) was also observed.  In a 
small United Kingdom cohort (n=12), a significant reduction in ALT was observed over the 12 month 
implant duration, but this improvement was lost at six months post-explant464.  To date one study has 
assessed markers of hepatic fibrosis and steatosis.  This was performed using hepatic transient 
elastography in a cohort of 19 patients with obesity and T2DM455.  Over a one year treatment period, 
there was a significant reduction in liver stiffness (as a marker of fibrosis) and the Controlled 
Attenuation Parameter (CAP; as a marker of steatosis).  Despite the reduction in stiffness, the authors 
noted the majority of patients still had high grade steatosis (on the basis of CAP) at device explant.  
Overall, these results suggest the DJBS may be beneficial for improving NAFLD parameters.   
de Jonge and colleagues assessed the effect of DJBS treatment on serum markers of inflammation471.  
In this cohort, serum C-reactive protein (CRP), TNF-α, IL-6 and myeloperoxidase were not 
significantly different from baseline following six months of treatment with DJBS, despite significant 
weight loss.  These data suggest implantation with DJBS may convey additional metabolic benefits; 
however, further research is needed, as to date, study numbers investigating metabolic parameters 
have been small. 
Two studies have identified parameters that may predict intervention success.  In a 52 week study of 
79 patients with obesity (22 with T2DM), univariate analysis revealed EWL at 52 weeks was 
inversely associated with fasting glucose, homeostatic model of insulin resistance (HOMA-IR) score 
and HbA1c, whilst multivariate analysis found only baseline HbA1c to be significantly associated with 
EWL at 52 weeks450.  In a large cohort of 185 patients with obesity and T2DM, c-peptide  
≥ 1.0 mmol/L and body weight ≥ 107 kg at baseline were independent predictors of intervention 
success452. 
The clinical benefit of the DJBS after device explant is poorly studied.  However, significant weight 
regain has been reported in six studies448, 454, 461, 462, 469, 472 over six months to four years post-explant.  
Deterioration of metabolic improvements achieved in the intervention period have been reported in 
six studies461, 462, 464, 465, 469, 473.  Combined, these data suggest the durability of the beneficial metabolic 
effects of DJBS implantation are likely to be lost post-explant, especially in the context of weight 
regain.  Further research on the long-term efficacy and factors predicting long-term success is 
required.  Table 1.1 summarises the safety, weight and diabetes-related outcomes for the DJBS. 
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Table 1.1: Safety, weight loss and glycaemic control outcomes following DJBS implantation in subjects with obesity. 
Authors/year Design Population Safety Outcomes Efficacy Outcomes 
Gersin et al., 
2007474 
12 weeks, no controls 1 F, age 36 years, 
BMI 45.2 kg/m2 
No SAEs Weight loss of 9.1 kg 
Rodriguez-
Grunert et al., 
2008475 
12 weeks, no controls, 4 with 
T2DM 
 
12 (7 F, 5 M, mean 
age 41, mean BMI 
43 kg/m2) 
71 adverse events total /55 device-related: 6 abdominal 
pain, 18 nausea, 16 vomiting, 1 diarrhoea, 12 implant site 
inflammation, 2 partial pharyngeal tears on explant; 2 
patients had device removed after 9 days due to poor 
placement 
Mean weight loss 10.2 kg.  No statistical 
analyses reported; 75% of patients with 
T2DM had ≥ 0.5% reduction in HbA1c 
within 12 weeks 
Tarnoff et al., 
2009444 
12 week RCT:  LFD + DJBS or 
LFD control, 25 treatment 
group, 3 T2DM, 14 control, 1 
T2DM  
At 12 weeks, 20 patients in 
treatment, 4 in control (10 lost to 
follow-up) 
Treatment: 15 F, 10 
M, mean age 38 ± 
10.1 years, mean 
BMI 42 ± 5.1 kg/m2 
Control: 8 F, 6 M, 
mean age 43± 10.6 
years, mean BMI 40 
± 3.5 kg/m2 
 
5 devices requiring early explant – 3 GI bleeding, 1 anchor 
migration and 1 sleeve obstruction. 
Weight loss of 10.3 ±3.2 kg in device 
group and 2.6±3.5 kg in the control 
group. No statistical analyses reported. 
Rodriguez et 
al., 2009443 
24 – 52 weeks, randomised, 
sham-controlled, 12 treatment, 6 
control, all with T2DM 
18 (11 F, 7 M, mean 
age 47 ± 10 years, 
mean BMI 38.9 ± 
6.1 kg/m2) 
 
3 devices requiring early explant – 3 device migration + 2 
migrations noted either at scheduled endoscopy or 
scheduled explant 
No significant weight loss; significant 
improvements in FPG and HbA1c at 12 
and 24 weeks 
Schouten et al., 
2010446 
12- 24 week RCT, 30 treatment, 
8 with T2DM, 11 control, 2 with 
T2DM  
 
Treatment: 30 (22 F, 
8 M, mean age 40.9 
years, mean BMI 
48.9 kg/m2 
Control: 11 (9 F, 2 
M, mean age 41.2 
years, mean BMI 
47.4 kg/m2 
 
4 devices requiring early explant – 1 migration, 1 
dislocation of anchor, 1 sleeve obstruction and 1 continuous 
epigastric pain 
Significant EWL at 12 weeks compared 
to control; no change in FPG or HbA1c. 
38 
 
Authors/year Design Population Safety Outcomes Efficacy Outcomes 
Gersin et al., 
2010445 
12 weeks, randomised, sham 
controlled, 21 treatment, 14 
T2DM, 26 control, 12 T2DM 
Treatment: 21 (15 F, 
6 M, mean age 45 ± 
7 years, mean BMI 
46 ± 5 kg/m2 
Control: 26 (23 F, 3 
M, mean age 43 ± 
10 years, mean BMI 
46 ± 6 kg/m2 
8 devices requiring early explant – 3 GI bleeding, 2 
abdominal pain, 2 nausea and vomiting, 1 device-unrelated 
illness (breast cancer) 
Significant weight loss at 12 weeks; nil 
diabetes-related outcomes reported. 
de Moura et al., 
2012447 
52 weeks, no controls, all with 
T2DM, 13 completed 52 weeks 
22 (19 F, 3 M, mean 
age 46.2 ± 10.5 
years, mean BMI 
44.8 ± 7.4 kg/m2 
9 early explants: 3 device migration, 1 GI bleed, 2 
abdominal pain, 2 principal investigator request, 1 unrelated 
malignancy 
Significant weight loss at 52 weeks; 
significant reductions in fasting glucose, 
insulin and HbA1c occurred 
Escalona et al., 
2012448 
52 weeks, no controls, 24 in 
completer population, 6 with 
T2DM 
39 (31 F, 8 M, mean 
age 36 ± 10 years, 
mean BMI 44.7 ± 
5.9 kg/m2 
15 adverse events requiring early explant: 8 anchor 
migration, 3 device obstruction, 2 abdominal pain, 1 acute 
cholecystitis, 1 patient request 
Significant weight loss at 52 weeks; 
significant reduction in HbA1c 
Cohen et al., 
2013449 
52 weeks, no controls, all with 
T2DM, 16 completed 52 weeks 
20 (7 F, 13 M, mean 
age 49.8 ± 6.7, mean 
BMI 30.0 ± 3.6 
kg/m2) 
4 early explants: 2 device migration, 1 abdominal pain, 1 
investigator request 
Significant weight loss at 52 weeks; 
significant reduction in FPG and HbA1c 
De Jonge et al., 
2013476 
Patients 
common  
to470, 471, 477-479 
 
24 weeks, no controls, all with 
T2DM 
17 (3 F, 14 M, mean 
age 51 ± 2 years, 
mean BMI 37.0 ± 
1.3 kg/m2) 
No early explants.  3 adverse events requiring 
hospitalisation: 1 melaena, 1 severe constipation, 1 
abdominal pain leading to dehydration  
Significant weight loss at 24 weeks; 
significant reduction in FPG , 
postprandial glucose response and 
glucagon response 
Cohen et al., 
2013473 
52 weeks, no controls, all with 
T2DM 
26 week follow-up period 
16 (6 F, 10 M, mean 
age 49.8 ± 6.7, mean 
BMI 30.0 ± 3.6 
kg/m2) 
No SAEs Significant weight loss at 52 weeks; 
significant reduction in FPG, HOMA-IR 
and HbA1c 
26 weeks post-explant, fasting glucose, 
HbA1c and insulin sensitivity 
deteriorated. 
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Authors/year Design Population Safety Outcomes Efficacy Outcomes 
Koehestanie et 
al., 2014467 
24 weeks, no controls, all with 
T2DM 
12 (5 F, 7 M, mean 
age 50.3 ± 1.9 years, 
mean BMI 33.5 ± 
0.8 kg/m2) 
 
 
No SAEs  Significant weight loss and reduction in 
fat mass at 24 weeks; reduced fasting 
insulin and HOMA-IR 
Muñoz et al., 
2014450 
Data on 39 
patients 
reported in448 
52 weeks, no controls , 22 with 
T2DM 
79 (44 F, 35 M, 
mean age 35.4 ± 9.7 
years, mean BMI 
43± 5.6 kg/m2) 
 
 
18 early explants: 8 device migration, 5 device obstruction, 
2 abdominal pain, 1 liver abscess, 1 upper GI bleed, 1 
cholangitis, 1 ulcerative colitis, 1 acute cholecystitis, 1 
patient request 
Significant EWL; no significant 
difference in EWL between patients 
with and without T2DM.  
Koehestanie et 
al., 2014480 
52 weeks, RCT:  6 months of 
device + 6 months of post-
explant lifestyle modification 
intervention vs. 52 weeks 
lifestyle modification 
intervention only, 34 treatment, 
35 control, all with T2DM 
Treatment:  34 (13 
F, 21 M, mean age 
49.5 years, mean 
BMI 34.6 kg/m2) 
Control: 39 (14 F, 
25 M, mean age 
49.0 years, mean 
BMI 36.8 kg/m2) 
 
 
 
8 adverse events requiring hospitalisation in device group– 
5 device-related, managed conservatively; 1 oesophageal 
perforation on removal requiring oesophageal tenting; 8 
adverse events requiring hospitalisation in control group – 
5 resolved without sequelae ; 2 early explants – 1 following 
obstruction, 1 following abdominal pain 
Significant weight loss at 24 weeks but 
no significant difference with control at 
52 weeks; improved HbA1c at 24 weeks 
but no significant difference with 
control at 52 weeks 
Koehestanie et 
al., 2015481 
36 months, no controls, all with 
T2DM 
Device inserted from 0-6 
months, patients followed-up for 
18 months and then device –re-
implanted from 24-36 months 
 
 
5 (1 F, 4 M, mean 
age 45 years, mean 
BMI 33 ± 1.3 kg/m2) 
No SAEs Significant weight loss at 24 weeks; 
increased body weight between implant 
periods; further significant weight loss 
in second implant period; It is safe and 
feasible to reimplant a DJBS 
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Authors/year Design Population Safety Outcomes Efficacy Outcomes 
Betzel et al., 
2015465 
12- 52 weeks, no controls 
12 week group: 8, 1 with T2DM 
24 week group: 26, all with 
T2DM 
52 week group: 118, 116 with 
T2DM  
24 week group: 26 
(15 F, 11 M, mean 
age 50 ± 8.9 years, 
mean BMI 35.6 ±  
4.6 kg/m2) 
52 week group: 118 
(52 F, 66 M, mean 
age 52 ± 7.5 years, 
mean BMI 35.1 ± 
4.2 kg/m2) 
 
24 adverse events requiring early explant, 16 abdominal 
pain, 5 GI bleeding, 2 pancreatitis, 1 hepatic abscess  
Significant weight loss in 24 week and 
52 week group; improved HbA1c in 24 
week group but no significant difference 
in 52 week group 
Stratmann et al., 
2016451 
52 weeks, no controls, all with 
T2DM 
18 (4 F, 14 M, mean 
age 50.1 ± 7.9 years, 
mean BMI 48.8 ± 
8.5 kg/m2) 
 
2 early explants: 1 abdominal pain and 2 device migration Significant EWL at 12 months without 
change in body fat percentage 
Kaválková et 
al., 2016469 
13 months, no controls, all with 
T2DM 
10 month device-dwell period 
30 (10 F, 20 M, 
mean age not 
reported, mean BMI 
42.7 ± 1.2 kg/m2) 
 
No SAEs. Unscheduled endoscopies performed to assess 
acute complications as result of abdominal pain, dyspepsia 
and suspected upper GI bleeding.  Nil bleeding or acute 
complications found; No early explants 
Significant decreases in weight, waist 
and hip circumference; body fat 
significantly reduced, with no change in 
lean body mass; fasting glucose, HbA1c, 
fasting insulin and HOMA-IR 
Gollisch et al., 
2017455 
13 months, no control, all with 
T2DM 
20 (14 F, 6 M, 
median age 53.0 
(47.3-61.0) years, 
median BMI 41 (38-
46) kg/m2) 
 
1 early explant due to abdominal pain,1 early explant due to 
migration, 1 early explant due to requirement for 
anticoagulants, 3 cases of obstruction resolved without early 
explantation 
Significant reduction in body weight, 
BMI and HbA1c at 13 months 
Trend toward reduction in daily insulin 
units (p=0.05) 
Rohde et al., 
2017456 
26 weeks, 10 patients with 
obesity and T2DM and 9 
patients with obesity with NGT 
24 (gender not 
reported, treatment 
median age 50 (40-
67), BMI 38.6 
(31.6-40.5) 
 
3 early explants in NGT group, and 2 in T2DM group – due 
to abdominal pain and participant request.  For 1 early 
explant, sleeve obstruction due to sleeve invagination was 
noted at explant; Adverse events that did not require early 
explant: 1 fever, 8 light-moderate abdominal pain, 5 light-
moderate nausea, 4 single episodes of vomiting 
No significant weight loss but 
significant change in body fat mass and 
visceral fat mass; in the T2DM group 
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Authors/year Design Population Safety Outcomes Efficacy Outcomes 
Betzel et al., 
2017453 
52 week post-explant follow-up 
study, 59 completers, 30 lost-to-
follow-up 
Completer: 59 (27 
F, 32 M, mean age 
52 ± 8 years, mean 
BMI 34.4 ± 3.5 
kg/m2) 
Non-completer: 30 
(12 F, 18 M mean 
age 50 ± 7 years, 
mean BMI 35.8 ± 
5.6 kg/m2) 
 
Post-explant study only – no SAEs  Significant decreases in body weight 
and BMI remained; statistically 
significant increases in HbA1c and 
fasting glucose  
Vilarrasa et al., 
2017482 
96 weeks, no controls, HbA1c 
≥8%, and on insulin 
48 week implant period, plus 48 
weeks of follow-up 
21 (9 F, 12 M, mean 
age 54.1 ± 9.5 years, 
mean BMI 33.4 ± 
1.9 kg/m2) 
2 adverse events requiring early explant: 1 abdominal pain,1 
cholecystitis 
Reduction in HbA1c was not correlated 
with weight loss; weight and HbA1c at 1 
month were predictive of HbA1c at 12 
months; HbA1c returned to baseline 
values 12 months after explant 
 
Betzel et al., 
2017452 
52 weeks, no controls, all with 
T2DM 
185 (90 F, 95 M, 
mean age 52 ± 8 
years, mean BMI 
35.1 ± 4.3 kg/m2) 
57 early explants (30.8%).  34 were due to device 
intolerance, 1 due to uterus carcinoma, 2 due to requirement 
to start anticoagulants.  20 were due to adverse events; 39 
adverse events requiring hospitalisation including 4 
perforations of the anchor into the stomach, 12 bleeds with 
device in situ, 2 bleeds following explant, 6 pancreatitis, 4 
liver abscess, and 2 procedure related (oesophageal 
lesion/perforation) 
 
Significant decreases in body weight 
and HbA1c 
Forner et al., 
2017454 
52 weeks, no controls, 38 with 
T2DM 
114 (47 F. 67 M, 
mean age 51 ± 13 
years, mean BMI 39 
± 6 kg/m2) 
 
28 (24%) early explants: 18 due adverse events (1 nausea 
and vomiting, 6 severe pain, 4 obstruction, 3 GI 
haemorrhage, 1 diarrhoea, 2 liver abscess, 1 pancreatitis) 
74% experienced some adverse event – 46% of which were 
mild 
 
Significant decrease in body weight 
No significant change in HbA1c, but 
reduction/cessation of insulin in 80% off 
those on insulin. 
Post-explant weight regain in 72% of 
patients up to 6 months and 69% beyond 
6 months 
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Authors/year Design Population Safety Outcomes Efficacy Outcomes 
van Rijn et al., 
2017457 
26 or 52 weeks of DJBS 
treatment,  
26 weeks of dietary treatment 
plus 26 weeks follow-up prior in 
control arm 
28 (11 F, 17 M, 
median age 50 (46-
56), median BMI 
37.0 (33.0-42.9) 
kg/m2) 
10 completed 26 
weeks of DJBS 
treatment, 18 
completed 52 weeks 
of DJBS treatment 
 
4 early explants in first 6 months – 1 obstruction, 3 
abdominal pain 
4 early explants between 6 and 12 months– 1 sleeve 
invagination, 1 obstruction, 1 migration, 1 vomiting 
Mild GI symptoms in 78.6% of patients. Hypoglycaemia in 
17.9% of patients 
Significant decrease in body weight, 
HbA1c and FPG at 6 months, stable at 12 
months 
Significant increase in body weight and 
fasting insulin 6 months post-explant 
Glucose lowering medication reduced in 
54% of patients 
Quezada et al., 
2018461 
12- 144 weeks, no controls 
Baseline: 80, 17 with T2DM 
52 weeks: 72, T2DM status not 
specified 
72 weeks: 56, T2DM status not 
specified 
96 weeks: 43, T2DM status not 
specified 
144 weeks: 11, 2 with T2DM 
 
 
80 (55 F, 25 M, 
mean age 35.4 ± 10 
years, mean BMI 
42.2 ± 5 kg/m2) 
55 patients with SAEs, a total of 55 device-related SAEs. 2 
upper oesophageal perforations during attempted device 
explant 
23 early explants: 2 abdominal pain, 9 device migration, 4 
upper GI bleeding, 3 liver abscess, 2 device obstruction, 1 
cholangitis, 1 ulcerative colitis, 1 pancreatitis 
Most SAEs occurred between 52 and 96 weeks 
95% of patients reported mild adverse events (nausea, pain 
and vomiting) 
Significant reduction in body weight 
and waist circumference up to 96 weeks, 
no significant difference at 144 weeks 
compared to baseline 
Significant reduction in HbA1c , insulin 
and HOMA-IR up to 96 weeks, no 
significant difference at 144 weeks 
compared to baseline 
No change in glucose lowering 
medication in patients with T2DM 
(n=17) 
Ryder et al., 
2018464 
52 weeks, no controls 
All with T2DM 
12 (8 F. 4 M, mean 
age 52.4 ± 9.3 years, 
mean BMI 41.7 ± 
9.8 kg/m2) 
75% of participants 
on insulin 
 
 
3 GI haemorrhages (2 devices explanted early), 1 hepatic 
abscess (device explanted early) 
Significant decrease in body weight, 
HbA1c and daily insulin dose at 52 
weeks.  33% of those on insulin ceased 
insulin.  Improvements maintained 6 
months post-explant.   
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Authors/year Design Population Safety Outcomes Efficacy Outcomes 
Patel et al., 
2018460 
 
 
 
 
 
72 weeks, no controls 
All with T2DM 
45 (23 F. 22 M, 
mean age 49.9 ± 7.9 
years, mean BMI 
40.0 ± 5.8 kg/m2) 
6 early explants – 1 melaena, 1 migration, 4 medical 
conditions contraindicating continued implant 
Significant decrease in body weight, 
HbA1c, fasting glucose and insulin at 52 
weeks. No significant change in fasting 
glucose or insulin between explant and 
6 months post-explant. 
28% reduced or discontinued metformin 
at 12 months.  31% reduced or 
discontinued sulphonylureas at 12 
months. 
Riedel et al., 
2018462 
Up to 46 months, no controls 
75 with T2DM in full cohort, 31 
with T2DM in 1 year follow-up 
cohort 
77 (51 F, 26 M, 
mean age 53.1 ± 
10.4 years, mean 
BMI 42.0 ± 6.8 
kg/m2) 
1 year follow-up: 32 
(22 F, 10 M, mean 
age 51.1 ± 11.1 
years, mean BMI 
43.2 ± 7.8 kg/m2) 
 
Abdominal pain reported in 36.4% of patients. 5 cases of 
liner obstruction, 5 cases of device migration, 1 case of 
hepatic abscess 
In entire cohort: 
Significant reduction in BMI was 
maintained post-explant, HbA1c was not 
significantly different to baseline post-
explant 
In cohort with 1 year follow-up: 
BMI and HbA1c still significantly 
reduced compared to baseline.  
Riedel et al., 
2018463 
52 weeks, no controls 
62 with T2DM 
66 (46 F, 20 M, 
mean age 51.8 ± 
10.2 years, mean 
BMI: 43.4 ± 6.5 
kg/m2) 
 
At explant visit, 1 case of obstruction, 1 case of device 
migration, 1 case of suspected hepatic abscess and 1 case of 
cardiac decompensation. 
Significant decrease in body weight, 
BMI, HbA1c, daily insulin units at 52 
weeks 
Laubner et al., 
2018459 
48 weeks, no controls 
All with T2DM; 64% on insulin 
111 (67 F, 44 M, 
mean age 51.9 ± 9.0 
years, mean BMI: 
42.6 ± 6.8 kg/m2) 
 
Abdominal pain reported in 27.7% of patients. 2 cases of 
liner obstruction, 6 cases of device migration, 4 cases of 
hepatic abscess,1 case of GI bleeding (with aspirin usage), 
1 case of biliary colic, 1 case of oesophageal lesions 
Significant decrease in body weight, 
waist circumference and HbA1c 
51% able to reduce usage of oral 
hypoglycaemics or GLP-1 receptor 
agonists.  Significant reduction in 
insulin usage 
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Authors/year Design Population Safety Outcomes Efficacy Outcomes 
Younas et al., 
2018483 
52 weeks, bariatric surgery 
group controls 
7 with T2DM in DJBS group. 6 
with T2DM in surgery group 
DJBS group:11 (4 F, 
7 M, median age 46 
(34-68) years, 
median BMI: 61 
(50-70) kg/m2) 
Surgery group:11 (4 
F, 7 M, median age 
48 (36-66) years, 
median BMI: 58 
(51-85) kg/m2) 
No SAEs Significant reduction in body weight 
(median TBWL was 12%). Significant 
reduction in HbA1c 
 
57% of patients with T2DM could 
reduce/cease glucose lowering 
medication after 12 months treatment 
with DJBS 
Deutsch et al., 
2018458 
24 months, no controls 
All with T2DM, 40.5% on 
insulin 
51 (22 F, 29 M, 
mean age 57.8 ± 8.0 
years, mean BMI 
37.3 ± 4.9 kg/m2) 
6 early explants due to discomfort, 2 cases of hepatic 
abscess, 2 cases of major bleeding, 1 case of obstruction, 1 
case of gastric outlet obstruction 
Body weight and BMI were 
significantly reduced, and remained 
significantly reduced compared to 
baseline 1 year post-explant.  HbA1c was 
significantly reduced at device explant, 
but not at 1 year post-explant 
33% of patients on insulin were able to 
discontinue insulin during treatment 
(n=4) or follow-up (n=1)  
van Rijn et al., 
2019472 
Four year post-explant follow-
up after 6-12 months treatment 
with DJBS 
15 (gender not 
reported, mean age 
not reported, 
median BMI 33.1 
(32.3-38.5) kg/m2) 
Post-explant study only – no SAEs Five of 15 patients underwent bariatric 
surgery in follow-up (4 RYGB and 1 
LAGB) 
In 10 remaining patients, there was a 
trend toward reduced body weight at 4 
years post-explant. No persistent 
improvement in metabolic parameters 
Leventi et al., 
2019484 
28 months, no controls 
Two 12 month implantation 
periods separated by 4 months 
5 (1F, 4 M, mean 
age: 48.6±21.2 
years, mean BMI: 
40.9±10.3 kg/m2) 
No SAEs 
Some patients has pseudo-polyps however; re-implantation 
was safe 
Body weight, BMI and HbA1c were 
reduced in first treatment period.  
Increase in all parameters 3 months 
post-explant.  Decreased again after re-
implantation. No statistics due to small 
number. 
Abbreviations: BMI; body mass index, DJBS; duodenal-jejunal bypass sleeve, EWL; excess weight loss, F; female, FPG; fasting plasma glucose, HbA1c; glycated haemoglobin, 
HOMA-IR; homeostatic model of assessment – insulin resistance, GI; gastrointestinal, M; male, NGT; normal glucose tolerance, LAGB: laparoscopic adjustable gastric banding, 
LFD; low fat diet, RCT; randomised controlled trial, RYGB; Roux en Y gastric bypass, SAE; serious adverse event, T2DM; Type 2 diabetes mellitus 
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A limited number of studies have evaluated possible mechanisms of action for the DJBS in inducing 
weight loss and metabolic improvements.  Due to the design of the device and extrapolation from the 
bariatric surgery literature, it has been proposed that the DJBS causes weight loss via reduced 
absorption of calories, although this has not been investigated446.  Two studies have evaluated device-
related changes in gastric emptying kinetics.  de Moura et al. conducted a small study (n=25), finding 
gastric emptying time increased while the device was in situ, and there was a trend toward a 
relationship between gastric emptying time and weight loss485.  Conversely, Rohde et al. found no 
change in gastric emptying kinetics in a cohort of 19 patients with obesity (10 with normal glucose 
tolerance and nine with T2DM), with a median (range) weight loss of 6.8 (2.5-16.1) kg in the normal 
glucose tolerance group and 6.2 (0.7-11.0) kg in the T2DM group over six months456. 
Rapid improvements in glycaemic control are observed following DJBS implantation.  One study has 
assessed changes in hepatic insulin sensitivity following DJBS implantation in seven patients with 
obesity (six with T2DM) via the hyperinsulinaemic-euglycaemic clamp method486.  Calorie intake 
was controlled via a VLCD throughout.  A clamp was performed at baseline, after one week of the 
VLCD prior to device implantation and again one week after device implantation.  There was a 
significant reduction in hepatic glucose production following one week of a VLCD, compared to 
baseline.  There was no significant difference in pre-implantation (VLCD) and post-implant hepatic 
glucose production, despite similar weight loss occurring between time-points.  These results suggest 
energy restriction may be the key driver of improvements in hepatic insulin sensitivity. 
To date, seven studies have evaluated changes in appetite control biomarkers as a possible 
mechanism, with conflicting findings.  GLP-1 has been suggested to significantly increase both in the 
fasting state451 and postprandially456, 476, which would increase satiety.  Conversely, other studies have 
reported no significant change in the fasting state467 or postprandially469, 482 during DJBS treatment.  
A significant increase in fasting PYY, which would increase satiety, has been reported after six to 12 
months of DJBS treatment477, 482.  Two studies have reported postprandial changes in PYY with one 
study reporting a significant increase477 and one reporting no significant change456. 
These studies also reported gut hormone profiles associated with increased hunger.  A significant 
increase in fasting plasma ghrelin, leading to increased hunger, in patients with obesity and T2DM 
was reported after six months of DJBS dwell time467, 477and 12 months of DJBS dwell482.   
Conversely, studies have also reported a reduction in both fasting451 and postprandial ghrelin 
response477.  GIP has been found to significantly decrease postprandially in one study476, which would 
increase hunger, whilst no change was reported in three other studies451, 456, 469. A trend towards a 
significant decrease in the fasting state467 after four weeks of DJBS treatment has also been reported.  
Another study reported no significant change in fasting GIP in a cohort of 18 patients with obesity 
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and T2DM451.  A significant decrease in postprandial glucagon response, which would increase 
hunger, has been reported in three studies456, 469, 476.  Additionally, a significant increase in adiponectin 
was reported 18 patients with obesity and T2DM451. 
One study has reported on the impact of DJBS treatment on the stool microbiota in 14 patients479.  
Between baseline and six months post-implant, a trend towards an increase in alpha diversity was 
observed.  A significant increase in Bacteroides uniformis et rel., two Lactobacillus species, three 
members of the Clostridium cluster IV, Veillonella and five members of the Proteobacteria phylum, 
including Klebsiella pneumoniae et rel., Serratia and Escherichia coli et rel.  There was a significant 
reduction in Dialister, Megamonas hypermegale et rel. and five members of the Clostridium cluster 
XIVa.  In this cohort, weight loss was negatively correlated with the RA of the Clostridium cluster 
XIVa and other members of the Firmicutes phylum on redundancy analysis.   
A positive correlation between EWL and the RA of the phyla Proteobacteria and Bacteroidetes and 
the Bacilli order was observed.  Improvements in fasting glucose and HbA1c were correlated with 
increases in Ruminococcus callidus et rel. and Oscillospira guillermondii et rel., respectively. 
Changes in the bile acid pool and signalling have also been observed following DJBS treatment.  
Kaválková et al. reported a significant increase in total plasma bile acids at 10 months post-DJBS 
implantation469.  Recently, Samuel van Nierop et al. have reported a significant increase in fasting 
and postprandial total bile acids, after 24 weeks treatment with a DJBS in 17 patients478.  They also 
assessed bile salt fraction, reporting this increase was driven by an increase in unconjugated bile 
acids, and specifically taurine conjugated bile acids.  A significant increase in fasting and postprandial 
cholic, deoxycholic and chenodeoxycholic acids, but not ursodeoxycholic acid was also observed.  
The ratio of cholic to deoxycholic acid was also significantly increased, suggesting mediation by 
changes in the GI microbiota.  There was no significant change in any of these parameters one week 
after device implantation, suggesting a gradual increase in the bile acid pool.  Both studies also 
assessed the impact of DJBS treatment on fibroblast growth factor (FGF) 19, a molecule involved in 
suppression of hepatic bile acid synthesis via FXR signalling487, with conflicting results.   
Kaválková et al. reported a significant increase in fasting plasma FGF19, without a reduction in total 
bile acids469.  At three months post-explant, there was no persistent increase in either fasting total bile 
acids or FGF-19.  Samuel van Nierop et al. reported no significant change in FGF19 at one or 24 
weeks post DJBS implantation478.  
  
 47 
 
1.4 SUMMARY AND AIMS 
In summary, obesity and related comorbidities are a growing challenge to the health of Western 
societies.  While primary prevention should have a high priority and long-term lifestyle interventions 
may be effective for a limited number of individuals, bariatric surgery is currently the most effective 
long-term treatment option.  Despite this, surgical procedures are grossly underutilised, in the context 
of the number of eligible patients.  Therefore, endoscopic bariatric therapies have been developed to 
provide additional, less invasive treatment options.  The DJBS is a 60 cm endoluminal sleeve device, 
which is proposed to act as a RYGB mimetic.  The mechanisms of RYGB for inducing weight loss 
are complex, with impacts on energy expenditure, food intake, glycaemic control, GI function, the 
GI microbiota and inflammation.  Similar to the recent paradigm shift in our understanding of the 
these mechanisms away from simple malabsorption to more broad reaching effects, the DJBS 
deserves the same thorough investigation if it is to be clinically useful. 
1.4.1 Aims and Hypotheses 
This thesis is divided into four experimental chapters which broadly aim to characterise potential 
mechanisms of action of the DJBS for inducing weight loss and improvements in glycaemic control, 
and how these might relate to device tolerability. 
Specific aims were to: 
• Characterise the clinical response to DJBS treatment in our centre, and to assess novel features 
of clinical efficacy such as dietary intake, health-related quality of life (HRQoL) and 
functional exercise capacity; 
• Determine the effect of DJBS implantation on gastric emptying and fat absorption and provide 
a detailed characterisation of GI symptoms in response to treatment; 
• Characterise changes in the luminal and MAM following DJBS treatment, characterise the 
growth of any microbes on the device surface and determine whether these findings relate to 
device efficacy and tolerability outcomes; and 
• Define changes in the local and systemic immune response to DJBS treatment and investigate 
whether these findings are linked to device tolerability. 
The key hypotheses are as follows: 
Treatment with a DJBS for up to 48 weeks will: 
• Result in clinically relevant and statistically significant weight loss and improvements in 
metabolic parameters that capture the severity of the metabolic syndrome; 
• Delay gastric emptying and reduce intraluminal lipolytic activity; 
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• Alter the gastric and duodenal MAM and result in a distinct microbial community forming on 
the mucosa-adjacent device surface; 
• Impact the morphology of the villi in the duodenum; and reduce systemic inflammation.  
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Chapter 2: Methods 
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2.1 STUDY SUMMARY 
This study was approved by the Metro South Human Research Ethics Committee 
(HREC/15/QPAH/246; see Appendix 1.1) and was prospectively registered on the Australian New 
Zealand Clinical Trials Registry (ACTRN12615001229561). 
At the time of study commencement, the DJBS was commercially available on the Australian market 
and appeared on the ATRG (ARTG ID: 186462).  We designed a trial with the aim of recruiting  
50 patients, with varying levels of intervention (dietary management) pre- and post-implant.  
However, in October 2016, the ARTG listing for the device was cancelled by the Therapeutic Goods 
Administration.  After liaison with the institutional ethics board and key stakeholders, it was decided 
that no further devices would be implanted, limiting recruitment to 15.  Those that were randomised 
to a six month delay period prior to implantation did not undergo treatment with the DJBS.   
Ethics approval was also gained to retrospectively include data from four patients who had undergone 
clinical treatment with the DJBS, and a limited number of investigations in a pilot study in 2015-16.  
As a result, post-explant dietetics follow-up was standardised to two sessions, at 26 and 52 weeks 
post-explant for all patients, to match standard post-bariatric surgery follow-up intervals and due to 
resource allocation. 
Patients underwent investigation of clinical and metabolic parameters (including weight; 
anthropometry; body composition; peripheral blood markers of metabolic health and nutrition status; 
hepatic fibrosis and steatosis; dietary intake and HRQoL), GI function (gastric emptying, intraluminal 
lipolytic activity and GI symptoms), the GI microbiota (mucosa- and sleeve-associated and stool 
microbiota composition and functional profiles and bacterial density); and immunological parameters 
(duodenal immune cell infiltration and morphology and peripheral blood immune cell phenotype and 
activation).  
Figure 2.1 details the consort flow diagram from receipt of referral to data analysis and study exit for 
the final cohort (n=19). 
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Figure 2.1: Consort diagram of study recruitment. 
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2.2 THE DJBS INTERVENTION 
2.2.1 Recruitment 
Patients were referred from the Complex Obesity Service at the PAH, private obesity physicians and 
local general practitioners. 
Upon receipt of referral, the hospital medical records of the patient were screened to determine initial 
eligibility.  Suitable patients were then screened over the phone.  For patients without a hospital 
medical record, phone screening was the first point of medical screening.  During phone screening, 
patients were asked to report anthropometric data, current medications and medical history, with 
particular emphasis on the study exclusion criteria. 
Patients were then invited to attend a small group information session detailing the device, procedure 
and safety and efficacy data from other studies.  Informed consent was provided (see Appendix 1.2).  
Recruitment commenced in July 2015.  The last patients were randomised to immediate treatment in 
July 2016 and recruitment was ceased in October 2016.  The consort flow diagram (Figure 2.1) details 
the volume of patients screened and reasons for exclusion. 
2.2.2 Inclusion and Exclusion Criteria 
The criteria for inclusion in the study were: 
• age between 18 and 65 years; 
• BMI of ≥ 35 kg/m2; 
• T2DM managed without exogenous insulin; 
• functional level (as measured by Eastern Cooperative Oncology Group score) of equal or less 
than 2.  The range of score for inclusion were 0 (“Fully active, able to carry on all pre-disease 
performance without restriction”) to 2 (“ambulatory and capable of all self-care but unable to 
carry out any work activities; up and about more than 50% of waking hours”); 
• English speaking with an ability to provide informed consent; and 
• ability to participate in a 3 year clinical trial.  
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The exclusion criteria were: 
• previous GI surgery; 
• structural or mucosal GI abnormality that would impede device insertion; 
• planned abdominal surgery during the study period; 
• any known inflammatory disease of the GIT; 
• requirement to use anti-coagulant and/or anti-platelet therapy or non-steroidal  
anti-inflammatory drugs during the intervention period; 
• personal or family history of connective tissue disease; 
• inadequate cardiopulmonary reserve for anaesthesia; 
• any active malignancy; 
• significant coronary artery disease; 
• any medical condition with a likely survival of 5 years or less; 
• pregnancy or desire to conceive during the study period; 
• chronic pancreatitis; 
• antibiotic use at the time of initial endoscopy; and 
• psychiatric comorbidity likely to interfere with trial safety. 
2.2.3 Procedure Details 
DJBS devices were endoscopically implanted under general anaesthetic by trained gastroenterologists 
(GH or GR) with the assistance of specially trained nursing staff.  The device was deployed using a 
capsule delivered by a proprietary catheter system.  In brief, the delivery capsule was positioned in 
the pylorus and the sleeve was deployed by releasing the tracking ball.  Fluoroscopic guidance was 
used to ensure correct positioning prior to anchor deployment.  Once correct positioning was 
confirmed, the anchor was deployed out of the capsule and fixed via a self-expanding stent. 
To minimise the risk of bleeding following the procedure, patients were prescribed a proton pump 
inhibitor (PPI; 40 mg pantoprazole) to be taken daily for the 48 week implant period and for four 
weeks post-explant. 
During the endoscopy procedure, prior to device placement, biopsies were taken from the gastric 
antrum for the detection of Helicobacter pylori infection.  Samples were processed, stained with 
haematoxylin and eosin and read by anatomical pathologists from Queensland Pathology.   
Patients with a positive result underwent PPI-based triple therapy for eradication. 
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For device removal, endoscopic retrieval of the device was conducted by a trained gastroenterologist 
(GH or GR) under general anaesthetic using a proprietary retrieval device with the assistance of 
specially trained nursing staff.  The anchor was collapsed using a grasping device and anchor barbs 
were encapsulated in the retrieval hood.  Fluoroscopic guidance was used to ensure all barbs were 
encapsulated prior to removal. 
2.2.4 Safety Monitoring 
All patients had monthly safety blood tests included fasting glucose, iron studies, full blood count, 
liver and kidney function and CRP.  Blood test results were reviewed by a gastroenterologist.   
At scheduled clinical assessments, the gastroenterologist also screened for any medical symptoms 
requiring further investigation.  SAEs were defined as any event resulting in hospital admission. 
2.3 CLINICAL INVESTIGATIONS 
2.3.1 Clinical Observations 
Height was measured at baseline on a stadiometer in metres and centimetres, rounded to the nearest 
centimetre.  Weight was measured on the same set of calibrated digital scales (Model GL-6000;  
G-Tech International, Gyeonggi-do, Korea) on all occasions.  Patients were weighed fully clothed 
without shoes, measured to the nearest 0.1 kg.  Baseline weight was measured on the day of device 
insertion.  All patients were weighed at each clinical review.  Final implant period weight was 
measured on the day of device removal. 
BMI was calculated as: 
Weight (kg)/ (height (m))2 
TBWL percentage was calculated at each time-point using the equation: 
((Baseline weight (kg) – current weight (kg)) / baseline weight (kg) x 100) 
EWL was calculated as: 
((Baseline weight (kg) – current weight (kg) / (baseline weight (kg) – weight at BMI of 24.9 kg/m2)) 
x 100) 
Waist circumference was measured at the level of the umbilicus with the tape kept horizontal, rounded 
to the nearest 0.5 cm.  Hip circumference was measured at the level of the iliac crest with the tape 
kept horizontal, rounded to the nearest 0.5 cm.  Neck circumference was measured at the midpoint of 
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the neck, between the mid-cervical spine and the mid-anterior neck, rounded to the nearest 0.5 cm.  
All measurements were conducted with a stretch resistant tape measure. 
Systolic and diastolic blood pressure were measured in the seated position as part of routine clinical 
care during follow-up visits and in the supine position on the day of device insertion using the 
outpatient clinic dynamap (Welych Allyn, NY, USA). 
2.3.2 Dual Energy X-ray Absorptiometry 
Bone mineral density (BMD) and body composition were measured at baseline, explant and one year 
post-explant at the PAH Department of Radiology using full body Dual Energy X-ray Absorptiometry 
(DEXA; GE Lunar Prodigy Advance, GE Healthcare, WI, USA).  Total body fat percentage, lean 
mass and fat mass were reported.  Total BMD (g/cm2) of the lumbar spine (L1-L4) and the proximal 
femur (left and right) was assessed.  At these sites, both a T-score and a Z-score was calculated.   
A BMD T score compares the BMD result with the peak BMD for a healthy young adult.  A BMD  
Z score compares the BMD result with that of age and gender matched individuals.  The threshold 
for normal BMD is a T-score above -1.0488. 
2.3.3 Clinical Blood Investigations 
As described above, a monthly ‘safety’ panel of fasting glucose, iron studies, CRP, liver and kidney 
function parameters and full blood count was assessed.  Additionally, at baseline and every 16 weeks 
during the study, markers of glycaemic control (fasting insulin and HbA1c), vitamin and mineral status 
(vitamin B12, folate, retinol, 25-hydroxyvitamin D, alpha-tocopherol and international normalised 
ratio, copper, selenium and zinc) and fasting lipid profile (total cholesterol, triglycerides, HDL- and 
low-density lipoprotein (LDL) cholesterol) were assessed.  The full panel of biomarkers was repeated 
at one year post-explant.  ALT results (from the liver enzyme panel) were compared to gender specific 
‘healthy’ upper limit of <31 U/L for males and <20 U/L for females489.  Clinical reference ranges 
derived from Pathology Queensland were used for all other parameters. 
All blood test parameters were measured by Pathology Queensland using the following platforms: 
UniCel® DxC 800 Biochemical Analyser (Beckman Coulter, CA, USA) (CRP, transferrin, transferrin 
saturation, fasting lipids, fasting glucose, liver enzymes); AU480 Chemical Analyser (Beckman 
Coulter) (serum zinc), XE-5000 Automated Hematology System (Sysmex, Kobe, Japan) (full blood 
count); Variant™ II (Bio-Rad, CA, USA) (HbA1c), ACL TOP 700 (Werfen, Barcelona, Spain) 
(international normalised ratio), 280Z Atomic Absorption Spectrometer (Varian, CA, USA) (serum 
copper and selenium), UniCel® DxI 800 Immunoassay System (Beckman Coulter) (ferritin, fasting 
insulin, folate, vitamin B12).  Retinol and alpha-tocopherol concentrations were measured by high 
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performance liquid chromatography. 25-hydroxyvitamin D concentrations were measured by mass 
spectrometry (Acquity Premier XE Mass Spectrometer, Waters, MA, USA). 
2.3.4 Transient Hepatic Elastography (Fibroscan®) 
Hepatic fibrosis was estimated as liver stiffness (kilopascals; kPa) measured by transient hepatic 
elastography (Fibroscan®; Echosens, Paris, France) with the patient in a dorsal decubitus position 
and the probe placed along the right mid-axillary line.  Scan results were considered valid where at 
least ten valid measures were obtained and the interquartile range was less than 30%.  Measures were 
performed using the XL probe following a three hour fast at baseline; 24 weeks post-implant; 
following device explant and one year post-explant by trained operators.  The XL probe has been 
validated for the determination of hepatic stiffness in obese individuals490.  The CAP (decibels/min) 
was used as an indicator of intrahepatic fat. 
2.3.5 Dietary Intake Assessment 
Dietary intake was assessed by 24 hour recall.  Patients were interviewed either in person or via phone 
consult.  Detailed records of food and beverage intake over the preceding 24 hours were obtained.   
24 hour recalls were obtained at baseline, and thereafter monthly for the duration of the implantation 
period.  Following device removal, an additional 24 hour recall was recorded at six months and one 
year post-explant.  On each occasion, the 24 hour recall was used as a basis for individualised dietary 
counselling provided by an Accredited Practising Dietitian based on the area of greatest concern or 
possible improvement.  In this scenario, a small number of practical alternatives were discussed and 
the patient was advised to focus on this for one month.  Dietary energy and macronutrient composition 
was analysed using FoodWorks 8 (Xyris Software, Brisbane, Australia). 
2.3.6 Six Minute Walk Test 
The six minute walk test (6MWT) is a validated and reproducible investigation to assess submaximal 
functional exercise capacity in patients with obesity491.  All participants completed the 6WMT on the 
same 30 metre point-to-point track at baseline, 24 weeks post-implant, at explant and one year  
post-explant.  A measure of the maximum distance covered in the six minutes was recorded at each 
time-point.  If patients stopped mid-way between the markers at the end of the six minutes, the 
distance walked between the markers was measured.  
Results were compared both to predictive equations previously utilised in a Caucasian Australian 
population492 and baseline results.  The following predictive equations were used to estimate 6MWT 
distance: 
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Males: 867 – (5.71 x age in years) + (1.03 x height in centimetres) 
Females: 525 – (2.86 x age in years) + (2.71 x height in centimetres) – (6.22 x BMI). 
2.3.7 Health and Wellbeing Questionnaires 
All health questionnaires are included in the Appendix 1.3.  All questionnaires were completed at 
baseline, 24 weeks post-implant, at explant and one year post-explant. 
2.3.7.1 SF-36 
The SF-36 is a 36 item self-administered questionnaire that assesses patient-reported health within 
eight domains (physical functioning, role limitations due to physical health, pain, general health, role 
limitations due to emotional problems, energy/fatigue, emotional wellbeing and social 
functioning)493.  Each domain was reported on a 0-100 scale.  A lower score indicates poorer quality 
of life for that domain.  Results were compared to gender-specific population norms for the Australian 
general population494 and an Australian population with obesity and T2DM495. 
2.3.7.2 Epworth Sleepiness Scale 
The Epworth Sleepiness Scale is a short self-administered questionnaire used to assess daytime 
sleepiness.  There are a total of eight questions, with a maximum score of 24.  Scores of 10 or more 
are considered to be indicative of likely sleep apnoea496. 
2.3.7.3 Active Australia Survey 
The Active Australia Survey was used to assess physical activity497.  Traditionally, this survey is 
administered as a computer assisted telephone interview.  For this study, it was conducted as a  
face-to-face interview with the patient.  A composite score (sufftime) was used to assess physical 
activity in minutes over a week.  The proportion of participants meeting national physical activity 
guidelines (150 minutes of moderate intensity activity per week)498 was also determined.  The formula 
for the composite score was: 
Sufftime = walking time (in minutes) + moderate activity time (in minutes) + (2 x vigorous activity 
time; in minutes) 
2.3.7.4 Hospital Anxiety and Depression Scale 
The Hospital Anxiety and Depression Scale (HADS) is a self-administered 14 item ordinal scale.  
Seven of the items are associated with anxiety and seven to depression, with a maximum possible 
score of three for each item.  The HADS has been demonstrated to be effective in assessing symptom 
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severity and for use as a diagnostic tool for depression and anxiety in the general population499.   
It has also been used to assess improvements in anxiety and depression after bariatric surgery500, 501.  
2.4 GASTROINTESTINAL FUNCTIONAL TESTING 
2.4.1 Gastric Emptying 
The test was performed at baseline, eight weeks post-implant and within three weeks after device 
explant.  The gastric emptying breath test utilises a stable, non-radioactive 13C isotope.   
Whilst naturally occurring, this isotope represents 1.11% of all atmospheric carbon and all 
measurements are associated with the baseline 13C enrichment in the breath, making this isotope 
appropriate for use in physiological testing502.  The isotope used in this test, 13C octanoic acid 
(Eurisotop, Saint-Aubin, France), is a medium chain triglyceride.  After ingestion, octanoic acid 
passes through the stomach and is rapidly absorbed in the small intestine.  The absorbed octanoic acid 
is oxidised and enters the body pool of CO2-HCO3.  Thus, 13CO2 is exhaled and can be quantified in 
the breath. 
Patients fasted overnight (from midnight) before the test.  The test meal consisted of a scrambled egg 
where the yolk has been injected with 91.4 µL 13C octanoic acid.  This was served with two slices of 
white bread, 12 g of butter (Western Star, Richmond, Australia) and 150 mL of water.  This meal 
contained approximately 300 calories and 11.4 g of protein, 16.4 g of fat and 28.8 g of carbohydrate.  
A breath sample was taken for baseline measurements before the meal.  After the test meal, breath 
samples were taken every 15 minutes during the first two hours and every 30 minutes for the last two 
hours of the test. 
13C enrichment in the breath was determined by Isotope Ratio Infrared Spectrometry (IRIS; Wagner 
Analysen Technik GmbH, Bremen, Germany).  The kinetics of appearance of 13C in breath CO2 
reflects the rate of gastric emptying of the solid phase of a meal503.  The results were reported as 
gastric emptying lag time (tlag) and half time (t1/2).  The normal reference range for gastric emptying 
lag time was 118±73 minutes. 
2.4.2 Intraluminal Lipolytic Activity 
The test was performed at baseline, eight weeks post-implant and within three weeks after device 
explant.  To ensure complete isotope clearance, this test and the gastric emptying breath test were not 
performed within seven days of each other. 
This non-invasive assessment of intraluminal lipolytic activity uses a 13C-labelled mixed triglyceride 
substrate, 1, 3-distearoyl-2-13C-carboxy-octanoyl glycerol (Eurisotop, Saint-Aubin, France).  The test 
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was undertaken following an overnight fast. The test meal consisted of 200 mg of the 13C labelled 
substrate mixed into 16 g of butter.  This was served with two pieces of white bread and 150 mL of 
water.  This meal contained approximately 260 calories and 5.1 grams of protein, 14.1 grams of fat 
and 28.2 grams of carbohydrate.  The substrate contains a 13C labelled medium chain fatty acid 
molecule, octanoic acid, at the sn-2 position101.  A long chain fatty acid, stearic acid, is located at the 
sn-1 and sn-3 position.  The two stearoyl chains must be hydrolysed for the labelled 13C to be 
absorbed.  The rate limiting enzyme for this reaction is pancreatic lipase.  The absorbed substrate is 
oxidised and enters the body pool of CO2-HCO3.  Thus, 13CO2 is exhaled and can be quantified in the 
breath.  A breath sample was taken before the test meal for baseline measurements and in the 
following six hours after the test meal, breath samples were taken every 30 minutes.  13C enrichment 
in the breath was determined by IRIS.  The cumulative percentage of 13C recovered in breath during 
the six hour collection period was used as the reporting parameter. 
To exclude concomitant PEI, faecal elastase (an enzyme produced by the exocrine pancreas) was 
assessed at baseline, eight weeks post-implant and within three weeks after device explant by 
Pathology Queensland using a commercial enzyme-linked immunosorbent assay (ELISA) kit 
(ScheBo Biotech AG, Giessen, Germany).  The sensitivity and specificity of this test for the diagnosis 
of PEI is >90%504. 
2.4.3 Standardised Nutrient Challenge Test 
This tool was used to assess meal-related symptoms in a standardised fashion.  Patients reported their 
baseline severity of five meal-related symptoms (fullness, abdominal pain, nausea, 
retrosternal/abdominal burning and acid regurgitation) on a visual analogue scale121, 124.  Patients were 
then asked to drink 200 mL of a liquid meal (Resource Plus, Nestlé) consisting of 5.5 g protein,  
22.4 g carbohydrate and 4.5 g fat/100 mL every five minutes and report their symptoms on a visual 
analogue scale after each five minute interval, up to a maximum consumed volume of 600 mL.   
If patients could not consume the full volume, the test was ceased and a maximal score was applied 
for each symptom domain for all remaining time-points.  The baseline value for each symptom was 
subtracted from the cumulative score for each symptom across the three post-ingestion time-points. 
A cumulative score of all symptoms was also calculated. 
2.4.4 Structured Assessment of Gastrointestinal Symptoms 
The Structured Assessment of Gastrointestinal Symptoms (SAGIS) instrument assesses the severity 
of 22 distinct GI symptoms across five symptom domains.  Individual symptoms are rated on a five 
point Likert scale - (0 = no problem, 1 = mild (“can be ignored”), 2 = moderate (“cannot be ignored 
but does not affect daily activities”), 3 = severe (“influencing your concentration on daily activities”) 
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and 4 = very severe problem (“markedly influences your daily activities and/or requires rest) over the 
last week.  The questionnaire has been previously validated in the clinical setting505.   
The questionnaire was completed by each patient upon arrival for clinical assessment at baseline, 
four, eight, 16, 24 and 36 weeks post-implant and at device explant.  At four (early post-implant) and 
36 (late post-implant) weeks post-implant, symptoms were compared to baseline both individually 
and in clustered symptom domains.  The five domains were epigastric pain (postprandial pain, 
epigastric pain, bloating, fullness, early satiety, retrosternal discomfort and abdominal cramps), 
diarrhoea and discomfort (diarrhoea, loose stools, urgency to defecate, pain prior to defecation, 
excessive gas flatulence and faecal incontinence), reflux (dysphagia, excessive belching and acid 
eructation), nausea/vomiting (sickness, nausea, vomiting, loss of appetite) and constipation 
(constipation and difficulty defecating). 
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2.5 GASTROINTESTINAL MICROBIOTA 
2.5.1 Sample collection 
At the time of endoscopy at baseline (device implant) and at device explant, biopsy samples were 
taken from the gastric antrum mucosa and the second part of the duodenum for assessment of the 
MAM.  Specifically, the duodenal biopsy taken at explant was taken from mucosa that had been 
covered by the device during the treatment period.  Samples were stored in RNAlater® (Qiagen, 
Venlo, Netherlands), incubated at room temperature for 30 minutes and stored at -80°C. 
Upon removal, DJBS devices were transferred in sterile surgical specimen containers from the 
endoscopy suite to the laboratory laminar flow biosafety cabinet for processing.  Six specimens were 
collected from each patient’s device (see Figure 2.2 below).  The device was separated into three 
segments of four cm in length: upper (just below the anchor), mid and lower.  Each section was cut 
lengthways to create a flat surface from which to remove material.  A sterile inoculation loop was 
used to scrape 50% of the material present on the mucosa-associated device surface into an Eppendorf 
tube containing 500 µL of sterile anaerobic phosphate-buffered saline (PBS).  This procedure was 
repeated for the luminal surface.  The Eppendorf tubes were centrifuged at room temperature for 10 
minutes at 16,000 rpm to form a pellet.  The supernatant was discarded and the pellet stored at -80°C. 
Stool samples were collected using screw cap containers with an inbuilt sampling spoon.   
Samples were collected at baseline, eight weeks post-implant and within three weeks after device 
explant.  Samples were frozen at -20°C and transferred to -80°C for long-term storage. 
 
Figure 2.2: Device sections for genomic DNA extraction. 
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2.5.2 Lysate preparation for genomic DNA extraction from gastric and duodenal biopsies 
Genomic deoxyribonucleic acid (gDNA) was isolated using a modified repeated bead beating 
protocol initially detailed by Morrison and Yu506.  Specimens were thawed on ice for 15 minutes and 
the biopsy tissue was transferred into 2 mL screw cap tubes with an O-ring (Quality Scientific 
Plastics, ThermoFisher Scientific, CA, USA) containing 0.4 g sterile zirconia beads (1:1 ratio of  
0.1 mm and 1 mm). 300 µL of lysis buffer (500 mM sodium chloride, 50 mM Tris-hydrochloric acid 
pH 8.0, 50 mM ethylenediaminetetraacetic acid (EDTA), 4% w/v sodium dodecyl sulphate) was 
added and the specimen was homogenised at 5,000 rpm for 3x60 second intervals, with 15 second 
pauses between intervals (Precelleys 24; Bertin Technologies, Berlin, Germany).  Samples were 
incubated at 70°C for 10 minutes, then centrifuged at 10°C for five minutes at 16,000 g (Centrifuge 
5424 R, Eppendorf, Hamburg, Germany).  Supernatant was removed and added to a fresh 1.5 mL 
Eppendorf tube.  The lysis procedure was repeated with an additional 200 µL of lysis buffer, with a 
reduced incubation period of five minutes.  The supernatant was then pooled for automated gDNA 
purification.  Tissue-free (reagent only) control samples were processed in an identical manner, 
commencing from the homogenization step.  All steps were performed in a laminar flow biosafety 
cabinet, utilising aseptic techniques.  Samples were processed in a random order to reduce processing 
bias. 
2.5.3 Lysate preparation for genomic DNA extraction from EndoBarrier device surfaces 
For lysate preparation, each pellet was resuspended in 300 µL of lysis buffer, which was transferred 
into a 2 mL screw cap tube with an O-ring (Quality Scientific Plastics) containing 0.4 g sterile zirconia 
beads (1:1 ratio of 0.1 mm and 1 mm).  The lysis/gDNA extraction procedure was then performed in 
an identical manner to the biopsy samples (Section 2.5.2). 
2.5.4 Lysate preparation for genomic DNA extraction from stool samples 
Stool specimens were thawed on ice for 25 minutes and 0.15-0.2 g of stool was transferred into 2 mL 
screw cap tubes with an O-ring (Quality Scientific Plastics) containing 0.4 g sterile zirconia beads 
(1:1 ratio of 0.1 mm and 1 mm).  400 µL of lysis buffer was added and the specimen was homogenised 
at 5,000 rpm for 3x60 second intervals, with 15 second pauses between intervals (Precelleys 24).  
Samples were incubated at 70°C for 10 minutes, then centrifuged at 10°C for five minutes at  
16,000 g (Centrifuge 5424 R, Eppendorf).  Supernatant was removed and added to a fresh 1.5 mL 
Eppendorf tube.  The lysis procedure was repeated with an additional 300 µL of lysis buffer and  
30 µL of Proteinase K (Qiagen) and incubated for 20 minutes at 56°C.  The supernatant was pooled 
for automated purification.  Tissue-free (reagent only) control samples were processed in an identical 
manner.  Where possible, all steps were performed in a laminar flow biosafety cabinet, utilising 
aseptic techniques. 
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2.5.5 Purification of genomic DNA 
For all samples, gDNA was purified from lysates prepared as described above, using a Maxwell MDx 
AS2000 (Promega, WI, USA) and Maxwell Tissue DNA Purification Kits (AS1030, Promega).   
In brief, 400 µL of each lysate sample was added to the first well of a tissue purification cartridge.  
For each sample, a separate elution tube was prepared with 300 µL of elution buffer.   
Tissue purification cartridges and elution tubes were loaded into the MDx and the Standard Elution 
Volume tissue DNA protocol was applied.  gDNA was eluted in approximately 200 µL of elution 
buffer, which was transferred to a 1.5 mL Eppendorf tube.  This was placed into a magnetic stand for 
removal of any remaining beads from the isolation process.  The supernatant was aliquotted into  
50 µL volumes for storage at -80°C.  gDNA was quantified using spectrophotometry (NanoDrop 
Lite®, ThermoFisher Scientific). 
2.5.6 High-throughput sequencing to assess microbial communities 
Amplicon sequencing of the 16S rRNA gene was performed on gDNA extracted from biopsy, device 
and stool samples in order to profile microbial communities present.  Library preparation for 
sequencing on the Illumina MiSeq platform (Illumina Inc., CA, USA) is detailed below (Figure 2.3). 
 
Figure 2.3: Illumina MiSeq library preparation and analysis workflow.  
Amplicon PCR PCR Clean-Up Barcoding PCR
PCR Clean-UpDNA Quantification
Library 
Normalising
and Pooling
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Amplicon polymerase chain reaction (PCR) was conducted to selectively amplify the hypervariable 
regions (V6-V8) of the bacterial 16S rRNA gene from total gDNA, using primers tagged with 
Illumina adapters.  The 917F and 1392R bacterial domain specific primers were used for biopsy and 
device samples.  For stool samples, amplification was performed with the 926F and 1392R universal 
primers to enhance detection of archaea in addition to bacteria (primer details in Appendix 1.4).   
PCR template amounts varied with respect to the proportion of bacterial DNA present in the 
specimen.  100 ng and 20 ng of gDNA was added for biopsy samples, and stool/device samples, 
respectively.  The PCR reaction and amplification protocol followed Illumina library preparation 
specifications (full details in Appendix 1.4).  A 96-well plate format was used, with each plate 
including tissue-free reagent controls, a positive control (purified Escherichia coli gDNA) and a 
template-free negative control.  PCR products were visualised on a 1% agarose gel using a 1 kb ladder 
(HyperLadder® 1 kb, Bioline, TN, USA).  PCR amplicons were purified using a paramagnetic bead 
system (AMPure XP® beads, Beckman Coulter).  In brief, PCR amplicons were bound to magnetic 
beads, washed in 80% ethanol and purified DNA was eluted in 10 mM Tris pH 8.5. 
Barcoding of amplicons for each sample was performed using the Nextera XT v2 dual-index system 
(Kits A and B; Illumina) as per the manufacturer’s instructions.  In brief, a PCR was performed in 
which 5 µL of purified amplicon PCR product was used as the template, with Nextera XT v2 primers 
used to barcode each sample.  The final library was visualised on a 1% agarose gel using a 1 kb ladder 
(HyperLadder® 1 kb, Bioline) and purified using AMPure XP beads.  Purified samples were 
quantified using the Quantifluor® dsDNA fluorimetry system (Promega).  The concentration of DNA 
was normalised to 10 ng per sample and samples pooled, with 10 mM Tris pH 8.5 used to dilute DNA 
to a total volume of 480 µL (per 96 well plate).  The pooled library was transferred to the Australian 
Centre for Ecogenomics (University of Queensland) for sequencing on the Illumina MiSeq Platform 
using the MiSeq Reagent Kit v3 (2 x 300 bp). 
Bioinformatics analysis was performed by Dr Erin Shanahan using the Quantitative Insights into 
Microbial Ecology (QIIME) pipeline version 1.9.1, via the Virtual Box package507.   
Specifically, fastq files for the forward and reverse reads were first joined using the 
join_paired_ends.py command through the fastq-join method.  The split_libraries_fastq.py command 
was then applied using a Phred quality threshold of Q20 (to remove low quality sequence reads).  
OTUs were assigned using the pick_open_reference_otus.py command508.  The Greengenes database 
(version 13.8) was used as the reference database and a sequence similarity of 97% applied138.   
The resulting OTU table was chimera-checked using ChimeraSlayer and subsequently filtered to 
remove sequences with a RA of less than 0.05%509.  The reagent control samples were concurrently 
processed to generate a list of specific “contaminant” OTUs.  These specific OTUs were then filtered 
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from the patient samples to ensure OTUs present for each sample were representative of mucosal, 
device or stool microbial communities.  All samples with a final read count of less than 500 sequence 
reads were also excluded from the OTU table due to insufficient sequence coverage. 
2.5.7 Functional metagenomics analysis of 16S rRNA gene sequencing data 
Functional metagenomics data was predicted from the 16S rRNA marker gene using the Phylogenetic 
Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) software 
package142, accessed via the Galaxy web application.  A compatible OTU table was created by closed-
reference OTU picking at 97% alignment to the Greengenes database and conversion of the hdf5 
biom file to a json biom file in QIIME.  The compatible table was normalised by 16S rRNA gene 
copy number.  A predicted metagenome was derived using the Kyoto Encyclopaedia of Genes and 
Genomes (KEGG) database and summarised into functional pathways510.  
2.5.8 Bacterial load assessment 
Bacterial load was assessed by quantitative PCR (qPCR) using gDNA from mucosal biopsy 
specimens.  Both the human β-actin gene and the bacterial 16S rRNA gene were amplified using 
optimised primer sets (β-actin: forward: TCCGCAAAGACCTGTACGC; reverse: 
CAGTGAGGACCCTGGATGTG, 16S rRNA: 1114-forward: CGGCAACGAGCGCAACCC; 
1221-reverse: CCATTGTAGCACGTGTGTAGCC).  The qPCR reactions used 15 ng/µL of template 
DNA and Power SYBR Green Master Mix (ThermoFisher Scientific) and samples were analysed 
using the ViiA 7 Real-Time PCR system.  Samples were compared to standards of known 
concentration (plasmids containing either the β-actin or 16S rRNA PCR product).  Template free 
controls were used as negative controls.  The standard curve was used for the quantification of gene 
copy number for β-actin and 16S rRNA.  The ratio of 16S rRNA to human β-actin was used as a 
measure of bacterial density as described previously511. 
2.6 IMMUNOLOGY ASSESSMENT 
2.6.1 Histology 
At baseline and explant, duodenal mucosal biopsies were taken for routine histology, from sites 
adjacent to, and immediately following, those collected for characterisation of the GI microbiota.  
These biopsies were stored in formalin and sent to the PAH Department of Pathology, where 
specimen processing, staining and mounting was performed.  Specifically, tissue was dehydrated in 
increasing concentrations of ethanol, washed in xylene and embedded in paraffin wax.  Blocks were 
cut into 4 µm sections and mounted on glass slides.  Tissue sections were stained with haematoxylin 
and eosin using a standard protocol.  Assessment of villous architecture was conducted by anatomical 
pathologists from Queensland Pathology as part of routine clinical care.  Approval to gain access to 
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these stored diagnostic slides of gastric and duodenal biopsy specimens was obtained from the Metro 
South Human Research Ethics Committee and Queensland Pathology.  Slides were scanned using an 
Olympus Slidescanner (VS120; Olympus, Tokyo, Japan) to high resolution digital images at  
40x magnification at the Translational Research Institute Microscopy Core Facility.  Immune cell 
populations were then manually counted using cellSens Standard (version 1.8, Olympus) by a 
consultant anatomical pathologist (AM).  Specifically, intraepithelial lymphocytes (IELs) were 
quantified per 500 enterocytes in one tissue section.  Duodenal eosinophils were quantified in the 
same tissue section.  Only eosinophils with an intact nucleus and granular structure in the mucosa 
were counted.  Tissue section areas were measured using Visiopharm (magnification 20x, sensitivity 
72%; Visiopharm, Hoersholm, Denmark) and eosinophil counts were expressed per mm2 of tissue. 
2.6.2 PBMC Phenotyping and Cytokine Production Following PBMC Culture 
2.6.2.1 PBMC Sample Preparation 
At baseline and explant, 12 mL of venous blood was collected in Vacutainer™ blood collection tubes 
with EDTA (BD Biosciences, NJ, USA).  Peripheral blood mononuclear cells (PBMCs) were isolated 
from whole blood diluted 1:1 in sterile PBS containing 2mM EDTA, using Ficoll-Paque Plus®  
(GE Healthcare; IL, USA).  Samples then underwent centrifugation at 4°C at 400 x g for 30 minutes 
(without acceleration and brake).  PBMCs were carefully obtained from the interface between the 
Ficoll and plasma layer.  Isolated PBMCs were washed in PBS and resuspended in freezing media 
(40% foetal bovine serum (FBS), 10% dimethyl sulfoxide (DMSO), Roswell Park Memorial Institute 
(RPMI) media).  The samples were stored in liquid nitrogen for long-term storage. 
For PBMC assessment, cryopreserved cells were thawed rapidly in a water bath at 37°C and 
resuspended in a dropwise manner in 14 mL of complete media (L-glutamine free RPMI media 1640; 
ThermoFisher Scientific) supplemented with 10% FBS, 100 U/mL penicillin streptomycin, 2 mM  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 2 mM GlutaMAX (ThermoFisher 
Scientific).  Cells were centrifuged at 400 x g for seven minutes to form a pellet.  The supernatant 
was discarded and the pellet resuspended with 14 mL PBS and centrifuged at 450 x g for five minutes.  
The supernatant was discarded and the pellet was resuspended in 3 mL complete media.  Cells were 
counted at 10 x magnification using a haemocytometer.  Cells suspended in complete media were 
centrifuged at 400 x g for five minutes, the supernatant discarded and the pellet resuspended in cold 
PBS to a concentration of one million cells per mL for flow cytometric analysis. 
2.6.2.2 Flow Cytometry 
The PBMCs were prepared for flow cytometric analysis to phenotype T lymphocytes.  A fixable 
viability stain (FSV700, BD Biosciences) was used to discriminate dead cells.  Samples were then 
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washed with FACS buffer (3% FBS in PBS) and centrifuged at 2,500 x g for one minute.   
Supernatant was removed and discarded.  Cells were resuspended in 100 µL FACS buffer and 
incubated with human Fc Block (BD Biosciences) for 10 minutes to prevent non-specific binding of 
antibodies to Fc. 
A panel of 13 fluorophore conjugated anti-human antibodies were used to assess T-cell phenotype.  
Cells were incubated with anti-human CD45RO for 10 minutes, followed by anti-human  
C-C Chemokine Receptor (CCR) type 7.  They were then incubated with a cocktail of 11 antibodies 
(CD3, CD4, CD8, CD45RA, α4, CCR4, Chemokine Receptor CXCR3, β7, CCR6, CD62L, CCR9) 
for 15 minutes.  These were sourced from Becton Dickson Biosciences (CD3 – BV510, CD4 – FITC, 
CD8 – APC-H7, CD45RO – PE-Cy7, CD45RA – BV711, α4 – PE/CF594, CCR4 – BV421, CCR6 – 
BV785) and from BioLegend (CXCR3 – APC, CCR7 – BV605, PE-CD62L – PE, β7 – PE, CCR9 – 
PerCP/Cy5.5; BioLegend; CA, USA).  Data was collected using a BD LSRFortessa (BD Biosciences) 
flow cytometer.  Data was visualised and analysed using Kaluza Analysis Software (Beckman 
Coulter). 
2.6.2.3 Cell Culture 
Stimulation of PBMCs with LPS was undertaken to assess cytokine production.  After thawing, 
PBMCs suspended in complete media were incubated at 37°C for 30 minutes.  After incubation, 
samples were centrifuged at 400 x g for six minutes and resuspended in culture media without FBS 
(L-glutamine free RPMI media 1640; ThermoFisher Scientific) supplemented with 100 U/mL 
penicillin streptomycin, 2 mM HEPES and 2 mM GlutaMAX (ThermoFisher Scientific).   
PBMCs were cultured for 24 hours at concentration of 1x106 cells/mL with or without stimulation by 
LPS (2 ng/mL).  Following this incubation, the culture supernatant was collected and stored in 140 
µL aliquots at -80°C for subsequent cytokine analysis. 
2.6.2.4 Cytokine Analysis 
The concentrations of four cytokines (TNF-α, IL-6, IL-8 and IL-10) from cultured PBMC 
supernatants were measured by commercial ELISAs (BD Biosciences).  For each patient sample 
(baseline and explant), both unstimulated and LPS-stimulated PBMC supernatant was assayed in 
duplicate.  Samples, standards and controls were prepared in accordance with manufacturer 
specifications. 
Flat bottom 96 well plates were coated with capture antibody diluted in coating buffer (0.1 M sodium 
carbonate, pH 9.5), sealed and incubated at 4°C overnight.  Plates were washed in triplicate using 
wash buffer (PBS with 0.05% Tween-20; Sigma Aldrich, MI, USA) and blotted to remove excess.  
Plates were blocked with assay diluent (PBS with 10% FBS), covered and incubated at room 
 68 
 
temperature for one hour.  Lyophilised standards were reconstituted in deionised water.   
Samples were diluted in assay diluent (IL-8: 1:800; IL-6 1:200, IL-10: 1:5, TNF: 1:10).  Assay diluent 
was used as the negative control.  Standards, samples and controls (100 µL) were added into 
individual wells (in duplicate), covered and incubated at room temperature for two hours.  Plates were 
washed five times with wash buffer and blotted to remove excess.  100 µL of working detector of 
diluted biotinylated antibody and streptavidin-horseradish peroxidase conjugate was added to each 
well, covered and incubated at room temperature for one hour.  Plates were washed seven times with 
wash buffer, with a 30 second soak between washes and blotted to remove excess.  A 1:1 solution of 
tetramethylbenzidine and hydrogen peroxide was added to each well (100 µL) and incubated 
uncovered for six minutes, resulting in a blue colour change for positive samples.  A stop solution of 
sulphuric acid was added to each well (50 µL), stopping the reaction and resulting in a colour change 
from blue to yellow. 
The absorbance of samples was immediately read at 450 nm on a spectrophotometer (Multiskan Go, 
ThermoFisher Scientific).  A seven point standard curve was created using the mean value of the 
replicates for each standard, minus the mean absorbance of the replicates of the blank control.   
The concentration of the samples was derived from the standard curve, with the limit of detection set 
to the mean value of the lowest standard.  Samples were multiplied by their dilution factor to give the 
final value and duplicates averaged to provide the final cytokine concentration per patient sample in 
pg/mL.  
  
 69 
 
 
 
 
 
 
 
Chapter 3: Effect of the Duodenal-Jejunal Bypass 
Sleeve on Clinical Measures of Obesity and the 
Metabolic Syndrome, Dietary Intake and Lifestyle 
Factors 
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3.1 INTRODUCTION 
In Australia, it is estimated that 28% of the adult population suffer from obesity512.  It is also estimated 
that 18% of the population have some form of cardiovascular disease and 4.3% have T2DM5.   
The burden of these chronic diseases on the healthcare system is immense.  In 2005, the estimated 
direct costs of obesity in Australia were AUD 8.3 billion513. 
Intentional weight loss, achieved via lifestyle modification intervention, was associated with a 28% 
reduction in cardiovascular disease- and diabetes-related mortality in a large cohort of 5,000 
individuals514.  However, lifestyle modification intervention has been demonstrated to result in poor 
long-term outcomes, with approximately 97% of patients regaining all weight initially lost within  
2-5 years271-273.  Similarly, the long-term efficacy profile for pharmacotherapeutic treatments is 
poor278, 279, in part due to the limited number of treatments approved for long-term use. 
Bariatric surgery is the most effective long-term solution for the treatment of obesity and is associated 
with significant improvements in obesity-related comorbidities.  In a large systematic review and 
meta-analysis of 135,246 bariatric surgery patients, total remission of T2DM was achieved in 78% 
of patients515. In 2014-15, a total of 18,036 bariatric surgery procedures were performed in 
Australia282.  Of these, 16.7% of primary surgeries listed T2DM as an additional diagnosis.   
However, despite the demonstrated benefits of surgery, very few individuals with obesity undergo 
bariatric surgery.  In a prospective, population-based cohort study of 49,364 Australian adults with 
obesity, 312 underwent surgery, with 307 of these procedures occurring in the private setting416. 
Thus, a treatment continuum exists, with escalation from lifestyle modification intervention and 
pharmacotherapy, which is readily available and is relatively cost effective but has low long-term 
efficacy, to bariatric surgery, which has a more limited availability and significant cost burden for the 
patient, but a more durable effect.  To combat this treatment gap, new minimally invasive 
technologies have been developed such as endoscopic techniques, which can be used to mimic the 
physiological changes induced by bariatric surgery in the stomach or small intestine. 
The DJBS is an endoscopically-placed weight loss aid implanted in the duodenum.  Over the past  
10 years, a number of studies have investigated the safety profile and clinical efficacy of the device, 
mostly in small cohorts of 20-30 participants.  In a recent systematic review and meta-analysis 
including 352 patients with obesity and T2DM that underwent treatment with a DJBS for  
12-52 weeks, DJBS treatment (mean duration 9.2 ± 3.1 months) was associated with a mean TBWL 
of 18.9%516.  A 1.3% reduction in HbA1c  was also reported in 388 patients (mean duration 8.4 ± 4.0 
months)516.  Other cohort studies have also demonstrated beneficial effects of DJBS treatment on 
cardiovascular disease risk454, 457, 459, 461-463, 469 and markers of NAFLD451, 455, 464, 470. 
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Despite these beneficial effects, significant weight regain has been reported during six to 12 months 
of post-explant follow-up454, 457, 461, 481 and deterioration in improvements in markers of glycaemic  
control have also been observed457, 460, 461, 473, 482.  Sustained improvements in cardiovascular disease 
risk over three months post-explant have been observed in some462, but not other studies464, 469.  
Notably, one study has reported sustained improvements in body weight and glycaemic control at six 
months post-explant464, whilst three other studies have reported sustained improvements in body 
weight but not glycaemic control one year post-explant453, 458, 462.  Two studies have reported 
improvements in plasma markers of NAFLD remain six to 12 months post-explant458, 470.  Thus, the 
DJBS appears to be effective in the short-term, with metabolic effects greatly diminished once the 
device is removed. 
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3.1.1 Aims and Hypotheses 
The overall aim, addressed in this chapter, was to characterise the clinical response of patients with 
obesity and T2DM to 48 weeks of treatment with a DJBS in our centre.  Additionally, the study aimed 
to assess the durability of improvements in clinical or metabolic parameters for one year following 
device explant. 
Specifically, anthropometric and metabolic markers, markers of hepatic fibrosis and steatosis, dietary 
intake, circulating micronutrient status and HRQoL were assessed. 
It was hypothesised that 48 weeks of treatment with a DJBS would: 
• Reduce body weight, BMI and waist, hip and neck circumference; 
• Reduce body fat percentage, measured by DEXA; 
• Improve glycaemic control, measured by fasting plasma glucose and HbA1c; 
• Improve markers of NAFLD, measured by hepatic enzymes and transient elastography; 
• Reduced self-reported energy intake, measured by monthly 24 hour recalls; 
• Reduce circulating micronutrient concentrations, measured by plasma or serum 
concentrations of relevant micronutrients; and 
• Improve HRQoL, measured by survey data. 
During the one year post-explant follow-up period, it was hypothesised: 
• Body weight, BMI and anthropometric measures would increase, but would remain lower 
than baseline values; and 
• Improvements in glycaemic control would deteriorate, as compared to baseline. 
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3.2 METHODS 
3.2.1 Safety Monitoring 
Monthly safety blood tests were conducted and patients were screened for symptoms of infection or 
other conditions warranting further investigation at all clinical reviews as described in Chapter 2 
Section 2.2.4. SAEs were defined as any event resulting in hospital admission. 
3.2.2 Anthropometric Measures and Body Composition 
Body weight, height, waist, hip and neck circumference were measured.  BMI, TBWL and EWL were 
calculated as described in Chapter 2 Section 2.3.1.  Blood pressure was measured at clinical reviews.  
BMD and body composition was measured at baseline, explant and one year post-explant by the PAH 
Department of Radiology by full body DEXA (GE Lunar Prodigy Advance, GE Healthcare, Madison, 
WI, USA) as described in Chapter 2 Section 2.3.2. 
3.2.3 Peripheral Blood Metabolic Profiles 
Full metabolic biochemical screening was performed at 16-week intervals throughout the intervention 
period and at one year post-explant.  Briefly, these included measures of glycaemic control, vitamin 
and mineral status and lipid profile.  These were assessed in addition to a ‘safety’ panel of fasting 
glucose, iron studies, CRP, liver and kidney function parameters and full blood count that were 
measured monthly during the intervention period and at one year post-explant.  All parameters were 
measured by Pathology Queensland.  Further details are described in Chapter 2 Section 2.3.3. 
Metabolic syndrome severity score (MetSSS) was calculated at baseline, explant and one year  
post-explant using an algorithm derived by Wiley and Carrington517.  This algorithm requires the 
input of gender, waist circumference, systolic and diastolic blood pressure, HDL-cholesterol, serum 
triglycerides and fasting blood glucose.  A z score of zero indicates average severity compared to an 
Australian cohort from the Healthy Hearts study, with a higher score (above 0) indicating greater 
severity. 
3.2.4 Markers of Hepatic Fibrosis and Steatosis 
Liver enzymes were measured monthly during the intervention period and at one year post-explant.  
ALT levels were compared to gender specific ‘healthy’ upper limits.  Further details are described in 
Chapter 2 Section 2.3.3. 
Hepatic fibrosis and steatosis were assessed by hepatic transient elastography (Fibroscan®) at 
baseline, 24 weeks, device explant and one year post-explant using the XL probe.  Further details are 
described in Chapter 2 Section 2.3.4. 
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3.2.5 Dietary Intake and Nutrition Status 
Dietary intake was measured by 24 hour recall on a monthly basis during the intervention period and 
at one year post-explant.  Raw data was input into FoodWorks 8 (Xyris Software, Brisbane, Australia) 
for the assessment of dietary energy, fibre and macronutrient intake. 
Serum markers of nutrition status (vitamins and minerals) were assessed at 16 week intervals 
throughout the intervention period and at one year post-explant.  See Chapter 2 Sections 2.3.5  
(dietary intake) and Section 2.3.3 (serum measures) for more detail. 
3.2.6 Health-Related Quality of Life 
At baseline, 24 weeks, device explant and one year post-explant, patients completed the SF-36 
questionnaire, HADS, Epworth Sleepiness Scale and Active Australia Survey.  At the same intervals, 
patients also completed a 6MWT.  SF-36 results were compared to gender-specific population norms 
for the Australian general population494 and an Australian cohort with obesity and T2DM495.   
Further details can be found in Chapter 2 Section 2.3.6 and Section 2.3.7. 
3.2.7 Statistical Analyses 
3.2.7.1 Power Calculation 
In the study, the sample size of 19 yielded a statistical power of 0.8 at the 0.05 (two-tailed) level of 
significance for a Cohen’s d effect size 0.75 or greater. 
3.2.7.2 Data Analysis 
All continuous variables were described as mean and standard deviation with missing data not 
imputed.  All analyses were presented as pre- to post-intervention measurements due to missing data 
at intermediate time-points.  Normality of distribution was assessed using the Shapiro-Wilk normality 
test.  Normally distributed data was analysed using paired t-tests.  Non-normally distributed data was 
assessed by the Wilcoxon signed rank test.  Dependent on normality of distribution, Pearson or 
Spearman bivariate correlations were used to screen for baseline variables correlating with weight 
loss response at 48 weeks (TBWL percentage). 
Medication usage at baseline and explant were converted into binary categories and change in usage 
was assessed using the McNemar’s test.  For the SF-36 survey, differences between patient data and 
population norms were compared using a one-sample t-test. 
The primary outcome was change in body weight (TBWL). Secondary outcomes included changes 
in anthropometrics and body composition, cardiovascular disease risk parameters (including blood 
pressure and lipid profile), metabolic parameters (including glycaemic control and liver enzymes), 
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liver stiffness, haematological parameters, nutrition status (including dietary intake and circulating 
vitamins and minerals) and HRQoL.  
Significance of results was determined by a two-tailed p value of less than 0.05. 
All analyses were performed using IBM Statistical Package for Social Sciences Version 24 (IBM 
Corp., NY, USA), and figures were generated using GraphPad Prism Version 7 (GraphPad Software 
Inc, CA, USA).  Statistical analysis was performed with the guidance of Justin Scott at QFAB and 
Professor Mike Jones from Macquarie University. 
  
 76 
 
3.3 RESULTS 
3.3.1 Safety 
There were eight SAEs - four instances of GI bleeding (evidenced by hematemesis or melena), three 
instances of severe abdominal pain and one device-unrelated admission (urinary tract infection).   
All complications were conservatively managed.  Patients underwent repeat endoscopy and/or 
imaging to confirm appropriate device positioning and patency.  One patient underwent early explant 
at 29 weeks post-implant secondary to GI bleeding and device migration. 
Three additional patients underwent elective early explant (at 17, 30 and 36 weeks post-implant) due 
to persistent abdominal pain.  
There were no cases of hepatic abscess in this cohort. 
3.3.2 Anthropometric Measures and Body Composition 
Body weight was significantly reduced following DJBS treatment (Figure 3.1A; baseline  
122.7±17.0 kg vs. explant 100.7±15.6 kg). The weight loss trajectory was more rapid in the first half 
of the intervention, with a mean TBWL of 11.0±4.1% and 17.0±6.5%, at 24 and 48 weeks 
respectively.  This corresponded with an EWL of 19.2±7.1% and 29.5±11.4%, at 24 and 48 weeks 
respectively. 
 
 
Figure 3.1: Body weight and BMI. 
Both body weight (A; p<0.001) and BMI (B; p<0.001) were significantly decreased from baseline to explant.  
Dotted line indicates obese threshold for BMI.  Each patient is displayed as an individual line.  Pre- and post-
intervention compared by paired t-test. 
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There was a significant reduction in BMI (Figure 3.1B), with a mean reduction of 6.9±3.0 kg/m2.  
At device explant, two patients were no longer classified as obese (e.g. BMI <30.0 kg/m2).   
There was a significant reduction in waist, hip and neck circumference (Figure 3.2); however, all 
patients still exceeded gender specific waist circumference targets at explant (Figure 3.3).  There was 
no significant change in systolic or diastolic blood pressure.  However, bivariate correlations revealed 
TBWL to be positively correlated with baseline diastolic blood pressure (r=0.57; p=0.03). 
 
Figure 3.2: Waist, hip and neck circumference. 
There was a significant reduction in waist (A; p<0.01), hip (B; p<0.001) and neck (C; p<0.01) circumferences 
from baseline to explant.  Each patient is displayed as an individual line.  Pre- and post-intervention compared 
by paired t-test. 
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Figure 3.3: Waist circumference, stratified by gender. 
Gender specific upper limits of <80 cm for females (A) and <94 cm for males (B) displayed as a dotted line 
on graph.  Each patient is displayed as an individual line. 
There was a significant reduction in body fat percentage (Figure 3.4A; baseline 47.1±6.7% vs. explant 
43.5±7.2%; n=14; p<0.01).  A concurrent loss in absolute fat and lean mass (in kg; Figure 3.4B  
and C) was observed; however, there was a significant increase in lean: fat mass ratio (Figure 3.4D), 
indicating a beneficial effect on body composition. 
There was no significant change in total BMD or Z score at any site; however, there was a significant 
reduction in T score at the right femur (p=0.04).  Improvements in anthropometric measures, body 
composition and BMD are summarised below (Table 3.1). 
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Figure 3.4: Body fat percentage, fat mass, lean mass and lean: fat mass ratio. 
There was a significant reduction in body fat percentage (A; p<0.001), fat mass (B; p<0.001), lean mass (C; 
p<0.001) and lean: fat mass ratio (D; p<0.05) from baseline to explant.  Each patient is displayed as an 
individual line.  Pre- and post-intervention compared by paired t-test. 
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Table 3.1: Anthropometric, body composition and BMD measures following DJBS treatment. 
Parameter (unit) Baseline  24 weeks 48 weeks P value at 24 
weeks 
P value at 
48 weeks 
Anthropometric and body composition measures 
Body Weight (kg) 122.2 ± 17.0 109.6 ± 17.9 100.7 ± 15.6 <0.0001^ <0.0001^^ 
TBWL (%) N/a 11.0 ± 4.1 17.0 ± 6.5 <0.0001^ <0.0001^^ 
BMI (kg/m2) 43.7 ± 5.3 39.1 ± 5.7 36.3 ± 6.0 <0.0001^ <0.0001^^ 
Waist circumference (cm) 132.2 ± 18.0 122.9 ± 16.0 118.8 ± 14.3 <0.0001^^^^ 0.001^^^^^ 
Hip circumference (cm) 133.7 ± 16.7 122.6 ± 17.2 121.1 ± 15.8 <0.0001^^^^ <0.0001^^^^^ 
Neck circumference (cm) 44.3 ± 5.7 42.7 ± 5.0 40.6 ± 3.9 <0.0001^^^^ 0.002^^^^^ 
Systolic blood pressure 
(mmHG) 
139 ± 19 134 ± 16 131 ± 15 0.540^^^ 0.231^^ 
Diastolic blood pressure 
(mmHG) 
80 ± 7 81 ± 8 81 ± 7 0.876^^^ 0.454^^ 
Body fat percentage (%) 47.1 ± 6.7 NM 43.5 ± 7.2 NM 0.003^^^ 
Fat Mass (kg) 56.1  ± 9.5 NM 45.2  ± 10.5 NM <0.0001^^^ 
Lean Mass (kg) 63.9  ± 13.9 NM 57.8  ± 10.2 NM <0.0001^^^ 
Lean:Fat Mass Ratio 1.18  ± 0.35 NM 1.36  ± 0.45 NM 0.013^^^ 
Bone Mineral Density 
Lumbar BMD (g/cm2) 1.337 ± 
0.183 
NM 1.353 ± 0.175 NM 0.974^^^ 
Lumbar T-Score 1.0 ± 1.5 NM 1.1 ± 1.4 NM 0.317^^^ 
Lumbar Z-Score 0.5 ± 1.5 NM 0.6 ± 1.4 NM 0.803^^^ 
Left Femur BMD (g/cm2) 1.173 ± 
0.133 
NM 1.192 ± 0.124 NM 0.862^^^ 
Left Femur T-Score 0.9 ± 1.0 NM 1.0 ± 0.9 NM 0.287^^^ 
Left Femur Z-Score 0.4 ± 1.2 NM 0.4 ± 1.0 NM 0.714^^^ 
Right Femur BMD (g/cm2) 1.203 ± 
0.154 
NM 1.207 ± 0.137 NM 0.118^^^ 
Right Femur T-Score 1.1 ± 1.2 NM 1.1 ± 1.0 NM 0.042^^^ 
Right Femur Z-Score 0.5 ± 1.4 NM 0.5 ± 1.1 NM 0.454^^^ 
^ n=17 ^ ^n=15 ^ ^^ n=14 ^ ^^^ n=13 ^ ^^^^ n=11. Data measured by paired t-test and displayed as mean ± SD.  Results deemed 
significant if p<0.05. 
BMD; Bone Mineral Density, BMI; Body Mass Index, NM; not measured, TBWL; total body weight loss. 
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3.3.3 Peripheral Blood Metabolic Profiles 
There was a significant reduction in fasting glucose, fasting insulin and HbA1c over the intervention 
period (Figure 3.5).  There was a significant reduction in total cholesterol (Figure 3.6A; p<0.05) and 
serum triglycerides (Figure 3.6B; p<0.01).  No significant change in HDL- or LDL-cholesterol was 
observed (Figure 3.6C and D). There was a significant improvement in MetSSS (Figure 3.7; n=15; 
p=0.001) between baseline and explant.  
 
Figure 3.5: Fasting glucose, fasting insulin and HbA1c. 
There was a significant reduction in fasting glucose (A; p<0.01), fasting insulin (B; p<0.05) and HbA1c (C; 
p<0.01) from baseline to explant.  Upper limit of clinical reference range (A: 6.0 mmol/L, B: 2.0-23.0 mU/L 
and C: 7.0% diabetic target) shown as a dotted line on graph.  Each patient is displayed as an individual line.  
Pre- and post-intervention compared by Wilcoxon signed rank test. 
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Figure 3.6: Total cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol. 
There was a significant reduction in total cholesterol (A; p<0.05) and serum triglycerides (B; p<0.01) but not 
HDL-cholesterol (C; p=0.22) or LDL-cholesterol (D; p=0.31) from baseline to explant.  Upper (A: 4.0 mmol/L, 
B: 1.5 mmol/L and D: 2.5 mmol/L) and lower (C: 1.0 mmol/L) limit of clinical reference range shown as a 
dotted line on graph.  Each patient is displayed as an individual line.  Pre- and post-intervention compared by 
paired t-test. 
 
Figure 3.7: MetSSS.  
There was a significant reduction in MetSSS from baseline to explant (p=0.001).  Each patient is displayed as 
an individual line. Results compared by Wilcoxon signed rank test.  
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There was also a significant decrease in ferritin, transferrin saturation and haemoglobin and a 
reduction in global inflammation, as indicated by the significant decrease in CRP (Figure 3.8).   
All female patients remained within the normal reference range for ferritin, whilst 60% of males (n=3) 
fell below the normal gender-specific reference range (Figure 3.9).  One male and one female patient 
fell below the normal reference range for haemoglobin (Figure 3.9).  Improvements in metabolic 
parameters are summarised below (Table 3.2). 
 
Figure 3.8: Ferritin, transferrin saturation, haemoglobin and CRP. 
There was a significant reduction in ferritin (A; p<0.01), transferrin saturation (B; p<0.01), haemoglobin (C; 
p<0.01) and CRP (D; p<0.05) from baseline to explant.  Upper and lower limit of clinical reference range 
shown as a dotted line on graph (B: 15-45 %; D: <5.0 mg/L).  Each patient is displayed as an individual line.  
Pre- and post-intervention compared by paired t-test (B and C) or Wilcoxon signed rank test (A and D). 
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Figure 3.9: Ferritin and haemoglobin, stratified by gender. 
Gender specific reference ranges for ferritin of 5-150 ug/L for females (A) and 45-715 for males (B) and 
haemoglobin 115-160 g/L for females (C) and 135-180 g/L for males (D) displayed as a dotted line on graph.  
Each patient is displayed as an individual line. 
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Table 3.2: Glycaemic control, cardiovascular risk, haematological and inflammatory and iron status 
parameters following DJBS treatment. 
Parameter (unit) Baseline  24 weeks 48 weeks P value at 24 
weeks 
P value at 48 
weeks 
Glycaemic control 
Fasting glucose (mmol/L) 8.7 ± 3.7 7.1 ± 2.2 6.5 ± 1.4 0.022^ 0.0012^^ 
Fasting insulin (mU/L) 21 ± 18 NM 10 ± 7 NM 0.012^^ 
HbA1c (%) 7.0 ± 1.4 NM 6.2 ± 0.8 NM 0.0032^^ 
Cardiovascular risk parameters 
Total cholesterol (mmol/L) 4.9 ± 1.3 NM 4.2 ± 1.2 NM 0.0451^^ 
Triglyceride (mmol/L) 2.1 ± 0.7 NM 1.6 ± 0.5 NM 0.0041^^ 
HDL-cholesterol (mmol/L) 1.1 ± 0.3 NM 1.1 ± 0.2 NM 0.2191^^ 
LDL-cholesterol (mmol/L) 2.8± 1.1 NM 2.4 ± 0.9 NM 0.3081^^ 
Haematological, inflammatory and iron status parameters 
Ferritin (µg/L) 119 ± 94 86 ± 81 70 ± 66 0.012^ 0.0012^^ 
Transferrin Saturation (%) 21 ± 4 16 ± 6 16 ± 4 0.0021^^^ 0.0011^^ 
Haemoglobin (g/L) 140 ± 13 136 ± 12 135 ± 14 0.051^ 0.0061^^ 
CRP (mg/L) 10.7 ± 9.4 11.4 ± 13.3 7.4 ± 6.7 0.532^^^ 0.012^^ 
^ n=17, ^^ n=15 ^^^ n=16. Data displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data 
not normally distributed analysed by 2.Wilcoxon signed rank test.  Results deemed significant if p<0.05. 
CRP; C-reactive protein, HbA1c; glycated haemoglobin, HDL; high-density lipoprotein, LDL; low-density lipoprotein, 
NM; parameter not measured at this time-point. 
 
3.3.4 Markers of Hepatic Fibrosis and Steatosis 
There was a significant reduction in ALT over the intervention period.  At baseline, 17 of 19 patients 
had ALT values outside of healthy clinical targets.  By device explant, 13 of these 17 patients had 
reached gender specific targets (Figure 3.10: 9 females and 4 males).  There was a statistically 
significant reduction in AST; however, the majority of patients were within the normal reference 
range at baseline.  There was a trend toward a reduction in hepatic stiffness, as measured by transient 
elastography (Figure 3.11).  There was a significant reduction in the CAP, which may be used as a 
surrogate marker of intrahepatic fat.  Improvements in liver-related parameters are summarised below 
(Table 3.3). 
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Figure 3.10: ALT, stratified by gender. 
Gender specific upper limit of <20 U/L for females (A) and <31 U/L for males (B) displayed as a dotted line 
on graph.  Each patient is displayed as an individual line.  For full cohort, pre- and post-intervention compared 
by Wilcoxon signed rank test. 
 
 
Figure 3.11: Hepatic stiffness and the CAP as indicators of hepatic fibrosis and steatosis. 
There was a trend toward a reduction in hepatic stiffness (A; p=0.07) and a significant reduction in the CAP 
(B; p<0.05) from baseline to explant.  Each patient is displayed as an individual line.  Pre- and post-intervention 
compared by Wilcoxon signed rank test (A) or paired t-test (B). 
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Table 3.3: Liver enzymes and indicators of hepatic fibrosis and steatosis following DJBS treatment. 
Parameter (unit) Baseline  24 weeks 48 weeks P value at 24 weeks P value at 48 weeks 
ALT (U/L) 37 ± 16 23 ± 11 18 ± 9 0.0021^ 0.0032^ 
AST (U/L) 25 ± 15 18 ± 8 16 ± 6 0.022^ 0.012^ 
Hepatic stiffness (kPa) 10.4 ± 7.3 6.4 ± 2.6 6.6± 2.0 0.172^^ 0.072^^ 
CAP (decibels/min) 339 ± 48 318 ± 60 302 ± 60 0.171^^ 0.021^ 
^ n=15 ^^ n=13. Data displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data not normally 
distributed analysed by 2.Wilcoxon signed rank test.  Results deemed significant if p<0.05. 
ALT, alanine transaminase; AST, aspartate transaminase, CAP; controlled attenuation parameter 
 
3.3.5 Dietary Intake and Nutrition Status 
At 24 weeks, there was a significant reduction in dietary energy intake, absolute (in grams) intake of 
protein, fat and carbohydrate and a reduction in the proportion of total energy derived from fat, 
compared to baseline.  At 48 weeks, dietary energy and fibre intake, absolute fat and carbohydrate 
intake and the proportion of total energy intake derived from fat were reduced.  Dietary intake is 
summarised in Table 3.4. 
Table 3.4: Dietary energy, fibre and macronutrient intake following DJBS treatment. 
Parameter (unit) Baseline 24 weeks  48 weeks P value at 24 
weeks 
P value at 48 
weeks 
Energy intake (kJ) 7703 ± 2978 4824 ± 2259 4474 ± 1468 0.0011 0.011 
Dietary fibre (g) 21.8 ± 9.1 14.7 ± 7.5 16.2 ± 7.5 0.062 0.021 
Protein intake (g) 95.7 ± 32.9  69.1 ± 29.9 67.4 ± 37.7 0.011 0.121 
TEI derived from protein (%) 22 ± 6 26 ± 7 25 ± 11 0.281 0.271 
Fat intake (g) 73.3 ± 32.0 36.6 ± 19.1 31.5 ± 13.7 0.0021 0.0021 
TEI derived from fat (%) 35 ± 6 28 ± 6 26 ± 9 0.021 0.031 
Carbohydrate intake (g) 185 ± 94 129 ± 77 118 ± 54 0.022 0.042 
TEI derived from carbohydrate (%) 39 ± 9 44 ± 7 44 ± 12 0.061 0.381 
Results displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data not normally distributed 
analysed by 2.Wilcoxon signed rank test.  Results deemed significant if p<0.05.  
TEI; total energy intake 
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There was a significant increase in vitamin D and a statistically significant reduction in vitamin E.  
The increase in vitamin D is suggested to be as a result of increased outdoor time and seasonal 
variation.  Despite the statistically significant reduction in vitamin E, all patients remained within the 
normal clinical reference range and no patient exhibited any symptoms of deficiency.  Serum vitamin 
and mineral status is summarised in the table below (Table 3.5). 
Table 3.5: Serum vitamin and mineral status following DJBS treatment. 
Parameter (unit) Baseline 48 weeks P value 
Fat soluble vitamins 
Vitamin A (µmol/L) 1.9 ± 0.3 1.7 ± 0.4 0.061^ 
Vitamin D (nmol/L) 72 ± 17 88 ± 29 0.021^ 
Vitamin E (µmol/L) 31 ± 8 27 ± 8 0.0041^^ 
INR 1.0 ± 0.1 1.1 ± 0.1 0.182^ 
Water Soluble Vitamins 
Vitamin B12 (pmol/L)^ 267 ± 102 280 ± 136 0.472^ 
Folate (nmol/L) 36.9 ± 11.8 41.0 ± 11.4 0.241^ 
Minerals 
Copper (µmol/L) 19 ± 3 19 ± 2 0.891^^^ 
Selenium (µmol/L) 1.1 ± 0.2 1.1 ± 0.1 0.341^^^ 
Zinc (µmol/L) 14 ± 1 13 ± 2 0.341^^^ 
^ n= 15 ^^ n=14 ^^^ n=11.  Data displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data 
not normally distributed analysed by 2.Wilcoxon signed rank test.  Results deemed significant if p<0.05. 
INR; international normalized ratio. 
 
3.3.6 Health-Related Quality of Life 
There was a significant improvement in daytime sleepiness and depression as measured by the 
Epworth Sleepiness Scale and HADS, respectively. There was a trend toward a reduction in anxiety 
as measured by the HADS (Table 3.6). Self-reported physical activity was significantly increased 
from a mean of 425±516 minutes/week at baseline to 874±767 minutes/week at explant.   
This represents an increase in the number of patients meeting national physical activity guidelines 
from 58% at baseline to 81% at explant. This was also matched by a significant increase in functional 
exercise capacity, with 6MWT distance increasing from 500±84 m at baseline to 607±92 m at  
48 weeks.  However, at baseline, only two patients could achieve the distance derived from the 
predictive equations in the six minute period.  Of these two patients, neither had valid repeat measures 
at explant (one due to protocol non-compliance (running) and one due to knee injury). 
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There was a significant improvement in the physical functioning, role limitations due to physical 
health, general health, energy/fatigue, emotional wellbeing and social functioning domains of the  
SF-36 measure of HRQoL.  Bivariate correlations revealed TBWL to be negatively correlated with 
baseline physical function domain score (r=-0.65; p=0.01), indicating a lower reported degree of 
physical function at baseline was associated with poorer weight loss outcomes. 
Compared to Australian general population norms, the female cohort reported a significantly lower 
score on each of the eight domains at baseline (Figure 3.12A).  However, scores were representative 
of norms derived in a study of females with obesity and T2DM, who also reported lower HRQoL 
scores than the general population.  At 48 weeks, scores for all domains except pain were not 
significantly different from the general population norms (Figure 3.12B).  Four of the eight domains 
(physical functioning, energy/fatigue, role limitations due to emotional problems, social functioning 
and emotional wellbeing) were also significantly higher than the female cohort with obesity and 
T2DM.  For male participants, mental health and general health domains were significantly lower 
than the Australian general population and for all eight domains were not significantly different from 
a cohort of males with obesity and T2DM (Figure 3.12C).  In males, at 48 weeks, scores for all 
domains were not significantly different from the general population norms, but all were significantly 
higher than the male cohort with obesity and T2DM (Figure 3.12D).  HRQoL outcomes are 
summarised below (Table 3.6).  The burden of polypharmacy was not significantly impacted by DJBS 
treatment, with no significant change in usage of any of the medication categories (Table 3.7). 
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Figure 3.12: HRQoL as measured by the SF-36 questionnaire.   
Australian norm data from Australian Bureau of Statistics data494.  AusDiab norm data from the Australian 
Diabetes, Obesity and Lifestyle study495.  
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Table 3.6: HRQoL measures following DJBS treatment. 
Parameter (unit) Baseline 
(n=19) 
24 weeks 
(n=12) 
48 weeks 
(n=16) 
P value at 
24 weeks^ 
P value at 
48 
weeks^^ 
Epworth Sleepiness Scale 7.6  ± 3.4 6.75  ± 4.0 4.6  ± 2.2 0.201 0.011 
HADS-Anxiety 8 ± 4 5 ± 4 6 ± 5 0.082 0.061 
HADS-Depression 6 ± 4 2 ± 3 3 ± 4 0.202 0.012 
Active Australia – sufficient time (mins) 425 ± 516 910 ± 1418 874 ± 767 0.352 0.012 
6MWT (m)* 500 ± 84 587 ± 107 607 ± 92 0.023^^^ 0.042^^^^ 
SF-36 – Physical functioning  52 ± 25 80 ± 17 73 ± 27 0.0021 0.012 
SF-36 – Role Limitations due to Physical 
Health 
46 ± 44 71 ± 45 77 ± 35 0.202 0.022 
SF-36 – Pain  54 ± 26 58 ± 27 60 ± 33 0.631 0.601 
SF-36 – General Health  44 ± 22 65 ± 23 64 ± 26 0.031 0.012 
SF-36 – Role Limitations due to Emotional 
Problems  
51 ± 44 83 ± 33 67 ± 44 0.262 0.182 
SF-36 – Energy/Fatigue  44 ± 20 55 ± 27 64 ± 23 0.611 0.0031 
SF-36 – Emotional Wellbeing 61 ± 24 73 ± 18 72 ± 19 0.511 0.0031 
SF-36 – Social Functioning 57 ± 29 75 ± 19 80 ± 21 0.101 0.0022 
^ n= 12 ^^ n=16 ^^^ n=8 ^^^^ n=7. * per protocol analysis due to protocol non-compliance. Data displayed as mean ± 
SD. Normally distributed data analysed by 1. Paired t-test. Data not normally distributed analysed by 2.Wilcoxon signed 
rank test. Results deemed significant if p<0.05. 
6MWT; six minute walk test, HADS; Hospital Anxiety and Depression Scale. 
 
Table 3.7: Medication usage. 
 Baseline (n=19) % 
(number) 
Explant (n=18) % 
(number) 
P value (n=18) 
Metformin 67 (13) 50 (9) 0.45 
Other oral agents  21 (4) 17 (3) 1.00 
GLP-1 analogues 0 (0) 11 (2) .50 
Hypertension 53 (10) 44 (8) .50 
Dyslipidaemia 32 (6) 28 (5) 1.00 
Mental Health 42 (8) 39 (7) 1.00 
Pain 16 (3) 17 (3) 1.00 
Reflux 21 (4) 22 (4) 1.00 
Other 37 (7) 33 (6) 1.00 
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3.3.7 Durability of Improvements 
3.3.7.1 Anthropometric Measures and Body Composition 
Following device explant, patients began to gain weight.  However, one year after device explant 
body weight (Figure 3.13A; n=14; p=0.02) and BMI (Figure 3.13B; n=14; p=0.02) were still 
significantly lower, compared to baseline.  At one year post-explant, the mean TBWL from baseline 
was 5.31±6.91% (n=14; p=0.01), representing approximately 25% of maximal weight loss at device 
explant.  Significant reductions in waist (Figure 3.14A; n=9; p=0.04), hip (Figure 3.14B; n=9; p=0.03) 
and neck circumferences (Figure 3.14C; n=9; p=0.04) were also maintained. 
There was no significant difference in systolic (n=9; p=0.62) or diastolic (n=9; p=0.18) blood 
pressure, compared to baseline values. However, this was not significantly changed during the 
intervention period.  There was no significant difference in body fat percentage or lean:fat mass; 
however, both absolute fat mass and absolute lean mass were significantly reduced at one year post-
explant, compared to baseline.  BMD was not significantly different, compared to baseline.  
Anthropometric measures, body composition and BMD measures one year after device explant are 
summarised below (Table 3.8). 
 
 
Figure 3.13: Body weight and BMI at one year post-explant. 
At one year post-explant, both body weight (A; n=14; p<0.05) and BMI (B; n=14; p<0.05) remained 
significantly reduced, as compared to baseline.  Dotted line indicates obese threshold for BMI.  Each patient 
is displayed as an individual line.  Results compared by paired t-test. 
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Figure 3.14: Waist, hip and neck circumference at one year post-explant. 
At one year post-explant, waist (A; p<0.05), hip (B; p<0.05) and neck (C; p<0.05) circumference remained 
significantly reduced, as compared to baseline (n=9 for all).  Each patient is displayed as an individual line.  
Results compared by paired t-test.  
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Table 3.8: Anthropometric, body composition and BMD measures one year after DJBS treatment. 
Parameter (unit) Baseline  One year post-
explant 
Mean reduction from 
baseline 
P value  
Anthropometric and body composition measures 
Body Weight (kg) 122.2 ± 17.0 117.7 ± 18.0 6.8 ± 9.4 0.018^ 
TBWL (%) N/a 5.3 ± 6.9 5.3 ± 6.9 N/a 
BMI (kg/m2) 43.7 ± 5.3 41.7 ± 6.8 2.3 ± 3.0 0.015^ 
Waist circumference (cm) 132.2 ± 18.0 122.8 ± 17.4 8.5 ± 10.4 0.039^^ 
Hip circumference (cm) 133.7 ± 16.7 124.9 ± 15.7 6.1 ± 6.8 0.028^^ 
Neck circumference (cm) 44.3 ± 5.7 43.7 ± 5.5 1.6 ± 1.9 0.028^^ 
Systolic blood pressure (mmHG) 139 ± 19 144 ± 12 -3 ± 15 0.618^^ 
Diastolic blood pressure (mmHG) 80 ± 7 82 ± 6 -3 ± 7 0.184^^ 
Body fat percentage (%) 47.1 ± 6.7 47.0 ± 7.5 0.7 ± 2.7 0.511^^^ 
Fat Mass (kg) 56.1  ± 9.5 50.7  ± 11.1 6.7 ± 4.8 0.011^^^ 
Lean Mass (kg) 63.9  ± 13.9 59.0  ± 12.9 5.0 ± 5.2 0.045^^^ 
Lean:Fat Mass Ratio 1.18  ± 0.35 1.21  ± 0.40 0.09 ± 0.53 0.163^^^ 
Bone Mineral Density 
Lumbar BMD (g/cm2) 1.337 ± 0.183 1.327 ± 0.226 -0.006 ± 0.031 0.650^^^ 
Lumbar T-Score 1.0 ± 1.5 0.96 ± 1.8 -0.03 ± 0.26 0.765^^^^ 
Lumbar Z-Score 0.5 ± 1.5 0.4 ± 1.7 0.0 ± 0.6 0.950^^^ 
Left Femur BMD (g/cm2) 1.173 ± 0.133 1.142 ± 0.147 -0.011 ± 0.074 0.703^^^ 
Left Femur T-Score 0.9 ± 1.0 0.6 ± 1.1 0.2 ± 0.4 0.320^^^^ 
Left Femur Z-Score 0.4 ± 1.2 -0.1 ± 1.1 0.3 ± 0.7 0.318^^^ 
Right Femur BMD (g/cm2) 1.203 ± 0.154 1.130 ± 0.123 0.020 ± 0.065 0.453^^^ 
Right Femur T-Score 1.1 ± 1.2 0.5 ± 0.9 0.2 ± 0.5 0.363^^^^ 
Right Femur Z-Score 0.5 ± 1.4 -0.2 ± 1.0 0.4 ± 0.8 0.287^^^ 
^ n=14 ^^n=9, ^^^ n=7, ^^^^ n=6.  Data measured by paired t-test and displayed as mean ± SD.  Results deemed significant 
if p<0.05. 
BMD; Bone Mineral Density, BMI; Body Mass Index, TBWL; total body weight loss. 
 
3.3.7.2 Peripheral Blood Metabolic Profiles 
At one year post-explant, there was no sustained improvement in fasting glucose, fasting insulin or 
HbA1c, compared to baseline (Figure 3.15).  There was no persistent improvement in total cholesterol 
or serum triglycerides.  LDL-cholesterol were not significantly different, compared baseline  
(Figure 3.16); however, HDL-cholesterol was significantly increased (Figure 3.16C). 
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Figure 3.15: Fasting glucose, fasting insulin and HbA1c at one year post-explant. 
At one year post-explant, there was no persistent improvement in fasting glucose (A; p=0.24), fasting insulin 
(B; p=0.86) or HbA1c (C; p=0.11) compared to baseline.  Upper limit of clinical reference range (A: 6.0 mmol/L, 
B: 2.0-23.0 mU/L and C: 7.0% diabetic target) shown as a dotted line on graph.  Each patient is displayed as 
an individual line.  Results compared by Wilcoxon signed rank test. 
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Figure 3.16: Total cholesterol, triglycerides, HDL-cholesterol and LDL-cholesterol at one year post-
explant. 
At one year post-explant there was no persistent improvement in total cholesterol (A; p=0.31), serum 
triglycerides (B; p=0.11) or LDL-cholesterol (D; p=0.25).  However, HDL-cholesterol was significantly 
increased (C; p<0.05), compared to baseline.  Upper (A: 4.0 mmol/L, B: 1.5 mmol/L and D: 2.5 mmol/L) and 
lower (C: 1.0 mmol/L) limit of clinical reference range shown as a dotted line on graph.  Each patient is 
displayed as an individual line.  Results compared by paired t-test. 
Despite the lack of clinically significant weight loss (>5% TBWL) maintenance in five of nine 
patients, at one year post-explant there was a trend toward a significant improvement in MetSSS  
(n=9; p=0.07).  Overall, seven of nine patients had a MetSSS that was lower than baseline, indicating 
an improved risk profile (Figure 3.17). 
One year post-explant, there was no significant difference in haemoglobin, transferrin or transferrin 
saturation, compared to baseline (Figure 3.18).  However, one year post-explant, ferritin was 
significantly lower than baseline (n=9; p<0.01).  There was no sustained improvement in global 
inflammation, as measured by CRP, compared with baseline.  Data on metabolic parameters one year 
post-explant, compared with baseline are summarised below (Table 3.9). 
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Figure 3.17: MetSSS at one year post-explant.  
There was a trend (p=0.07) toward a maintained improvement in MetSSS at one year post-explant, compared 
to baseline.  Each patient is displayed as an individual line. Results compared by Wilcoxon signed rank test. 
 
 
Figure 3.18: Ferritin, transferrin saturation, haemoglobin and CRP at one year post-explant. 
At one year post-explant, ferritin was significantly reduced (A; p<0.01), compared to baseline.  There was no 
significant difference in transferrin saturation (B; p=0.88), haemoglobin (C; p=0.27) or CRP (D; p=0.74). 
Upper and lower limit of clinical reference range shown as a dotted line on graph (B: 15-45 %; D: <5.0 mg/L).  
Each patient is displayed as an individual line. Results compared by paired t-test (B and C) or Wilcoxon signed 
rank test (A and D).  
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Table 3.9: Glycaemic control, cardiovascular risk, haematological and inflammatory and iron status 
parameters one year after DJBS treatment. 
Parameter (unit) Baseline  One year post-
explant 
Mean reduction from 
baseline 
P value (n=9) 
Glycaemic control 
Fasting glucose (mmol/L) 8.7 ± 3.7 7.7 ± 1.8 1.8 ± 3.4 0.2362 
Fasting insulin (mU/L) 21 ± 18 22 ± 25 2 ± 21 0.8592 
HbA1c (%) 7.0 ± 1.4 6.5 ± 1.1 0.7 ± 1.3 0.1092 
Cardiovascular risk parameters 
Total cholesterol (mmol/L) 4.9 ± 1.3 4.8 ± 1.3 -0.4 ± 1.0 0.3101 
Triglyceride (mmol/L) 2.1 ± 0.7 1.6 ± 0.7 0.4 ± 0.6 0.1141 
HDL-cholesterol (mmol/L) 1.1 ± 0.3 1.1 ± 0.2 -0.1 ± 0.2 0.0291 
LDL-cholesterol (mmol/L) 2.8 ± 1.1 2.9 ± 1.2 -0.4 ± 0.9 0.2481 
Haematological, inflammatory and iron status parameters 
Ferritin (µg/L) 119 ± 94 47 ± 44 41 ± 31 0.0082 
Transferrin Saturation (%) 21 ± 4 20 ± 10 -0.0 ± 9 0.8831 
Haemoglobin (g/L) 140 ± 13 140 ± 16 1 ± 4 0.2681 
CRP (mg/L) 10.7 ± 9.4 8.0 ± 11.8 1.0 ± 5.6 0.7352 
Data displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data not normally distributed 
analysed by 2.Wilcoxon signed rank test.  Results deemed significant if p<0.05. 
CRP; C-reactive protein, HbA1c; glycated haemoglobin, HDL; high-density lipoprotein, LDL; low-density lipoprotein 
 
3.3.7.3 Markers of Hepatic Fibrosis and Steatosis 
One year after device explant, ALT levels remained significantly reduced (Figure 3.19; p<0.05).   
Of the nine patients who completed the one year post-explant blood test, six remained within the 
gender specific targets (3 females and 3 males).  The majority of patients were in the normal range at 
baseline and all patients who completed follow-up were within the normal range at one year  
post-explant.  Despite the maintained improvements in hepatic enzymes, there was no significant 
difference in hepatic stiffness between baseline and one year post-explant (Figure 3.20A; n=7; p=0.35) 
nor the CAP (Figure 3.20B; n=7; p=0.69).  Outcome data associated with liver enzymes and hepatic 
stiffness and steatosis are summarised below (Table 3.10). 
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Figure 3.19: ALT at one year post-explant. 
Patient’s gender indicated by colour of baseline value (pink for female, blue for male).  Gender specific upper 
limit of <20 U/L for females (marked with pink dotted line) and <31 U/L for males (marked with blue dotted 
line).  Each patient is displayed as an individual line.  For the full cohort (n=9; p<0.05), results compared by 
Wilcoxon signed rank test. 
 
 
 
Figure 3.20: Hepatic stiffness and the CAP as measures of hepatic fibrosis and steatosis at one year post-
explant. 
There was no sustained improvement in hepatic stiffness (A; p=0.35) or the CAP (B; p=0.69) as indicators of 
hepatic fibrosis and steatosis at one year post-explant, compared to baseline (n=7).  Each patient is displayed 
as an individual line.  Results compared by Wilcoxon signed rank test. 
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Table 3.10: Liver enzymes and markers of hepatic fibrosis and steatosis one year after treatment with a 
DJBS. 
Parameter (unit) Baseline  One year 
post-explant 
Mean 
reduction 
from baseline 
P value 
ALT (U/L) 37 ± 16 26 ± 14  11 ± 9 0.0172^ 
AST (U/L) 25 ± 15 17 ± 7 4 ± 6 0.0502^ 
Hepatic stiffness (kPa) 10.5 ± 7.1 5.5 ± 1.8 1.6 ± 3.1 0.3522^^ 
CAP (decibels/min) 342 ± 49 329  ± 47 11 ± 68 0.6891^^ 
^ n=9 ^^ n=7. Data displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data not normally 
distributed analysed by 2.Wilcoxon signed rank test.  Results deemed significant if p<0.05. 
ALT, alanine transaminase; AST, aspartate transaminase, CAP, controlled attenuation parameter 
 
3.3.7.4 Dietary Intake and Nutrition Status 
At six months post-explant, there was no significant difference in any measured dietary parameter, 
compared to baseline.  However, at one year post-explant, there was a significant reduction in dietary 
energy intake and absolute (in grams) intake of fat and carbohydrates, compared to baseline.   
There was also a trend toward a reduction in dietary energy intake from protein.  The differences 
between the two post-explant time-points are likely to reflect the static nature of 24 hour recall 
assessment.  Post-explant dietary intake is summarised in Table 3.11. 
Table 3.11: Dietary energy, fibre and macronutrient intake following DJBS device removal. 
Parameter (unit) Baseline Six months post 
explant 
One year post-
explant  
P value: six 
months post-
explant vs 
baseline^ 
P value: One 
year post-
explant vs 
baseline^ 
Energy intake (kJ) 7703 ± 2978 5810 ± 2071 6422 ± 4034 0.161 0.042 
Dietary fibre (g) 21.8 ± 9.1 18.9 ± 8.3 21.9 ± 14.8 0.161 0.652 
Protein intake (g) 95.7 ± 32.9  78.6 ± 16.8 88.4 ± 34.0 0.081 0.461 
TEI derived from 
protein (%) 
22 ± 6 25 ± 8 26 ± 6 0.501 0.071 
Fat intake (g) 73.3 ± 32.0 51.5 ± 21.5 53.3 ± 27.9 0.181 0.031 
TEI derived from fat 
(%) 
35 ± 6 33 ± 6 31 ± 5 0.721 0.091 
Carbohydrate intake 
(g) 
185.3 ± 94.5 142.4 ± 77.6 142.4 ± 105.7 0.262 0.022 
TEI derived from 
carbohydrate (%) 
39 ± 9 39 ± 11 37 ± 6 0.791 0.221 
^ n = 9. Results displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data not normally 
distributed analysed by 2.Wilcoxon signed rank test.  Results deemed significant if p<0.05.  
TEI; total energy intake 
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At one year post-explant, there was no significant difference in vitamins A, E, INR (as a proxy marker 
for vitamin K) or vitamin B12; however, vitamin D levels were significantly lower than baseline and 
folate levels were significantly higher than baseline.  Copper levels were not significantly different 
compared to baseline; however, selenium was significantly higher than baseline (n=7; p<0.001).   
Due to a laboratory ordering error, blood zinc was measured instead of serum zinc for 66% of patients 
at one year post-explant, precluding analysis of serum zinc at this time-point.  Post-explant circulating 
nutrient status is summarised below (Table 3.12). 
Table 3.12: Circulating vitamin and mineral status at one year post-explant. 
Parameter (unit) Baseline  One year post-explant Mean reduction from baseline P value 
Fat soluble vitamins  
Vitamin A (µmol/L) 1.9 ± 0.3 1.8 ± 0.4 0.3 ± 1.0 0.8051^ 
Vitamin D (nmol/L) 72 ± 17 52 ± 9 20 ± 9 <0.00011^^ 
Vitamin E (µmol/L) 31 ± 8 28 ± 9 1 ± 4 0.6741^ 
INR 1.0 ± 0.1 1.0 ± 0.2 -0.1 ± 0.3 0.3802^^ 
Water Soluble Vitamins  
Vitamin B12 (pmol/L)^ 267 ± 102 268 ± 84 15 ± 42 0.3421^^^ 
Folate (nmol/L) 36.9 ± 11.8 41.3 ± 7.1 -7.4 ± 6.8 0.0121^^ 
Minerals  
Copper (µmol/L) 19 ± 3 20 ± 5 -2 ± 3 0.0842^ 
Selenium (µmol/L) 1.1 ± 0.2 1.7 ± 0.3 -0.7 ± 0.2 <0.00011^ 
^ n= 7 ^^ n=9 ^^^ n=8.  Data displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data not 
normally distributed analysed by 2.Wilcoxon signed rank test.  Results deemed significant if p<0.05. 
INR; international normalized ratio, N/A not applicable 
 
3.3.7.5 Health-Related Quality of Life 
With the exception of the 6MWT distance, which remained increased as compared to baseline, there 
was no significant persistent difference in any other HRQoL parameter.  At this time-point, only one 
patient exceeded the predicted 6MWT distance.  When separated by gender, female participants 
reported a significantly reduced “role limitations due to emotional problems” score than both the 
Australian general population norms and the female cohort with obesity and T2DM.   
Overall, our patient cohort were most closely matched with the female cohort with obesity and T2DM 
(Figure 3.21).  For male participants, no statistical differences between the cohort and either the 
Australian general population norms or the male cohort with obesity and T2DM were observed.   
Post-explant HRQoL outcomes are summarised below (Table 3.13). 
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Figure 3.21: HRQoL at one year post-explant. 
Australian norm data from Australian Bureau of Statistics data494.  AusDiab norm data from the Australian 
Diabetes, Obesity and Lifestyle study495. 
 
Table 3.13: HRQoL parameters one year post-explant. 
Parameter (unit) Baseline One year 
post-
explant 
Mean 
reduction from 
baseline 
P value (n=9) 
Epworth Sleepiness Scale 7.6  ± 3.4 5.7 ± 3.9 2.4 ± 4.1 0.111 
HADS-Anxiety 8 ± 4 7 ± 3 0 ± 4 0.8701 
HADS-Depression 6 ± 4 4 ± 3 0 ± 4 0.372 
Active Australia – sufficient time (mins) 425 ± 
516 
604 ± 316 -209 ± 616 0.172 
6MWT (m)* 500 ± 84 588 ± 58 -3 ± 190 0.041^ 
SF-36 – Physical functioning  52 ± 25 61 ± 26 -5 ± 29 0.621 
SF-36 – Role Limitations due to Physical Health 46 ± 44 56 ± 41 0 ± 47 0.732 
SF-36 – Pain  54 ± 26 61 ± 26 8 ± 34 0.521 
SF-36 – General Health  44 ± 22 63 ± 23 -15 ± 22 0.071 
SF-36 – Role Limitations due to Emotional 
Problems  
51 ± 44 52 ± 38 7 ± 66 0.672 
SF-36 – Energy/Fatigue  44 ± 20 62 ± 16 -1 ± 14 0.911 
SF-36 – Emotional Wellbeing 61 ± 24 65 ± 12 6 ± 19 0.242 
SF-36 – Social Functioning 57 ± 29 65 ± 29 1 ± 36 0.921 
^ n= 8. Data displayed as mean ± SD. Normally distributed data analysed by 1. Paired t-test. Data not normally 
distributed analysed by 2.Wilcoxon signed rank test. Results deemed significant if p<0.05. 
6MWT; six minute walk test, HADS; Hospital Anxiety and Depression Scale. 
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3.4 DISCUSSION 
In our cohort, treatment with a DJBS was effective, resulting in significant improvements in body 
weight and markers of metabolic health.  Mean weight loss was 19.5±8.7 kg over the 48 week 
intervention period.  This represents a mean TBWL of 17.0% and a mean EWL of 29.5%.   
This exceeds the threshold for clinical significance of 5.0% total weight loss reported in a 2013 
consensus guideline258, as well as the EWL threshold for treatment success with an endoscopic 
bariatric therapy outlined in the 2011 ASGE guidelines420.  Our findings are similar to those reported 
in a 2018 systematic review and meta-analysis, which assessed 352 patients across 10 studies516.   
The mean weight loss was 11.3 kg across a mean duration of 9.2±3.1 months.  In a subset analysis 
(n=305 from four studies), this corresponded to a TBWL of 18.9% or a mean EWL of 36.9% (n=301 
from four studies).  However, relative weight loss is infrequently reported across studies of the DJBS, 
leading to only four studies being included in the subset analyses of the meta-analysis.  This is despite 
the Joint Bariatric Taskforce guidelines using EWL at 12 months as the parameter for defining 
treatment success420. 
We also assessed changes in body composition (by DEXA) following DJBS treatment.  There was a 
significant reduction in body fat percentage and both lean and fat mass (in kg) following DJBS 
treatment.  Other studies have also reported reductions in fat mass over six to 12 months  
post-implantation451, 456, 467, 469, 518.  However, the concurrent loss of lean body mass observed in our 
cohort are in contrast to what has previously been reported451, 469, 518.  This predisposes patients to 
weight regain (due to a reduction in basal metabolic rate29, 519) and poorer metabolic outcomes (due 
to the role of skeletal muscle mass in glucose metabolism) when the DJBS is removed. 
At baseline, 9 of our 19 patients had HbA1c levels above 7%, exceeding the target for good control of 
diabetes520.  After DJBS treatment, four of these nine patients met the above threshold for good 
control of diabetes.  Overall, we observed a mean reduction in HbA1c of 0.9± 1.0%, reflecting a 
clinically significant (>0.5%520) reduction in HbA1c in 10 of 19 patients.  It is important to note that 
of the nine patients who did not achieve at least a 0.5% reduction in HbA1c, eight had good control at 
baseline (<7%).  Our results are consistent with other published observations.  A 2018 systematic 
review and meta-analysis assessed glycaemic control outcomes in 388 patients with obesity and 
T2DM.  The mean reduction in HbA1c was 1.3 % across 14 studies with a mean study duration of  
9.2 ± 3.1 months516.  Most studies to date have included patients receiving insulin444, 446, 447, 451-454, 457-
460, 462-465, 467, 469, 476, 480-482, 518.  The difference in baseline HbA1c, and reduction in HbA1c with treatment 
may be because we excluded these patients in our study.  These results add to the body of literature, 
with approximately the same magnitude of improvements in weight and glycaemic control parameters 
as previously reported. 
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Whilst clinical efficacy has been demonstrated, concerns surrounding the safety profile of the DJBS 
have been voiced in recent years521.  The major issue identified with the DJBS was the 3% incidence 
of hepatic abscess reported in one US trial.  This lead to the early termination of the study.  While we 
observed no cases of hepatic abscess in our cohort, four devices were removed early, accounting for 
21% of our study cohort.  Three of these cases were due to persistent abdominal pain and one early 
explant was secondary to GI bleeding and device migration when the patient did not adhere to the 
prescribed diet.  This early explant rate is consistent with existing literature, which has ranged from 
0-69%449, 461.  In a 2018 systematic review and meta-analysis of nine studies including 350 patients 
who underwent DJBS treatment, the overall SAE rate was 15.7%516.  In this report, nearly a third (16) 
of the reported SAEs were episodes of GI bleeding requiring hospital admission leading to early 
removal in 15 of 16 cases.  Bleeding and migration may occur secondary to patient non-compliance 
with medication or dietary prescriptions464 and thus can be considered preventable with appropriate 
patient selection, education and close monitoring.  However, the need for early device removal 
occurred despite strict patient selection, proper device positioning and close clinical monitoring and 
education of patients, indicating the need to develop strict inclusion and exclusion criteria for patients 
that ideally should incorporate criteria that should predict patient compliance. 
Besides the early removal due to GI bleeding and migration, we had seven other SAEs resulting in 
hospital admission.  There were three cases of GI bleeding, three instances of severe abdominal pain 
and one urinary tract infection.  This represents a 42% SAE rate.  In all cases, patients were 
conservatively managed and underwent repeat endoscopy to confirm device positioning and patency.  
All events resolved without further sequelae.  Despite this, the safety data from our cohort does not 
meet the 5% threshold of SAEs considered acceptable by the ASGE423. 
Our study also aimed to assess other measures of metabolic health, with a focus on components of 
the metabolic syndrome.  The effect on waist circumference in the current study is consistent with 
existing literature459, 461, 469, with a statistically significant reduction observed (132.2±18.0 cm vs 
118.8±14.3 cm).  However, waist circumference at explant exceeded population guidelines for risk 
of chronic disease in all patients (>80 cm for females and >90 cm for males)15.  Over the 48 week 
intervention period, a significant reduction in total cholesterol and triglycerides was reported.   
There was no significant change in LDL- or HDL-cholesterol.  The evidence for the DJBS leading to 
improvement in cardiovascular disease risk is mixed.  A significant increase in HDL-cholesterol has 
been reported in one study469, whilst other studies did not find a significant change in HDL-
cholesterol449, 451, 454, 459, 461, 463, 480, 482.  A significant improvement in total cholesterol447, 448, 452, 454, 459, 
465, 469, 482 and LDL-cholesterol447-449, 451, 452, 459, 465, 469, 480, 482 has been observed in a number of studies.  
Unfavourable changes in cholesterol have also been reported443, 446.  Significant reductions in serum 
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triglycerides have also been reported447-449, 452, 457, 465, whilst other studies have reported no significant  
change451, 454, 459, 461, 463, 469, 480.  Improvements in blood pressure have been reported in eight  
studies448, 449, 452, 454, 457, 461, 464, 469.  In this cohort, no statistically significant impact on blood pressure 
was observed following DJBS treatment.  However, at baseline 13 of 19 patients had systolic blood 
pressures meeting metabolic syndrome criteria (baseline mean: 139±19).  At device explant, this was 
reduced to six of 19 (explant mean: 131±15), suggesting clinical benefits occur despite the lack of 
statistical significance. 
Besides weight loss, one of the key objectives of this project was to assess the impact of treatment on 
the metabolic syndrome.  At device explant, all patients still met diagnostic criteria for metabolic 
syndrome using a widely accepted consensus definition15.  However, when a novel scoring system 
(MetSSS) was used to determine metabolic syndrome severity517, there was a significant reduction in 
MetSSS from baseline to explant, indicating a significant improvement of the metabolic syndrome 
over the 48 week treatment period. 
More broadly, obesity and T2DM impact liver function, with NAFLD being a common  
obesity-related comorbidity.  In out cohort, significant improvements in ALT and AST were observed 
following DJBS treatment.  These improvements in liver enzymes following DJBS treatment have 
previously been reported451, 454, 464, 470.  However, we also assessed hepatic elastography measures.  
To date, only one study has reported on hepatic stiffness (an indirect measure of hepatic fibrosis) and 
the CAP (an indicator of hepatic steatosis) using vibration controlled transient elastography in a 
cohort of 20 patients455.  Hepatic stiffness is increased by a variety of factors including hepatic 
fibrosis, steatosis and necro-inflammation, with histologically more severe NAFLD being associated 
with higher transient elastography scores522.  The authors reported a trend toward a reduction in liver 
stiffness after 52 weeks of DJBS treatment.  In a subgroup of 11 patients where the standard probe 
(M probe) could be used, they observed a significant reduction in the CAP, which implies an 
improvement in hepatic steatosis.  These results are similar to what was observed in the current 
cohort; however, we used the XL probe, which was designed for use in patients with obesity for the 
assessment of fibrosis490 and steatosis523. 
The DJBS is purported to act as a RYGB mimetic, interfering with absorption of both macro- and 
micronutrients in the proximal GIT.  Following bariatric surgery, changes in BMD and vitamin and 
mineral deficiencies have been reported524, 525, secondary to changes in vitamin and mineral 
absorption.  In the current study, there was no significant change in BMD or Z score at any site.   
There was a significant reduction in the right femur T score, which is reflective of a comparison to a 
young healthy female.  In all patients, this change in T score was clinically significant (defined as 
>5.6% change526) despite all patients remaining within the normal range as per WHO criteria527.   
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At one year post-explant, there was no statistically significant difference in BMD compared to 
baseline.  To date, only one other study has evaluated the impact of DJBS treatment on BMD518.   
In a 52 week study of 19 patients with obesity and T2DM, a significant reduction (4.1±4.0%) in BMD 
at the femoral neck was observed.  The authors observed no significant change in osteocalcin and a 
significant increase in Insulin-like Growth Factor-1, concluding the changes in BMD observed were 
not clinically significant.  These results suggest DJBS treatment does not have a negative long-term 
impact on BMD. 
In our cohort, a statistically significant reduction in vitamin E was observed over the 48 week 
intervention period.  No significant change in any other fat soluble vitamin was observed and despite 
the statistically significant difference in vitamin E, values remained within the normal clinical 
reference range.  This is consistent with other data469 and suggests DJBS treatment does not have a 
clinically significant effect on fat soluble vitamin status. 
A significant reduction in serum ferritin was also observed.  Three other studies have reported a 
significant decrease in serum ferritin, a marker of iron storage, following DJBS treatment452, 469, 518.  
This could imply that the DJBS reduces iron absorption in the duodenum or that low volume GI 
bleeding at the anchor site may occur.  However, ferritin may not be an appropriate marker of iron 
status in our cohort.  Iron is an acute phase reactant, and therefore the reductions observed may be 
reflective of an improvement in diabetes528 and NAFLD-related529 inflammation. 
A significant increase in vitamin D was observed across the intervention period.  This may reflect 
increased outdoor time associated with increased physical activity (as reported in the Active Australia 
Survey).  Two previous studies have reported a significant increase in vitamin D following DJBS 
treatment463, 518, whist two have reported no change452, 469.  In one study, this increase in vitamin D 
was attributed to the study supplementation protocol; however, the second study used data from a 
national registry so information about supplementation protocol or seasonal variation was not 
provided.  In those who completed follow-up at one year post-explant, vitamin D was significantly 
lower than baseline.  This is possibly associated with seasonal variation secondary to a delay in blood 
test sampling for this marker in some patients, with testing occurring at the end of winter. 
A number of centres have prescribed a daily multivitamin and iron supplement as part of their 
treatment protocol; however, circulating micronutrient status was not reported in these  
studies447, 448, 450, 461.  The prescription of micronutrient supplementation aligns with recommendations 
for nutrition care following bariatric surgery530.  In our study, prophylactic supplementation was not 
prescribed.  Our results show that, with the exception of iron status, no clinically significant negative 
effect on vitamin and mineral status was observed.  Overall, the results from our cohort do not suggest 
that blanket supplementation is warranted.  It is possible the frequent dietetics input, which focussed 
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on improving diet quality to facilitate weight loss, may contribute to the lack of deficiencies observed 
in our cohort.  Unlike surgical procedures, which result in permanent anatomical changes, the DJBS 
is used as a transient measure to facilitate weight loss.  This may reduce the long-term impacts on 
nutrition status; however, this is the first study to assess long-term post-explant markers of nutrition 
status.  At one year post-explant, ferritin remained significantly lower than baseline.  This warrants 
further investigation to determine if duodenal morphology is impacted by DJBS treatment, as villous 
atrophy could reduce iron absorption, as observed in coeliac disease531. 
A number of novel investigations were conducted as part of this study.  This is the first study to report 
on diet following DJBS implantation, either in the form of dietary intake data or detail on dietary 
compliance, despite the majority of studies prescribing a calorie-controlled diet that in itself would 
initiate weight loss.  The magnitude of weight loss observed after DJBS treatment is greater than that 
typically achieved by dietary modification alone, which is most efficacious in the first six months of 
treatment, with weight loss plateauing at 12 months269.  The majority of studies define dietary 
prescriptions or recommendations poorly, particularly beyond the first two weeks post-procedure 
where a texture modified diet is recommended by the device manufacturer.  Further, the 
heterogeneous nature of advice given may impact study results.  In the present study, diet was 
measured monthly using a 24 hour recall and individualised dietary advice was provided to facilitate 
weight loss by improving diet quality.  Broadly, favourable changes in dietary intake, such as a 
significant reduction in energy intake (7,703±2978 kJ vs 4474±1468) and the contribution of fat to 
overall intake (35±6% vs 26±9%) were observed during the treatment period.  At one year post-
explant, self-reported energy intake remained significantly reduced, as compared to baseline.   
In parallel, there was a significant reduction in fat and carbohydrate intake.  The impact on overall 
dietary macronutrient distribution was limited.  A 24 hour recall is not an indicator of long-term 
intake, and the weight regain that occurred in our cohort suggests an increase in energy intake has 
occurred. 
This is the first study to assess functional exercise capacity and HRQoL following DJBS treatment.  
There was a significant improvement in exercise tolerance and self-reported physical activity.   
At one year post-explant, functional exercise capacity remained significantly improved, with patients 
able to walk significantly further (500±84 m vs 607±92 m) during the 6MWT, despite no maintained 
increase in self-reported physical activity.  There was also a significant improvement in six of eight 
HRQoL domains during the intervention period.  Improvements in HRQoL have been observed in 
other weight loss interventions.  In a systematic review of 53 weight loss intervention studies, there 
was a significant improvement in HRQoL in 17 studies; but that was not significantly associated with 
weight loss532.  This suggests that weight loss itself is not the key driver for improvement in HRQoL.  
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In our cohort, there was no persistent improvement in HRQoL at one year post-explant, despite 
maintenance of significant weight loss.  This may be associated with patient expectations, as whilst 
a significant amount of weight loss was maintained, a large magnitude of weight regain occurred.   
This phenomenon warrants further investigation to determine the modulators of quality of life 
following treatment with a removable endoscopic weight loss aid. 
There have been limited reports of data from long-term follow-up of patients after device 
explantation.  These data have mostly been limited to weight and metabolic outcomes.  The majority 
of studies with follow up to one year post-explant have reported a statistically significant reduction 
in body weight, compared to baseline453, 458, 462.  Conversely, the majority of studies have reported no 
persistent improvement in glycaemic control at one year post-explant453, 458, 482; although, one study 
has reported a sustained reduction in HbA1c at one year post-explant462.  The results of our study mirror 
the literature, with a statistically significant reduction in body weight at one year post-explant 
compared to baseline, but no sustained improvement in glycaemic control.  Whilst this could be 
interpreted as a negative finding, there was a trend toward a significant reduction in MetSSS.   
This suggests that despite deteriorations in metabolic parameters that were improved through 
treatment, there may be some persistent metabolic benefit following DJBS treatment.  Similarly, there 
was no sustained improvement in markers of hepatic fibrosis and steatosis, although ALT remained 
significantly reduced as compared to baseline.  Of the nine patients that completed follow-up at one 
year post-explant, seven underwent repeat transient elastography studies.  Of these, only three had 
been able to maintain clinically significant ( ≥7% in the context of NASH) weight loss, which has 
previously been demonstrated to improve hepatic fibrosis and steatosis533, 534 and this may explain 
the amelioration of beneficial effects. 
In any weight loss intervention, establishing baseline predictors of success is helpful for triaging 
patients based on their unique physiology to maximise positive weight loss outcomes.  One study has 
evaluated baseline predictors of success in a cohort of 185 individuals with severe obesity and 
T2DM452.  In this cohort, regression modelling revealed high fasting c-peptide level (a marker of 
insulin production) and higher body weight (>107 kg) were independent predictors of treatment 
success, which was defined as TBWL of ≥5% (with separate targets for improvements in T2DM).   
In the present cohort, bivariate correlations were used to screen for baseline predictors of weight loss.  
Two predictors were found - baseline diastolic blood pressure, which was positively correlated with 
weight loss and baseline self-reported physical function score, with poorer physical function being 
negatively correlated with weight loss.  Clinically, these are not useful for triaging patients for weight 
loss interventions, and statistically the study is underpowered to accurately capture baseline predictors 
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of treatment efficacy.  Further studies are required to determine clinically meaningful baseline 
predictors of intervention success. 
The overarching limitations of the study include the small sample size and lack of a randomised 
control group (either diet only or sham endoscopy).  Further, the dietary collection methodology,  
a monthly 24 hour recall, provides an isolated snapshot of dietary intake and cannot be representative 
of an entire month.  Additionally, like all dietary intake assessment methodologies, this method 
requires accurate self-report.  This method was selected to reduce participant burden. 
The study also has several strengths.  This is the first study to report on dietary intake, functional 
exercise capacity and HRQoL during the treatment period.  However, the key strength of the study is 
the breadth of post-explant follow-up investigations.  This is the first study to assess body 
composition, BMD, dietary intake, functional exercise capacity and HRQoL following device 
explant.  We also assessed patients using a number of “gold standard” or clinically practical 
techniques.  To date, there have been limited reports of body composition and BMD following DJBS 
treatment using the “gold standard” DEXA methodology.  This is only the second study to use 
transient elastography to assess hepatic stiffness and the CAP (as a marker of steatosis) following 
DJBS treatment.  Whilst this is not the “gold standard” for assessment of NAFLD pathology, this tool 
is a simple, non-invasive measure that is commonly used in clinical practice.  Overall, the breadth of 
these investigations provide new clinical information on the impact of DJBS treatment on  
obesity-related comorbidities. 
In summary, significant improvements in body weight and markers of the metabolic syndrome were 
observed at the end of DJBS treatment.  While some patients were able to maintain clinically 
significant improvements in body weight, the majority of patients regained a significant amount of 
weight after removal of the DJBS.  Despite this, there was a trend towards an improvement in 
metabolic syndrome severity.  Little is known about the mechanisms via which the DJBS leads to 
significant weight loss.  Subsequent chapters of this thesis will assess the impact of DJBS treatment 
on GI function, the GI microbiota and the immune system.  These investigations may identify critical 
factors for a clinical response to treatment. 
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Chapter 4: Effect of the Duodenal-Jejunal Bypass 
Sleeve on Gastrointestinal Function  
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4.1 INTRODUCTION 
Obesity and related comorbidities such as T2DM have been associated with a number of perturbations 
of normal GI function.  In particular, obesity and T2DM have been associated with delayed gastric 
emptying535-538.  However, the largest study of patients with obesity reported significantly accelerated 
gastric emptying of solids in a cohort of 323 patients85.  Gastric emptying rate is a relevant 
determinant of food intake, associated with feelings of fullness and satiation539.  Therefore, in an 
obese cohort, delaying gastric emptying to enhance satiety would likely facilitate weight loss.   
T2DM has also been associated with an increased prevalence of PEI106, 540, 541, which results in a 
decrease in pancreatic enzymes and therefore changes to nutrient digestion and absorption.  Many 
treatments for obesity and T2DM, including pharmacotherapy, endoscopic techniques and surgery, 
target the GIT to facilitate weight loss and metabolic improvements.  As such, measures of GI 
function, and measurements of the impact of individual treatments on satiety and digestion are 
critical, as they have implications for treatment outcomes and tolerability. 
The DJBS dwells in the proximal duodenum, yet there have been a limited number of studies 
assessing the impact of DJBS implantation on GI function.  Two studies have assessed gastric 
emptying kinetics following DJBS implantation.  In a cohort of 25 patients with obesity and T2DM, 
de Moura et al. used gastric scintigraphy to assess gastric emptying kinetics over four hours485.   
At baseline, 88% of patients had normal gastric emptying kinetics.  The in situ presence of the DJBS 
significantly delayed gastric emptying at all time-points over the four hour test.  There was also a 
trend towards a relationship between gastric retention at four hours and weight loss.  Four weeks after 
device explant, there was a significant persistent delay of gastric emptying kinetics in the first two 
hours of the test.  In a second study of 19 patients with obesity (10 with normal glucose tolerance and 
nine with T2DM), gastric emptying was assessed by paracetamol absorption kinetics over four 
hours456.  In this study, no significant change in gastric emptying following DJBS implantation was 
reported.  However, there was no description of whether patients had normal gastric emptying at 
baseline, making interpretation of these results difficult. 
There are no published reports on the impact of DJBS implantation on fat absorption, despite 
suggestion that fat absorption may be impaired by the device separating chyme from bile and 
pancreatic secretions to the mid-jejunum, where the two streams meet446.  Further, whilst  
GI symptoms have been reported as adverse events of treatment in the majority of published 
studies445, 447-452, 454-459, 461, 462, 465, 469, 475, 482, they have not been investigated thoroughly, particularly 
as a potential mechanism of action for inducing weight loss.  Therefore, to more fully understand the 
mechanisms of action of the DJBS, more detailed characterisation of the impact of the device on GI 
function is required. 
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4.1 Aims and Hypotheses 
The overall aim of this chapter was to characterise the effect of the in situ presence of the DJBS on 
GI function in patients with obesity and T2DM. 
Specifically, gastric emptying, intraluminal lipolytic activity, self-reported GI symptoms and 
symptom response to a meal challenge were assessed, along with any links to magnitude of weight 
loss achieved. 
It was hypothesised the in situ presence of the DJBS would: 
• Delay gastric emptying, measured by the 13C octanoic acid breath test; 
• Reduce intraluminal lipolytic activity, measured by the 13C mixed triglyceride breath test; 
• Increase self-reported GI symptoms, measured using the SAGIS instrument; and 
• Increase meal-related GI symptoms, measured by a standardised nutrient challenge. 
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4.2 METHODS 
4.2.1 Gastric Emptying 
Gastric emptying was assessed at baseline, eight weeks post-implant and within three weeks after 
device explant using the 13C octanoic acid breath test.  Patient classification was based on gastric 
emptying lag time, with a normal reference range of 118±73 minutes.  Further details can be found 
in Chapter 2 Section 2.4.1. 
4.2.2 Intraluminal Lipolytic Activity 
Intraluminal lipolytic activity was assessed at baseline, eight weeks post-implant and within three 
weeks after device explant using the 13C mixed triglyceride breath test.  The key reporting outcome 
was cumulative 13CO2 recovered after six hours.  Faecal elastase was also assessed by Pathology 
Queensland to exclude concomitant PEI.  Further details can be found in Chapter 2 Section 2.4.2. 
4.2.3 Gastrointestinal Symptoms 
Meal-related GI symptoms were assessed at baseline, four weeks post-implant and within three weeks 
after device explant using a standardised nutrient challenge test.  GI symptoms were also evaluated 
at each clinical review using the SAGIS instrument.  Further details can be found in Chapter 2  
Section 2.4.3 and Section 2.4.4. 
4.2.4 Statistical Analysis 
All quantitative measures were described as mean and standard deviation and were assessed for 
normality of distribution using the Shapiro-Wilk normality test.  Normally distributed data was 
analysed using paired t-tests, which compared pre- to DJBS in situ measurements or pre- to post-
explant measurements.  Non-normal data was assessed by the Wilcoxon signed rank test.   
Dependent on normality of distribution, Pearson or Spearman bivariate correlations were used to 
screen for variables (baseline or change from baseline) correlating with weight loss response at device 
explant (TBWL percentage) and to assess the relationship between change in energy intake and GI 
symptoms.  Where a significant correlation was observed, linear regression was performed and 
reported. 
All analyses were performed using IBM Statistical Package for Social Sciences Version 24 (IBM 
Corp., NY, USA), and figures were generated using GraphPad Prism Version 7 (GraphPad Software 
Inc, CA, USA).  Statistical analysis was performed with the guidance of Justin Scott at QFAB and 
Professor Mike Jones from Macquarie University.
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4.2.5 Schedule of Investigations 
 
Figure 4.1: Schedule of GI function investigations. 
Baseline
• Gastric emptying assessment
• Intraluminal lipolytic activity assessment
• Standardised nutrient challenge test
• SAGIS questionnaire
4 weeks 
post-implant
• Standardised nutrient challenge test
• SAGIS questionnaire
8 weeks 
post-implant
• Gastric emptying assessment
• Intraluminal lipolytic activity assessment
36 weeks 
post-implant
• SAGIS questionnaire
Explant
• Gastric emptying assessment
• Intraluminal lipolytic activity assessment
• Standardised nutrient challenge test
• SAGIS questionnaire
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4.3 RESULTS 
4.3.1 Gastric Emptying 
At baseline, gastric emptying lag time was normal in all patients.  DJBS implantation did not 
significantly impact gastric emptying lag time (Figure 4.2A, n=14; p=0.35) or half time (Figure 4.2C, 
n=14; p=0.45) measured after eight weeks of device dwell.  At device explant, there was no significant 
difference in gastric emptying lag time (Figure 4.2B, n=14; p=0.93) or half time (Figure 4.2D, n=14; 
p=0.57), compared to baseline.  There was no significant correlation between baseline gastric 
emptying rates, or change in gastric emptying rates from baseline to eight weeks, and weight loss at 
device explant.  Gastric emptying lag time and half time at all time-points are presented in Figure 4.3. 
 
Figure 4.2: Gastric emptying kinetics. 
The in-situ presence of the device (measured after eight weeks of dwell time) did not delay gastric emptying 
lag time (A; p=0.35) or half time (C; p=0.45) as measured by the 13C octanoic acid breath test.  There was no 
significant difference between baseline and post-explant gastric emptying lag time (B; p=0.93) or half time 
(D; p=0.57).  Normal reference range for lag time of 118±73 minutes (A and B) shown as a dotted line on 
chart.  Each patient is displayed as an individual line.  One outlier at 8 weeks dwell time removed for graphical 
purposes, but included in statistical analysis.  Baseline vs 8 weeks dwell time (A) and baseline vs. explant (B) 
gastric emptying lag time compared by paired t-test. Baseline vs 8 weeks dwell time (C) and baseline vs. 
explant (D) gastric emptying half time compared by Wilcoxon signed rank test. 
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Figure 4.3: Gastric emptying lag time and half-time at baseline, with the DJBS in situ and within three 
weeks after device explant. 
There was no significant difference in gastric emptying lag time (A) or half-time (B) across the three time-
points as measured by the 13C octanoic acid breath test.  Data are presented grouped by time-point.  One outlier 
excluded for graphical purposes. 
4.3.2 Intraluminal Lipolytic Activity 
With the exception of one patient with a low faecal elastase throughout, all other patients had normal 
faecal elastase measures at all time-points. 
There was no significant impact of DJBS implantation on intraluminal lipolytic activity compared to 
baseline at any time-point (Figure 4.4A; n=18; p=0.72 and Figure 4.4B; n=11; p=0.06).   
In addition, there was no significant correlation between baseline intraluminal lipolytic activity, or 
change in lipolytic activity (baseline to eight weeks) and weight loss at device explant.  Indeed, those 
patients with the greatest magnitude of weight loss both after eight weeks of dwell time and at device 
explant also had the highest levels of intraluminal lipolytic activity with the device in situ (r=0.49; 
p= 0.03 at eight weeks and r=0.53; p=0.04 at explant).  This further suggests that reduced intraluminal 
lipolytic activity is not a contributing mechanism to DJBS induced weight loss.  Intraluminal lipolytic 
activity at all time-points is summarised in Figure 4.5. 
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Figure 4.4: Intraluminal lipolytic activity. 
The in-situ presence of the device (measured after eight weeks of device dwell time) did not impact the 
cumulative dose of 13C recovered in breath samples (A; n=18; p=0.72) as measured by the 13C mixed 
triglyceride breath test.  There was no significant change in post-explant cumulative recovery of 13C in breath 
samples, compared to baseline (B; n=11; p=0.06).  Each patient is displayed as an individual line.  Results 
assessed by paired t-test. 
 
 
Figure 4.5: Intraluminal lipolytic activity at baseline, with the DJBS in situ and within three weeks after 
device explant. 
There was no significant difference in the cumulative dose of 13C recovered in breath samples across the three 
time-points as measured by the 13C mixed triglyceride breath test.  Data are presented grouped by time-point. 
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4.3.3 Gastrointestinal Symptoms 
A standardised nutrient challenge test was performed to assess meal-related GI sensory function.   
There was a significant increase in postprandial pain, fullness, retrosternal burning and total symptom 
score four weeks after device implant (Figure 4.6, Table 4.1).  After device explant, symptoms 
returned to baseline levels in all but two patients, who still had a significant symptom burden 
(Figure 4.7, Table 4.1).  Although meal-related symptoms increased with the device in situ, there was 
no direct correlation between baseline symptom scores (individual or cumulative), or change in 
symptom scores (individual or cumulative) from baseline to four weeks and weight loss at device 
explant.  Similarly, there was no significant relationship between change in dietary energy intake 
from baseline and change in symptom scores (individual or cumulative) from baseline to four weeks.  
GI symptom responses to a standardised nutrient challenge at all time-points are summarised in  
Figure 4.8. 
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Figure 4.6: GI symptom response to a standardised nutrient challenge with the device in situ. 
There was a significant increase in postprandial pain (A), fullness (B), retrosternal burning (D) and total 
symptom score (F) four weeks after device implantation.  There was no significant change in nausea (C) or 
acid regurgitation (E).  Each patient is displayed as an individual line.  Results analysed by Wilcoxon signed 
rank test. 
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Figure 4.7: GI symptom response to a standardised nutrient challenge within three weeks after device 
explant. 
There was no significant difference in scores for any symptom within three weeks after device explant, 
compared to baseline.  Each patient is displayed as an individual line.  Results analysed by Wilcoxon signed 
rank test. 
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Figure 4.8: GI symptom response to a standardised nutrient challenge test at baseline, with the DJBS in 
situ and within three weeks after device explant. 
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There was a significant increase in postprandial pain (A), fullness (B), retrosternal burning (D) and total 
symptom score (F) four weeks after device implantation, but this did not persist within three weeks after device 
explant  Data are presented grouped by time-point. 
Table 4.1: Meal-related GI symptoms following a standardised nutrient challenge test. 
Parameter (unit) Baseline  4 weeks Explant (48 weeks) P value at 4 weeks^ P value at explant^^ 
Nutrient Challenge Test 
Pain 9 ± 10 48 ± 58 34 ± 66 0.01 0.24 
Fullness 84 ± 57 148 ± 101 126 ± 75 0.02 0.17 
Nausea 30 ± 51 49 ± 65 44 ± 71 0.37 0.51 
Retrosternal Burning 7 ± 12 50 ± 58 29 ± 63 0.02 0.67 
Acid Regurgitation 11 ± 17 39 ± 47 34 ± 62 0.07 0.37 
Total Score 141 ± 100 334 ± 269 267 ± 307 0.003 0.16 
^ n=15 ^^ n=13 ^^^ n=8. Results analysed by Wilcoxon signed rank test as compared to baseline, and displayed as mean 
± SD. 
 
The intensity of 22 upper and lower GI symptoms was assessed using the SAGIS questionnaire.   
Four weeks after device implant, there was a significant increase in 14 individual GI symptoms and 
the total symptom score (Table 4.2).  There was also a significant increase in symptoms from the 
epigastric pain, reflux, nausea/vomiting and constipation domains, but not the diarrhoea and 
discomfort domain (Figure 4.9).  At 36 weeks post-implant, there was a significant increase in  
12 individual GI symptoms and the total symptom score (Figure 4.9; Table 4.2).  At the domain level, 
there was a significant increase in symptoms from all domains, including the diarrhoea and discomfort 
domain.  Although symptoms increased with the device in situ, there was no correlation between 
baseline symptom domain scores, or change in domain scores from baseline at four or 36 weeks and 
weight loss at device explant.   
Linear regression was used to assess the relationship between SAGIS scores, domain scores,  
or change in these score from baseline and dietary energy intake.  There was no significant 
relationship between symptom intensity and change in dietary energy intake.  It should be noted that 
the study was not powered for assessment of these relationships. However, these results suggest GI 
symptoms are persistent, and whilst not directly correlated with weight loss or changes in dietary 
intake, are likely to contribute to the reduction in energy intake reported in Chapter 3 Section 3.3.5. 
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Figure 4.9: GI symptom (SAGIS) domain scores during the peri-implant period and late treatment period. 
At four weeks (blue), there was a significant increase in all symptom domains, with the exception of diarrhoea 
and discomfort.  At 36 weeks (red), there was a significant increase in all symptom domains.  Mean of patient 
scores displayed on graph.  Results assessed by Wilcoxon signed rank test. 
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Table 4.2: Self-reported GI symptoms measured by the SAGIS instrument. 
Parameter Baseline 4 weeks 36 weeks P value at 4 
weeks^ 
P value at 36 
weeks^^ 
Individual Symptom Score 
Acid eructation 0.4 ± 0.8 0.7 ± 0.9 0.6 ± 1.0 0.10 0.32 
Dysphagia 0.2 ± 0.4 0.3 ± 0.5 0.1 ± 0.3 0.08 0.32 
Fullness 0.2 ± 0.5 1.2 ± 1.0 1.1 ± 1.1 0.003 0.01 
Early satiety 0.1 ± 0.3 1.2 ± 1.0 1.3 ± 1.0 0.002 0.002 
Postprandial pain 0.2 ± 0.5 1.3 ± 1.2 0.8 ± 1.0 0.001 0.01 
Epigastric pain 0.2 ± 0.4 1.3 ± 1.2 0.9 ± 1.1 0.003 0.02 
Retrosternal discomfort 0.2 ± 0.4 1.1 ± 1.1 0.7 ± 0.9 0.003 0.03 
Pain/discomfort prior to 
defecation 
0.4 ± 0.8 0.5 ± 0.8 0.5 ± 0.8 0.43 0.10 
Difficulty defecating 0.5 ± 0.8 1.4 ± 1.4 0.8 ± 1.2 0.01 0.08 
Constipation 0.4 ± 0.7 1.7 ± 1.3 0.9 ± 1.0 0.001 0.01 
Loose stools 0.5 ± 0.8 0.7 ± 0.9 0.6 ± 0.8 0.21 0.41 
Faecal incontinence 0.3 ± 0.6 0.2 ± 0.4 0.1 ± 0.3 0.66 0.16 
Urgency to defecate 0.6 ± 0.8 0.5 ± 0.8 0.5 ± 0.8 0.53 0.41 
Diarrhoea 0.5 ± 0.8 0.4 ± 0.8 0.1 ± 0.3 0.56 0.08 
Loss of appetite 0.3 ± 0.6 1.0 ± 0.9 0.9 ± 0.7 0.01 0.01 
Abdominal cramps 0.3 ± 0.6 1.2 ± 1.2 1.0 ± 1.1 0.01 0.01 
Sickness 0.1 ± 0.2 0.4 ± 0.8 0.7 ± 0.9 0.03 0.02 
Nausea 0.1 ± 0.2 0.5 ± 0.8 0.6 ± 1.0 0.02 0.03 
Vomiting 0.1 ± 0.2 0.1 ± 0.2 0.4 ± 0.5 1.00 0.01 
Bloating 0.7 ± 0.9 1.6 ± 1.3 1.2 ± 1.0 0.01 0.07 
Excessive gas flatulence 0.6 ± 1.0 1.4 ± 1.2 1.4 ± 0.8 0.01 0.01 
Belching 0.3 ± 0.6 0.9 ± 1.2 1.1 ± 1.2 0.02 0.01 
Cumulative GI symptoms  6.8 ± 9.1 19.5 ± 
14.2 
15.7 ± 
13.2 
<0.001 0.001 
Domain Score 
Epigastric pain 1.8 ± 2.6 8.8 ± 6.8 6.8 ± 5.4 <0.001 0.001 
Diarrhoea and discomfort 2.8 ± 3.7 3.7 ± 3.1 3.1 ± 2.4 0.11 0.04 
Reflux 0.9 ± 1.5 1.9 ± 2.3 1.7 ± 2.2 0.01 0.02 
Nausea/vomiting 0.4 ± 0.8 2.0 ± 2.2 2.6 ± 2.8 0.002 0.004 
Constipation 0.9 ± 1.5 3.1 ± 2.6 1.8 ± 2.1 0.002 0.02 
^ n=19 ^^ n=16 ^^^ n=12. Results displayed as mean ± SD. Data analysed by Wilcoxon signed rank test. Results 
deemed significant if p<0.05. 
GI; gastrointestinal 
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4.4 DISCUSSION 
Over the past ten years, the DJBS has been investigated for clinical efficacy and safety; however, 
little is known about the potential mechanisms of action in inducing weight loss.  The key finding of 
our study was, contrary to our expectations, there was no evidence that DJBS treatment altered 
intraluminal lipolytic activity, as measured by the absorption of a 13C labelled mixed triglyceride.  
This finding is important as the device has previously been proposed to alter fat absorption446. 
In patients with obesity, a delay in gastric emptying could enhance satiety and thus may facilitate 
weight loss.  However, gastric emptying has been investigated in two studies after DJBS implantation, 
with conflicting results456, 485.  In our cohort, we found no evidence of alteration in gastric emptying 
following DJBS treatment. 
This is the first study to determine the prevalence of GI symptoms following placement of the DJBS.  
Epigastric pain symptoms have been widely reported as adverse events of DJBS treatment in the 
literature445, 447-452, 454-459, 461, 462, 465, 469, 475, 482 (see Chapter 1 Section 1.3.4.2).  However, we believe 
they are key to the weight loss response to treatment.  Assessment of GI symptoms with the SAGIS 
instrument showed there was a significant increase in GI symptoms from the early (four weeks post-
procedure) to the late (36 weeks post-procedure) intervention period.  In particular, epigastric pain 
domain symptoms (such as pain, fullness and early satiety) were increased nearly five-fold in the 
early intervention period, when weight loss is most rapid.  Similarly, there was a significant increase 
in meal-related symptom response to a nutrient challenge test (self-reported abdominal pain, fullness 
and retrosternal burning).  This suggests the generation of these epigastric symptoms are a relevant 
meal-related response.  An alternate explanation for the relationship between the meal challenge and 
symptoms is that the study meal was a liquid meal, which does not reflect a typical meal for the 
patients.  Therefore, it is possible that the liquid meal triggered an increase in symptoms for reasons 
other than DJBS placement, such as taste aversion.  However, the finding of increased GI symptoms 
with the DJBS in situ from survey data measured over the preceding week supports a relationship 
between the DJBS and GI symptoms.  Therefore, in concert with the reduction in dietary energy 
intake observed (Chapter 3 Section 3.3.5), these data suggest that an increase in meal-related 
symptoms may precipitate a reduction in dietary intake, facilitating weight loss. 
In this study, the 13C mixed triglyceride breath test was used to assess intraluminal lipolytic activity 
as a measure of lipid absorption.  At baseline, a detailed clinical assessment of pancreatic exocrine 
function was undertaken, with no clinically significant abnormalities detected.  We hypothesised that 
DJBS implantation would reduce intraluminal lipolytic activity.  However, we did not observe a 
significant reduction in intraluminal lipolytic activity following device implantation.  This suggests 
that fat malabsorption is not a key mechanism of device action.  Further supporting this is the lack of 
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clinical evidence of fat malabsorption (such as diarrhoea) reported on the SAGIS questionnaire.   
Data from a study of the RYGB has suggested at least 70 cm of jejunum must be included in the 
biliopancreatic limb to induce significant fat malabsorption284.  At a total length of 60 cm, the DJBS 
device has only a limited projection into the jejunum.  Taken together, these data suggest the DJBS 
does not induce significant fat malabsorption. 
In this study, we utilised non-invasive breath tests using 13C labelled substrates to measure gastric 
emptying kinetics and intraluminal lipolytic activity.  These tests were selected as they are well 
validated, safe and can be repeated frequently without exposing the patient to ionising radiation.   
The “gold standard” for assessment of gastric emptying is scintigraphy, a measure which involves 
exposing patients to ionising radiation.  Although the breath test has been validated against 
scintigraphy, the method relies on uptake of the 13C labelled isotope in the duodenum.  In the current 
study, the duodenum is excluded by the DJBS device, which theoretically reduces the accuracy of the 
in situ measure.  However, little is known about the amount of chyme that is able to travel down the 
mucosa-adjacent surface of the sleeve for absorption.  If truly completely excluded, the labelled 
substrate would not be absorbed until it reached the mid-jejunum.  Despite this, small intestinal transit 
time is rapid and therefore a significant difference in gastric emptying induced by increased transit to 
the jejunum may not be detectable using this test methodology.  Indeed, we observed no significant 
reduction in 13C labelled substrate absorption with the device in situ suggesting the test is appropriate 
for use in this population. 
In relation to fat malabsorption, the “gold standard” of indirect measurement of steatorrhoea is 
measuring 72 hour faecal fat on a standardised relatively high fat diet.  The measurement of faecal 
fat is burdensome for the patient and requires compliance with a diet of known fat quantity (100 g) 
for the test duration.  It also provides a significant calorie load (2,700 calories from fat), which is 
counterintuitive in a weight loss intervention.  Therefore the mixed triglyceride breath test was 
considered suitable for use in our patient group. 
A limitation of the study is the relatively small sample size.  Indeed, the associations between any of 
the measured variables and weight loss did not reach statistical significance, and this might be due to 
the small sample size.  Another limitation of the study is that we did not measure appetite-related 
changes.  This study was focused on the thorough investigation of GI function, not changes in GI 
appetite regulatory hormones and subjective changes in appetite.  These are likely to be relevant for 
inducing weight loss and would provide further insight into the links between device mechanisms of 
action, GI function and symptoms, and magnitude of weight loss. 
Based on the results of this study, the significant increase in GI symptoms following DJBS treatment 
appears relevant to the weight loss response to treatment.  Contrary to our expectations, and what has 
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been suggested previously in the literature, no significant change in gastric emptying or intraluminal 
lipolytic activity was observed.  This suggests changes to these aspects of GI function are of limited 
relevance to the weight loss response.  Whilst the study is small, future studies should aim to assess 
the contribution of GI symptoms, and in particular meal-related symptoms, to the weight loss 
response observed after deployment of the DJBS, as well as the precise mechanisms behind symptom 
generation.  
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Chapter 5: Effect of the Duodenal-Jejunal Bypass 
Sleeve on the Gastrointestinal Microbiota 
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5.1 INTRODUCTION 
Alterations in the GI microbiota have been implicated in the pathogenesis of both obesity171, 173 and 
T2DM181, 542.  In humans, a key reporting outcome has been the ratio of Firmicutes to Bacteroidetes, 
with patients with obesity having a higher ratio than lean controls.  Murine models have elegantly 
suggested a more causative role in obesity pathogenesis, with germ free mice having less body fat, 
despite a greater feed intake169.  By allowing these mice to become colonised with caecal microbes, 
body fat was increased, despite a reduction in feed intake.  A number of factors have been implicated 
linking changes in the microbiota with obesity, and perhaps the most noteworthy is  
diet166, 167. 
Both the influence of diet on the human gut microbiota and the rapid impact of changes in diet on the 
microbiota have been clearly demonstrated151, 377, 543.  However, there is conflicting evidence on the 
impact of dietary weight loss intervention trials on the microbiota (at phylum level), with some studies 
showing no change175, 189-192, two studies showing increases in Bacteroidetes and decreases in  
Firmicutes171, 193 and one study reporting increases in Firmicutes and decreases in Bacteroidetes194. 
The majority of studies assessing the impact of weight loss on the GI microbiota come from bariatric 
surgery, which causes permanent anatomical changes to the GIT.  Following LSG, the most 
commonly performed bariatric surgical procedure in Australia, four studies have reported increases 
in Bacteroidetes and/or decreases in Firmicutes372, 378-380, one study has reported a decrease in 
Bacteroidetes 371, whilst two others report no change in either phylum370, 382.  Following RYGB, three 
studies have reported a decrease in Firmicutes to Bacteroidetes367-369, one has reported a significant 
increase in Firmicutes to Bacteroidetes371 and one has reported no change370.  Broadly, following 
either LSG or RYGB, increases in Bacteroidetes, Fusobacteria, Proteobacteria (in particular members 
of the Gammaproteobacteria class and Enterobacteriaceae family) and Verrucomicrobia 
(specifically Akkermansia) have been reported, whilst a reduction in Firmicutes (in particular 
members of the Lactobacillaceae and Lachnospiraceae families) have been reported. 
To date, there is one published report on the impact of DJBS treatment on the GI microbiota479.   
In this study, transient taxonomic changes in the stool microbiota were reported after DJBS 
implantation.  Specifically, significant increases in Gammaproteobacteria (including members of the 
Enterobacteriaceae family) and the Clostridiaceae family were observed.  In parallel, reductions in 
butyrate-producers, such as Ruminococcus were observed.  However, due to the paucity of 
investigations, changes in the microbiota following bariatric surgery are the closest thoroughly 
investigated comparator, as the transient changes in GI physiology induced by the device most closely 
mimic those induced by RYGB.  The evidence for changes in the GI microbiota following bariatric 
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surgery is derived from reports of changes in the stool microbiota.  We hypothesize that the DJBS 
will result in changes to the stool microbiota.  However, given the observed impacts of the DJBS on 
upper GI symptoms, such as epigastric pain (Chapter 1 Section 1.3.4.2), the MAM in the upper GIT, 
which is not reflected by the stool544, may also play an important role. 
The microbial community in the gut adapts to the host environment.  The proximal small intestine is 
usually an area of high nutrient availability and rapid transit.  Nutrient digestion is facilitated by bile 
and digestive enzymes, while bile itself exerts a selective pressure on the microbiota545.  The DJBS 
excludes nutrients from the duodenal mucosa and separates bile and digestive enzymes from the 
chyme.  The impacts of this on the MAM have not been studied.  Further, the acid environment is 
altered by mandatory PPI treatment during DJBS implantation to reduce the risk of upper GI bleeding.  
As the device dwells in the small intestine, characterisation of microbial community formation on the 
sleeve itself may provide a link between microbial communities and treatment efficacy, as well as the 
effect the presence of the device exerts on the MAM in the duodenum.  In addition to the potential to 
understand the mechanisms of action of the device, profiling of the microbiota following treatment 
with the DJBS may also be important for understanding the drivers of complications.  In particular, 
this may be relevant for understanding the pathogenesis of hepatic abscess, a rare complication of 
DJBS treatment proposed to occur as a result of ascending cholangitis or secondary to perforations 
induced by the anchor barbs. 
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5.1.1 Aims and Hypotheses 
The aims of this chapter were to assess the changes in mucosal-, stool-, and sleeve-associated 
microbial communities following DJBS treatment, and to correlate microbiota changes with clinical 
characteristics. 
It was hypothesised that implantation of a DJBS for 48 weeks would: 
• Alter the gastric and duodenal MAM, measured by community profiling of gastric and 
duodenal mucosa at baseline and explant;  
• Alter the stool microbiota, measured by community profiling of stool at baseline, 8 weeks and 
explant; 
• Result in a microbial community forming on the mucosa-adjacent surface of the DJBS, 
measured by community profiling of mucosa-adjacent and luminal-adjacent biofilm 
microbiota at explant; 
• Result in an increase in bacterial load in the duodenum, measured by qPCR of gDNA isolated 
from mucosal biopsies; and 
• Result in a change in microbiota profile that will correlate with either the presence of 
constipation and/or with weight loss observed. 
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5.2 METHODS 
5.2.1 Sample collection 
At the time of endoscopy at baseline and explant, biopsy samples were taken from the mucosa of the 
gastric antrum and the second part of the duodenum.  At explant, the duodenal biopsy was taken from 
mucosa that had been covered by the device during the treatment period.  Device specimens were 
taken from six points along the device (see Figure 2.2) to represent the mucosa-adjacent and luminal-
adjacent microbiota at the upper, mid and lower sections of the device.  Stool samples were taken at 
baseline, eight weeks post-implant and within three weeks after device explant.  Mucosal samples 
were stored in RNAlater® (Qiagen), incubated at room temperature for 30 minutes, snap-frozen, and 
stored at -80°C.  Stool and device samples were snap-frozen and stored at -80°C.  Full details are 
outlined in Chapter 2 Section 2.5.1. 
5.2.2 16S rRNA sequencing for microbiota identification 
In brief, gDNA was isolated using a modified repeated bead beating method506 and purified using an 
automated system.  Purified gDNA was amplified using primers targeting the hypervariable region 
(V6-V8) of the 16S rRNA gene using either bacterial specific primers (for biopsy and device 
samples), or universal primers (for stool and repeated device samples).  PCR amplicons were 
barcoded using the Nextera XT v2 dual-index system and sequenced using the Illumina MiSeq 
platform.  Raw data underwent bioinformatics analysis using the QIIME pipeline.  OTUs were 
assigned using Greengenes version 13.8 as the reference database.  Full details are outlined in Chapter 
2 Sections 2.5.2-2.5.6. 
5.2.3 Functional metagenomics analysis of 16S rRNA sequencing data 
Functional metagenomics data was predicted from the 16S rRNA marker gene using the PICRUSt 
software package.  Data were summarised as functional pathways for analysis.  Further details can be 
found in Chapter 2 Section 2.5.7. 
5.2.4 Bacterial load assessment 
Bacterial load was assessed by qPCR using gDNA from mucosal biopsy specimens.  Both the human 
β-actin gene and the bacterial 16S rRNA gene were amplified using optimised primer sets.  The ratio 
of 16S rRNA to human β-actin was used as a measure of bacterial load.  Further details can be found 
in Chapter 2 Section 2.5.8. 
5.2.5 Statistical analyses 
Prior to analysis, a total of 81 contaminant OTUs were removed (55 for 917 primer; 26 for 926 primer; 
see Chapter 2 Section 2.5.6 and Appendix 1.5) and microbial community profile data (OTU table) 
was normalised using total sum scaling with square root transformation, accounting for RA of taxa.   
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A full list of OTUs present in samples can be found in Appendix 1.6.  Data was analysed using the 
web-based program Calypso v8.48 (for phylogenetic analysis) and v8.68 (for functional 
predictions)546 and GraphPad Prism Version 7 (GraphPad Software Inc., CA, USA). 
Alpha diversity (abundance and evenness of taxa) was assessed by the Shannon Index, with paired  
t-tests or Wilcoxon matched pairs signed rank tests used to test for significance, dependent on 
normality of distribution.  Beta-diversity (inter-individual microbiota profile similarity) was 
visualised using principal co-ordinate analysis using a weighted UniFrac distance matrix.   
Differences in community profiles between groups was assessed using the Adonis metric, a 
multivariate analysis of variance technique that accounts for phylogenetic distance.  A constrained 
analysis (sparse partial least squares discriminant analysis) was applied to discriminate the relative 
importance of taxa based on sample grouping (for example, baseline vs explant)547.  Data on 
longitudinal change in abundance of individual taxa and functional pathways were assessed in 
Calypso by the inbuilt repeated measures analysis (mixed effects linear regression modelling), and 
corrected for repeated measures using the False Discovery Rate (FDR).  Taxonomic differences 
between those who had their devices explanted early secondary to abdominal pain, compared to the 
rest of the cohort, were assessed by the Mann Whitney U test.  Differences between DJBS patients 
and controls were assessed by the Mann Whitney U test.  Bacterial load results were assessed for 
significance using a Wilcoxon signed rank test. 
To assess the relationship between the RA of taxa and clinical measures, bivariate correlations were 
performed using IBM Statistical Package for Social Sciences Version 24 (IBM Corp., NY, USA) to 
screen for candidate variables for univariate linear regression analyses.  Taxa were only screened 
where the minimum mean RA of that taxon was 1%.  Non-normally distributed data was square root 
transformed.  Any variables that were significant on univariate analysis were added to a multiple 
linear regression model with backward elimination.  Significance of results was determined by a  
two-tailed p value of less than 0.05. 
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5.2.6 Schedule of investigations 
 
Figure 5.1: Schedule of gastrointestinal microbiota investigations. 
 
Baseline
• Community profile assessment:
• Mucosal biospy: gastric antrum and second part of the duodenum
• Stool sample
• Bacterial load assessment:
• Mucosal biospy: gastric antrum and second part of the duodenum
8 weeks 
post-implant
• Community profile assessment:
• Stool sample
Explant
• Community profile assessment:
• Mucosal biospy: gastric antrum and second part of the duodenum
• Stool sample
• Device sampling
• Bacterial load assessment:
• Mucosal biospy: gastric antrum and second part of the duodenum
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5.3 RESULTS 
5.3.1 Mucosa-associated microbiota 
We assessed microbial profiles of the MAM in the antrum and second part of the duodenum at 
baseline and device explant using high-throughput sequencing methods.  After data quality control 
and filtering, a sequencing profile was successfully obtained for 11 of 19 baseline gastric biopsies 
and eight of 19 baseline duodenal biopsies.  At explant, a sequencing profile was successfully 
obtained from all 19 patients at both sites, allowing for longitudinal comparison for 11 patients 
(gastric) and eight patients (duodenum).  A control group of 23 patients referred for investigation of 
iron-deficiency anaemia (n=10) or positive faecal occult blood test (n=13) who underwent identical 
investigation of the gastric and duodenal MAM were recruited from a separate study at the same site 
(HREC/13/QPAH/690).  From these patients, a total of 15 (five with BMI <25 kg/m2, five with BMI 
25-29.9 kg/m2, five with BMI > 30 kg/m2) gastric mucosal biopsies and 20 (six with BMI <25 kg/m2, 
seven with BMI 25-29.9 kg/m2, seven with BMI > 30 kg/m2) duodenal mucosal biopsies were 
included for analysis. 
A total of 765,812 reads were generated from mucosal samples, representing 248 OTUs.   
Specifically, sequences were identified from eight phyla, 13 classes, 17 orders, 29 families and  
44 genera.  At baseline, the mean number of reads following bioinformatics processing was 7,573 
and 6,675 from gastric and duodenal biopsies, respectively.  At explant, the mean number of reads 
was 14,212 and 9,941 from gastric and duodenal biopsies, respectively.  In the control cohort, the 
mean number of reads following bioinformatics processing was 6,348 and 3,750 from gastric and 
duodenal biopsies, respectively.  More specifically, the mean number of reads from gastric biopsies 
was 4,473, 6,209 and 8,363 for controls with a BMI < 25 kg/m2, with a BMI of 25-29.9 kg/m2 and 
with a BMI of > 30 kg/m2, respectively.  The mean number of reads from duodenal biopsies was 
3,147, 4,873 and 3,413 for control with a BMI < 25 kg/m2, with a BMI of 25-29.9 kg/m2 and with a 
BMI of > 30 kg/m2, respectively. 
At baseline, both the duodenal and gastric biopsies were similar to the control biopsies.  In the 
stomach, Streptococcus and Prevotella were the predominant genera.  In the DJBS cohort, four 
patients were infected with H.pylori, leading to this being the third most abundant organism (at genus 
level).  In the control cohort, the third most abundant genus was Veillonella.  Similarly, in the 
duodenum, Streptococcus, Prevotella and Veillonella were the most abundant genera in both the 
DJBS and control cohorts.  However, at device explant, the stomach was primarily colonised by 
Prevotella, Lactobacillus and members of the Enterobacteriaceae family.   
The duodenum was primarily colonised by Lactobacillus, Prevotella, and Streptococcus.  Table 5.1 
summarises the most abundant taxa at each sample site across the three comparison groups. 
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Table 5.1: RA of the three most abundant taxa (at genus level) in biopsy specimens 
 Baseline Explant Control 
Gastric Streptococcus (mean RA 35%) 
Prevotella (mean RA 21%) 
Helicobacter (mean RA 20%) 
Prevotella (mean RA 17%) 
Lactobacillus (mean RA 12%) 
Enterobacteriaceae (mean RA 10%) 
Streptococcus (mean RA 43%) 
Prevotella (mean RA 16%) 
Veillonella (mean RA 9%) 
Duodenum Streptococcus (mean RA 43%) 
Prevotella (mean RA 24%) 
Veillonella (mean RA 8%) 
Lactobacillus (mean RA 19%) 
Prevotella (mean RA 14%) 
Streptococcus (mean RA 9%) 
Streptococcus (mean RA 50%) 
Prevotella (mean RA 15%) 
Veillonella (mean RA 7%) 
 
5.3.1.1 Gastric biopsies 
We assessed the MAM at baseline and explant in the gastric antrum.  Full statistical analyses can be 
found in Appendix 1.7.  In the overall cohort, between baseline and explant, there was a significant 
increase in the RA of two phyla - Fusobacteria and Synergistetes (Table 5.2).  At the genus level, 
there was a significant increase in the RA of 11 taxa (Table 5.2).  All of these taxa had a low baseline 
RA (mean RA <1%).  Conversely, there was a significant reduction in seven genera, including 
Streptococcus and Helicobacter which were the most and third most abundant genera at baseline, 
respectively.  The reduction in Helicobacter is as a direct result of antibiotic triple therapy H.pylori 
eradication in four patients.  This occurred within the first eight weeks post-implant, with no further 
antibiotic treatment provided in the remaining 40 weeks until post-explant measures.  The remaining 
seven patients with baseline gastric biopsy data did not have a significant presence of Helicobacter 
(<0.01% RA).  When the antibiotic treatment patients were removed, a significant increase in the RA 
of four of the initial 11 taxa (at genus level) remained, whilst a significant decrease in the RA of six 
of the initial seven genera remained.  In the full cohort, at OTU level, there was a significant increase 
in 28 OTUs, including 10 Enterobacteriaceae OTUs, 10 Lactobacillus OTUs, three Klebsiella OTUs, 
two Selenomonas OTUs and one each of Gammaproteobacteria, Bifidobacterium and 
Fusobacterium.  A significant decrease in five Streptococcus OTUs, two Actinomyces OTUs and one 
Prevotella melaninogenica OTU was also observed.  Broadly, the overall results suggest the DJBS 
causes significant changes in the gastric microbiota and promotes proliferation of taxa that are 
otherwise low abundance in this region.  In addition to these broad taxonomic changes, there was a 
trend towards a significant increase in alpha diversity in gastric biopsies from baseline to explant 
(Figure 5.2; Shannon Index; n=11; 1.50±0.51 vs. 2.00±0.39; p=0.0529). 
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Table 5.2: Taxonomic changes in the MAM of the gastric antrum from baseline to explant. 
Taxon 
FDR q Change 
from 
Baseline 
Baseline 
RA (%) 
Explant 
RA (%) 
Phylum Level 
Fusobacteria 0.0048 Increased 1.21±1.28 8.78±10.28 
Synergistetes 0.04 Increased 0.00±0.01 0.09±0.12 
Genus Level 
Rothia 0.00024 Decreased 1.47±1.46 0.16±0.23 
Streptococcus 0.00035 Decreased 35.02±19.97 8.37±11.09 
Dialister 0.0039 Increased 0.05±0.09 1.48±1.83 
Fusobacterium 0.0039 Increased 0.88±1.14 6.89±9.42 
Unclassified Enterobacteriaceae 0.0039 Increased 0.90±2.45 10.30±10.79 
Unclassified Gammaproteobacteria 0.0039 Increased 0.02±0.02 6.30±7.62 
Lactobacillus 0.0041 Increased 0.53±0.89 12.30±14.67 
Klebsiella 0.0041 Increased 0.02±0.05 3.55±4.45 
Actinomyces 0.0048 Decreased 2.76±2.89 0.50±0.64 
Granulicatella 0.0048 Decreased 0.88±0.81 0.20±0.38 
Bifidobacterium 0.0072 Increased 0.00±0.00 1.51±2.34 
Helicobacter 0.012 Decreased 19.86±33.91 0.00±0.00 
Selenomonas 0.013 Increased 0.20±0.22 2.83±4.76 
Neisseria 0.021 Decreased 3.37±4.44 0.93±2.49 
Bulleidia 0.021 Decreased 0.73±1.18 0.09±0.12 
Erwinia 0.024 Increased 0.00±0.00 0.02±0.03 
Megasphaera 0.024 Increased 0.66±0.88 1.75±1.70 
TG5 0.024 Increased 0.00±0.01 0.09±1.70 
 
  
 138 
 
OTU 
FDR q Change 
from 
Baseline 
Baseline 
RA (%) 
Explant 
RA (%) 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 0.00006 Decreased 15.28±10.85 2.27±3.52 
p__Fusobacteria__g__Fusobacterium_34791 0.000078 Increased 0.31±0.71 3.23±4.01 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU379777 0.00098 Decreased 9.97±6.77 2.52±4.16 
p__Firmicutes__g__Streptococcus__s__infantis_517754 0.00098 Decreased 2.59±2.15 0.44±0.76 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.00098 Increased 0.04±0.06 2.81±3.23 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0.002 Decreased 1.37±1.39 0.26±0.50 
p__Actinobacteria__g__Actinomyces_4350499 0.002 Decreased 1.53±1.66 0.20±0.24 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 0.0022 Decreased 15.95±12.80 3.67±6.13 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.0028 Increased 0.02±0.02 6.30±7.62 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.0028 Increased 0.02±0.04 0.31±0.35 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.003 Increased 0.00±0.00 0.86±1.15 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.0037 Increased 0.01±0.02 1.85±2.52 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.0037 Increased 0.02±0.06 0.86±1.11 
p__Firmicutes__g__Lactobacillus_563654 0.0037 Increased 0.00±0.01 0.30±0.49 
p__Actinobacteria__g__Actinomyces_565136 0.0037 Decreased 1.15±1.25 0.21±0.33 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.0066 Increased 0.00±0.00 0.43±0.63 
p__Firmicutes__g__Lactobacillus_574021 0.0074 Increased 0.02±0.05 0.11±0.19 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.0076 Increased 0.00±0.00 0.46±0.82 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.0076 Increased 0.00±0.00 0.27±0.45 
p__Actinobacteria__g__Bifidobacterium_4426298 0.0076 Increased 0.00±0.00 1.26±1.96 
p__Firmicutes__g__Lactobacillus_586093 0.0076 Increased 0.00±0.00 0.23±0.40 
p__Firmicutes__g__Lactobacillus_592160 0.011 Increased 0.01±0.02 3.88±6.80 
p__Proteobacteria__g__Klebsiella_786708 0.012 Increased 0.01±0.02 0.30±0.42 
p__Firmicutes__g__Lactobacillus_539647 0.015 Increased 0.00±0.00 0.14±0.30 
p__Proteobacteria__f__Enterobacteriaceae_510870 0.02 Increased 0.00±0.00 0.14±0.29 
p__Firmicutes__g__Lactobacillus_533133 0.02 Increased 0.00±0.00 0.05±0.10 
p__Firmicutes__g__Lactobacillus_331248 0.02 Increased 0.01±0.02 0.05±0.08 
p__Firmicutes__g__Lactobacillus_582884 0.021 Increased 0.00±0.01 0.43±0.83 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.021 Increased 0.05±0.13 0.22±0.33 
p__Firmicutes__g__Streptococcus_349024 0.025 Decreased 3.00±3.14 1.06±2.10 
p__Proteobacteria__f__Enterobacteriaceae_797229 0.027 Increased 0.32±0.89 1.59±2.46 
p__Firmicutes__g__Selenomonas_4297955 0.027 Increased 0.02±0.05 0.92±2.00 
p__Proteobacteria__f__Enterobacteriaceae_1109844 0.029 Increased 0.44±1.35 1.75±2.71 
p__Firmicutes__g__Selenomonas_295019 0.029 Increased 0.17±0.20 1.43±2.84 
p__Firmicutes__g__Lactobacillus_590168 0.029 Increased 0.01±0.02 0.08±0.14 
p__Firmicutes__g__Lactobacillus_573010 0.036 Increased 0.05±0.07 2.18±4.31 
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Figure 5.2: Alpha diversity analysis of gastric mucosal biopsy samples at genus level. 
There was a trend toward a significant increase in alpha diversity (p=0.0529) from baseline to explant.  Each 
patient is displayed as an individual line.  Pre- and post-intervention compared by paired t-test. 
During the intervention period, three patients underwent elective early device explant secondary to 
persistent abdominal pain.  When early explant patients were removed from the analysis, the pattern 
of taxonomic change was similar.  A significant increase in the RA of nine of the initial 11 genera 
remained (Erwinia and TG5 lost significance), whilst a significant decrease in the RA of three genera 
remained (Actinomyces, Granulicatella, Neisseria and Bulleidia lost significance).   
When comparing the early explant group to those who completed the full intervention period, there 
was a significantly greater reduction in Actinomyces and Granulicatella (both FDR q<0.05) from 
baseline to explant in those who underwent early explant. 
The beta-diversity of gastric biopsy samples was assessed using principal coordinate analysis.  
Although some separation of the baseline and explant samples, based on overall community profile, 
is visible on principal coordinate 1, this was not significant (Figure 5.3A; Adonis UniFrac p=0.56).  
This remained non-significant if the Helicobacter positive patients were removed  
(Figure 5.3B; Adonis UniFrac p=0.57).  Sparse partial least squares discriminant analysis was 
performed to discriminate samples based on collection time-point (Figure 5.4).  The genera most 
strongly associated with baseline biopsies were Streptococcus, Neisseria, Prevotella, Helicobacter 
and Rothia.  Conversely, the genera most strongly associated with explant biopsies were 
Bifidobacterium, Dialister, Klebsiella and members of the Coriobacteriaceae family.  
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Figure 5.3: Principal co-ordinate analysis of gastric biopsies using a weighted UniFrac distance matrix. 
Helicobacter positive patients are showed in the red grouped rectangle.  Overall there was no significant 
difference in community profiles observed between time-points (A; Adonis UniFrac p=0.56), which remains 
non-significant if the Helicobacter positive patients are removed (B; Adonis UniFrac p=0.57). 
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Figure 5.4: Sparse partial least squares discriminant analysis of gastric biopsies. 
The taxa most associated with baseline biopsies (red) were Streptococcus, Neisseria, Prevotella, Helicobacter, 
Rothia and Moryella. The taxa most associated with explant biopsies (blue) were Bifidobacterium, Dialister, 
members of the Coriobacteriaceae family and Klebsiella.  The x-axis shows the strength of association with a 
particular group. 
The gastric biopsies of the DJBS cohort at baseline were most similar to the control biopsies.   
Indeed, there were no significant differences in overall community composition (beta-diversity) 
(Figure 5.5; Adonis UniFrac p=0.99), taxonomic or alpha diversity metrics (Figure 5.6; Shannon 
Index, baseline 1.50±0.51 vs. control 1.56±0.51; p=0.79) between the gastric biopsies at baseline and 
the control group.  The overlap between baseline and control samples was retained when the controls 
were stratified by BMI class. 
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Figure 5.5: Principal co-ordinate analysis of gastric biopsies using a weighted UniFrac distance matrix, 
compared to a control group.   
There was no significant difference between the microbiota profiles of DJBS patients compared to control 
patients (grey diamonds) at baseline (red circles; Adonis UniFrac p=0.99) or explant (blue squares; Adonis 
UniFrac p=0.36). 
The explant biopsy samples appear separated on the principal coordinate analysis plot as compared 
to the baseline and control samples.  Due to large inter-individual variation, there was no significant 
difference in overall community profile between explant and control biopsies (Figure 5.5, Adonis 
UniFrac p=0.36) although alpha diversity was significantly higher in the explant biopsies (Figure 5.6; 
Shannon Index, explant 1.96±0.36 vs. control 1.56±0.51; p=0.01).  Specifically, in the explant 
biopsies, there was a significantly higher RA of members of the Gammaproteobacteria class and the 
Enterobacteriaceae (both FDR q<0.001) and Coriobacteriaceae (FDR q<0.01) families, as well as 
the genera Klebsiella (FDR q<0.001), Dialister, Lactobacillus, Bifidobacterium, Selenomonas, 
Morganella, TG5, Erwinia, Collinsella, Fusobacterium (all FDR q<0.01), Megasphaera and 
Parvimonas (both FDR q<0.05), compared to controls.  Conversely, there was a significantly lower 
RA of members of the S24-7 family (FDR q<0.05) and the genera Streptococcus (FDR q<0.001), 
Actinomyces, Gemella and Granulicatella (all FDR q<0.01) in the explant biopsies, compared to 
controls.  Interestingly, these taxonomic differences largely overlap with the taxa that were changed 
from baseline to explant.  Specifically, there were only four taxa that were significantly higher in the 
explant biopsies, compared to controls that were not also significantly increased from baseline to 
explant.  Similarly, with the exception of the S24-7 family, the other taxa that were significantly lower 
in explant biopsies were also significantly reduced from baseline to explant.  Overall, these results 
suggest the gastric MAM has shifted away from a “typical” profile following treatment with a DJBS. 
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Figure 5.6: Alpha diversity analysis of gastric mucosal biopsy samples (at genus level), compared to a 
control group. 
There was no significant difference in alpha diversity between baseline mucosal biopsies in the DJBS cohort 
and the control cohort (p=0.79).  Alpha diversity was significantly higher in the explant biopsies, compared to 
the control group (p=0.01).  Between groups comparisons by unpaired t-test. 
5.3.1.2 Duodenal biopsies 
We assessed the MAM at baseline and explant in the second part of the duodenum.  Full statistical 
analyses can be found in Appendix 1.7.  Between baseline and explant, there was a significant 
increase in the RA of members of the Fusobacteria phylum (Table 5.3).  At the genus level, there was 
a significant increase in 10 taxa.  Similar to what was observed in the gastric biopsies, these increases 
were all in rare taxa with a maximum mean RA of <3% at baseline.  Conversely, there was a 
significant reduction in seven taxa.  In particular, Streptococcus, which at baseline was the most 
abundant organism in the duodenal MAM, was reduced from a mean RA of 43% at baseline to 9% at 
explant.  In the full cohort, at OTU level, there was a significant increase in 24 OTUs (Table 5.3), 
including eight Lactobacillus OTUs, seven Enterobacteriaceae OTUs, three Klebsiella OTUs, two 
Selenomonas OTUs and one each of Gammaproteobacteria, Bifidobacterium, Fusobacterium and 
Prevotella tannerae.  A significant decrease in five Streptococcus OTUs, one Haemophilus 
parainfluenzae OTU and one Prevotella melaninogenica OTU was also observed.  Despite the 
taxonomic changes observed, there was no significant change in alpha diversity from baseline to 
explant (Figure 5.7: Shannon Index; n=8, 1.68±0.31 vs. 2.02±0.38, p=0.24).  Three patients underwent 
early explant due to persistent abdominal pain, and it would be ideal to capture any taxonomic 
changes in this group.  Unfortunately, we are not able to further discriminate changes in the early 
explant group, as only one baseline duodenal sample in this subset of patients passed quality control. 
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Table 5.3: Taxonomic changes in the MAM of the second part of the duodenum from baseline to explant. 
Taxa 
FDR q Change 
from 
Baseline 
Baseline RA (%) Explant RA (%) 
Phylum Level 
Fusobacteria 0.031 Increased 12.78±8.54 19.28±16.46 
Genus Level 
Streptococcus 2.9E-07 Decreased 43.22±10.26 9.27±11.23 
Dialister 0.000031 Increased 0.09±0.16 1.12±0.62 
Haemophilus 0.0013 Decreased 2.86±1.76 0.51±0.60 
Helicobacter 0.0043 Decreased 0.60±1.12 0.00±0.00 
Lactobacillus 0.0056 Increased 0.57±0.70 19.34±20.52 
Klebsiella 0.0062 Increased 0.01±0.02 2.78±3.38 
Unclassified Gammaproteobacteria 0.0075 Increased 0.05±0.10 5.24±6.52 
Gemella 0.0099 Decreased 1.19±0.84 0.91±2.24 
Bifidobacterium 0.011 Increased 0.00±0.01 1.13±1.56 
Selenomonas 0.011 Increased 0.23±0.20 2.76±3.26 
Neisseria 0.013 Decreased 4.57±6.67 0.55±1.32 
Megasphaera 0.019 Increased 0.59±0.57 2.03±1.78 
Unclassified Enterobacteriaceae 0.026 Increased 2.83±6.72 8.89±8.54 
Fusobacterium 0.026 Increased 1.49±2.05 8.56±11.34 
Granulicatella 0.026 Decreased 1.05±1.13 0.25±0.46 
Bulleidia 0.033 Decreased 0.73±1.22 0.10±0.10 
Slackia 0.044 Increased 0.00±0.00 0.08±0.16 
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OTU 
FDR q Change from 
Baseline 
Baseline 
RA (%) 
Explant 
RA (%) 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 2.8E-08 Decreased 19.32±7.07 2.96±4.85 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU3797
77 2.2E-06 Decreased 
11.81±4.24 2.71±3.61 
p__Firmicutes__g__Streptococcus__s__infantis_517754 9.5E-06 Decreased 3.01±1.48 0.43±0.55 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 0.00014 Decreased 17.66±10.69 3.33±5.44 
p__Fusobacteria__g__Fusobacterium_34791 0.00061 Increased 0.52±0.69 3.69±3.76 
p__Firmicutes__g__Streptococcus_349024 0.00076 Decreased 4.94±4.02 0.77±1.36 
p__Proteobacteria__g__Haemophilus__s__parainfluenzae_ 
New.ReferenceOTU100511 0.0023 Decreased 
1.49±1.08 0.29±0.38 
p__Firmicutes__g__Lactobacillus_592160 0.0023 Increased 
0.04±0.08 6.36±10.7
1 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0.0033 Decreased 1.03±0.44 0.33±0.64 
p__Proteobacteria__g__Klebsiella_786708 0.0035 Increased 0.00±0.01 0.20±0.37 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.0035 Increased 0.00±0.00 0.60±0.82 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.0035 Increased 0.00±0.01 0.65±0.78 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.0042 Increased 0.03±0.05 0.22±0.27 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.0043 Increased 0.05±0.10 5.24±6.52 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.0047 Increased 0.00±0.00 1.35±1.75 
p__Firmicutes__g__Lactobacillus_331248 0.0075 Increased 0.00±0.00 0.09±0.13 
p__Firmicutes__g__Lactobacillus_574021 0.0076 Increased 0.01±0.02 0.23±0.27 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.0079 Increased 0.22±0.47 3.03±4.13 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.0079 Increased 0.00±0.00 0.27±0.36 
p__Firmicutes__g__Lactobacillus_582884 0.012 Increased 0.01±0.03 0.74±1.32 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.012 Increased 0.02±0.04 0.29±0.40 
p__Firmicutes__g__Lactobacillus_590168 0.014 Increased 0.00±0.00 0.13±0.17 
p__Firmicutes__g__Lactobacillus_573010 0.016 Increased 0.03±0.08 2.97±4.70 
p__Firmicutes__g__Selenomonas_295019 0.017 Increased 0.14±0.16 1.08±1.43 
p__Actinobacteria__g__Bifidobacterium_4426298 0.019 Increased 0.00±0.01 0.83±1.39 
p__Proteobacteria__f__Enterobacteriaceae_510870 0.019 Increased 0.00±0.01 0.11±0.20 
p__Firmicutes__g__Selenomonas_4297955 0.022 Increased 0.01±0.01 1.15±2.27 
p__Firmicutes__g__Lactobacillus_563654 0.023 Increased 0.03±0.09 0.41±0.58 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.024 Increased 0.00±0.00 0.18±0.29 
p__Firmicutes__g__Lactobacillus_533133 0.037 Increased 0.00±0.00 0.07±0.12 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.042 Increased 0.14±0.17 2.46±4.31 
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Figure 5.7: Alpha diversity analysis of duodenal mucosal biopsy samples at genus level. 
There was no significant change in alpha diversity (p=0.24) from baseline to explant.  Each patient is displayed 
as an individual line.  Pre- and post-intervention compared by paired t-test. 
There was considerable overlap between the changes seen from baseline to explant in the gastric and 
duodenal MAM.  At the genus level, there were 13 common taxonomic changes (Table 5.2 and  
Table 5.3).  Of these, eight were taxa that were commonly increased from baseline to explant, whilst 
five were commonly decreased.  Furthermore, despite the patients having obesity and T2DM, the 
biopsies of the DJBS cohort at baseline were similar to the control biopsies.  Indeed, there were no 
significant differences in community profile (Figure 5.8, Adonis UniFrac p=0.22) or alpha diversity 
metrics (Figure 5.9; Shannon Index, baseline 1.68±0.31 vs. control 1.43±0.56; p=0.24) between the 
duodenal biopsies of DJBS patients at baseline and the control group.  With the exception of 
Helicobacter, which was higher in the DJBS patients at baseline, there were no taxonomic differences 
between DJBS patients and controls.  Similarly, there were no observable differences when the 
controls were stratified by BMI class.  Cumulatively, these data suggest DJBS treatment is inducing 
similar shifts in the gastric and duodenal MAM away from the profile observed in control patients. 
There was also a significant overlap in the taxonomic difference between the control group and those 
that were increased from baseline to explant in the DJBS group, with 10 common taxonomic groups.  
However, the explant biopsy samples appear separated on the principal co-ordinate analysis plot, 
compared to the baseline and control samples.  Indeed, there was a significant difference in overall 
community profile when comparing the explant biopsies and the control group (Figure 5.8; Adonis 
UniFrac p<0.001).  Further, alpha diversity was significantly higher in the explant biopsies, compared 
to controls (Figure 5.9; Shannon Index, explant 2.07±0.36 vs. control 1.43±0.56; p<0.001).  At the 
phylum level, there was a significantly higher RA of Fusobacteria and Synergistetes (both FDR 
q<0.001) in the explant biopsies, compared to controls.  More specifically, there was a higher RA of 
members of the Gammaproteobacteria class (FDR q<0.00001), members of the Enterobacteriaceae, 
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Coriobacteriaceae (both FDR q<0.001), Aeromonadaceae and Veillonellaceae (both FDR q<0.05) 
families, and the genera Klebsiella, Dialister, Lactobacillus, Fusobacterium, Selenomonas, TG5 (all 
FDR q<0.001), Slackia, Morganella, Collinsella, Parvimonas, Bifidobacterium (all FDR q<0.01), 
Megasphaera, Erwinia, Leptotrichia and Bacteroides (all FDR q<0.05).  Conversely, there was a 
significantly lower RA of six typical upper GIT genera548 - Streptococcus, Actinomyces (both FDR 
q<0.001), Rothia, Granulicatella (both FDR q<0.01), Gemella and Neisseria (both FDR q<0.05).  
Overall, these results show a shift in the overall community profile of the duodenal MAM following 
treatment with a DJBS away from the taxa more typically observed in the duodenum. 
 
 
Figure 5.8: Principal co-ordinate analysis of duodenal biopsies using a weighted UniFrac distance matrix, 
compared to a control group. 
There was no significant difference between the microbiota profiles of DJBS patients compared to controls 
(grey diamonds) at baseline (red circles; Adonis UniFrac p=0.221).  However, there was a significant 
difference between the control group and explant biopsies (blue squares; Adonis UniFrac p=0.000666). 
  
 148 
 
 
 
Figure 5.9: Alpha diversity analysis of duodenal mucosal biopsy samples (at genus level), compared to a 
control group. 
There was no significant difference in alpha diversity between baseline mucosal biopsies in the DJBS cohort 
and the control cohort (p=0.24).  Alpha diversity was significantly higher in the explant biopsies, compared to 
the control group (p<0.001).  Within group comparisons by paired t-test.  Between groups comparisons by 
unpaired t-test. 
Beta-diversity was assessed for duodenal biopsy samples using principal co-ordinate analysis.   
There was moderate clustering of baseline duodenal biopsies; however, in the full cohort, there was 
no significant difference between community profiles by time-point (Figure 5.10A; Adonis UniFrac 
p=0.90), which remained non-significant if Helicobacter positive patients (n=2) were removed 
(Adonis UniFrac p=0.40).  When only patients with paired baseline and explant data were assessed, 
there was a significant difference in community profile by time-point (Figure 5.10B, Adonis UniFrac 
p<0.001).  Sparse partial least squares discriminant analysis was performed to discriminate between 
collection time-points.  The genera most strongly associated with baseline biopsies were 
Streptococcus, Helicobacter and Prevotella.  The genera mostly strongly associated with explant 
biopsies were Lactobacillus, Leptotrichia, Klebsiella and Collinsella. 
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Figure 5.10: Principal co-ordinate analysis of duodenal biopsies using a weighted UniFrac distance matrix. 
Overall, there was no significant difference between community profiles based on time-point (A; including 
two Helicobacter positive patients (red oval); Adonis UniFrac p=0.90), which remains non-significant if the 
Helicobacter positive patients are removed (Adonis UniFrac p=0.40).  However, when only patients with both 
baseline and explant data are compared, there is a significant difference between baseline and explant (B; 
Adonis UniFrac p=0.0006). 
5.3.2 Device-associated microbiota 
Upon explant, the device was kept for assessment of device-associated microbiota via high 
throughout sequencing methods.  A biofilm had formed on the device, and particularly on the 
mucosal-adjacent device surface.  Three samples were taken from the luminal-adjacent device surface 
and three samples were taken from the mucosa-adjacent device surface.  After filtering, a sequencing 
profile using the bacterial domain specific primers (917F/1392R) was successfully obtained for  
150 of 152 device samples.  Two luminal-adjacent device samples did not pass quality control (read 
depth <500).  A total of 3,281,576 reads were generated from 245 OTUs.  Specifically, sequences 
were identified from eight phyla, 13 classes, 17 orders, 28 families and 43 genera.  A mean of 19,733 
and 24,080 reads were generated from the mucosa-associated and luminal device surfaces, 
respectively. 
Overall, at explant, the device was predominantly colonised by the genus Lactobacillus (mean RA 
42%; mucosa-adjacent surface 37%, luminal surface 47%), members of the Enterobacteriaceae 
family (mean RA 12%; mucosa-adjacent surface 14%, luminal surface 12%) and Bacteroides (mean 
RA 9%; mucosa-adjacent surface 11%, luminal surface 5%).  Overall, the RA of the predominant 
members of the duodenal community, as observed in the control duodenal biopsies above, were low; 
such as Streptococcus (mean RA 1%; mucosa-adjacent surface 0.3%, luminal surface 2%) and 
Prevotella (mean RA 1%; mucosa-adjacent surface 0.2%, luminal surface 3%). 
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Broadly, whilst there was no significant difference in overall community profile (Adonis UniFrac 
p=0.61) or diversity (p=0.68) between the luminal-adjacent and mucosa-adjacent device surfaces, 
there were significant taxonomic differences observed between the surfaces when all device samples 
(upper, mid and lower) were included.  Specifically, seven genera were significantly higher in RA on 
the mucosa-adjacent device surface, whilst 13 were significantly lower in RA (Table 5.4).   
At OTU level, five Enterobacteriaceae OTUs, three Klebsiella OTUs, two Veillonella OTUs, and 
one each of Gammaproteobacteria, Bacteroides and Lactobacillus were significantly higher on the 
mucosa-adjacent device surface, compared to the luminal-adjacent device surface.   
Conversely, 10 Lactobacillus OTUs, five Streptococcus OTUs, three Prevotella OTUs, one 
Actinomyces OTU and one Fusobacterium OTU were significantly lower in RA on the mucosa-
adjacent device surface, compared to the luminal-adjacent device surface. The majority of these 
differences reflect the taxonomic shifts that were also observed in the duodenal biopsy samples from 
baseline to explant, with the mucosa-adjacent device surface being more similar to explant biopsies.  
When the mucosa-adjacent device surface samples were compared along the length of the device  
(e.g. upper vs mid or lower), there were no significant overall community profile or taxonomic 
differences.  This suggests colonisation is consistent along the length of the mucosa-adjacent surface 
of the device.  
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Table 5.4: Taxonomic difference between the mucosa-adjacent and luminal-adjacent device surfaces at 
explant. 
Taxa 
FDR q Mucosa-
adjacent RA 
(%) 
Luminal-adjacent RA 
(%) 
Phylum Level 
Proteobacteria 0.00031 28.06±22.36 20.23±22.38 
Synergistetes 0.028 0.00±0.01 0.38±1.91 
Genus Level 
Klebsiella 0.00009 5.07±5.52 2.86±4.31 
Streptococcus 0.00009 0.25±0.74 1.58±2.58 
Atopobium 0.000097 0.02±0.05 0.20±0.44 
Unclassified Gammaproteobacteria 0.00028 7.92±10.43 4.99±8.42 
Parvimonas 0.00031 0.01±0.02 0.10±0.24 
Unclassified Coriobacteriaceae 0.00052 0.24±0.95 1.58±3.99 
Prevotella 0.0011 0.15±0.43 2.94±8.35 
Porphyromonas 0.0011 0.00±0.01 0.12±0.44 
Bacteroides 0.0032 11.24±21.12 4.73±18.29 
Slackia 0.0032 0.01±0.02 0.29±1.24 
Megasphaera 0.0047 1.88±2.91 1.02±2.27 
Veillonella 0.0047 2.21±3.32 1.19±1.76 
Bulleidia 0.0053 0.00±0.01 0.02±0.07 
Rothia 0.0071 0.00±0.01 0.02±0.07 
Gemella 0.0075 0.00±0.01 0.01±0.01 
Unclassified Enterobacteriaceae 0.012 13.92±11.74 11.73±12.64 
Actinomyces 0.014 0.15±0.56 0.71±2.37 
TG5 0.016 0.00±0.01 0.38±1.91 
Peptostreptococcus 0.032 0.00±0.01 0.04±0.13 
Morganella 0.037 0.14±0.50 0.10±0.45 
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OTU 
FDR q Mucosa-
adjacent RA 
(%) 
Luminal-adjacent RA 
(%) 
p__Proteobacteria__g__Klebsiella_786708 4.1E-06 0.68±0.88 0.33±0.62 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.000048 1.68±2.07 1.06±1.70 
p__Firmicutes__g__Lactobacillus_331248 0.00017 0.22±0.32 0.90±1.41 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.00032 7.92±10.43 4.99±8.42 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.00037 0.38±0.42 0.25±0.48 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.00037 1.80±2.52 0.94±1.61 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.00037 0.82±1.14 0.59±1.11 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.00037 0.03±0.11 0.48±1.24 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 0.00089 0.02±0.06 0.13±0.35 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.0018 1.03±1.31 0.68±1.24 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.0023 0.64±0.69 0.45±0.72 
p__Firmicutes__g__Streptococcus_349024 0.0032 0.02±0.05 0.06±0.15 
p__Fusobacteria__g__Fusobacterium_545299 0.0032 0.05±0.16 0.27±0.68 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU13477 0.0032 0.06±0.24 0.25±0.55 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0.0043 0.00±0.01 0.01±0.04 
p__Firmicutes__g__Lactobacillus_582884 0.0066 1.10±3.96 1.62±2.55 
p__Firmicutes__g__Lactobacillus_354225 0.0066 6.53±17.36 9.97±16.77 
p__Bacteroidetes__g__Prevotella__s__nigrescens_2195 0.0066 0.03±0.10 1.48±5.90 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.0066 0.39±0.35 0.29±0.37 
p__Firmicutes__g__Veillonella_561537 0.008 0.89±1.24 0.57±0.89 
p__Firmicutes__g__Lactobacillus_533133 0.012 0.40±0.72 0.75±0.91 
p__Firmicutes__g__Lactobacillus_539647 0.013 1.27±2.18 2.18±2.37 
p__Firmicutes__g__Lactobacillus_573010 0.013 4.31±8.48 7.27±10.84 
p__Firmicutes__g__Lactobacillus_586093 0.013 1.86±3.93 2.84±3.29 
p__Firmicutes__g__Veillonella_518743 0.013 0.96±1.50 0.60±1.11 
p__Bacteroidetes__g__Bacteroides_568118 0.013 4.25±16.63 0.17±0.67 
p__Firmicutes__g__Lactobacillus_574021 0.014 0.71±1.04 1.28±1.53 
p__Firmicutes__g__Lactobacillus_340960 0.021 1.89±3.21 2.91±3.12 
p__Firmicutes__g__Lactobacillus_590168 0.022 0.48±1.09 0.67±0.79 
p__Actinobacteria__g__Actinomyces_4350499 0.03 0.03±0.12 0.08±0.22 
p__Firmicutes__g__Streptococcus__s__infantis_517754 0.034 0.01±0.02 0.01±0.03 
p__Firmicutes__g__Lactobacillus_823803 0.039 2.07±6.48 0.78±4.77 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 0.039 0.01±0.05 0.17±0.99 
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5.3.2.1 Relationship between biopsies and device 
At explant, the duodenal MAM was distinct from the mucosa-adjacent device sections (Figure 5.11; 
explant biopsy vs. device p=0.029).  Visually, on principal component analysis, the baseline biopsies 
were more distinct than the explant biopsies.  However, there was no statistically significantly 
difference between the baseline biopsies and the mucosa-adjacent device sections (baseline biopsy 
vs. device p=0.11).  This is likely to reflect the low sample number at baseline (n=8). 
 
Figure 5.11: Principal co-ordinate analysis of device samples compared to duodenal biopsy samples, using 
a weighted UniFrac distance matrix. 
At explant, the mucosal biopsy samples (blue circles) visually appear closer to the mucosa-adjacent device 
samples (grey circles; explant biopsy vs. device Adonis UniFrac p=0.0029) than the baseline biopsies (red 
circles; baseline biopsy vs. device Adonis UniFrac p=0.11). 
In the duodenum, the mucosa-adjacent device surface and the mucosal biopsy collocated with the 
device formed two distinct communities.  Full statistical analyses can be found in Appendix 1.7.   
At genus level, there was a significantly higher RA of 22 taxa, and lower abundance of four, in the 
explant duodenal biopsies, compared to the collocated mucosa-adjacent device surface (Table 5.5).  
At OTU level, there was a significantly higher abundance of six Streptococcus OTUs, three 
Prevotella OTUs, two Actinomyces OTUs, two Veillonella OTUs, two Fusobacterium OTUs, two 
Selenomonas OTUs and one Haemophilus parainfluenzae OTU in the explant duodenal biopsies, 
compared to the collocated mucosa-adjacent device surface.  There was a significantly lower RA of 
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six Enterobacteriaceae OTUs, one Bifidobacterium OTU, and one Klebsiella OTU in the explant 
duodenal biopsies, compared to the collocated mucosa-adjacent device surface. 
Similarly, there was a significantly higher RA of 18 taxa in the baseline duodenal biopsies, with six 
taxa lower, compared to the mucosa adjacent device surface (Table 5.6).  At OTU level, there was a 
significantly higher abundance of six Streptococcus OTUs, three Prevotella OTUs, two Actinomyces 
OTUs, two Veillonella OTUs, one Fusobacterium OTU and one Haemophilus parainfluenzae OTU 
in the baseline duodenal biopsies, compared to the collocated mucosa-adjacent device surface.   
There was a significantly lower RA of eight Enterobacteriaceae OTUs, eight Lactobacillus OTUs, 
three Klebsiella OTUs, one Gammaproteobacteria OTU and one Bifidobacterium OTU, in the 
baseline duodenal biopsies, compared to the collocated mucosa-adjacent device surface. 
There was a significantly higher alpha diversity in the explant biopsies, compared to the mucosa-
adjacent device surface (biopsy: 2.02±0.38 vs device: 1.43±0.37; p<0.001).  Broadly, a number of 
taxa that were significantly higher in the mucosal samples as compared to the device are those 
considered typical of the upper GIT microbiota.  Specifically, Streptococcus and Veillonella were the 
dominant genera in the duodenum.  This indicates there is a difference in the growth environment on 
the device as compared to the mucosa, facilitating the formation of these distinct communities. 
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Table 5.5: Taxonomic differences between the mucosa-adjacent device surface collocated with the 
duodenal biopsy at device explant. 
Taxa 
FDR q Mucosa-
adjacent RA 
(%) 
Explant 
Biopsy RA 
(%) 
Phylum Level 
Bacteroidetes 0.00025 11.10±24.88 20.57±16.04 
Fusobacteria 0.00025 3.11±4.50 10.49±12.50 
Synergistetes 0.0026 0.01±0.01 0.36±0.91 
Genus Level 
Prevotella 4.4E-09 0.18±0.50 14.03±11.07 
Parvimonas 3.1E-08 0.01±0.02 0.44±0.38 
Streptococcus 1.4E-06 0.22±0.44 9.27±11.23 
Bulleidia 0.00002 0.00±0.01 0.10±0.10 
Porphyromonas 0.000038 0.00±0.02 0.66±0.92 
Veillonella 0.000043 1.95±2.64 5.77±4.79 
Dialister 0.000057 0.34±0.52 1.12±0.62 
Atopobium 0.00006 0.01±0.02 0.36±0.49 
Selenomonas 0.00011 0.90±1.43 2.76±3.26 
Actinomyces 0.00016 0.09±0.30 0.64±0.71 
Granulicatella 0.00024 0.00±0.01 0.25±0.46 
Fusobacterium 0.00032 2.15±3.53 8.56±11.34 
Peptostreptococcus 0.00081 0.00±0.01 0.23±0.37 
Haemophilus 0.0022 0.19±0.45 0.51±0.60 
TG5 0.0029 0.01±0.01 0.36±0.91 
Rothia 0.0061 0.00±0.00 0.55±1.66 
Gemella 0.0067 0.00±0.01 0.91±2.24 
Erwinia 0.0083 0.07±0.12 0.02±0.04 
Slackia 0.016 0.01±0.02 0.08±0.16 
Leptotrichia 0.017 0.26±0.71 1.01±1.95 
Neisseria 0.021 0.00±0.01 0.55±1.32 
Unclassified Aeromonadaceae 0.024 0.27±0.55 0.71±1.22 
Unclassified Enterobacteriaceae 0.024 13.40±11.11 8.89±8.54 
Moryella 0.024 0.00±0.01 0.33±0.97 
Klebsiella 0.026 4.67±4.97 2.78±3.38 
Bifidobacterium 0.037 6.69±10.68 1.13±1.56 
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OTU Level 
FDR q Mucosa-
adjacent 
RA (%) 
Explant 
Biopsy 
RA (%) 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 0.00006 0.01±0.02 2.96±4.85 
p__Actinobacteria__g__Actinomyces_4350499 0.00006 0.01±0.02 0.26±0.28 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU379777 0.00008 0.06±0.21 2.71±3.61 
p__Bacteroidetes__g__Prevotella__s__nigrescens_2195 0.00017 0.05±0.16 1.42±2.81 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 0.00017 0.01±0.03 3.33±5.44 
p__Firmicutes__g__Veillonella_561537 0.00017 0.90±1.45 1.99±1.59 
p__Firmicutes__g__Streptococcus_349024 0.00017 0.01±0.01 0.77±1.36 
p__Firmicutes__g__Streptococcus__s__infantis_517754 0.00017 0.00±0.01 0.43±0.55 
p__Actinobacteria__g__Actinomyces_565136 0.0002 0.01±0.02 0.30±0.42 
p__Firmicutes__g__Veillonella_518743 0.00024 0.81±1.15 2.82±2.70 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.00034 0.04±0.15 2.46±4.31 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0.00071 0.00±0.00 0.33±0.64 
p__Proteobacteria__g__Haemophilus__s__parainfluenzae_New.ReferenceOTU100511 0.00081 0.07±0.17 0.29±0.38 
p__Fusobacteria__g__Fusobacterium_34791 0.001 1.64±2.20 3.69±3.76 
p__Fusobacteria__g__Fusobacterium_545299 0.001 0.07±0.22 2.38±6.16 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU13477 0.001 0.06±0.18 0.52±0.80 
p__Firmicutes__g__Selenomonas_295019 0.0013 0.37±0.74 1.08±1.43 
p__Firmicutes__g__Selenomonas_4297955 0.0047 0.46±0.92 1.15±2.27 
p__Proteobacteria__g__Klebsiella_786708 0.0068 0.55±0.64 0.20±0.37 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.011 0.39±0.57 0.12±0.17 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.011 1.60±2.11 0.65±0.78 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.014 0.84±1.39 0.29±0.40 
p__Actinobacteria__g__Bifidobacterium_4426298 0.022 5.66±9.15 0.83±1.39 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.023 0.37±0.38 0.18±0.29 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.026 0.60±0.61 0.27±0.36 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.029 0.38±0.32 0.22±0.27 
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Table 5.6: Taxonomic differences between the mucosa-adjacent device surface collocated with the 
duodenal biopsy at baseline. 
Taxa 
FDR q Mucosa-
adjacent RA 
(%) 
Baseline 
Biopsy RA 
(%) 
Phylum Level 
Bacteroidetes 0.035 11.10±24.88 25.43±12.42 
Genus Level 
Streptococcus 0 0.22±0.44 43.22±10.26 
Prevotella 1.7E-13 0.18±0.50 23.85±12.73 
Gemella 4.7E-11 0.00±0.01 1.19±0.84 
Haemophilus 0.0000035 0.19±0.45 2.86±1.76 
Rothia 0.0000035 0.00±0.00 1.69±2.00 
Granulicatella 0.0000035 0.00±0.01 1.05±1.13 
Atopobium 0.0000098 0.01±0.02 0.37±0.33 
Actinomyces 0.000011 0.09±0.30 1.31±1.06 
Neisseria 0.00012 0.00±0.01 4.57±6.67 
Porphyromonas 0.00023 0.00±0.02 1.48±1.74 
Bulleidia 0.00023 0.00±0.01 0.73±1.22 
Peptostreptococcus 0.0003 0.00±0.01 0.26±0.34 
Veillonella 0.00043 1.95±2.64 7.87±8.95 
Unclassified Enterobacteriaceae 0.00043 13.40±11.11 2.83±6.72 
Moryella 0.00086 0.00±0.01 0.64±1.10 
Klebsiella 0.00089 4.67±4.97 0.01±0.02 
Helicobacter 0.0014 0.00±0.01 0.60±1.12 
Parvimonas 0.005 0.01±0.02 0.26±0.50 
Unclassified Gammaproteobacteria 0.005 7.61±10.74 0.05±0.10 
Lactobacillus 0.01 37.07±37.07 0.57±0.70 
Erwinia 0.033 0.07±0.12 0.00±0.00 
Actinobacillus 0.035 0.00±0.00 0.49±1.20 
Bifidobacterium 0.045 6.69±10.68 0.00±0.01 
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OTU Level 
FDR q Mucosa-
adjacent 
RA (%) 
Baseline 
Biopsy RA 
(%) 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 0 0.01±0.02 19.32±7.07 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU379777 0 0.06±0.21 11.81±4.24 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0 0.00±0.00 1.03±0.44 
p__Firmicutes__g__Streptococcus__s__infantis_517754 6.2E-14 0.00±0.01 3.01±1.48 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 2.3E-12 0.01±0.03 17.67±10.69 
p__Firmicutes__g__Streptococcus_349024 8.1E-09 0.01±0.01 4.94±4.02 
p__Actinobacteria__g__Actinomyces_565136 1E-07 0.01±0.02 0.50±0.39 
p__Actinobacteria__g__Actinomyces_4350499 1.1E-06 0.01±0.02 0.67±0.65 
p__Proteobacteria__g__Haemophilus__s__parainfluenzae_New.ReferenceOTU100511 1.6E-0.6 0.07±0.17 1.49±1.08 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.000035 2.78±2.61 0.22±0.47 
p__Bacteroidetes__g__Prevotella__s__nigrescens_2195 0.000095 0.05±0.16 0.97±1.27 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.00022 1.60±2.11 0.00±0.01 
p__Firmicutes__g__Veillonella_518743 0.00046 0.81±1.15 5.11±4.98 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU13477 0.00075 0.06±0.18 0.38±0.33 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.00097 0.84±1.39 0.02±0.04 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.00097 0.38±0.32 0.03±0.05 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.001 0.37±0.38 0.00±0.00 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.0011 0.60±0.61 0.00±0.00 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.0013 0.95±1.08 0.00±0.00 
p__Fusobacteria__g__Fusobacterium_545299 0.0018 0.07±0.22 0.96±1.67 
p__Proteobacteria__g__Klebsiella_786708 0.0029 0.55±0.64 0.00±0.01 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.0036 1.76±2.48 0.00±0.00 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.0048 7.61±10.74 0.05±0.10 
p__Firmicutes__g__Lactobacillus_592160 0.013 5.61±10.17 0.04±0.08 
p__Firmicutes__g__Lactobacillus_331248 0.024 0.21±0.30 0.00±0.00 
p__Proteobacteria__f__Enterobacteriaceae_510870 0.032 0.52±0.76 0.00±0.01 
p__Firmicutes__g__Lactobacillus_590168 0.032 0.48±1.12 0.00±0.00 
p__Firmicutes__g__Lactobacillus_533133 0.032 0.39±0.74 0.00±0.00 
p__Firmicutes__g__Lactobacillus_539647 0.033 1.23±2.16 0.01±0.02 
p__Firmicutes__g__Veillonella_561537 0.033 0.90±1.45 2.13±3.54 
p__Firmicutes__g__Lactobacillus_574021 0.034 0.73±1.08 0.01±0.02 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.038 0.04±0.15 0.14±0.17 
p__Firmicutes__g__Lactobacillus_563654 0.038 1.17±1.88 0.03±0.09 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.038 0.39±0.57 0.10±0.25 
p__Firmicutes__g__Lactobacillus_340960 0.043 1.86±3.17 0.01±0.02 
p__Actinobacteria__g__Bifidobacterium_4426298 0.044 5.66±9.15 0.00±0.01 
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5.3.3 Stool microbiota 
Stool samples were collected at baseline, 8 weeks post-implant and within three weeks after device 
explant for the assessment of the microbiota via high-throughput sequencing methods.  After filtering, 
a sequencing profile was successfully obtained for all stool samples collected (n=37).  A total of 
631,267 reads were generated from stool samples, representing 257 OTUs.  Specifically, sequences 
were identified from 9 phyla, 13 classes, 16 orders, 28 families and 48 genera.  At baseline, the mean 
number of reads was 16,879 (n=14).  At eight weeks, the mean number of reads was 19,665 (n=12).  
At explant, the mean number of reads was 14,453 (n=11). 
At baseline, the stool microbiota were dominated by the members of the Lachnospiraceae family 
(mean RA 18%) and Bacteroides (mean RA 11%).  At 8 weeks, the stool microbiota were dominated 
by the genus Lactobacillus (mean RA 17%) and members of the Lachnospiraceae family (mean RA 
10%).  At explant, the stool microbiota were dominated by members of the Lachnospiraceae (mean 
RA 15%) and Ruminococcaceae families (mean RA 14%).  Beta-diversity was measured in the stool 
using principal coordinate analysis.  Overall, the stool microbiota profile was not significantly 
different between time-points based on principal coordinate analysis (Figure 5.12; Adonis UniFrac: 
baseline vs. 8 weeks p=0.25, baseline vs. explant p=0.69, 8 weeks vs explant p=0.80). 
However, at eight weeks post-implant, there was a significant increase in 15 taxa in the stool at the 
genus level, compared to baseline (Table 5.7).  All of these were rare taxa at baseline, with a maximum 
mean RA of <2%.  Conversely, there was a significant reduction in members of the Lachnospiraceae 
family, the most abundant genus at baseline.  Notably, other stool microbes such as Ruminococcus 
had a low baseline RA (mean: 3.36±3.43%).  Indeed, Bifidobacterium was only detected in one 
baseline stool sample, at a very low abundance (0.01%).  These findings are mirrored at OTU level, 
with a significant increase in the RA of 13 Lactobacillus OTUs, four Enterobacteriaceae OTUs, two 
Veillonella parvula OTUs and one each of Citrobacter, Bifidobacterium, Fusobacterium, Klebsiella 
and Streptococcus.  A significant decrease in four Lachnospiraceae OTUs and one Clostridiales OTU 
(to which the Lachnospiraceae family belong) was observed from baseline to eight weeks  
post-implant.  A full statistical analysis can be found in Appendix 1.7. 
For the eight week time-point, three of eight patients had recently completed antibiotic triple therapy 
eradication for H.pylori infection.  When these patients were removed, the taxonomic changes from 
baseline remained, with the exception of the increase in members of the Enterobacteriaceae family, 
which was no longer significant.  In addition to a significant reduction in members of the 
Lachnospiraceae family seen in the full cohort, there was a significant reduction in Blautia and 
members of the Clostridiales order (both FDR q<0.05) when H.pylori eradication patients were 
removed. 
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Broadly, the changes observed in the stool have a moderate amount of overlap with what was seen in 
the gastric and duodenal mucosa.  Of the 15 genera that were significantly increased in the stool at 
eight weeks post-implant, six were also increased at explant in both the gastric and duodenal biopsies.  
These include taxa with high RA in the stool, such as Lactobacillus, Klebsiella and members of the 
Enterobacteriaceae family.   
Overall, the taxonomic changes observed in the stool were reversed rapidly following device removal.  
Indeed, there was no significant difference in the RA of any taxa between stool samples collected at 
baseline and within 3 weeks of device explant (n=9).  Further, there was no significant change in 
alpha diversity at any time-point (Figure 5.13: Shannon Index; baseline: 2.02±0.32, 8 weeks: 
2.19±0.35, explant: 1.90±0.36).  There was no significant change in the ratio of Firmicutes to 
Bacteroidetes at any time-point (Figure 5.14; baseline: 543±1530 vs. 8 weeks: 463±987 vs. explant: 
394±680). 
 
Figure 5.12: Principal co-ordinate analysis of stool samples using a weighted UniFrac distance matrix. 
There is no significant difference in overall microbiota profiles at baseline (blue squares) compared to eight 
weeks (red circles; Adonis UniFrac p=0.25) or explant (grey diamonds; Adonis UniFrac p=0.69).  There was 
no significant difference in overall community profile between eight weeks and explant (Adonis UniFrac 
p=0.80). 
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Table 5.7: Taxonomic changes in the stool microbiota from baseline to eight weeks post-implant. 
Taxa 
FDR q Compared 
to 
Baseline 
Baseline 
RA (%) 
8 week RA 
(%) 
Phylum Level 
Fusobacteria 0.0041 Increased 0.00±0.01 0.08±0.08 
Proteobacteria 0.0041 Increased 4.19±8.69 13.58±9.70 
Genus Level 
Citrobacter 0.000024 Increased 0.00±0.00 0.07±0.07 
Enterococcus 0.000024 Increased 0.00±0.00 0.93±1.21 
Bifidobacterium 0.0025 Increased 0.00±0.00 3.25±6.44 
Unclassified Clostridiaceae 0.0025 Increased 0.00±0.00 0.17±0.24 
Fusobacterium 0.0025 Increased 0.00±0.01 0.08±0.08 
Lactobacillus 0.0025 Increased 1.67±5.85 16.86±19.75 
Clostridium 0.0025 Increased 0.00±0.01 0.15±0.20 
Serratia 0.0037 Increased 0.00±0.00 0.10±0.16 
Acinetobacter 0.0059 Increased 0.00±0.00 0.45±0.85 
Unclassified Lachnospiraceae 0.0086 Decreased 17.54±9.92 9.55±7.20 
Unclassified Enterobacteriaceae 0.013 Increased 1.73±3.00 6.98±7.37 
Klebsiella 0.013 Increased 1.93±6.25 5.88±6.14 
Veillonella 0.019 Increased 0.04±0.07 1.11±1.57 
Unclassified Gammaproteobacteria 0.025 Increased 0.00±0.00 0.03±0.05 
Unclassified Bacteria 0.048 Increased 0.00±0.00 0.07±0.16 
Erwinia 0.048 Increased 0.00±0.00 0.01±0.16 
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OTU Level 
FDR q Compared 
to 
Baseline 
Baseline 
RA (%) 
8 week 
RA (%) 
p__Proteobacteria__g__Citrobacter_786708 0.00005 Increased 0.00±0.00 0.07±0.07 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.0006 Increased 0.00±0.01 0.23±0.29 
p__Actinobacteria__g__Bifidobacterium_4426298 0.003 Increased 0.00±0.00 3.19±6.37 
p__Firmicutes__g__Lactobacillus_563654 0.0032 Increased 0.03±0.03 2.35±2.94 
p__Fusobacteria__g__Fusobacterium_545299 0.0033 Increased 0.00±0.01 0.08±0.08 
p__Firmicutes__g__Lactobacillus_582884 0.0036 Increased 0.01±0.01 3.34±5.30 
p__Firmicutes__g__Lactobacillus_329402 0.0036 Increased 0.01±0.01 5.49±8.77 
p__Firmicutes__g__Lactobacillus_549756 0.0036 Increased 0.00±0.01 1.05±1.61 
p__Firmicutes__f__Lachnospiraceae_New.CleanUp.ReferenceOTU93368 0.0041 Decreased 4.00±4.49 1.18±1.60 
p__Firmicutes__f__Lachnospiraceae_New.ReferenceOTU100192 0.0041 Decreased 2.57±2.90 0.86±1.19 
p__Proteobacteria__f__Enterobacteriaceae_New.ReferenceOTU100973 0.0041 Increased 0.00±0.00 0.20±0.30 
p__Firmicutes__g__Lactobacillus_New.CleanUp.ReferenceOTU388917 0.0079 Increased 0.00±0.00 0.04±0.06 
p__Firmicutes__g__Lactobacillus_586093 0.0088 Increased 0.01±0.01 0.55±0.83 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.0093 Increased 0.03±0.09 2.99±6.50 
p__Firmicutes__g__Veillonella__s__parvula_518743 0.0093 Increased 0.01±0.02 0.47±0.55 
p__Proteobacteria__g__Klebsiella_822899 0.011 Increased 1.93±6.25 5.74±6.06 
p__Firmicutes__g__Lactobacillus_539647 0.011 Increased 0.00±0.01 0.25±0.40 
p__Firmicutes__g__Lactobacillus_590168 0.014 Increased 0.00±0.00 0.11±0.18 
p__Firmicutes__f__Lachnospiraceae_369709 0.014 Decreased 1.92±2.38 0.62±1.11 
p__Firmicutes__o__Clostridiales_470382 0.016 Decreased 2.72±1.92 1.01±0.86 
p__Firmicutes__g__Lactobacillus_725198 0.017 Increased 0.00±0.01 0.46±0.79 
p__Proteobacteria__f__Enterobacteriaceae_812379 0.02 Increased 0.00±0.00 0.57±1.56 
p__Firmicutes__g__Streptococcus_516966 0.02 Increased 0.17±0.23 1.89±2.50 
p__Firmicutes__g__Lactobacillus_340960 0.02 Increased 0.00±0.00 0.07±0.14 
p__Firmicutes__g__Lactobacillus_New.ReferenceOTU100589 0.02 Increased 0.00±0.00 0.03±0.06 
p__Firmicutes__g__Veillonella__s__parvula_4352537 0.021 Increased 0.01±0.02 0.26±0.52 
p__Firmicutes__f__Lachnospiraceae_New.CleanUp.ReferenceOTU1164950 0.028 Decreased 1.18±0.95 1.86±0.98 
p__Firmicutes__g__Lactobacillus_823803 0.043 Increased 0.00±0.00 0.12±0.32 
p__Firmicutes__g__Lactobacillus_331248 0.043 Increased 0.00±0.00 0.03±0.07 
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Figure 5.13: Alpha diversity analysis of stool samples at genus level. 
There was no significant change in alpha diversity (p=0.12; n=8) from baseline to eight weeks (A), eight weeks 
to explant (p=0.25; n=9; data not shown) or baseline to explant (B; p=0.77; n=10).  Each patient is displayed 
as an individual line.  Results compared by Wilcoxon signed rank test.  
 
Figure 5.14: Firmicutes to Bacteroidetes ratio in stool samples. 
There is no significant difference in Firmicutes to Bacteroidetes ratio between baseline and eight weeks (A: 
p=0.28) or baseline and explant (B: p=0.70).  Each patient is displayed as an individual line.  Results compared 
by Wilcoxon signed rank test. 
5.3.4 Functional predictions from 16S sequencing 
Sequencing data was used to predict functional pathways using PICRUSt.  In the gastric biopsies, 
there was a significant increase in six functional pathways, and a significant decrease in 10 functional 
pathways from baseline to explant (Table 5.8; Figure 5.15).  Broadly, these can be summarised as a 
significant increase in cellular processes and signalling, particularly membrane transport, and genetic 
information processing, in particular transcription factors.  There was a significant reduction in energy 
metabolism, amino acid metabolism, translation, replication and repair and genetic information 
processing.  At baseline, there was no significant difference with the control group for any of the 
pathways.  At explant, the functional profiles were markedly different from controls, with 72 
pathways being significantly higher than baseline biopsies and 54 being significantly lower.   
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A full list of these can be seen in Appendix 1.7.  Of the 16 pathways that were significantly different 
from baseline to explant, 11 were also significantly different at explant, compared to the control 
group.  Interestingly, a number of the pathways that were significantly higher in the explant biopsies 
were for pathways associated with nutrient metabolism, in particular fat and protein metabolism 
pathways.  Additionally, there was a significantly higher relative gene count for bile secretion and 
bile acid biosynthesis in the explant gastric biopsies. 
Table 5.8: KEGG ortholog functional pathways that were significantly different from baseline to explant 
in gastric biopsy samples. 
KEGG Ortholog Direction of change 
ABC transporters Increased 
Amino acid related enzymes Decreased 
Aminoacyl-tRNA biosynthesis Decreased 
Carbon fixation pathways in prokaryotes Decreased 
DNA replication Decreased 
DNA replication proteins Decreased 
Function unknown Increased 
Lysine biosynthesis Decreased 
Mismatch repair Decreased 
Other ion-coupled transporters Increased 
Oxidative phosphorylation Decreased 
Phosphotransferase system (PTS) Increased 
Protein folding and associated processing Decreased 
Ribosome Decreased 
Transcription factors Increased 
Transporters Increased 
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Figure 5.15: KEGG ortholog functional pathways that were significantly different from baseline to explant 
in gastric biopsies.   
Data analysed by using mixed effects linear regression modelling using paired data for each patient.  For 
graphical purposes, data is presented as grouped data. Significance indicated by *. 
In the duodenal biopsies, there was a significant increase in carbohydrate metabolism (starch and 
sucrose metabolism) and cellular processes and signalling (transporters), particularly membrane 
transport (the phosphotransferase system) at explant, compared to baseline.  There was a significant 
decrease in amino acid metabolism (glycine, serine and threonine metabolism; Figure 5.16).   
At baseline, there was no significant difference with the control group for any of the pathways.   
At explant, the functional profiles were markedly different from controls, with 75 pathways being 
significantly higher than baseline biopsies and 75 being significantly lower.  A full list of these can 
be seen in Appendix 1.7.  Similar to the gastric biopsies, the relative gene count of bile secretion, bile 
acid biosynthesis and fat and protein metabolism pathways were significantly higher in the explant 
biopsies than controls. 
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Figure 5.16: KEGG ortholog functional pathways that were significantly different from baseline to explant 
in duodenal biopsies. 
Data analysed by using mixed effects linear regression modelling using paired data for each patient.  For 
graphical purposes, data is presented as grouped data. Significance indicated by *. 
In the stool samples, there were no significant differences in functional pathways between baseline 
and explant or 8 weeks and explant.  However, between baseline and 8 weeks, there was a significant 
increase in transcription machinery.  There was a significant decrease in other components of genetic 
information processing (replication and recombination and repair) and signalling and cellular 
processes (secretion system, two component system and bacterial motility proteins). 
5.3.5 Bacterial load 
qPCR was used to assess the bacterial load of mucosal biopsy specimens.  There was a trend toward 
a significant increase in bacterial load in the stomach (baseline: 0.02±0.02 vs. explant 0.07±0.07; 
n=11; p=0.05).  There was no significant change in bacterial load in the duodenum as a result of DJBS 
treatment (baseline: 0.02±0.01 vs. explant 0.04±0.04; n=11; p=0.21).  However, compared to a 
control group (control: 0.16±0.18), bacterial load in the duodenum was significantly lower at both 
baseline (p<0.0001) and explant (p=0.002). 
5.3.6 Relationships between microbiota and device efficacy 
Linear regression analysis was performed to assess the relationship between weight loss and the RA 
of microbial taxa with a mean RA of at least 1%.  There was a significant positive relationship 
between TBWL at device explant and the RA Streptococcus (r=0.73; p=0.04) in the baseline gastric 
biopsy.  There was a significant negative relationship between TBWL at explant and the RA of 
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Helicobacter in the baseline gastric biopsy (r=-0.53; p=0.03).  On multivariate analysis, Helicobacter 
was retained (r=-0.75, r2=0.57, p=0.03).  There was a significant negative relationship between 
TBWL at device explant and the RA of members of the Gammaproteobacteria class (r=-0.52; p=0.05) 
in the explant gastric biopsy.  There were no significant relationships between weight loss and any 
taxa in the duodenal biopsies with a mean RA of >1%.  Significance of the above analyses was not 
altered by the removal of early explant patients from the analyses. 
In the full cohort, linear regression revealed a significant positive relationship between weight loss 
and the mean RA of Megasphaera (r=0.55; p=0.02) and Klebsiella (r=0.46; p=0.05) on the device.  
On multivariate analysis, only Megasphaera was retained (r=0.55, r2=0.30, p=0.02).  When all early 
explants were removed (n=4), no significant relationship between weight loss and the mean RA of 
any taxon with a minimum RA of 1% remained. 
On linear regression, there was a significant positive relationship between TBWL at device explant 
and the RA of Dorea (r=0.55; p=0.04) in the stool at baseline.  There was a significant positive 
relationship between TBWL at device explant and the RA of Lactobacillus (r=0.74; p=0.002) and 
Klebsiella (r=0.56; p=0.03) in the stool at eight weeks post-implant.  On multiple linear regression 
analysis, only Lactobacillus was retained in the model (r=0.74, r2=0.55, p=0.002).  There were no 
significant relationships between TBWL at device explant and the RA of any taxa in the stool within 
three weeks after device explant. 
5.3.7 Relationships between microbiota and device tolerability 
Three patients had devices explanted early due to persistent GI symptoms.  Compared to patients that 
completed the full intervention, there was a significantly higher mean RA of members of the 
Gammaproteobacteria class (p=0.02) and the genera Klebsiella (p=0.01) and Veillonella (p=0.01) 
identified on these devices.  There was also a significantly lower RA of Megasphaera (p=0.01) 
present on these devices.  At OTU level, this was driven by significantly higher RA of four Klebsiella 
OTUs (p<0.05), two Veillonella OTUs (p<0.05) and one Gammaproteobacteria OTU (p=0.02).   
In addition, the mean RA of three Enterobacteriaceae OTUs (p<0.05) and one Streptococcus OTU 
(p<0.05) was significantly higher in those that underwent early explant. 
Following the observation of constipation after device placement, linear regression analysis was 
performed to assess the relationship between constipation and the RA of microbial taxa in the stool 
with a mean RA of at least 1%.  At baseline and explant, there were no significant relationships 
between constipation (as measured by the SAGIS) and the RA of any taxon in the stool with a 
minimum mean RA of 1%.  At eight weeks, the RA of Klebsiella was positively associated with the 
severity of constipation reported (r=0.77; p=0.04).  
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5.3.8 Relationships between microbiota and dietary intake  
An exploratory analysis of the relationship between dietary variables and the RA of taxa at the genus 
level was conducted.  It should be noted 24 hour recall data was not collected on the same day as 
biological samples for microbiota analyses and this limits the strength of conclusions that can be 
drawn from this analyses.  At baseline, there was no relationship between the RA of any microbial 
taxon with at least 1% RA and energy, fibre, protein, fat or carbohydrate intake. 
At explant, a number of taxa were associated with energy, fibre and macronutrient intake.   
Univariate linear regression analyses of dietary intake and microbial abundances in MAM are 
summarised below in Table 5.9.  On multivariate analysis, the RA of Collinsella in the duodenal 
biopsies was positively associated with fibre intake (r=0.67, r2=0.45, p=0.009) and negatively 
associated with energy intake (r=-0.68, r2=0.47, p=0.007) and carbohydrate intake (r=0.60, r2=0.35, 
p=0.03).  Klebsiella in the duodenal biopsies was positively associated with protein intake (r=0.61, 
r2=0.37, p=0.02) whilst Bifidobacterium in the gastric biopsies was positively associated with fat 
intake (r=0.62, r2=0.39, p=0.018). 
Table 5.9: Relationship between dietary intake and the RA of microbial taxa (at genus level) isolated from 
gastric and duodenal biopsy samples on univariate analysis. 
Variable Baseline Explant 
 Positive 
Associations 
Negative 
Associations 
Positive Associations Negative Associations 
Energy Nil Nil Gastric: Lactobacillus 
(r=0.57; p=0.04) 
 
Duodenum: nil 
Gastric: nil 
 
Duodenum: Collinsella 
(r=-0.68; p=0.01) 
Fibre Nil Nil Gastric: Lactobacillus 
(r=0.54; p=0.05) 
 
Duodenum: nil 
Gastric: Collinsella  
(r=-0.58; p=0.03) 
 
Duodenum: Collinsella 
(r=-0.67; p=0.01) 
Protein intake Nil Nil Gastric: nil  
 
Duodenum: Klebsiella 
(r=0.61; p=0.02) and 
Gammaproteobacteria 
(r=0.55; p=0.04) 
Nil 
Fat intake Nil Nil Gastric: Bifidobacterium 
(r=0.62; p=0.02) 
 
Duodenum: Klebsiella 
(r=0.55; p=0.04) and 
Bifidobacterium (r=0.54; 
p=0.05) 
Nil 
Carbohydrate 
intake 
Nil Nil Gastric: Lactobacillus 
(r=0.54; p=0.05) 
 
Duodenum: nil 
Gastric: nil 
 
Duodenum: Collinsella 
(r=-0.60; p=0.03) 
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We also investigated the relationship between dietary constituents and the stool microbiota.   
At baseline, there was no relationship between dietary variables and any taxa with a minimum mean 
RA of 1% in the stool.  After eight weeks of DJBS dwell time, both energy and fibre intake were 
negatively associated with the RA of members of the Enterobacteriaceae family in the stool.   
Within three weeks after device explant, a positive relationship between fat intake and the RA of 
Klebsiella in the stool was observed.  A negative relationship between fibre intake and the RA of 
members of the Clostridiales order and carbohydrate intake and the RA of Collinsella and members 
of the Lachnospiraceae family was also observed.  Linear regression analyses of dietary intake and 
microbial abundances in the stool are summarised below in Table 5.10. 
Table 5.10: Relationship between dietary intake and the RA of microbial taxa (at genus level) isolated 
from stool samples on univariate analysis. 
Variable Baseline 8 weeks dwell time Explant 
 Positive 
Association 
Negative 
Association 
Positive 
Association 
Negative 
Association 
Positive 
Association 
Negative 
Association 
Energy Nil Nil Nil Enterobacteriaceae 
(r=-0.53; p=0.04) 
Nil Nil 
Fibre Nil Nil Nil Enterobacteriaceae 
(r=-0.55; p=0.03) 
Nil Clostridiales  
(r=-0.70; p=0.02) 
Protein 
intake 
Nil Nil Nil Nil Nil Nil 
Fat intake Nil Nil Nil Nil Klebsiella 
(r=0.77; 
p=0.01) 
Nil 
Carbohydrate 
intake 
Nil Nil Nil Nil Collinsella 
(r=-0.70; 
p=0.02)  
Lachnospiraceae 
(r=-0.66; p=0.04) 
  
 170 
 
5.3.9 Results summary 
High-throughput sequencing techniques were used to characterise the gastric and duodenal MAM 
and the stool microbiota, in addition to the microbial community on the device itself.  Bacterial load 
of mucosal biopsies was assessed using qPCR.  Following DJBS treatment there was a shift in both 
the gastric and duodenal MAM away from the profile observed in controls.  Common upper GIT 
microbes, such as Streptococcus were significantly reduced following DJBS treatment.  There was a 
concurrent increase in rare microbes that were of low abundance at baseline, such as Lactobacillus.  
Neither alpha diversity nor bacterial load were changed in the stomach or the duodenum following 
DJBS treatment.  However, alpha diversity was significantly higher at both sites at explant, compared 
to controls.  Bacterial load was significantly lower in the duodenum at baseline and explant, compared 
to controls. 
The mucosa-adjacent device surface formed a distinct microbial community.  On the device, there 
was a low RA of organisms typically seen in the duodenum such as Prevotella and Streptococcus.  
Indeed, the device was primarily colonised by microbes more common to the distal GIT such as 
Lactobacillus and members of the Enterobacteriaceae family.  However, overall, the MAM in the 
duodenum at explant was distinct from the collocated mucosa-adjacent device community. 
Treatment with a DJBS resulted in distinct changes in the stool microbiota during the device in situ 
phase.  Similar to the MAM, a shift away from a “typical” stool microbiota profile was observed with 
a reduction in members of the Lachnospiraceae family and a proliferation of rare taxa.   
However, these taxonomic changes did not persist after device removal. 
Functional gene predictions from the sequencing data suggest alterations in nutrient metabolism 
pathways from baseline to explant.  In the stomach, this was reflected by a reduction in energy 
metabolism and protein metabolism pathways.  In the duodenum, this was reflected by an increase in 
carbohydrate metabolism pathways and a reduction in protein metabolism pathways.  In comparison 
to controls, there was an enrichment in pathways associated with bile secretion and bile acid synthesis 
in both the gastric and duodenal biopsies at device explant. 
Interestingly, it was possible to correlate weight loss and device tolerability outcomes with the 
microbes colonising either the MAM or the device itself.  Further, a number of taxa in the MAM at 
explant could be associated with dietary macronutrient intake data.  
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5.4 DISCUSSION 
Obesity and T2DM have been demonstrated to alter the GI microbiota, with weight loss partially 
reversing these changes.  The DJBS is a foreign body that resides in the upper GIT for up to 48 weeks, 
and is in contact with the duodenal mucosa.  This potentially provides an ideal growth environment 
for microorganisms on the device surface.  It is possible that changes in the local environment induced 
by the DJBS may lead to alterations in the duodenal MAM community.  This may have important 
implications for device efficacy, tolerability and safety.  Despite this, this is the first study to 
thoroughly assess the GI microbiota following DJBS treatment. 
The MAM of the stomach and the duodenum were characterised at baseline and explant using high-
throughput sequencing techniques.  The overall community profiles (beta-diversity) observed in the 
stomach and the duodenum were not significantly different from a control population of patients with 
a positive faecal occult blood test or iron deficiency anaemia.  Indeed, there were no significant 
differences between the baseline biopsies and the controls of similar BMI (≥35 kg/m2).   
However, there were significant taxonomic shifts as a result of DJBS treatment and considerable 
overlap in the taxonomic changes observed in the stomach and the duodenum, with eight taxa 
increased at both sites.  Broadly, there was a significant increase in a number of lactate producing and 
lactate utilising taxa, including Lactobacillus, Dialister and members of the Enterobacteriaceae 
family.  This is possibly reflective of changes in the environment induced by the presence of the 
device which may allow migration of aerotolerant distal bowel bacteria in addition to providing a 
surface for adhesion and growth, which may then seed an alteration the MAM.  Once colonisation 
with lactate producing bacteria had occurred this will then define the succession of lactate utilising 
bacteria. 
In addition to characterising the MAM, another aim of this chapter was to characterise any microbial 
community that formed on the device itself.  A distinct community formed on the mucosa-adjacent 
device surface, with a preference for colonisation by more typically distal microorganisms such as 
Lactobacillus and Bacteroides than the most abundant core duodenal community members such as 
Streptococcus and Prevotella544, 548.  Indeed, the mucosa-adjacent device surface that was collocated 
with the mucosal biopsy at explant was distinct, suggesting a difference in growth requirements at 
two geographically collocated sites. 
We also characterised changes in the stool microbiota following treatment with the DJBS.  This is 
particularly useful as the literature surrounding changes in the GI microbiota following bariatric 
surgery all use stool sampling, allowing for a more direct comparison of the results obtained.  In the 
stool samples, treatment with a DJBS leads to distinct phylogenetic changes, without impacting the 
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overall community profile or alpha diversity.  This was characterised by an increase in taxa that were 
at very low abundance at baseline and a decrease in members of the dominant Lachnospiraceae 
family.  This is particularly interesting as colonisation with Lachnospiraceae has been associated 
with increased fasting glucose in a rodent model of obesity549.  To date, one other study of the DJBS 
has assessed the stool microbiota at baseline and after six months of treatment in 14 patients479.   
There was considerable overlap between the results observed in their cohort and ours.  The RA of 
Lactobacillus, Veillonella, Klebsiella and Serratia increased in both study cohorts.  In the de Jonge 
cohort, increases in Clostridium cluster IV, Enterobacter, Escherichia coli and Yersinia were also 
reported.  These taxa belong to the Clostridiaceae family (Clostridium cluster IV), the 
Enterobacteriaceae family (Enterobacter and Escherichia) and Gammaproteobacteria class 
(Yersinia), which were all increased in our cohort.  Therefore it is possible that further analysis to 
increase granularity may have also allowed us to discriminate to these lower taxonomic levels.   
In contrast to our results, they observed a decrease in Ruminococcus and Megamonas, where we 
observed a reduction in members of the Lachnospiraceae family.  Broadly, all of these taxon are 
butyrate producers, suggesting the changes are functionally similar despite taxonomic differences.  
The taxonomic changes observed in our study are also broadly similar to those observed following 
bariatric surgery.  One key difference between DJBS treatment and bariatric surgery is the transient 
nature of DJBS treatment.  Indeed, transient phylogenetic changes were observed in the stool, with a 
return to baseline profile being observed within three weeks after device explant.   
Whilst we do not have any measures of the MAM after explant, it is possible that these changes are 
also reversed after device removal.  Therefore, unlike surgery, the long-term implications of these 
changes may be of limited relevance in long-term weight and metabolic outcomes post-explant. 
Functional predictions constructed from the sequencing data were used to assimilate taxonomic 
changes with changes in the genetically encoded functional potential of the microbial communities 
(for example, the presence of genes encoding particular enzymatic/metabolic pathways).  An increase 
in membrane transport was observed after device dwell, as was an increase in carbohydrate 
metabolism.  A reduction in overall energy metabolism, and more specifically amino acid 
metabolism, was also observed.  These changes may reflect a shift towards more efficient utilisation 
of carbohydrate in the context of reduced consumption (Chapter 3 Section 3.3.5).  They also mirror 
the taxonomic changes seen on the mucosa, with an increase in taxa that ferment carbohydrates, such 
as Lactobacillus550 and Bifidobacterium551.  In particular, the increase in the phosphotransferase 
system (a major mechanism of carbohydrate uptake by bacteria) observed is likely to reflect the 
dominant colonisation by Lactobacillus552.  A number of these functional changes have also been 
reported previously in the stool following bariatric surgery.  Specifically, three studies that have 
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broadly assessed changes in KEGG orthologs have reported an increase in the phosphotransferase 
system pathway after RYGB368, 372, 375.  Graessler et al. proposed that these changes occur as a 
compensatory effect to enhance substrate assimilation to meet energy demands in the context of 
reduced substrate availability368.  Carbon fixation by prokaryotes and glycine, serine and threonine 
metabolism pathways have also been reported to be increased following LSG, as observed in our 
cohort372.  Tremaroli et al. observed an increase in the two component system following RYGB, 
whereas our results indicate a reduction in this pathway375.  The other changes in functional pathways 
from the stool observed in this cohort have not previously been reported. 
As part of the treatment protocol, patients were prescribed a PPI for the duration of the intervention, 
and for four weeks after device removal.  This will impact all follow-up data points, but not the 
baseline data, and exerts an additional confounder into the analysis.  PPI use has been associated with 
reduced alpha diversity and distinct phylogenetic changes in the stomach553.  However, the majority 
of work regarding the impact of PPI use on the GI microbiota has assessed changes in the stool 
microbiota.  In our study, three of 14 taxonomic groups that were increased (Enterococcus, 
Lactobacillus and Veillonella) after DJBS treatment have also been shown to be increased in the stool 
after chronic PPI treatment554.  In our cohort, there was a significant reduction in members of the 
Lachnospiraceae family.  PPI use has not been demonstrated to have a consistent effect, with both an 
increased555 and a reduced556 RA of this family reported with PPI use.  Further, in our cohort, in the 
stomach, Rothia and Actinomyces were significantly decreased, whilst in the duodenum Haemophilus 
and Gemella were decreased.  Broadly, these organisms are typical of the oral microbiota and are 
acidogenic genera.  These organisms have been reported to be enriched with PPI use554, which 
suggests DJBS treatment is exerting a stronger effect on the GI microbiota than PPI use in our cohort.   
Whilst significant taxonomic changes were observed, there was no significant change in alpha 
diversity or bacterial density in the stomach or duodenum following DJBS treatment. 
There was a trend toward an increase in bacterial load in the stomach following DJBS treatment.   
This is more likely to be reflective of chronic PPI use than a device-related effect.  Studies have 
demonstrated an increase in the number of colony forming units in gastric juice aspirate following 
chronic PPI use, indicating the possibility for enhanced proliferation of the microbial  
community557, 558.  Contrary to our expectations, there was no significant effect of DJBS treatment on 
bacterial load in the duodenum.  This is likely to reflect the small sample size for paired comparisons 
(n=8), as bacterial load at explant was significantly higher than observed in a control group.   
However, the physical presence of the device and the microbial community on the mucosa-adjacent 
surface leads to an increase in bacteria overall in the region.  Whilst PPI use was mandatory for all 
patients to reduce the risk of upper GI bleeding, the use of PPIs may also modulate the weight loss 
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response.  In a study of RYGB patients, PPI use at six months post-surgery was associated with both 
a higher RA of Firmicutes and a lower EWL559.  This evidence highlights the complexity of 
understanding the modulators of clinical response to DJBS treatment. 
Antibiotic therapy has widespread and persistent impacts on the GI microbiota560, 561.  In our cohort, 
antibiotic use was only precluded in the four weeks prior to recruitment and indeed four patients were 
treated with antibiotics for eradication of H.pylori following device implantation.  Antibiotic therapy 
is likely to impact other taxonomic groups besides Helicobacter.  As this treatment occurred soon 
after device implantation, this is most likely to impact the eight weeks post-implant stool sample, as 
this was the only device in situ measure of the GI microbiota.  Despite this, the taxonomic differences 
between baseline and eight weeks post-implant time-points were not profound, with all but one 
taxonomic group remaining significantly increased when antibiotic-treated patients were removed.  
In the stool, the majority of the taxa increased after DJBS implantation are facultative anaerobes, even 
when H.pylori eradication treatment patients are removed.  This is noteworthy as recent Helicobacter 
eradication therapy has been shown to increase the presence of facultative anaerobes in the stool562.  
However, with this trend persisting when these patients are removed, it suggests the device 
environment supports the growth of facultative anaerobes (such as the dominant Lactobacillus and 
Enterobacteriaceae), which are shed, thereby influencing the stool profile.  This is strengthened by 
the observation of a reduction in obligate anaerobic taxa with a high baseline RA such as members 
of the Clostridiales order, Lachnospiraceae family and Blautia even when H.pylori eradicated 
patients were removed.  These results suggest the DJBS is exerting a stronger and/or independent 
effect on the microbial community than antibiotic use. 
A rare complication of DJBS treatment is the formation of pyogenic hepatic abscess.  It has been 
postulated that this occurs either as a result of ascending cholangitis or secondary to perforations 
induced by the barbs563.  Another potential mechanism is translocation of bacteria across the mucosal 
membrane.  Obesity has been associated with an increase in small intestinal permeability564 and our 
results indicate a distinct microbial community is formed on the mucosa-adjacent device surface.  
Overall, this leads to more bacteria being in close contact with the duodenal mucosa, and may provide 
an opportunity for bacterial translocation and seeding into the portal vein.  This is a possible 
explanation for the development of pyogenic hepatic abscess that has been observed as a complication 
of DJBS treatment.  Indeed, while there were no cases in our cohort, some of the taxonomic changes 
observed are congruent with reports of sequencing data obtained from aspirated pyogenic liver 
abscess material.  In particular, between baseline and explant there was a significant increase in the 
RA of Klebsiella, Fusobacterium, Dialister and members of the Enterobacteriaceae family in the 
duodenal biopsy samples, all of which have been reported in liver abscess fluid565.  In the case of 
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Klebsiella, which has been frequently reported in hepatic abscess fluid in patients with diabetes 
mellitus566, there was a nearly 200-fold increase in the RA in the duodenum (baseline mean: 0.01% 
vs. explant mean: 2.78%).  Moreover, the RA of Klebsiella was significantly higher on the collocated 
mucosa-adjacent device surface (mean: 5.07%) than in the explant biopsy.  Furthermore, members of 
the Enterobacteriaceae family were one of the most dominant taxa to colonise the mucosa-adjacent 
device surface.  Therefore, the changes induced by DJBS treatment both in the MAM and the 
proliferation of a bacterial community on the mucosa-adjacent device surface may be relevant for the 
manifestation of one of the key SAEs of device treatment. 
A number of relationships between the RA of microbial taxa and weight loss were observed across 
the various sites of measurement.  In the mucosa and on the device surfaces, these relationships 
suggested that a lesser degree of disturbance from a taxonomic profile that is characteristic of the 
upper GIT microbiota observed in controls was associated with better weight loss outcomes.   
For example, the RA Streptococcus in the stomach at baseline, a site typically high in RA of this 
taxon567, was associated with weight loss.  Conversely, the RA of Helicobacter, a common pathogen, 
in the stomach at baseline, was negatively associated with weight loss.  Similarly, the RA of members 
of the Gammaproteobacteria class in the stomach at device explant was negatively associated with 
weight loss.  These organisms would typically dwell in the distal GIT.  On the device surface, weight 
loss was positively associated with the RA of Megasphaera.  This genus has been reported to increase 
after bilio-intestinal bypass568, but no direct correlation with weight loss was reported.  In the stool at 
baseline, the RA of Dorea, a normal luminal microbe, was positively associated with weight loss.  
However, as this is only one of many core luminal taxa, this is insufficient evidence to suggest a more 
“typical” stool profile at baseline may be associated with weight loss.  At the eight week post-implant 
time-point, the only device in situ measure of the GI microbiota, the RA of Lactobacillus was 
associated with weight loss.  This is likely to be reflective of a flow through effect, as Lactobacillus 
is the predominant taxa colonising the device itself.  Although the evidence is conflicting, a similar 
relationship between Lactobacillus and weight loss response has been reported in one dietary weight 
loss intervention study193.  Further investigation is required to determine the relationship between 
microbial taxa and weight loss outcomes. 
Changes in the GI microbiota induced by DJBS treatment may also be relevant for device tolerability.  
Indeed, it was possible to identify microbes that were associated with early explant in this group.   
In these patients, a significantly higher RA of members of the Gammaproteobacteria class and the 
genera Klebsiella and Veillonella were observed, whilst a significantly lower RA of Megasphaera 
was observed.  Some of these taxa have been linked to either organic or functional bowel disorders.  
For example, the RA of Veillonella in the stool has been reported to be higher in IBS patients than 
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controls569.  Similarly, an increase RA of members of the Gammaproteobacteria class has been 
reported in both IBS570 and active inflammatory bowel disease571.  However, these taxa have not 
specifically been linked to abdominal pain.  Finally, Megasphaera and Klebsiella have not previously 
been linked to GI symptoms.  One limitation of these links between GI disorders and the abundance 
of bacterial taxa is that they are often performed using a stool sample.  Given the location of the 
symptoms (primarily epigastric), further studies in a larger cohort should aim to assess taxonomic 
differences in the proximal small intestine in those who undergo elective early removal due to GI 
symptoms.  This could provide insight into any microbial regulation of upper GI symptoms.   
Due to the observation of constipation following DJBS treatment, we aimed to assess taxa that may 
be related.  Members of the Gammaproteobacteria class and Enterobacteriaceae family, Klebsiella 
and Bifidobacterium were all negatively associated with constipation at device explant.  
Bifidobacterium administration as a probiotic supplement has been demonstrated to relieve 
constipation in humans and mice572, 573.  The other three taxonomic groups have not specifically been 
associated with constipation; however, they could be considered “pro-inflammatory” taxa574.  
Inflammation has been associated with diarrhoea in patients with IBS575, and therefore the abundance 
of these taxa could perhaps be linked with more rapid motility.  Alternatively, recent data suggest that 
methane, produced by methanogenic archaea and in particular Methanobrevibacter smithii576, 577, can 
cause constipation.  These archaea were not revealed in our sequencing data.  Future studies could 
assess methane production by using a targeted quantitative assessment of methanogenic archaea via 
qPCR or a qualitative assessment by using a glucose hydrogen breath test578.  This could improve 
conclusions drawn about the relevance of archaeal changes in the pathogenesis of constipation 
following DJBS treatment. 
Very little is known about the impact of diet on the MAM of the proximal GIT.  However, this is the 
site at which exposure to simple carbohydrates and amino acids is maximal, and therefore dietary 
intake is likely to have a profound effect on the composition of the microbiota.  Due to the lack of 
literature, our results will be compared to findings in the stool microbiota.  At device explant, energy, 
carbohydrate and fibre intake were negatively associated with the RA of Collinsella, a typical upper 
GI microbe.  In the literature, the RA of Collinsella (aerofaciens) in stool samples has been reported 
to decrease with a low carbohydrate weight loss diet192.  Conversely, low fibre intake has been 
associated with an enrichment of Collinsella579, 580.  Therefore it may be the fibre content rather than 
overall carbohydrate intake that is of importance.  Macronutrient intake was also positively associated 
with the RA of Lactobacillus, Bifidobacterium and Gammaproteobacteria in the MAM.  These 
organisms are typically higher in abundance in the distal bowel.  Calorie restriction has been shown 
to increase Lactobacillus in a limited number of human studies581.  However, calorie restriction in 
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humans is an imprecise assessment as it leads to weight loss, which may induce confounding effects.  
Dietary fat and protein intake were positively associated with the RA of Klebsiella.  During the 
intervention, higher fat intake was discouraged due to the high contribution to energy intake.   
Klebsiella is a bile tolerant bacterial group582.  Five day administration of an animal-based diet (30% 
of energy from protein with high saturated fat) has been associated with an increased abundance of 
bile tolerant bacteria151.  Klebsiella has also been associated with pyogenic hepatic abscess566.  
Therefore, future studies should aim to assess dietary intake and the GI microbiota to validate the 
potential links between dietary intake and unfavourable changes in the microbiota that could relate to 
safety outcomes. 
A major strength of the study is the breadth of sampling sites, as this allows for a more detailed 
characterisation of the impacts of the DJBS on the GI microbiota across the length of the GIT.   
In parallel, the dataset allowed for matched comparisons, which helps to overcome the large  
inter-individual variation inherent in studies of the GI microbiota, increasing the confidence the 
changes observed are as a result of the treatment protocol.  The V6-V8 hypervariable region of the 
16S rRNA gene was selected to provide the most accurate representation of communities present at 
genus and OTU level583; however, certain taxa such as Bacteroides may be underrepresented584.   
To enhance the accuracy of the data set, the post-sequencing data processing protocol removed any 
environmental contaminants, ensuring the data was representative of the samples themselves.   
Another strength is the inclusion and exclusion criteria for the DJBS group.  Despite their status as 
patients with obesity and T2DM, which are both know modulators of the GI microbiota, the presence 
of any inflammatory disease of the GIT was an exclusion criteria.  Further to this, the control group 
selected included patients with overweight and obesity and patients with metabolic comorbidities 
such as T2DM.  This provided a useful control group to compare the impact of the DJBS, compared 
to a “healthy” control population. 
The primary weakness of the study is the small sample size, which was further hampered by a number 
of baseline mucosal samples with reads that did not meet quality control standards, likely due to 
relatively low bacterial density.  However, other limitations exist that may confound the conclusions 
drawn from the study.  In this study, the ability to integrate dietary data into the analysis is suboptimal.  
Firstly, the primary site of interest is the duodenum, as this is where the device dwells; however, the 
impact of diet on the duodenal MAM is not well characterised.  Further, dietary data was collected in 
the form of a monthly 24 hour recall, and this did not always occur at the time of specimen collection.  
Furthermore, there was no explicit capture of probiotic consumption, particularly in supplement form.  
Unless patients reported consumption of probiotic foods in their 24 hour recall, this was not captured, 
despite the relevant effect on the microbiota.  From the dietary data that was collected (Chapter 3 
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Section 3.3.5), participants significantly reduced the amount of food they were eating, including 
carbohydrates, and more specifically dietary fibre, and this would impact the microbiota profile.  
However, regardless of the dietary data collection methodology, it is difficult to discern if the impacts 
on the microbiota are associated with changes in dietary intake or the diverse changes in body weight 
and metabolism that occurred in parallel as a results of DJBS treatment. 
In summary, there were significant taxonomic changes in the MAM and stool microbiota induced by 
treatment with the DJBS.  These were mirrored by changes in functional genetic profile that would 
indicate an enhancement in bacterial carbohydrate metabolism, in the context of reduced carbohydrate 
intake.  A distinct microbial community colonised the mucosa-adjacent device surface, largely 
representing organisms that are more typical to the distal small intestine and large bowel than the 
duodenum.  Whilst significant changes in the stool microbiota were observed, the post-explant stool 
data suggests these changes are transient.  Further work in a larger sample size could aim to delineate 
the role of the microbiota in weight loss responsiveness and device tolerability, and further 
characterise the microbiota in the case of SAEs, in particular hepatic abscess. 
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Chapter 6: Effect of the Duodenal-Jejunal Bypass 
Sleeve on Histological and Immune Parameters 
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6.1 INTRODUCTION 
The proximal GIT is an important site for nutrient uptake, and thus an attractive target for intervention 
in obesity management.  Contact of nutrients with the small intestinal mucosa appears important for 
maintenance of normal architecture, which in turn is important for nutrient absorption585.   
Surgical models of duodenal-jejunal bypass have reported villous atrophy in the excluded limb.  In a 
rodent model, duodenal villous blunting was observed 14 days after duodenal-jejunal bypass 
surgery586.  In the jejunum; however, there was an increase in epithelial cell proliferation and 
intestinal wall circumference.  Therefore, these intestinal adaptations appear to occur in response to 
nutrient contact. 
Conceptually, the DJBS separates bile and pancreatic secretions from chyme for 60 cm, thereby 
excluding nutrients from the duodenal mucosa and reducing the absorptive surface during small 
intestinal transit.  The impact of DJBS treatment on the excluded mucosa has not been studied in 
humans.  In a porcine model, Tarnoff et al. investigated the morphology of the duodenum and jejunum 
following 90 days of DJBS implantation587.  In these animals, focal chronic inflammation was 
reported immediately adjacent to the anchor barbs, with normal mucosa observed in close proximity 
to the barbs.  Additionally, normal mucosa was observed in duodenal and jejunal tissue that had been 
in contact with the sleeve.  Conversely, a rat model has utilised a DJBS anchored in the gastric antrum 
and extending to the ligament of Treitz588.  In this model, after 27 days of DJBS implantation 
flattening of the duodenal submucosa was observed, with a significant increase in villi length.   
This phenomenon was not seen in the pair-fed sham operated control animals, suggesting this occurs 
independent of changes in body weight.  Cumulatively, these results suggest the DJBS may exert a 
more modest effect on duodenal morphology than surgical exclusion. 
The DJBS is also a foreign body in the duodenum, with the anchor barbs implanting into the duodenal 
mucosa.  This may induce a local inflammatory response, although this has not been assessed in 
humans.  In the porcine study by Tarnoff et al587, local inflammation was reported immediately 
adjacent to the anchor barbs, but immune cell populations were not quantified.  In other populations, 
immune cell infiltration has been associated with an increase in GI symptoms589, 590.  Thus, the effect 
of DJBS implantation on immune cell infiltration in the duodenum warrants further investigation, as 
this may be a relevant modulator of device tolerability. 
Further, obesity has been associated with chronic, low grade systemic inflammation.   
This inflammation is largely driven by the secretion of pro-inflammatory cytokines from adipose 
tissue deposits591.  Weight loss could also benefit patients with obesity by reducing inflammation, 
which has been recognised as a key factor in the pathogenesis of a number of obesity-related 
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comorbidities, including T2DM592.  In obesity, T cells, a key component of the adaptive immune 
system, have been implicated in adipose tissue inflammation593 and insulin resistance594.   
Knowledge of the impact of weight loss on T cell phenotype in the circulation is limited.  In two 
studies, weight loss following adjustable gastric banding was not associated with any significant 
alteration in CD4+ T cell population595, 596, whilst RYGB has been associated with a reduction in 
CD4+ T cells597.  Similarly, no significant alteration in CD8+ T cells was observed after significant 
weight loss following adjustable gastric banding596.  More broadly, a reduction in circulating 
cytokines has been observed following weight loss, achieved by dietary intervention597-599 or bariatric 
surgery597, 600, 601. 
There have been conflicting reports of the impact of obesity on T cell phenotypes in the circulation 
in cross-sectional studies.  The majority of studies have either reported no significant  
correlation602-604 or a positive correlation between proportion of CD4+ T cells and BMI605-609.  
Conversely, a number of studies have reported an inverse relationship between the proportion of 
CD8+ T cells and BMI603, 604, 607, 608. 
Even fewer studies have reported on the impact of weight loss following DJBS treatment on immune 
parameters.  Involvement of specific immune cell populations have not been reported following DJBS 
treatment.  Only one study of 17 patients with obesity and T2DM has reported a minimal impact of 
DJBS treatment on plasma markers of inflammation (TNF-α and IL-6) after three months of DJBS 
treatment471.  However, after six months of DJBS treatment, these levels were no longer significantly 
different to baseline471.  Defining changes in systemic immune activation is important, as this may be 
relevant for device efficacy outcomes, in particular glycaemic control outcomes. 
6.1.1 Aims and Hypotheses 
The aim of this study was to determine the impact of DJBS treatment on local and systemic 
inflammation.  A post-hoc secondary analysis was conducted to determine any links between the 
immune system and the GI microbiota. 
It was hypothesised that implantation of a DJBS for 48 weeks would: 
• Impact the morphology of villi in the duodenum; measured by assessment of histological 
specimens; 
• Trigger a local immune response due to the presence of a foreign body in the duodenum; 
measured by immune cell infiltration visualised on histological slides; and 
• Reduce systemic markers of inflammation due to weight loss; cytokines produced by  
LPS-stimulated PBMCs and PBMC phenotype measured by flow cytometry.  
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6.2 METHODS 
6.2.1 Histology 
Duodenal mucosal biopsy samples were taken at baseline and explant for routine histology.   
Villous architecture was assessed as part of routine clinical histological assessment by anatomical 
pathologists from Queensland Pathology.  Additionally, a consultant anatomical pathologist 
quantified immune cell populations from histological slides.  Specifically, one tissue section was 
selected and IELs were quantified (per 500 enterocytes).  In the same tissue section, intact eosinophils 
were counted.  The area of tissue was quantified using Visopharm software (Visopharm).  The number 
of eosinophils in the duodenal tissue section were expressed as a count per mm2.  For further details, 
see Chapter 2 Section 2.6.1. 
6.2.2 PBMC Phenotyping and Cytokine Production Following PBMC Culture 
Whole blood was collected for the assessment of systemic immune cell phenotype and immune 
activation at baseline and explant.  PBMCs were isolated from whole blood and subjected to flow 
cytometry analysis.  A 13 fluorophore panel was used to assess T cell phenotype using the following 
markers: cytotoxic T cells: CD3+CD8+, T helper cells: CD3+CD4+, central memory T cells: CD45RA-
CD45RO+CD62L+CCR7+, effector memory T cells: CD45RA-CD45RO+CD62L-CCR7-, effector T 
cells: CD45RA+CD45RO-CD62L-CCR7-, naïve T cells: CD45RA+CD45RO-CD62L+CCR7+ and gut 
homing T cells: α4+β7+CCR9+.  For further details, see Chapter 2 Section 2.6.2.1 and Section 2.6.2.2. 
The concentrations of TNF, IL-6, IL-8 and IL-10 from LPS-stimulated cultured PBMC supernatant 
were measured by ELISA.  For further details, see Chapter 2 Section 2.6.2.3 and Section 2.6.2.4. 
Results were compared to a control group of 30 patients referred for investigation of iron-deficiency 
anaemia or positive faecal occult blood test who underwent immunological assessment as part of a 
separate study (HREC/13/QPAH/690). 
6.2.3 Statistical Analysis 
All quantitative measures were described as mean and standard deviation and were assessed for 
normality of distribution using the Shapiro-Wilk normality test.  Normally distributed data was 
analysed using paired t-tests, which compared pre- to post-procedure measurements.  Non-normal 
data was assessed by the non-parametric Wilcoxon signed rank test.  To assess the relationship 
between immunological parameters and the GI microbiota, bivariate correlations were performed to 
screen for candidate variables for univariate linear regression analysis.  Taxa were only screened 
where the minimum mean RA of that taxon was at least 1%.  Non-normally distributed data was 
square root transformed.  Any variables that were significant on univariate analysis were added to a 
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multiple linear regression model with backward elimination.  Significance of results was determined 
by a two-tailed p value of less than 0.05. 
All analyses were performed using IBM Statistical Package for Social Sciences Version 24 (IBM 
Corp., NY, USA), and figures were generated using GraphPad Prism Version 7 (GraphPad Software 
Inc, CA, USA).
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6.2.4 Schedule of Investigations 
 
Figure 6.1: Schedule of histological and immune parameter investigations. 
Baseline
• Duodenal tissue biopsy for histological assessment of:
• Morphology
• Immune cell populations (IELS and eosinophils)
• Blood collection for:
• Systemic immune cell phenotyping (flow cytometry of PBMCs)
• Systemic immune activation (IL-6, IL-8, IL-10 and TNF; ELISA of LPS-stimulated PBMCs)
Explant
• Duodenal tissue biopsy for histological assessment of:
• Morphology
• Immune cell populations (IELs and eosinophils)
• Blood collection for:
• Systemic immune cell phenotyping (flow cytometry of PBMCs)
• Systemic immune activation (IL-6, IL-8, IL-10 and TNF; ELISA of LPS-stimulated PBMCs)
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6.3 RESULTS 
6.3.1 Histology 
Duodenal villous architecture was assessed during routine clinical histological assessment by 
Queensland Pathology.  At baseline, 18 of 19 patients had normal villous architecture.  One patient 
was reported to have mildly disturbed villous architecture.  At explant, 11 of 19 patients were reported 
to have normal villous architecture.  In seven of 19 patients, architectural distortions such as blunting 
and focal erosion were observed.  One patient specimen had insufficient tissue material to assess 
architecture.  To determine if there was a relationship between atrophic changes and weight loss, a 
subgroup analysis was conducted.  There was no significant difference in weight loss between those 
with normal morphology and those with villous blunting (p=0.32). 
Immune cell populations in the duodenal mucosa were quantified by a consultant anatomical 
pathologist.  There was a significant increase in eosinophils in the duodenal mucosa from baseline to 
explant (baseline: 58±34 eosinophils per mm2 vs. explant: 112±69 eosinophils per mm2; n=19; 
p<0.01; Figure 6.2A).  IELs in the duodenum also significantly increased from baseline to explant 
(baseline: 14±10 IELs/100 enterocytes vs. explant: 17±10 IELs/500 enterocytes; n=19; p=0.05; 
Figure 6.2B). 
 
Figure 6.2: Histological analysis of immune cell populations. 
Eosinophils in the duodenal mucosa (per mm2) (A) and IELs (B), counted per 500 enterocytes, from baseline 
to explant.  There was a significant increase in the number of eosinophils per mm2 of duodenal mucosa from 
baseline to explant (n=19; p=0.0039). There was a significant increase in the number of IELs per 500 
enterocytes from baseline to explant (n=19; p=0.0456).  Each patient is displayed as an individual line on the 
graph.  (B) Reference range of 25 IELs/100 enterocytes610 represented by dotted line.  Results assessed by 
paired t-test (A) and Wilcoxon signed rank test (B).  
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A control group of patients that did not receive the DJBS, with a positive FOBT or iron deficiency 
anaemia were included for comparison.  These patients were chosen to represent a diverse range of 
body habitus, from lean to severe obesity (BMI range: 20-41 kg/m2).  The baseline number of 
eosinophils in the duodenal mucosa was significantly higher, compared the control group (26±13 
eosinophils per mm2; n=16; p<0.001; Figure 6.3A), or control patients with obesity (n=7, p=0.01).  
There was no significant difference in duodenal eosinophil count between the overall control group 
and those patients with obesity (26±13 vs 24±10 eosinophils per mm2; Figure 3A).  At explant, the 
number of eosinophils in the duodenal mucosa was also higher than the control group (p<0.0001).  
Again, in comparison to control patients with obesity, the number of eosinophils was higher at DJBS 
explant (p=0.0002).  There was no significant difference in the number of IELs per 100 enterocytes 
at baseline or explant, compared to the control group (14±6 IELs/100 enterocytes; n=13), or only the 
control patients with obesity (15±9 IELs/100 enterocytes; n=6; Figure 6.3B). 
 
Figure 6.3: Histological analysis of immune cell populations compared to a control group. 
The number of eosinophils in the duodenal mucosal was significantly higher at both baseline and explant, 
compared to the entire control group (vs baseline p=0.0013, vs explant p<0.0001) and control patients with 
obesity (vs baseline p=0.0069, vs explant p=0.0002).  The number of IELs per 100 enterocytes was not 
significantly different at baseline or explant, compared to the control group, or control patients with obesity.  
Results analysed by unpaired t-test (eosinophils baseline vs control and explant vs control) or  
Mann-Whitney test (eosinophils baseline vs controls with obesity and explant vs controls with obesity and 
IELs for all comparisons). 
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6.3.2 PBMC Phenotyping 
A panel of 13 antibodies was used to assess circulating T cell phenotype from PBMCs collected at 
baseline and within three weeks after device explant.  The T cell subgroups were defined as: cytotoxic 
T cells: CD3+CD8+, T helper cells: CD3+CD4+, central memory T cells: CD45RA-
CD45RO+CD62L+CCR7+, effector memory T cells: CD45RA-CD45RO+CD62L-CCR7-, effector T 
cells: CD45RA+CD45RO-CD62L-CCR7-, naïve T cells: CD45RA+CD45RO-CD62L+CCR7+ and gut 
homing T cells: α4+β7+CCR9+. 
There was a significant decrease in the proportion of T helper (CD4+) cells from baseline to explant 
(baseline: 45.4±13.9% vs. explant: 38.6±13.2%; n=12; p<0.01; Figure 6.4A).  Comparing the control 
group to the DJBS patients, there was no difference in the proportion of CD4+ T cells at baseline; 
however, at explant, there was a significantly lower proportion of CD4+ T cells in the DJBS cohort 
(p=0.02; Figure 6.4B).  There was no significant difference in CD4+ T cells proportion between the 
DJBS cohort and control patients with obesity at any time-point. 
 
Figure 6.4: T helper cells (CD4+) populations from baseline to explant and compared to a control group. 
There was a significant reduction in the proportion of T helper cells from baseline to explant (A; n=12; 
p=0.0052).  T helper cells were not significantly different at baseline compared to the control group.  However, 
there was a significantly lower proportion or T helper cells at explant, compared to controls (B; p=0.0324).  
When compared only to controls with obesity, there was no significant difference in the proportion of CD4+ 
T cells.  A) Each patient is displayed as an individual line on the graph, B) grouped data presented.  A) assessed 
by paired t-test, B) assessed by unpaired t-test, when comparing to controls. 
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The proportion of cytotoxic (CD8+) cells did not significantly change from baseline to explant 
(baseline: 23.0±14.8% vs. 27.6±15.2%; n=12; p=0.13; Figure 6.5A).  Compared to controls, the 
proportion of CD8+ T cells was significantly lower at baseline (p=0.0009) and there was a trend 
toward a lower proportion at explant (p=0.05; Figure 6.5B).  Compared to control patients with 
obesity, the proportion of CD8+ T cells was significantly lower at baseline (n=13 controls; p=0.01), 
but not explant (n=13 controls; p=0.23). 
 
Figure 6.5: Cytotoxic T cell (CD8+) populations from baseline to explant and compared to a control group. 
There was no significant change in the proportion of cytotoxic T cells from baseline to explant (A; n=13; 
p=0.13).  Cytotoxic T cells were significantly lower at both baseline (B; p=0.0009) and there was a trend at 
explant (B; p=0.0535), compared to the control group.  When only control patients with obesity (n=13) were 
included, there was a significantly lower proportion of cytotoxic T cells at baseline (B; p=0.0107), but not 
explant (B; p=0.2254).  A) Each patient is displayed as an individual line on the graph, B) grouped data 
presented.  A) assessed by Wilcoxon signed rank test, B) baseline vs control/controls with obesity and explant 
vs controls with obesity assessed by Mann Whitney test, explant vs control assessed by unpaired t-test. 
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More specifically, both CD4+ and CD8+ T cell subgroups in the DJBS cohort were assessed.   
There was no significant change in CD4+ effector T cells (baseline: 46.1±18.3% vs. explant: 
52.5±23.8%; n=12; p=0.17; Figure 6.6A), CD4+ central memory T cells (baseline: 3.0±2.0% vs. 
explant: 2.3±2.5%; n=12; p=0.20; Figure 6.6B) or CD4+ effector memory T cells (baseline: 
73.2±8.7% vs. explant: 74.9±17.2%; n=12; p=0.76; Figure 6.6C).  However, there was a significant 
reduction in CD4+ naïve T cells from baseline to explant (baseline: 17.9±10.8% vs. explant: 
11.8±11.2%; n=12; p=0.003; Figure 6.6D). 
 
Figure 6.6: CD4+ T cell subtypes from baseline to explant. 
There was no significant change in CD4+ effector T cells (A; p=0.1766), CD4+ central memory T cells (B; 
p=0.2036) or CD4+ effector memory T cells (C; p=0.7554).  There was a significant decrease in CD4+ naïve 
T cells (D; p=0.0030).  Each patient is displayed as an individual line on the graph.  A, C and D assessed by 
paired t-test.  B assessed by Wilcoxon signed rank test. 
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There was a trend toward a significant increase in CD8+ effector T cells (baseline: 94.2±3.8% vs. 
explant: 96.6±3.2%; n=12; p=0.06; Figure 6.7A).  There was no significant change in CD8+ effector 
memory T cells (baseline: 88.7±4.4% vs. explant: 90.6±10.7%; n=12; p=0.30; Figure 6.7B),  
CD8+ central memory T cells (baseline: 0.6±0.7% vs. explant: 0.4±0.5%; n=12; p=0.37; Figure 6.7C) 
or CD8+ naïve T cells from baseline to explant (baseline: 0.4±0.5% vs. explant: 0.2±0.3%; n=12; 
p=0.13; Figure 6.7D). 
 
Figure 6.7: CD8+ T cell subtypes from baseline to explant. 
There was a trend toward a significant increase in CD8+ effector T cells (A; p=0.0640).  There was no 
significant change in CD8+ effector memory T cells (B; p=0.3013), CD8+ central memory T cells (C; 
p=0.3652) or CD8+ naïve T cells (D; p=0.1299).   Each patient is displayed as an individual line on the graph.  
A, B and C assessed by Wilcoxon signed rank test, D assessed by paired t-test. 
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We also assessed gut homing T cell markers on PBMCs.  There was a significant reduction in gut 
homing T cells from baseline to explant (baseline: 1.9±1.6% vs. explant: 0.5±0.2%; n=11; p=0.01; 
Figure 6.8A).  At baseline, DJBS patients had a significantly higher proportion of gut homing T cells, 
compared to both the overall control population (p<0.001) and controls with obesity (p=0.001;  
Figure 6.8B).  However, after device explant, the proportion of gut homing T cells was not different 
compared to controls or controls with obesity. 
 
Figure 6.8: Gut homing T cells from baseline to explant. 
There was a significant reduction in gut homing T cells from baseline to explant (A; p=0.0124).  At baseline, 
DJBS patients had a significantly higher proportion of gut homing T cells, compared to both the overall control 
population (p=0.0006) and controls with obesity (p=0.0012).  However, after device explant, the proportion of 
gut homing T cells was not different compared to controls (p=0.7117) or control patients with obesity 
(p=0.1813).  A) Each patient is displayed as an individual line on the graph.  B) Group data. A) assessed by 
Wilcoxon signed rank test. B) Between group comparisons by Mann Whitney U test. 
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6.3.3 Cytokine Production Following PBMC Culture 
The production of four cytokines (IL-6, TNF, IL-8 and IL-10) following LPS stimulation of PBMCs 
was assessed at baseline and explant.  There was no significant change in IL-6 production (baseline: 
27,730±15,202 pg/mL vs. explant: 26,451±17,177 pg/mL; n=10; p=0.77; Figure 6.9A),  
TNF production (baseline: 3,490±1,540 pg/mL vs. explant: 2,981±1,959 pg/mL; n=10; p=0.32;  
Figure 6.9B) or IL-8 production (baseline: 100,359±58,306 pg/mL vs. explant: 96,231±51,018 pg/mL; 
n=11; p=0.78; Figure 6.9C).  However, there was a significant increase in IL-10 production from 
baseline to explant (baseline: 98±111 pg/mL vs. explant: 186±160 pg/mL; n=11; p=0.03;  
Figure 6.9D). 
 
Figure 6.9: Cytokine production following LPS stimulation from baseline to explant. 
There was no significant change in IL-6 production (A; p=0.7674), TNF production (B; p=0.3223) or IL-8 
production (C; p=0.7772).  There was a significant increase in IL-10 production (D; p=0.0273).  Each patient 
is displayed as an individual line on the graph.  A and C assessed by paired t-test.  B and D assessed by 
Wilcoxon signed rank test. 
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Compared to the control group, there was no significant difference in IL-6 production at baseline or 
explant (Figure 6.10A).  However, IL-10 was significantly higher at explant, compared to both the 
entire control group (explant: 203±156 pg/mL vs. control: 61±117 pg/mL; p=0.002; Figure 6.10B) 
and control patients with obesity (50±43 pg/mL; p=0.02).  Due to differences in PBMC culture 
duration, TNF could not be compared to the control group.  IL-8 was not measured in the control 
group. 
 
Figure 6.10: Cytokine production following LPS stimulation compared to a control group. 
IL-6 production was not significantly different at baseline or explant, compared to the control group, or control 
patients with obesity.  IL-10 production was significantly higher at explant, compared to the entire control 
group (p=0.0024) and control patients with obesity (p=0.0194).  Results analysed by unpaired t-text (IL-6 
explant vs control and explant vs controls with obesity) or Mann-Whitney test (IL-6 baseline vs control and 
baseline vs controls with obesity and explant vs controls with obesity, IL-10 baseline vs control and baseline 
vs controls with obesity, IL-10 explant vs control and explant vs controls with obesity). 
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6.3.4 Correlation with the Gastrointestinal Microbiota 
An exploratory analysis was conducted to determine the relationship between immunological 
parameters and the RA of GI microbes.  To constrain the analyses, only taxa with a minimum mean 
RA of 1% were included.  Univariate linear regression analyses of immunological parameters in 
comparison with the RA of taxon with a mean RA of >1% are displayed in Table 6.1 below. 
A number of relationships between T cell proportions and the RA of microbial taxa were observed.  
At baseline, positive univariate relationships were observed between CD4+ and CD8+ T cell subtypes 
and the RA of Prevotella and Neisseria in the baseline duodenal biopsies.  At explant, the RA of 
bacterial taxa in the gastric biopsies was associated with a number of immune parameters.   
On multivariate analysis, the proportion of CD8+ T cells was positively associated with the RA of 
Dialister and Prevotella in the gastric biopsies (r=0.85, r2=0.72, p=0.003).  The proportion of  
CD4+ central memory T cells was positively associated with the RA of Klebsiella in the gastric 
biopsies on multivariate analysis (r=0.62, r2=0.38, p=0.02).  The proportion of CD8+ central memory 
T cells was negatively associated with the RA of Dialister in the gastric biopsies on multivariate 
analysis (r=-0.66, r2=0.43, p=0.01).  At explant, the RA of Klebsiella and members of the 
Gammaproteobacteria class in the duodenal biopsies was negatively associated with the proportion 
of CD4+ effector memory T cells in the circulation (r=-0.92; r2=0.84; p<0.001).  There were no 
relationships between the microbiota and the proportion of gut homing T cells, CD4+ naïve T cells, 
and CD4+ or CD8+ effector T cells at baseline or explant.  
Isolated PBMCs were cultured with LPS and cytokine production was measured.  At baseline, there 
were no significant relationships between bacterial taxa and cytokine production.  At explant,  
IL-6 production was negatively associated with the RA of member of the Gammaproteobacteria class 
and bacterial load in the explant gastric biopsies on multivariate analysis (r=0.89; r2=0.78; p=0.002).  
At explant, IL-8 production was negatively associated with the RA of members of the 
Enterobacteriaceae family in the explant gastric biopsies on multivariate analysis (r=0.88; r2=0.68; 
p=0.002). 
Eosinophils in the duodenal tissue at baseline were associated with the RA of Veillonella in the 
baseline duodenal biopsies.  IELs were positively associated with the RA of Rothia and bacterial load 
in the duodenum on multivariate analysis (r=0.96; r2=0.92; p=0.02).  At explant, immune cell 
numbers in the duodenal mucosa were associated with the RA of taxa in the explant duodenal 
biopsies.  Specifically, the number of eosinophils in the duodenal mucosa was negatively associated 
with the RA of Veillonella and bacterial load in the duodenal biopsies on multivariate analysis 
(r=0.84, r2=0.71, p=0.001).  The number of IELs in the duodenal mucosa was positively associated 
with the RA of Lactobacillus and Dialister in the explant duodenal biopsies (r=0.64, r2=0.41, p=0.02).  
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Table 6.1: The relationship between immunological parameters and the RA of microbial taxa or bacterial 
load isolated from gastric and duodenal biopsies.  
Variable Baseline Explant 
 Positive  Negative  Positive Negative 
CD4+ T cells Nil Nil Nil Nil 
CD8+ T cells Nil Nil Gastric: Dialister (r=0.77; 
p=0.004) and Prevotella 
(r=0.66; p=0.02) 
 
Duodenum: Dialister 
(r=0.66; p=0.02) and 
Prevotella (r=0.62; p=0.03) 
Gastric: Gammaproteobacteria (r=-
0.69; p=0.01) and Klebsiella (r=-0.66; 
p=0.02) 
CD4+ central 
memory T 
cells 
Nil Nil Gastric: Klebsiella (r=0.62; 
p=0.02) and 
Gammaproteobacteria 
(r=0.59; p=0.03) 
Nil 
CD4+ effector 
memory T 
cells 
Gastric: nil 
 
Duodenum: 
Prevotella 
(r=0.77; p=0.03) 
Nil Nil Duodenum: Gammaproteobacteria 
(r=-0.80; p=0.002) and Klebsiella (r=-
0.64; p=0.03) 
CD8+ naïve T 
cells 
Nil Nil Gastric: Klebsiella (r=0.54; 
p=0.05) 
Nil 
CD8+ central 
memory T 
cells 
Duodenum: 
Prevotella 
(r=0.73; p=0.04) 
Nil Gastric: Klebsiella (r=0.62; 
p=0.02) 
Gammaproteobacteria 
(r=0.62; p=0.02) 
Gastric: Dialister (r=-0.66; p=0.01) 
 
CD8+ effector 
memory T 
cells 
Duodenum: 
Neisseria (r=0.78; 
p=0.02) 
Nil Nil Nil 
IL-6 Nil Nil Gastric: Prevotella (r=0.61; 
p=0.05) 
Gastric: Enterobacteriaceae (r=-0.85; 
p=0.001), Klebsiella (r=-0.67; p=0.02) 
and Gammaproteobacteria (r=-0.62; 
p=0.05); bacterial load (r=-0.61; 
p=0.05) 
 
Duodenum: Enterobacteriaceae (r=-
0.76; p=0.01)  
TNF Nil Nil Duodenum: Lactobacillus 
(r=0.57; p=0.03) 
Nil 
IL-8 Nil Nil Gastric: Enterobacteriaceae 
(r=0.83; p=0.002) 
 
Duodenum: 
Enterobacteriaceae (r=0.76; 
p=0.01) 
Nil 
 
IL-10 Nil Nil Nil Gastric: Enterobacteriaceae (r=-0.61; 
p=0.02) 
Eosinophils in 
the duodenal 
mucosa 
Nil Duodenum: 
Veillonella (r=-
0.84; p=0.01) 
Duodenum: Fusobacterium 
(r=0.55; p=0.02); bacterial 
load (r=0.56; p=0.03) 
Duodenum: Veillonella (r=-0.62; 
p=0.01)  
IELs Duodenum: 
Rothia (r=0.77; 
p=0.03), bacterial 
load (r=0.64; 
p=0.03) 
Nil Duodenum: Lactobacillus 
(r=0.51; p=0.03) and 
Dialister (r=0.49; p=0.04) 
Nil 
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6.4 DISCUSSION 
Obesity is a chronic, low-grade inflammatory state and this inflammation is critical for the 
pathogenesis of a number of obesity related comorbidities, including T2DM.  Treatments for obesity 
related comorbidities often centre on weight loss, which can improve inflammation401, 406.  One of the 
most effective weight loss methods, the RYGB, separates the nutrient stream from bile and pancreatic 
secretions to facilitate weight loss.  The DJBS mimics this endoscopically, using a fluoropolymer 
sleeve to separate bile and pancreatic secretions from the chyme.  However, the effects of this nutrient 
diversion by the DJBS on the morphology of the small intestine are unknown.  This is the first study 
to assess the effect of DJBS treatment on duodenal morphology and duodenal immune cell infiltration 
in humans and assess systemic T cell phenotype.  Overall, a modest impact on duodenal morphology 
was observed; however, a marked local immune response occurred in the duodenum following DJBS 
treatment.  The changes in systemic T cell phenotype observed broadly suggest an increase in immune 
activation following DJBS treatment. 
A number of factors are involved in maintaining normal villous morphology, which is important for 
nutrient absorption585.  Villous morphology appears to be related to contact with the nutrient 
stream586.  Nutrient exclusion (total parenteral nutrition) has been associated with atrophic changes 
in animal models, with enteral feeding restoring villous morphology611.  In approximately 50% of our 
patients, DJBS treatment had no impact on villous morphology.  This suggests that at least a portion 
of luminal contents may still have contact with the duodenal mucosa.  Bile acid recirculation has also 
been implicated in maintenance of villous morphology612.  This is unlikely to have been negatively 
impacted by DJBS treatment, as two studies have reported an increase in circulating bile acids after 
DJBS treatment469, 478.  Atrophic changes have also been associated with an increase in intestinal 
permeability613.  This may be linked to a rare adverse event of DJBS treatment, as bacterial 
translocation across a permeable intestinal epithelium is a possible mechanism for the development 
of hepatic abscess.  Further investigations into the impact of DJBS treatment on duodenal morphology 
and mucosal integrity may provide insight into the mechanisms of hepatic abscess formation. 
The DJBS is endoscopically implanted into the wall of the duodenum via a self-expanding metal 
stent.  This anchor site may provide a location for a local immune response to develop due to the 
presence of the foreign body.  Immune cells, such as eosinophils and IELs, are resident in the healthy 
small intestine233; however, the impact of obesity or T2DM on eosinophils in the duodenal mucosa is 
not known.  In this study, at baseline, duodenal eosinophils were increased compared with duodenal 
histology performed in a control cohort (n=16), including those with obesity (n=7), or a previously 
reported Australian control cohort590.  In the Walker et al. study, controls were not stratified by 
weight, nor was BMI reported.  In our study, the severity of obesity differed significantly between 
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the groups.  Despite there being six patients with severe obesity in the control cohort, the mean BMI 
was still significantly higher in the DJBS group at baseline (DJBS: 43.7±5.3 vs control:35.4±3.6 
kg/m2).  This may help explain the increased eosinophils counts in our cohort at baseline; however, 
further investigation in larger cohorts is required. 
The increase in eosinophils observed may also be linked with the increase in GI symptoms seen in 
the in situ phase, as duodenal eosinophilia has previously been associated with GI symptoms in FGID 
patients590.  There was no significant difference in the proportion of eosinophils in the blood from 
baseline to explant (from full blood count; data not shown), suggesting a localised eosinophil 
response.  It is possible that increased intestinal permeability facilitates bacterial translocation, 
leading to increased eosinophil recruitment614. 
There was also a significant increase in IELs from baseline to explant, further suggesting a chronic 
inflammatory response615, 616.  Whilst IELs were statistically significantly increased, the clinical 
impact was modest.  At baseline, all but two patients had a normal number of duodenal IELs  
(defined as <25/ 100 enterocytes610).  At device explant, one of the patients with high baseline values 
remained high, and three other patients who were previously within normal clinical limits had 
elevated IELs.  Despite this, there was no significant difference in the number of IELs at baseline or 
explant, compared to controls (n=13), or controls with obesity (n=6).  However, it may be the function 
of these cells rather than the overall number that may be of importance617.  For example, tissue 
resident γδ IELs have been implicated in mucosal repair after inflammatory damage616 and could 
represent an important population mediating tolerability of the device.  Further phenotypic 
characterisation of IELs by flow cytometry would be an interesting avenue for further investigation. 
In the literature, a number of patients have undergone early explant due to ‘device intolerance’.   
In our cohort, three patients underwent early explant due to abdominal pain.  Statistical analyses could 
not reliably be performed on this subgroup.  However, these patients were unremarkable from the rest 
of the cohort on the basis of histological assessment.  Two of these three patients had normal duodenal 
morphology at explant.  Only one patient had elevated IELs at explant and all were below the  
post-explant mean for the number of eosinophils in the duodenal mucosa.  Within the constraints of 
a small sample size, this suggests local immunological changes are not associated with device 
intolerance.  However, it may be the functional aspects of the infiltrated immune cells that mediate 
tolerance (e.g. perhaps infiltrated cells in those with persistent pain are not those involved in mucosal 
repair).  Further characterisation of the local immune cell populations may provide further insight. 
Weight loss has been demonstrated to impact circulating immune markers222, 223 and this is the first 
study to assess changes in systemic T cell phenotype following DJBS treatment.  The overall 
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circulating CD8+ T cell proportion was not significantly altered by DJBS treatment, but the 
proportion of CD8+ T cells was significantly lower than controls.  This has previously been reported 
in a cross-sectional study of 10 patients with obesity and 10 lean subjects608.  This study also reported 
a significantly higher proportion of CD4+ T cells in patients with obesity, compared to lean controls.  
In our cohort, CD4+ T cells were significantly lower at explant, compared to controls, contrasting the 
literature605-609.  However, we also observed a high proportion of CD4 and CD8 double positive  
T cells, and this may distort our findings.  Further investigations to define the relevance of double 
positive T cell populations in obesity are required. 
Characterisation of circulating T cell subtypes was performed to further discriminate response to 
treatment.  There was a significant decrease in the proportion of CD4+ naïve T cells and a trend 
towards a significant increase in CD8+ effector T cells from baseline to explant.  Broadly, these 
results suggest an increase in antigen presentation and activation of cells, leading to an increase in 
CD8+ effector T cells618.  This may be associated with an increase in microbial antigen as a result of 
colonisation of the DJBS device. 
There was a significant reduction in circulating gut homing T cell markers from baseline to explant.  
At baseline only, patients in the DJBS cohort had a significantly higher proportion of gut homing  
T cells in the circulation than the control group, or control patients with obesity.  There was a trend 
toward a significant correlation between reduction in BMI and change in gut homing T cells 
(p=0.0656).  This suggests obesity may play a role in the elevated proportion observed at baseline, 
although to date no literature has reported the effect of obesity on gut homing T cell markers.   
In our cohort, we did not have a matched tissue sample for quantification of lamina propria gut 
homing T cells.  However, in the control cohort, 17 patients had lamina propria gut homing T cells 
quantified.  In this group, there was no correlation between the proportion of gut homing T cell 
markers across the two sites (r=-0.34; p=0.18).  Overall, this suggests that changes in the circulation 
may not reflect what is occurring in the tissue. 
The GI microbiota, and in particular the MAM, provide a significant source of potential antigens and 
are in constant contact with the host.  However, despite recent advances, the relationship between the 
MAM and the immune system is poorly understood.  Treatment with the DJBS increases the amount 
of bacterial antigen present due to colonisation of the device surface by microbes.  As such, an 
exploratory analysis was performed to assess the relationship between the RA of taxa with a minimum 
mean RA of 1% and immunological parameters.  In the duodenal mucosa, there was a negative 
relationship between the number of eosinophils and the RA of Veillonella in the duodenal biopsy 
samples at both baseline and explant.  Conversely, there was a positive relationship between the 
number of eosinophils in the mucosa and the RA of Fusobacterium at explant.  This is the first time 
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a relationship between intestinal microbes and eosinophils in the duodenal mucosa has been reported.  
However, Veillonella is a normal upper GIT microbe.  In healthy adults, it is a highly abundant 
coloniser of the duodenum619, 620.  Some Fusobacterium species have been demonstrated to invade 
the epithelium, and this may induce a local immune response621.  The number of IELs in the 
duodenum was positively associated with the RA of Rothia in the duodenal biopsies at baseline and 
Dialister and Lactobacillus in the duodenal biopsies at explant.  The impact of these taxa on IELs has 
not previously been reported.  However, a high abundance of Rothia in the stool has been reported in 
patients with primary sclerosing cholangitis, suggesting it may be a relevant taxon in the context of 
GI inflammation228.  Finally, bacterial load was positively associated with both the number of IELs 
at baseline and the number of eosinophils in the duodenal mucosa at explant.  Therefore, it may be 
that the quantity of bacteria is also important, particularly to the local immune response, in addition 
to the composition of the microbial community present. 
A number of relationships were observed between circulating immune markers and the microbiota.  
At baseline, the RA of “typical” upper GIT microbes were positively associated with CD4+ and  
CD8+ effector memory T lymphocytes and CD8+ central memory T lymphocytes.  This aligns with 
the literature, which has demonstrated an interaction between memory T lymphocytes and commensal 
microbes in healthy individuals622.  At explant, members of the Gammaproteobacteria class, 
Klebsiella, Dialister and Prevotella were associated with a number of immunological parameters.  
Klebsiella is a member of the Enterobacteriaceae family and the Gammaproteobacteria class.   
At class and family level, the proliferation of these taxa has been reported to be greater in 
inflammatory bowel disease623-625 , demonstrating a link between inflammatory state and these taxa.  
Similarly, Dialister and Prevotella have also been linked to inflammatory conditions such as 
spondyloarthritis, rheumatoid arthritis and the metabolic syndrome626, 627.  Furthermore, there was a 
positive relationship between Gammaproteobacteria and Klebsiella and central memory  
T lymphocyte populations; whereas there was a negative relationship between these taxa and effector 
memory T lymphocyte populations.  This suggests a differential response in lymphoid and  
non-lymphoid tissues as central memory T lymphocytes act within lymphoid tissue when restimulated 
while effector memory T lymphocytes act within peripheral tissues233. 
Members of the Gammaproteobacteria class and Klebsiella were also positively associated with  
IL-6 production, whilst members of the Enterobacteriaceae family were negatively associated with 
production of IL-10 following LPS stimulation.  While these pro-inflammatory bacteria could be 
linked to cytokine production, overall, there was actually a significant increase in IL-10 production 
following LPS stimulation of PBMCs following DJBS treatment.  These results suggest an interplay 
between inflammation and microbial colonisation that may be relevant for device efficacy, as the  
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RA of Gammaproteobacteria was negatively associated with weight loss (see Chapter 5 Section 
5.3.6).  Further investigation is required to confirm these findings. 
In summary, DJBS treatment resulted in a significant chronic local immune response, in particular 
leading to an increase in eosinophils in the mucosa.  This occurred without alterations to duodenal 
morphology in the majority of patients.  In the circulation, DJBS treatment partially normalised  
CD4+ T cell populations.  Overall, assessment of T cell subtype suggested an increase in T cell 
activation following DJBS treatment.  It is possible this is associated with the presence of microbes 
in the GIT, but further work in a larger cohort should attempt to validate these relationships.   
Overall, there was no pronounced improvement in systemic immune activation.  This may be due to 
the strong local immune response, which may overcome the improvements that would be expected 
with a reduction in obesity-related inflammation secondary to weight loss.  Future studies should aim 
to include more patients and time-points of sampling to better identify the progression of the immune 
response following DJBS treatment.  Finally, future studies should aim to assess changes in immune 
cell phenotype in the lamina propria of the duodenum.  This may provide insight into complications 
such as ‘device intolerance’ that lead to elective early explant. 
  
 201 
 
 
 
 
 
 
 
 
Chapter 7: General Discussion 
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7.1 SUMMARY 
Obesity and T2DM represent a significant health burden to society.  Most treatment modalities are 
ineffective at the population level for these highly prevalent conditions.  Lifestyle and 
pharmacotherapeutic measures are front line treatments.  Lifestyle modification interventions are 
attractive, as they can be applied to a broad target audience, and practitioners and resources to 
facilitate lifestyle changes are relatively readily available.  Lifestyle modification interventions target 
a reduction in energy intake and an increase in energy expenditure by behavioural means.   
However, long-term efficacy with diet-based approaches is poor271-273.  The majority of 
pharmacotherapeutic obesity treatments act centrally, and long-term efficacy is contingent on 
continual medication usage. 
Bariatric surgery is considered the most effective obesity treatment, but use in the public health care 
setting is limited due to costs.  In Australia, bariatric surgery is primarily performed in a private health 
care setting.  To address a gap in the treatment continuum, minimally invasive endoscopic techniques 
have been developed that aim to mimic physiological changes induced by bariatric surgery.   
A number of these techniques are approved for use in the clinical setting; however, limited data are 
available regarding the precise mechanisms of action.  Indeed, a better understanding of the 
mechanisms of action of the current surgical and endoscopic treatment options would be of value to 
refine or individualise interventions in order to optimise patient outcomes and ultimately design of 
next generation techniques that offer safe, effective and durable solutions. 
The GIT is an obvious target for obesity management.  The proximal GIT is of critical importance, 
as it is the site at which the majority of absorption of ingested nutrients occurs.  Bariatric surgery 
specifically targets the proximal GIT and brings about weight loss by making permanent anatomical 
changes.  These approaches have been demonstrated to be efficacious in inducing significant and 
sustainable weight loss.  Therefore, endoscopic techniques seek to mimic some of the beneficial 
anatomical changes to the proximal GIT that occur with bariatric surgery. 
In this study, we explored the DJBS.  This is a 60 cm fluoropolymer sleeve endoscopically implanted 
into the proximal small intestine.  Whilst clinical efficacy has been demonstrated, little is known 
about the mechanisms of action of the DJBS.  It has been suggested that as a RYGB mimetic, the 
DJBS may cause weight loss by inducing fat malabsorption446.  The impact of the DJBS on gastric 
emptying has also been investigated, with conflicting findings456, 485.  The relevance of impacts on 
other parameters of GI function, such as nutrient absorption or sensory function have not previously 
been explored. 
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It is now recognised that the complex interplay between the GI microbiota and immune homeostasis 
can contribute to obesity, weight gain/loss and metabolic outcomes628.  However, the impacts of the 
DJBS on the GI microbiota and local/systemic immune parameters have not been reported.  This is 
of relevance, as the device is implanted directly into the duodenum, and the device surface is in 
contact with the mucosa.  The surface of the DJBS appears to offer an ideal growth environment for 
microbes.  Microbial and immunological responses may be relevant for device efficacy, particularly 
as there are differences in the GI microbiota in obesity and T2DM, compared to lean controls171, 542 
and these differences are reduced following weight loss194, 374.  Finally, the relevant effect of the GI 
microbiota on key device-related complications, such as pyogenic liver abscess, have not been 
reported. 
Although our primary interest was in defining potential mechanisms of action, we first wanted to 
define the clinical response to DJBS treatment in our centre.  We demonstrated that treatment with 
the DJBS was efficacious in our cohort.  Clinically significant reductions in body weight were 
observed in all patients.  There were associated improvements in markers of metabolic health, 
including glycaemic control, cardiovascular disease risk and markers of liver function. 
In parallel, we reported dietary intake and HRQoL outcomes for the first time.  There was a significant 
reduction in dietary energy intake over the intervention period.  This was driven by a reduction in 
food intake rather than an improvement in diet quality.  Significant improvements in HRQoL were 
also reported across the intervention period.  Despite significant weight gain over the one year  
post-explant follow-up period, a trend toward a significant improvement in MetSSS persisted. 
In addition to assessing efficacy, we also examined the effect of DJBS treatment on GI function, the 
GI microbiota and the immune system.  This revealed an increase in meal-related symptoms, and 
changes in the intestinal microbiota concurrent with mucosal inflammation.  These key findings 
provide insight into the potential mechanisms by which the DJBS induces weight loss.  These findings 
also identity potential factors associated with device tolerability and safety, as discussed below. 
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DJBS treatment increases meal-related GI symptoms, facilitating weight loss by reducing 
energy intake 
We aimed to assess the impact of the DJBS on GI function.  In the literature, there were suggestions 
that device placement may alter GI motility456, 485 or fat metabolism446.  To investigate these 
possibilities, we assessed the impact of DJBS treatment on gastric emptying and measured 
intraluminal lipolytic activity.  Contrary to our expectations, no impact on gastric emptying was 
observed.  A previous study of the DJBS485 found that gastric emptying was significantly delayed 
after device placement and there was a trend towards a relationship between weight loss and gastric 
retention at four hours, suggesting a relevance in the weight loss response.   
In our cohort, no relationship between weight loss and gastric emptying was observed, but gastric 
emptying was not delayed by device placement.  Further investigation is required to determine the 
links between gastric emptying and weight loss following DJBS treatment. 
We detected no significant change in intraluminal lipolytic activity following DJBS treatment.   
The concept of fat malabsorption as a relevant mechanism to induce weight loss had been extrapolated 
from the bariatric surgery literature.  The DJBS is seen as an endoscopic RYGB mimetic due to its 
ability to separate luminal contents from bile and pancreatic secretions in a similar way to the 
biliopancreatic limb of the RYGB.  However, it has been reported that fat malabsorption after RYGB 
is only significant when at least 70 cm of jejunum is included in the biliopancreatic limb284.  If this is 
required, the DJBS is unlikely to cause significant fat malabsorption due to its limited projection into 
the jejunum. 
My research group has a long standing interest in FGIDs and as part of our studies of the DJBS we 
also assessed its effect on GI sensory function.  We found there was a significant increase in GI 
symptoms following a meal study, and also on a self-reported questionnaire measuring symptom 
intensity over the preceding seven days.  This is the first study to postulate a possible role for GI 
symptoms in the weight loss response to DJBS placement.  Previous studies have reported GI 
symptoms as adverse events of treatment445, 447-452, 454-459, 461, 462, 465, 469, 475, 482.  We believe that meal-
related GI symptoms are important to weight loss with the DJBS, contributing to a reduction in dietary 
energy intake. 
More specifically, epigastric pain was a prominent symptom following DJBS placement.   
One possible mechanism for this is that following a meal, gastric accommodation increases the 
pressure placed on the barbs that anchor the DJBS, triggering a pain response.  This would be more 
pronounced with a larger meal, possibly prompting a reduction in food intake.  Other explanations 
for the reduction in energy intake that were not assessed in our cohort include changes in appetite 
control biomarkers, or changes in self-reported appetite or food preferences. 
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DJBS treatment induces changes in the GI microbiota, and these changes may be linked to a 
key adverse event of treatment 
This study also aimed to explore the impact of DJBS treatment on the GI microbiota, across a number 
of sites in the GIT.  To the candidate’s knowledge, this is the first study that has assessed the MAM 
and the biofilm formed on the device surface after DJBS placement.  DJBS treatment resulted in a 
strong taxonomic shift in the gastric and duodenal MAM away from taxa that could be considered 
the core microbiota of the upper GIT544, 629, 630.  In the duodenum, a possible explanation for the 
changes observed is the lack of available nutrients at the mucosa due to the presence of the sleeve.  
This may explain the high abundance of more large bowel-type microbiota, such as members of the 
Enterobacteriaceae family, as the distal intestine is an area with lower nutrient availability.  As part 
of the study protocol, all patients were placed on a PPI.  Yet, in the stomach, the changes seen in the 
gastric MAM were somewhat distinct from what would be anticipated with acid suppression, such as 
reductions in acidogenic taxa that would typically be enriched with chronic PPI use such as Rothia 
and Actinomyces554.  Transient taxonomic changes were also observed in the stool microbiota while 
the device was in situ, without impacting the overall community profile or alpha diversity.  At eight 
weeks post-implant, the predominant taxon was Lactobacillus, which was also a primary coloniser of 
the device surface.  As with the MAM, the changes observed in the stool during the treatment period 
largely reflected a shift away from the organisms that typically make up the core of a healthy stool 
microbiota631-633.  This may be a flow through effect of microbes shed from the device surface into 
the lumen.  Overall, these data demonstrate that DJBS treatment alters the microbiota along the length 
of the gut. 
Whilst we didn’t assess the MAM post-explant, long-term data from other cohorts suggest a relative 
stability of the GI microbiota634.  DJBS removal (and cessation of PPI) would allow a return to the 
baseline physiological conditions in the stomach and duodenum, thus removing the key stimulus for 
a shift in the MAM.  Further, the resolution of GI symptoms after device explant may lead to a return 
to prior eating habits, which would also influence the microbiota.  Given the links between alterations 
of the microbiota in obesity171, 548, 635, 636, murine models demonstrating a causative role of the 
microbiota in weight gain637, and improved energy harvesting in obesity170, 638, it is possible that a 
shift back to a baseline microbiota profile may precipitate weight regain.  Indeed, during the 
intervention period, the relative abundance (RA) of microbial taxa in the MAM and the stool could 
be linked with weight loss outcomes.  A greater magnitude of weight loss was associated with a lesser 
deviation from a “typical” site-specific core microbiota.  Assessment of the MAM following device 
removal would allow for the relationship between these communities and long-term weight outcomes 
to be established. 
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In addition to changes in the MAM and stool microbiota, a distinct microbial community was also 
formed on the device surface.  The mucosa-adjacent device surface was colonised by taxa that were 
either absent from, or only low in abundance on the duodenal mucosa prior to device implantation.  
At explant, the duodenal mucosa was more dominantly colonised by microbes that are “typical” in 
the upper GIT such as Streptococcus, Prevotella and Veillonella, whereas the collocated device 
surface was more dominantly colonised by organisms that are typically lower in abundance in the 
upper GIT, such as Klebsiella, Bifidobacterium and members of the Enterobacteriaceae family.   
The differences between what grows on the mucosa and what grows on the device may be due to 
specific growth requirements, including the ability of organisms to adhere, form a biofilm, or colonise 
and utilise mucin.  It is difficult to determine the relationship between the MAM and the device 
communities.  It is likely that the MAM is altered by the DJBS being in place, due to changes in pH 
(associated with acid suppression), nutrient availability and oxygen environment.  These changes will 
also influence what is able to grow on the device surface. 
Diet is a relevant mediator of the microbiota profile and DJBS treatment resulted in significant 
changes in dietary intake.  Whilst dietary constituents have been associated with microbial taxa in the 
stool, there is no literature on the impact of diet on the gastric or duodenal MAM, despite this being 
an area with high nutrient availability.  Therefore, we conducted an exploratory analysis to determine 
the relationship between dietary intake (collected by 24 hour recall) and the stool microbiota and 
MAM.  In our cohort, a number of the associations between dietary constituents and the MAM match 
what has been reported in studies that have assessed this in the stool.  There were also novel 
observations, such as the relationship between Gammaproteobacteria and Klebsiella and protein 
intake, which has not previously been reported.  This may be related to a regional variation between 
the proximal and distal GIT and/or mucosa-adjacent vs luminal environments.  However, our data 
may also be impacted by measurement imprecision.  A 24 hour recall was used to assess dietary 
intake.  This tool captures recent not habitual dietary intake, which may have a more pronounced 
effect on shaping microbiota composition639. 
Finally, the development of pyogenic liver abscess is a rare complication of DJBS treatment.  To date, 
there are no published data on the microbes found in these abscesses.  In our cohort, there were no 
cases of hepatic abscess.  However, some of the changes in the MAM and taxa that colonised the  
mucosa-adjacent device surface are consistent with taxa previously isolated from sequenced pyogenic 
material from typical liver abscesses565, 566.  In particular, Klebsiella, which was at very low 
abundance in the duodenal MAM at baseline, but was highly abundant on the mucosa-adjacent device 
surface at explant, has commonly been reported in cases of hepatic abscess in patients with  
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T2DM565, 566.  This suggests that modifications of the device that inhibit bacterial growth may help to 
maintain clinical outcomes and possibly reduce the likelihood of developing hepatic abscess. 
DJBS treatment induces a local immune response in the duodenum and does not improve 
systemic markers of inflammation 
Following DJBS implantation, a modest atrophy of duodenal mucosal villi was found in seven of 19 
patients.  This may be relevant for weight reduction, by influencing nutrient absorption, and requires 
further investigation.  Despite the modest impact on villous architecture, a pronounced impact on 
local immune cell infiltration was observed after device implantation.  There was significant increase 
in duodenal eosinophils and IELs from baseline to explant.  There are a number of possible 
explanations for this.  Firstly, peristalsis is likely to cause small movements in the anchor barbs, which 
would act as a local irritant, triggering a local immune response.  In addition, the anchor barbs are 
likely to be colonised by microbes, and the movements induced by peristalsis have the potential to 
allow these bacteria entry into the mucosa.  Finally, the overall quantity of bacteria in close contact 
with the mucosa is increased by the biofilm formed on the device surface.  This increases the amount 
of microbial antigen present, which may trigger a local immune response. 
The MAM is of great relevance to the local immune response, as these microbes have direct contact 
with the host.  Significant relationships between bacterial taxa and the number of eosinophils in the 
duodenal mucosa at both baseline and explant were observed.  Specifically, the eosinophil count in 
the duodenum had an inverse correlation with the RA of “typical” upper GIT microbes, and a positive 
correlation with Fusobacterium (more typical of the distal GIT).  Similar relationships were observed 
between the number of IELs and bacterial taxa, with a positive association between IEL count and 
the RA of Lactobacillus and Dialister, which are typically present in low abundance in the duodenum.  
These results suggest that perturbation from a “typical” upper GI MAM results in increased local 
immune infiltration. 
The pro-inflammatory cytokine response of PBMCs to LPS stimulation was not significantly changed 
by DJBS treatment.  A major source of cytokine production in obesity is the adipose tissue640.   
At explant, all but two patients were still obese.  Therefore, despite the significant weight loss 
observed, the PBMCs will still be exposed to adipose tissue-derived cytokines and thus be primed to 
respond accordingly. 
However, specific changes in T lymphocyte phenotype were noted.  The proportion of CD4+ naïve 
T lymphocytes was significantly decreased, whilst there was a trend towards an increase in the 
proportion of CD8+ effector T lymphocytes.  This implies that DJBS placement is associated with an 
increase in T lymphocyte activation.  This may be secondary to increased translocation of bacteria or 
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bacterial products, either across the epithelial membrane or via perforations induced by the anchor 
barbs. 
Overall, these results suggest the DJBS is triggering a strong local immune response.  Despite the 
significant weight loss that occurred across the intervention period, DJBS treatment appears 
ineffective in improving global inflammation.  This may be related to the local immune response, 
which may overcome the beneficial effects of weight loss, or may be related to changes in the gut 
microbiota that perpetuate a systemic immune response. 
  
 209 
 
7.2 STRENGTHS AND WEAKNESSES 
7.2.1 Strengths 
There are a number of strengths of this study.  This study combined clinical techniques with 
microbiological and immunological techniques to characterise the mechanisms of action of the DJBS.  
A number of novel clinical investigations were conducted, including the first reports of dietary intake, 
HRQoL and functional exercise capacity following DJBS implantation.  We also explored the impact 
of DJBS treatment on hepatic elastography measures, for which there is only one prior report455.  
Overall, the assessment methodologies were selected on the basis of their clinical utility and 
validation, in addition to ensuring patient safety.  This is a strength as we aimed to reduce participant 
burden to ensure maximum retention of study participants. 
A key strength of the microbiota work is the diversity of sites that were repeatedly sampled.   
The majority of studies that assess the effect of weight loss on the microbiota use stool samples, 
which reflect the luminal contents of the large intestine.  Assessment of the MAM provides insight 
into the microbial community that is in direct contact with the host, and therefore more likely to be 
mediating a relevant physiological response. 
There is a large amount of inter-individual variability in gut microbiota profiles.  Therefore the 
longitudinal sampling at each site, combined with repeated measures statistical techniques, increase 
confidence that changes in the microbiota are occurring as a result of DJBS treatment.  The inclusion 
of a control group for the microbiota and immune parameters also allows for identification of how 
obesity and comorbidities are influencing the results, compared to a cohort processed in an identical 
manner in the same centre, using the same protocols.  The inclusion of controls with a diverse range 
of BMIs allows us to compare our cohort at baseline to determine if there is already an altered profile 
(as may be expected in obesity), and if the changes observed are related to DJBS treatment. 
This study has also included novel exploratory investigations of the relationship between diet and the 
microbiota, and the microbiota and the immune system.  These investigations are inherently valuable 
in a region of the GIT where little is known about the interplay between diet, the microbiota and the 
immune system. 
7.2.2 Weaknesses 
Sample Size, Cohort Study Design and Data Collection 
A limitation of the study is the small number of study participants.  We initially aimed to recruit 50 
patients.  However, this was not possible as the device was removed from the ARTG and we decided 
to discontinue the use of this device in our centre.  Secondary to this, a pilot group of patients who 
underwent a limited number of investigations were retrospectively included.  This introduced a 
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methodological bias as review schedules and investigations were different.  However, outcome data 
was collected within the same post-explant duration of up to three weeks. 
We did not have a control group who received only dietary counselling, instead conducting a cohort 
study.  This limits definitive conclusions about the impact of the DJBS on body weight compared to 
dietary modification and exercise.  However, the weight loss observed in this cohort exceeds that 
expected following 12 months of lifestyle intervention aimed at reducing energy intake269. 
Missing data is a common feature of clinical studies, and in particular weight loss interventions, where 
up to an 80% drop-out rate has been reported641.  In addition to the four early explants, interim data 
collection points were missed for a number of other patients.  As a consequence, only pre- to  
post-procedure statistical analyses were conducted for a number of measures.  This reduced the power 
of the study, as we initially designed the study to use repeated measures statistical analysis 
methodologies. 
We also experienced an approximately 50% loss to follow-up at the one year post-explant interval.  
Therefore our conclusions regarding long-term outcomes are limited.  However, given the majority 
of patients assessed had regained a large amount of weight, it is possible that weight gain resulted in 
reduced motivation to attend follow-up appointments in those that were lost to follow-up. 
Dietary Assessment Methodology and Recall Bias 
Unless using biomarker calibrated methods (such as urinary nitrogen as a marker of protein intake), 
which are more invasive for the patient, all dietary data collection methods are subject to recall bias.  
However, all interviews were conducted by an Accredited Practising Dietitian with training in 
conducting detailed interviews to maximise the precision of the data set.  Despite this, underreporting 
of energy intake, a key parameter on which we have postulated, is significant in patients with 
obesity642.  The precision of the dataset could be improved by triangulating multiple 24 hour recalls 
collected within a short time frame, albeit this increases the burden for both participant and researcher. 
One important aim was to integrate the dietary data set with data from sequencing of the GI 
microbiota.  We used a 24 hour recall, which provides a snapshot of recent intake.  However, this 
data was not collected close to microbiota sample collection.  This results in the assumption that 
neither the diet nor the microbiota has changed in the time that has elapsed between dietary data 
collection and microbiota sampling.  Major dietary change has been demonstrated to alter the stool 
microbiota very rapidly151.  In future studies, it would be valuable to have a 24 hour recall that was 
matched to specimen collection, in addition to a measure of long-term dietary intake, such as a 
validated food frequency questionnaire. 
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Use of “Gold Standard” Techniques 
At the time of study design, considerations around the patient burden of a large number of 
investigations (27 appointments required over the 48 week intervention period) were made.  As a 
result, this study was not able to employ a number of “gold standard” techniques.  A 13C mixed 
triglyceride breath test was used for the assessment of intraluminal lipolytic activity.  This was 
selected in preference to the gold standard of 72 hour faecal fat.  This investigation has a high patient 
burden and provides a significant calorie load that is counterintuitive in a weight loss intervention.  
This test would also be inappropriate if the device did induce fat malabsorption, which was our 
hypothesis. 
The gold standard of assessment of gastric emptying is gastric scintigraphy.  This method was not 
selected due to the risk of ionising radiation exposure for patients.  The method selected, the 13C 
octanoic acid breath test, has been validated against scintigraphy71, 72. 
Whilst a “gold standard” of microbiota assessment does not exist, the use of metagenomic 
sequencing, where the entire genome of a sample is sequenced, would allow for a greater granularity 
in the data obtained643.  It would also provide definitive information about the functional capabilities 
of the microbes present in the sample, instead of the inferences made from the 16S data set in the 
present study.  However, this method was not selected due to the small sample size (underpowered 
for such detailed analysis). 
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7.3 FUTURE DIRECTIONS 
The investigations in this study have identified a number of mechanisms associated with  
DJBS-induced weight loss.  We identified relevant changes in gut sensory function, the GI microbiota 
and immune parameters following DJBS placement.  Our results strongly suggest the induction of 
meal-related GI symptoms are a key component of the weight loss response.  These findings need to 
be validated in a larger cohort.  Assessments of other mechanisms for dietary intake reduction should 
be conducted in concert with assessment of GI symptoms.  Whilst previous studies have shown mixed 
changes in appetite control biomarkers446, 451, 456, 469, 476, 477, 482, subjective measures of appetite, 
changes in food preferences and eating behaviours should also be assessed. 
The current prototype of the DJBS has limitations and some of these may explain the high SAE rate 
observed in patients treated with the DJBS.  In particular, the development of pyogenic hepatic 
abscess is a major concern.  One of the key findings of this study is the taxonomic changes in the 
MAM and the growth of bacterial taxa on the mucosa-adjacent device surface that are similar to taxa 
previously reported in pyogenic liver abscess material565, 566.  To date, two mechanisms for this have 
been proposed: i) ascending cholangitis, and ii) bacterial translocation to the liver secondary to 
perforation of mucosal surfaces via the anchor barbs563.  It is also possible that bacterial translocation 
across the epithelial membrane occurs.  Future studies should aim to assess this.  It is recommended 
this is done using biopsy specimens, with assessment of tight junctions using genetic or protein 
markers (such as zonulin) or scanning electron microscope assessment of tight junctions.  This is 
recommended as the impact of the DJBS on clinical measures of permeability, specifically the 
absorption of lactulose and rhamnose in the small intestine, is not known. 
Future investigations of endoscopic obesity treatments, or indeed any investigations with access to 
high quality data on dietary intake, the duodenal MAM and immune function would bolster 
knowledge about the interplay of these factors.  This is relevant for diet-microbiota interactions in the 
duodenum, as it is the site of absorption for simple sugars and amino acids, which are key energy 
sources for commensal microbes.  Methodological recommendations on better capturing these 
relationships include measuring both long-term dietary intake (e.g. via a validated food frequency 
questionnaire) and recent intake (via 24 hour recall on the day of biological sampling); aseptic 
sampling of the duodenal microbiota; the use of metagenomic sequencing methods; and taking 
matched biopsy samples for histology and/or immunohistochemistry. 
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7.4 CONCLUSIONS 
In conclusion, significant improvements in body weight and markers of metabolic health occurred 
during the 48 week DJBS treatment period.  However, the majority of changes were not maintained 
at one year post-explant.  Despite this, there was a persistent trend toward an overall improvement in 
metabolic syndrome severity. 
Contrasting our expectations, we found no evidence that DJBS-induced weight loss was associated 
with changes in gastric emptying or fat absorption.  Instead, meal-related GI symptoms increased 
following DJBS placement and this was associated with a significant reduction in energy intake.   
In particular, the epigastric pain score was increased nearly five-fold following DJBS placement. 
After initiation of the study, concerns were raised in relation to safety.  This was associated with the 
development of pyogenic hepatic abscess, a rare SAE of treatment reported in up to 3% of patients in 
other trials.  In response to this, we investigated the GI microbiota.  After placement of the DJBS, a 
substantial shift in the duodenal MAM occurred.  We observed a significant increase in the RA of 
taxa such as Fusobacterium and Klebsiella that have previously been associated with hepatic abscess 
in other cohorts.  These bacteria were also dominant colonisers of the DJBS device surface.  
Therefore, our data suggest that assessment of the GI microbiota, and any changes induced by the 
DJBS or similar devices should be included as part of longitudinal safety assessment. 
DJBS treatment was associated with chronic local inflammation and modest changes in villous 
architecture in the duodenum.  Systemically, immune activation appears to be increased.   
The relationship between local immune changes and GI symptoms and systemic immunity need to 
be further defined. 
Overall, this study shows that the DJBS induces meal-related symptoms by interfering with “normal” 
upper gut digestive function.  This results in a reduced energy intake and subsequent weight loss, as 
well as metabolic improvements.  Unfortunately, long-term effects after removal of the device appear 
to be limited.  Therefore interventions, including bariatric surgery or minimally invasive endoscopic 
procedures, that alter upper gut function and induce meal-related symptoms are a rational approach 
to achieve more sustainable weight loss if other measures have failed.  
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1.4 Microbiology Primers and Reactions  
Illumina 16S rRNA sequencing primers 
Amplicon PCR 
16S rRNA forward primer: 917-F with Illumina adapter (adapter underlined): 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAATTGRCGGGGRCC 
16S rRNA reverse primer: 1392-R with Illumina adapter (adapter underlined): 
GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGACGGGCGGTGWGTRC 
Universal forward primer: 926-F with Illumina adapter (adapter underlined): 
TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGAAACTYAAAKGAATTGRCGG 
 
Product size: 556 bp (917-F and 1392-R) or 499 bp (926-F and 1392-R) 
 
Barcoding PCR 
Forward Index Primer (P5 seq primer region – Index I5 – Adapter (underlined)): 
AATGATACGGCGACCACCGAGATCTACACiiiiiiiiTCGTCGGCAGCGTCAGATGTGTATAA
GAGACAG 
Reverse Index Primer (P7 seq primer region – Index I7 – Adapter (underlined)): 
CAAGCAGAAGACGGCATACGAGATiiiiiiiiGTCTCGTGGGCTCGGAGATGTGTATAAGAG
ACAG 
Product size: 625 bp 
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Index Kit A 
I5 Index Sequence 
S502 CTCTCTAT 
S503 TATCCTCT 
S505 GTAAGGAG 
S506 ACTGCATA 
S507 AAGGAGTA 
S508 CTAAGCCT 
S510 CGTCTAAT 
S511 TCTCTCCG 
 
I7 Index Sequence 
N701 TAAGGCGA 
N702 CGTACTAG 
N703 AGGCAGAA 
N704 TCCTGAGC 
N705 GGACTCCT 
N706 TAGGCATG 
N707 CTCTCTAC 
N710 CGAGGCTG 
N711 AAGAGGCA 
N712 GTAGAGGA 
N714 GCTCATGA 
N715 ATCTCAGG 
 
Index Kit B 
I5 Index Sequence 
S502 CTCTCTAT 
S503 TATCCTCT 
S505 GTAAGGAG 
S506 ACTGCATA 
S507 AAGGAGTA 
S508 CTAAGCCT 
S510 CGTCTAAT 
S511 TCTCTCCG 
 
I7 Index Sequence 
N716 ACTCGCTA 
N718 GGAGCTAC 
N719 GCGTAGTA 
N720 CGGAGCCT 
N721 TACGCTGC 
N722 ATGCGCAG 
N723 TAGCGCTC 
N724 ACTGAGCG 
N726 CCTAAGAC 
N727 CGATCAGT 
N728 TGCAGCTA 
N729 TCGACGTC 
  
 276 
 
PCR reaction set up – 16S rRNA sequencing and qPCR 
qPCR 
Volume per sample (µL) Reagent 
0.2 Forward Primer (16S rRNA or human β-actin) 
0.2 Reverse Primer (16S rRNA or human β-actin) 
10 Power SYBR Green Master Mix 
9.6 gDNA template (15 ng diluted in Ultrapure water) 
20 Total 
 
qPCR cycle program 
95 °C 10 minutes 
40 cycles of 
95 °C 
 
15 seconds 
60 °C 1 minute 
  
Melt Curve: 95 °C – 60 °C – 95 °C  
 
16S rRNA sequencing reaction set up 
Amplicon PCR 
Volume per 
sample (µL) 
Reagent 
2  Forward Primer (917-F or 926-F), with Illumina adapter (10 µM) 
2  Reverse Primer (1392-R), with Illumina adapter (10 µM) 
25 Q5® High Fidelity DNA Polymerase(New England Biolabs,  MA, USA) 
21 gDNA template (diluted in Ultrapure water to 100 ng for biopsies and 20 
ng for device and stool samples) 
50 Total 
 
PCR cycle program 
Temperature Time 
98 °C 3 minutes 
25 cycles of 
95 °C 
 
20 seconds 
51 °C 20 seconds 
72 °C 20 seconds 
72 °C 2 minutes 
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Barcoding PCR 
Volume per 
sample (µL) 
Reagent 
5 Nextera XT index 1 primer (N7xx) 
5 Nextera XT index 2 primer (N5xx) 
25 Q5® High Fidelity DNA Polymerase(New England Biolabs,  MA, USA) 
5 PCR water 
10 gDNA template (from cleaned amplicon PCR) 
50 Total 
 
PCR cycle program 
Temperature Time 
95 °C 3 minutes 
25 cycles of 
95 °C 
 
30 seconds 
55 °C 30 seconds 
72 °C 30 seconds 
72 °C 5 minutes 
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1.5 Contaminants Removed from Sequencing Results 
Table 1S: Full list of OTUs present in negative controls removed as contaminants prior to analysis  
(917 primer set). 
The number following the taxonomic description is the Greengenes identification number. 
OTU 
p__Actinobacteria; f__Microbacteriaceae 179312 
p__Actinobacteria; f__Microbacteriaceae New Reference OTU 11347 
p__Actinobacteria; f__Microbacteriaceae New Reference OTU 28099 
p__Actinobacteria; f__Microbacteriaceae; s__NA New Reference OTU 8606 
p__Actinobacteria; g__Cryocola; s__NA 223593 
p__Actinobacteria; g__Microbacterium; s__NA 1760354 
p__Actinobacteria; f__Micrococcaceae 526833 
p__Actinobacteria; g__Propionibacterium; s__Acnes New Reference OTU 13881 
p__Firmicutes; g__Staphylococcus; s__NA New Reference OTU 27998 
p__Firmicutes; g__Staphylococcus; s__Aureus New Reference OTU 14856 
p__Firmicutes; g__Staphylococcus; s__Epidermidis New Reference OTU 11839 
p__Firmicutes; g__Planifilum; s__NA 1725586 
p__Firmicutes; g__Enterococcus; s__NA 303838 
p__Firmicutes; g__Enterococcus; s__NA 593781 
p__Firmicutes; o__Clostridiales 351309 
p__Firmicutes; o__Clostridiales 352222 
p__Firmicutes; o__Clostridiales 354097 
p__Firmicutes; f__Clostridiaceae 346666 
p__Firmicutes; g__Allobaculum; s__NA 1105860 
p__Firmicutes; g__Allobaculum; s__NA 274912 
p__Firmicutes; g__Allobaculum; s__NA 277143 
p__Firmicutes; g__Allobaculum; s__New Reference OTU 18502 
p__Proteobacteria; o__Rhizobiales New Reference OTU 94795 
p__Proteobacteria; f__Bradyrhizobiaceae New Reference OTU 14380 
p__Proteobacteria; g__Paracoccus 812921 
p__Proteobacteria; g__Sphingomonas New Reference OTU 85436 
p__Proteobacteria; g__Achromobacter; s__NA 846710 
p__Proteobacteria; f__Comamonadaceae 275296 
p__Proteobacteria; f__Comamonadaceae 838837 
p__Proteobacteria; g__Comamonas; s__NA 576010 
p__Proteobacteria; g__Delftia; s__NA 816420 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU 106355 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU 95717 
p__Proteobacteria; f__Oxalobacteraceae 335466 
p__Proteobacteria; f__Oxalobacteraceae 332293 
p__Proteobacteria; f__Oxalobacteraceae 341936 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU 103772 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU 64692 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU 74027 
p__Proteobacteria; g__Ralstonia; s__NA 783719 
p__Proteobacteria; g__Ralstonia; s__NA New Reference OTU 36969 
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OTU 
p__Proteobacteria; g__Ralstonia; s__NA New Reference OTU 54789 
p__Proteobacteria; g__Ralstonia; s__NA New Reference OTU 31241 
p__Proteobacteria; g__Ralstonia; s__NA New Reference OTU 66558 
p__Proteobacteria; g__Ralstonia; s__NA New Reference OTU 41823 
p__Proteobacteria; f__Moraxellaceae New Reference OTU 25185 
p__Proteobacteria; g__Enhydrobacter 574102 
p__Proteobacteria; g__Enhydrobacter; s__NA New Reference OTU 12057 
p__Proteobacteria; f__Pseudomonadaceae New Reference OTU 41836 
p__Proteobacteria; g__Pseudomonas; s__NA 573184 
p__Proteobacteria; g__Pseudomonas; s__NA 813945 
p__Proteobacteria; g__Pseudomonas; s__NA 827497 
p__Proteobacteria; g__Pseudomonas; s__NA 817734 
p__Proteobacteria; g__Pseudomonas; s__NA 780261 
p__Proteobacteria; f__Xanthomonadaceae 884604 
Abbreviations: f; family, g; genus, NA; not assigned, o; order, OTU; operational taxonomic unit, p; phylum s; 
species  
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Table 2S: Full list of OTUs present in negative controls removed as contaminants prior to analysis  
(926 primer set). 
The number following the taxonomic description is the Greengenes identification number. 
OTU 
p__Actinobacteria; f__Microbacteriaceae New Reference OTU 102495 
p__Actinobacteria; f__Microbacteriaceae New.CleanUp.ReferenceOTU 1094657 
p__Actinobacteria; g__Cryocola; s__NA 223593 
p__Actinobacteria; g__Microbacterium; s__NA 814909 
p__Actinobacteria; g__Microbacterium; s__chocolatum New Reference OTU201158 
p__Actinobacteria; g__Micrococcus; s__luteus 338075 
p__Actinobacteria; g__Micrococcus; s__luteus 526833 
p__Actinobacteria; g__Propionibacterium; s__acnes New Reference OTU 203234 
p__Actinobacteria; g__Propionibacterium; s__acnes New Reference OTU155864 
p__Firmicutes; g__Staphylococcus; s__NA New Reference OTU235149 
p__Firmicutes; g__Staphylococcus; s__epidermidis New Reference OTU139851 
p__Firmicutes; o__Lactobacillales 667621 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU103939 
p__Proteobacteria; f__Oxalobacteraceae 335466 
p__Proteobacteria; f__Oxalobacteraceae 332293 
p__Proteobacteria; f__Oxalobacteraceae 341936 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU 97535 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU210997 
p__Proteobacteria; f__Oxalobacteraceae New Reference OTU 62539 
p__Proteobacteria; g__Ralstonia; s__NA 783719 
p__Proteobacteria; g__Enhydrobacter 574102 
p__Proteobacteria; g__Enhydrobacter; s__NA New Reference OTU151729 
p__Proteobacteria; g__Pseudomonas; s__NA 813945 
p__Proteobacteria; g__Pseudomonas; s__NA 827497 
p__Proteobacteria; g__Pseudomonas; s__NA 817734 
p__Proteobacteria; g__Pseudomonas; s__NA 780261 
Abbreviations: f; family, g; genus, NA; not assigned, o; order, OTU; operational taxonomic unit, p; phylum s; 
species 
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1.6 Full List of OTUs Recovered in Samples 
Table 3S: Full list of OTUs present in samples, sorted alphabetically. 
 
The number following the taxonomic description is the Greengenes identification number. 
 
OTU Biopsy Device Stool 
k__Bacteria New.ReferenceOTU106958   Y 
p__Actinobacteria; f__Coriobacteriaceae 1106384 Y Y  
p__Actinobacteria; f__Coriobacteriaceae 87668 Y Y  
p__Actinobacteria; f__Coriobacteriaceae 196140   Y 
p__Actinobacteria; f__Coriobacteriaceae New.CleanUp.ReferenceOTU272839 Y Y  
p__Actinobacteria; f__Coriobacteriaceae New.ReferenceOTU100235 Y Y  
p__Actinobacteria; f__Coriobacteriaceae New.ReferenceOTU36643 Y Y  
p__Actinobacteria; g__Actinomyces 1066410 Y Y  
p__Actinobacteria; g__Actinomyces 4318624 Y Y  
p__Actinobacteria; g__Actinomyces 4350499 Y Y  
p__Actinobacteria; g__Actinomyces 565136 Y Y  
p__Actinobacteria; g__Adlercreutzia 198774   Y 
p__Actinobacteria; g__Atopobium 2163609 Y Y  
p__Actinobacteria; g__Atopobium 251702 Y Y  
p__Actinobacteria; g__Bifidobacterium 362214 Y Y  
p__Actinobacteria; g__Bifidobacterium 4426298 Y Y Y 
p__Actinobacteria; g__Bifidobacterium New.CleanUp.ReferenceOTU81261   Y 
p__Actinobacteria; g__Bifidobacterium New.ReferenceOTU103436 Y Y  
p__Actinobacteria; g__Bifidobacterium New.ReferenceOTU10855 Y Y  
p__Actinobacteria; g__Bifidobacterium New.ReferenceOTU13067 Y Y  
p__Actinobacteria; g__Bifidobacterium New.ReferenceOTU37474 Y Y  
p__Actinobacteria; g__Bifidobacterium New.ReferenceOTU60116 Y Y  
p__Actinobacteria; g__Bifidobacterium__s__animalis New.ReferenceOTU11994 Y Y  
p__Actinobacteria; g__Bifidobacterium__s__animalis 
New.ReferenceOTU102970 
  Y 
p__Actinobacteria; g__Bifidobacterium__s__animalis New.ReferenceOTU85119 Y Y  
p__Actinobacteria; g__Collinsella 193575   Y 
p__Actinobacteria; g__Collinsella 302647   Y 
p__Actinobacteria; g__Collinsella 365181 Y Y Y 
p__Actinobacteria; g__Collinsella 414949 Y Y  
p__Actinobacteria; g__Collinsella 415315 Y Y  
p__Actinobacteria; g__Collinsella New.CleanUp.ReferenceOTU235731 Y Y  
p__Actinobacteria; g__Collinsella New.ReferenceOTU2563 Y Y  
p__Actinobacteria; g__Collinsella New.ReferenceOTU47451 Y Y  
p__Actinobacteria; g__Collinsella New.ReferenceOTU57797 Y Y  
p__Actinobacteria; g__Collinsella New.ReferenceOTU6884 Y Y  
p__Actinobacteria; g__Collinsella__s__aerofaciens New.ReferenceOTU111175   Y 
p__Actinobacteria; g__Collinsella__s__aerofaciens 1811927 Y Y  
p__Actinobacteria; g__Collinsella__s__aerofaciens 196140 Y Y  
p__Actinobacteria; g__Collinsella__s__aerofaciens New.ReferenceOTU19159 Y Y  
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OTU Biopsy Device Stool 
p__Actinobacteria; g__Rothia 532388 Y Y  
p__Actinobacteria; g__Slackia 471157 Y Y  
p__Bacteroidetes; f__S24-7 3293886 Y   
p__Bacteroidetes; f__S24-7 333695   Y 
p__Bacteroidetes; f__S24-7 357305   Y 
p__Bacteroidetes; g__Bacteroides 1531298 Y Y  
p__Bacteroidetes; g__Bacteroides 198449 Y Y Y 
p__Bacteroidetes; g__Bacteroides 198530 Y Y  
p__Bacteroidetes; g__Bacteroides 270094   Y 
p__Bacteroidetes; g__Bacteroides 323231 Y Y Y 
p__Bacteroidetes; g__Bacteroides 326626   Y 
p__Bacteroidetes; g__Bacteroides 359538   Y 
p__Bacteroidetes; g__Bacteroides 363887 Y Y  
p__Bacteroidetes; g__Bacteroides 364029   Y 
p__Bacteroidetes; g__Bacteroides 369449   Y 
p__Bacteroidetes; g__Bacteroides 568118 Y Y Y 
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU10143 Y Y  
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU102603 Y Y  
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU106777 Y   
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU12980   Y 
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU18528 Y Y  
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU24310 Y Y  
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU36879 Y Y  
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU49181 Y Y  
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU54418   Y 
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU72131   Y 
p__Bacteroidetes; g__Bacteroides New.ReferenceOTU89660 Y Y  
p__Bacteroidetes; g__Bacteroides__s__fragilis 130007   Y 
p__Bacteroidetes; g__Bacteroides__s__fragilis 1795137 Y Y Y 
p__Bacteroidetes; g__Bacteroides__s__fragilis 1918384 Y Y  
p__Bacteroidetes; g__Bacteroides__s__fragilis 2944933 Y Y  
p__Bacteroidetes; g__Bacteroides__s__uniformis 323619   Y 
p__Bacteroidetes; g__Bacteroides__s__uniformis 584541   Y 
p__Bacteroidetes; g__Dysgonomonas New.ReferenceOTU40751   Y 
p__Bacteroidetes; g__Parabacteroides__s__distasonis 577294   Y 
p__Bacteroidetes; g__Porphyromonas 970138 Y Y  
p__Bacteroidetes; g__Porphyromonas__s__endodontalis 573034 Y Y  
p__Bacteroidetes; g__Prevotella 1011398 Y Y Y 
p__Bacteroidetes; g__Prevotella 2228 Y Y  
p__Bacteroidetes; g__Prevotella 269907 Y Y  
p__Bacteroidetes; g__Prevotella 369077   Y 
p__Bacteroidetes; g__Prevotella 4295238 Y Y  
p__Bacteroidetes; g__Prevotella 4307006 Y Y  
p__Bacteroidetes; g__Prevotella 535359   Y 
p__Bacteroidetes; g__Prevotella 610111 Y Y  
p__Bacteroidetes; g__Prevotella 851822 Y Y  
p__Bacteroidetes; g__Prevotella 851923 Y Y  
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OTU Biopsy Device Stool 
p__Bacteroidetes; g__Prevotella 851961 Y Y  
p__Bacteroidetes; g__Prevotella 926362 Y Y  
p__Bacteroidetes; g__Prevotella New.CleanUp.ReferenceOTU507256   Y 
p__Bacteroidetes; g__Prevotella New.ReferenceOTU113938   Y 
p__Bacteroidetes; g__Prevotella__s__copri 545061   Y 
p__Bacteroidetes; g__Prevotella__s__copri 840914   Y 
p__Bacteroidetes; g__Prevotella__s__intermedia 246785 Y Y  
p__Bacteroidetes; g__Prevotella__s__melaninogenica 535359 Y Y  
p__Bacteroidetes; g__Prevotella__s__nigrescens 2195 Y Y  
p__Bacteroidetes; g__Prevotella__s__nigrescens 3746312   Y 
p__Bacteroidetes; g__Prevotella__s__pallens 2222 Y Y  
p__Bacteroidetes; g__Prevotella__s__tannerae 2887205   Y 
p__Bacteroidetes; g__Prevotella__s__tannerae 38227 Y Y  
p__Euryarchaeota; g__Methanobrevibacter 849440   Y 
p__Euryarchaeota; g__Methanobrevibacter New.ReferenceOTU105789   Y 
p__Firmicutes; f__Clostridiaceae 328059   Y 
p__Firmicutes; f__Clostridiaceae 346666   Y 
p__Firmicutes; f__Erysipelotrichaceae 580008   Y 
p__Firmicutes; f__Lachnospiraceae 184729   Y 
p__Firmicutes; f__Lachnospiraceae 195186   Y 
p__Firmicutes; f__Lachnospiraceae 198909   Y 
p__Firmicutes; f__Lachnospiraceae 2148365 Y Y  
p__Firmicutes; f__Lachnospiraceae 230741   Y 
p__Firmicutes; f__Lachnospiraceae 3175741 Y Y  
p__Firmicutes; f__Lachnospiraceae 369709   Y 
p__Firmicutes; f__Lachnospiraceae 4087649 Y Y  
p__Firmicutes; f__Lachnospiraceae 524219   Y 
p__Firmicutes; f__Lachnospiraceae 574290   Y 
p__Firmicutes; f__Lachnospiraceae New.CleanUp.ReferenceOTU103377   Y 
p__Firmicutes; f__Lachnospiraceae New.CleanUp.ReferenceOTU1075895   Y 
p__Firmicutes; f__Lachnospiraceae New.CleanUp.ReferenceOTU1164950   Y 
p__Firmicutes; f__Lachnospiraceae New.CleanUp.ReferenceOTU209487   Y 
p__Firmicutes; f__Lachnospiraceae New.CleanUp.ReferenceOTU499544   Y 
p__Firmicutes; f__Lachnospiraceae New.CleanUp.ReferenceOTU93368   Y 
p__Firmicutes; f__Lachnospiraceae New.ReferenceOTU100062   Y 
p__Firmicutes; f__Lachnospiraceae New.ReferenceOTU100098   Y 
p__Firmicutes; f__Lachnospiraceae New.ReferenceOTU100192   Y 
p__Firmicutes; f__Lachnospiraceae New.ReferenceOTU100341   Y 
p__Firmicutes; f__Ruminococcaceae 1062061   Y 
p__Firmicutes; f__Ruminococcaceae 1813887   Y 
p__Firmicutes; f__Ruminococcaceae 196902   Y 
p__Firmicutes; f__Ruminococcaceae 198053   Y 
p__Firmicutes; f__Ruminococcaceae 215855   Y 
p__Firmicutes; f__Ruminococcaceae 515869   Y 
p__Firmicutes; f__Ruminococcaceae 538322   Y 
p__Firmicutes; f__Ruminococcaceae 566899   Y 
p__Firmicutes; f__Ruminococcaceae 761968   Y 
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p__Firmicutes; f__Ruminococcaceae New.CleanUp.ReferenceOTU926888   Y 
p__Firmicutes; f__Veillonellaceae 3581088 Y Y  
p__Firmicutes; g__Acidaminococcus 179067 Y Y Y 
p__Firmicutes; g__Allobaculum 277143   Y 
p__Firmicutes; g__Blautia 367790   Y 
p__Firmicutes; g__Blautia 532203   Y 
p__Firmicutes; g__Blautia New.CleanUp.ReferenceOTU1168251   Y 
p__Firmicutes; g__Blautia New.CleanUp.ReferenceOTU240620   Y 
p__Firmicutes; g__Blautia New.CleanUp.ReferenceOTU30692   Y 
p__Firmicutes; g__Blautia New.CleanUp.ReferenceOTU418707   Y 
p__Firmicutes; g__Blautia New.CleanUp.ReferenceOTU758589   Y 
p__Firmicutes; g__Blautia New.CleanUp.ReferenceOTU830420   Y 
p__Firmicutes; g__Blautia New.ReferenceOTU102422   Y 
p__Firmicutes; g__Bulleidia 851938 Y Y  
p__Firmicutes; g__Catenibacterium 330294   Y 
p__Firmicutes; g__Clostridium__s__perfringens 355471   Y 
p__Firmicutes; g__Coprococcus 355175 Y  Y 
p__Firmicutes; g__Coprococcus New.CleanUp.ReferenceOTU1009188   Y 
p__Firmicutes; g__Dialister 2160415 Y Y Y 
p__Firmicutes; g__Dialister 2866420 Y Y  
p__Firmicutes; g__Dialister 535901 Y Y Y 
p__Firmicutes; g__Dorea New.CleanUp.ReferenceOTU444829   Y 
p__Firmicutes; g__Dorea New.ReferenceOTU100101   Y 
p__Firmicutes; g__Dorea New.ReferenceOTU109445   Y 
p__Firmicutes; g__Enterococcus 303838   Y 
p__Firmicutes; g__Enterococcus 539447   Y 
p__Firmicutes; g__Enterococcus 543824   Y 
p__Firmicutes; g__Enterococcus 593781   Y 
p__Firmicutes; g__Enterococcus 667621 Y Y  
p__Firmicutes; g__Enterococcus New.ReferenceOTU4904   Y 
p__Firmicutes; g__Eubacterium__s__biforme 523132   Y 
p__Firmicutes; g__Eubacterium__s__biforme 527208   Y 
p__Firmicutes; g__Faecalibacterium__s__prausnitzii 523892   Y 
p__Firmicutes; g__Gemella 4384936 Y Y  
p__Firmicutes; g__Gemella 529233 Y Y  
p__Firmicutes; g__Granulicatella New.ReferenceOTU14113 Y Y  
p__Firmicutes; g__Granulicatella New.ReferenceOTU61217 Y Y  
p__Firmicutes; g__Lactobacillus 133892 Y Y  
p__Firmicutes; g__Lactobacillus 137580 Y Y Y 
p__Firmicutes; g__Lactobacillus 221299 Y Y Y 
p__Firmicutes; g__Lactobacillus 255367 Y Y  
p__Firmicutes; g__Lactobacillus 266445 Y Y  
p__Firmicutes; g__Lactobacillus 276632   Y 
p__Firmicutes; g__Lactobacillus 288521 Y Y  
p__Firmicutes; g__Lactobacillus 316438 Y Y  
p__Firmicutes; g__Lactobacillus 318764 Y Y  
p__Firmicutes; g__Lactobacillus 329402   Y 
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p__Firmicutes; g__Lactobacillus 331248 Y Y Y 
p__Firmicutes; g__Lactobacillus 340960 Y Y Y 
p__Firmicutes; g__Lactobacillus 354225 Y Y Y 
p__Firmicutes; g__Lactobacillus 354911 Y Y  
p__Firmicutes; g__Lactobacillus 354971 Y Y Y 
p__Firmicutes; g__Lactobacillus 383885 Y Y  
p__Firmicutes; g__Lactobacillus 4321285   Y 
p__Firmicutes; g__Lactobacillus 4337090 Y Y  
p__Firmicutes; g__Lactobacillus 484444 Y Y  
p__Firmicutes; g__Lactobacillus 509452 Y Y Y 
p__Firmicutes; g__Lactobacillus 519673 Y Y Y 
p__Firmicutes; g__Lactobacillus 533133 Y Y  
p__Firmicutes; g__Lactobacillus 536754   Y 
p__Firmicutes; g__Lactobacillus 539647 Y Y Y 
p__Firmicutes; g__Lactobacillus 541135 Y Y  
p__Firmicutes; g__Lactobacillus 549756 Y Y Y 
p__Firmicutes; g__Lactobacillus 563654 Y Y Y 
p__Firmicutes; g__Lactobacillus 564037   Y 
p__Firmicutes; g__Lactobacillus 573010 Y Y  
p__Firmicutes; g__Lactobacillus 573214   Y 
p__Firmicutes; g__Lactobacillus 574021 Y Y Y 
p__Firmicutes; g__Lactobacillus 581474 Y Y Y 
p__Firmicutes; g__Lactobacillus 582884 Y Y Y 
p__Firmicutes; g__Lactobacillus 584001 Y Y Y 
p__Firmicutes; g__Lactobacillus 584571 Y Y  
p__Firmicutes; g__Lactobacillus 586093 Y Y Y 
p__Firmicutes; g__Lactobacillus 586968 Y Y Y 
p__Firmicutes; g__Lactobacillus 588197 Y Y Y 
p__Firmicutes; g__Lactobacillus 590168 Y Y Y 
p__Firmicutes; g__Lactobacillus 592160 Y Y  
p__Firmicutes; g__Lactobacillus 593376 Y Y  
p__Firmicutes; g__Lactobacillus 716286 Y Y  
p__Firmicutes; g__Lactobacillus 725198 Y Y Y 
p__Firmicutes; g__Lactobacillus 805007 Y Y Y 
p__Firmicutes; g__Lactobacillus 808562 Y Y  
p__Firmicutes; g__Lactobacillus 818672   Y 
p__Firmicutes; g__Lactobacillus 823803 Y Y Y 
p__Firmicutes; g__Lactobacillus 851733 Y Y Y 
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU1204606   Y 
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU1285289   Y 
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU229135 Y Y  
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU292621 Y Y  
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU388917   Y 
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU600388   Y 
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU675106   Y 
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU744612   Y 
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU744633   Y 
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p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU859886   Y 
p__Firmicutes; g__Lactobacillus New.CleanUp.ReferenceOTU980504   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100078 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100080   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100146   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100298   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100383   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100507   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100549 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100589   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100668   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU100849   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU10089 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU101020   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU101346 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU101393   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU102320   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU10236 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU102911   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU103058 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU103611   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU10377   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU104376   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU106105   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU107798   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU108675   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU11157 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU113378   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU11593 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU116651   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU118335   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU119630   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU130718   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU136613   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU140599   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU14451 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU15184 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU167255   Y 
p__Firmicutes; g__Lactobacillus New.ReferenceOTU20734 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU24218 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU24936 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU3201 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU49108 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU63911 Y Y  
p__Firmicutes; g__Lactobacillus New.ReferenceOTU87765 Y Y  
p__Firmicutes; g__Lactobacillus__s__reuteri 564037 Y Y  
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p__Firmicutes; g__Lactobacillus__s__reuteri New.ReferenceOTU100628   Y 
p__Firmicutes; g__Lactobacillus__s__reuteri New.ReferenceOTU104864   Y 
p__Firmicutes; g__Lactobacillus__s__vaginalis 536754 Y Y  
p__Firmicutes; g__Megasphaera 173744 Y Y Y 
p__Firmicutes; g__Megasphaera 41128 Y Y Y 
p__Firmicutes; g__Megasphaera 518686 Y Y  
p__Firmicutes; g__Megasphaera 539819 Y Y Y 
p__Firmicutes; g__Moryella 714766 Y Y  
p__Firmicutes; g__Parvimonas 851704 Y Y Y 
p__Firmicutes; g__Peptostreptococcus__s__anaerobius 532521 Y Y  
p__Firmicutes; g__Ruminococcus 333096   Y 
p__Firmicutes; g__Ruminococcus New.CleanUp.ReferenceOTU672208   Y 
p__Firmicutes; g__Ruminococcus__s__gnavus 
New.CleanUp.ReferenceOTU1129070 
  Y 
p__Firmicutes; g__Selenomonas 258034   Y 
p__Firmicutes; g__Selenomonas 28118   Y 
p__Firmicutes; g__Selenomonas 295019 Y Y Y 
p__Firmicutes; g__Selenomonas 4297955 Y Y Y 
p__Firmicutes; g__Selenomonas 4310995 Y Y  
p__Firmicutes; g__Selenomonas 4387963   Y 
p__Firmicutes; g__Selenomonas New.ReferenceOTU14349   Y 
p__Firmicutes; g__Streptococcus 1098340 Y Y  
p__Firmicutes; g__Streptococcus 1141646   Y 
p__Firmicutes; g__Streptococcus 349024 Y Y Y 
p__Firmicutes; g__Streptococcus 516966 Y Y Y 
p__Firmicutes; g__Streptococcus New.CleanUp.ReferenceOTU379777 Y Y  
p__Firmicutes; g__Streptococcus New.CleanUp.ReferenceOTU885632   Y 
p__Firmicutes; g__Streptococcus New.ReferenceOTU101   Y 
p__Firmicutes; g__Streptococcus New.ReferenceOTU100710 Y Y  
p__Firmicutes; g__Streptococcus New.ReferenceOTU101677 Y Y  
p__Firmicutes; g__Streptococcus New.ReferenceOTU102486   Y 
p__Firmicutes; g__Streptococcus New.ReferenceOTU104459 Y Y  
p__Firmicutes; g__Streptococcus New.ReferenceOTU13477 Y Y  
p__Firmicutes; g__Streptococcus New.ReferenceOTU137100   Y 
p__Firmicutes; g__Streptococcus New.ReferenceOTU30299 Y Y  
p__Firmicutes; g__Streptococcus New.ReferenceOTU32130 Y Y  
p__Firmicutes; g__Streptococcus__s__anginosus 217734 Y Y  
p__Firmicutes; g__Streptococcus__s__anginosus 2959075   Y 
p__Firmicutes; g__Streptococcus__s__anginosus 561636 Y Y  
p__Firmicutes; g__Streptococcus__s__anginosus 797560 Y Y  
p__Firmicutes; g__Streptococcus__s__anginosus New.ReferenceOTU42852 Y Y  
p__Firmicutes; g__Streptococcus__s__infantis 517754 Y Y  
p__Firmicutes; g__Veillonella 222433 Y Y  
p__Firmicutes; g__Veillonella 2283862   Y 
p__Firmicutes; g__Veillonella 518743 Y Y  
p__Firmicutes; g__Veillonella 561537 Y Y  
p__Firmicutes; g__Veillonella New.ReferenceOTU23742   Y 
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p__Firmicutes; g__Veillonella New.ReferenceOTU60029 Y Y  
p__Firmicutes; g__Veillonella__s__parvula 4352537   Y 
p__Firmicutes; g__Veillonella__s__parvula 518743   Y 
p__Firmicutes; o__Clostridiales 193731   Y 
p__Firmicutes; o__Clostridiales 321005   Y 
p__Firmicutes; o__Clostridiales 337403   Y 
p__Firmicutes; o__Clostridiales 365484   Y 
p__Firmicutes; o__Clostridiales 470382   Y 
p__Firmicutes; o__Clostridiales 798164   Y 
p__Firmicutes; o__Clostridiales New.CleanUp.ReferenceOTU666868   Y 
p__Firmicutes; o__Clostridiales New.ReferenceOTU100675   Y 
p__Fusobacteria; g__Cetobacterium__s__somerae 825815 Y Y  
p__Fusobacteria; g__Cetobacterium__s__somerae 828162 Y Y Y 
p__Fusobacteria; g__Cetobacterium__s__somerae New.ReferenceOTU100037 Y Y  
p__Fusobacteria; g__Fusobacterium 1749615   Y 
p__Fusobacteria; g__Fusobacterium 1750702   Y 
p__Fusobacteria; g__Fusobacterium 1875986 Y Y  
p__Fusobacteria; g__Fusobacterium 34791 Y Y  
p__Fusobacteria; g__Fusobacterium 4479600 Y Y  
p__Fusobacteria; g__Fusobacterium 545299 Y Y Y 
p__Fusobacteria; g__Leptotrichia 2480553 Y Y  
p__Fusobacteria; g__Leptotrichia 251967 Y Y  
p__Fusobacteria; g__Leptotrichia 4483174 Y Y Y 
p__Lentisphaerae; f__Victivallaceae 158404 Y Y Y 
p__Proteobacteria; c__Gammaproteobacteria 808486 Y Y  
p__Proteobacteria; c__Gammaproteobacteria New.ReferenceOTU101477 Y Y  
p__Proteobacteria; c__Gammaproteobacteria New.ReferenceOTU102522   Y 
p__Proteobacteria; c__Gammaproteobacteria New.ReferenceOTU102591   Y 
p__Proteobacteria; c__Gammaproteobacteria New.ReferenceOTU127027   Y 
p__Proteobacteria; f__Aeromonadaceae 423025   Y 
p__Proteobacteria; f__Aeromonadaceae 834097 Y Y  
p__Proteobacteria; f__Aeromonadaceae 837030 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 1109844 Y Y Y 
p__Proteobacteria; f__Enterobacteriaceae 1111874 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 168254 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 1935544 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 2016095 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 228556 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 2651538 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 268101 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 332958 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 3908647   Y 
p__Proteobacteria; f__Enterobacteriaceae 4439606   Y 
p__Proteobacteria; f__Enterobacteriaceae 510870 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 544824 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 588216 Y Y Y 
p__Proteobacteria; f__Enterobacteriaceae 687940 Y Y  
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p__Proteobacteria; f__Enterobacteriaceae 788593   Y 
p__Proteobacteria; f__Enterobacteriaceae 797229 Y Y Y 
p__Proteobacteria; f__Enterobacteriaceae 808486   Y 
p__Proteobacteria; f__Enterobacteriaceae 812379   Y 
p__Proteobacteria; f__Enterobacteriaceae 819636 Y Y Y 
p__Proteobacteria; f__Enterobacteriaceae 820346 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 822899 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 823118 Y Y Y 
p__Proteobacteria; f__Enterobacteriaceae 825033 Y Y  
p__Proteobacteria; f__Enterobacteriaceae 833731 Y Y Y 
p__Proteobacteria; f__Enterobacteriaceae New.CleanUp.ReferenceOTU1065258   Y 
p__Proteobacteria; f__Enterobacteriaceae New.CleanUp.ReferenceOTU226028   Y 
p__Proteobacteria; f__Enterobacteriaceae New.CleanUp.ReferenceOTU52125 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.CleanUp.ReferenceOTU648007   Y 
p__Proteobacteria; f__Enterobacteriaceae New.CleanUp.ReferenceOTU652965   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU100065   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU100205 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU100333   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU10037 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU100485   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU100937 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU100973   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU100999   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU101 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU101122   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU101818   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU101916   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU102806   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU103662   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU103828   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU105580 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU106446   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU111272   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU111780   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU112161   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU15281 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU156121   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU193868   Y 
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU19530 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU22731 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU23274 Y Y  
p__Proteobacteria; f__Enterobacteriaceae New.ReferenceOTU87048 Y Y  
p__Proteobacteria; g__Acinetobacter 562618   Y 
p__Proteobacteria; g__Acinetobacter New.ReferenceOTU104469   Y 
p__Proteobacteria; g__Actinobacillus__s__parahaemolyticus 9610 Y Y  
p__Proteobacteria; g__Aggregatibacter 92231 Y Y  
p__Proteobacteria; g__Aggregatibacter__s__segnis 4295455   Y 
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p__Proteobacteria; g__Aggregatibacter__s__segnis New.ReferenceOTU54822 Y Y  
p__Proteobacteria; g__Citrobacter 786708   Y 
p__Proteobacteria; g__Erwinia New.ReferenceOTU127469   Y 
p__Proteobacteria; g__Erwinia New.ReferenceOTU32508 Y Y  
p__Proteobacteria; g__Haemophilus__s__parainfluenzae 
New.CleanUp.ReferenceOTU280946 
Y Y  
p__Proteobacteria; g__Haemophilus__s__parainfluenzae 
New.ReferenceOTU100511 
Y Y  
p__Proteobacteria; g__Haemophilus__s__parainfluenzae 
New.ReferenceOTU100889 
Y Y  
p__Proteobacteria; g__Helicobacter__s__pylori 132837 Y Y  
p__Proteobacteria; g__Klebsiella 103166 Y Y  
p__Proteobacteria; g__Klebsiella 511908   Y 
p__Proteobacteria; g__Klebsiella 546384 Y Y  
p__Proteobacteria; g__Klebsiella 786708 Y Y  
p__Proteobacteria; g__Klebsiella 807118 Y Y  
p__Proteobacteria; g__Klebsiella 822899   Y 
p__Proteobacteria; g__Klebsiella New.CleanUp.ReferenceOTU288972 Y Y  
p__Proteobacteria; g__Klebsiella New.CleanUp.ReferenceOTU571714   Y 
p__Proteobacteria; g__Klebsiella New.ReferenceOTU101071 Y Y  
p__Proteobacteria; g__Klebsiella New.ReferenceOTU101209 Y Y  
p__Proteobacteria; g__Klebsiella New.ReferenceOTU102659 Y Y  
p__Proteobacteria; g__Klebsiella New.ReferenceOTU103022 Y Y  
p__Proteobacteria; g__Klebsiella New.ReferenceOTU103878 Y Y  
p__Proteobacteria; g__Klebsiella New.ReferenceOTU105022 Y Y  
p__Proteobacteria; g__Klebsiella New.ReferenceOTU14298 Y Y  
p__Proteobacteria; g__Klebsiella New.ReferenceOTU4524 Y Y  
p__Proteobacteria; g__Klebsiella New.ReferenceOTU57954 Y Y  
p__Proteobacteria; g__Morganella__s__morganii 631768 Y Y  
p__Proteobacteria; g__Neisseria New.CleanUp.ReferenceOTU184570 Y Y  
p__Proteobacteria; g__Neisseria New.ReferenceOTU15692 Y Y  
p__Proteobacteria; g__Neisseria New.ReferenceOTU29961 Y Y  
p__Proteobacteria; g__Proteus 4484484   Y 
p__Proteobacteria; g__Serratia 820346   Y 
p__Proteobacteria; g__Sutterella 1820513   Y 
p__Proteobacteria; g__Sutterella 189076   Y 
p__Synergistetes; g__TG5 68345 Y Y Y 
p__Verrucomicrobia; g__Akkermansia__s__muciniphila 358757 Y Y Y 
p__Verrucomicrobia; g__Akkermansia__s__muciniphila 359105   Y 
p__Verrucomicrobia; g__Akkermansia__s__muciniphila 587822   Y 
Abbreviations: c; class, f; family, g; genus, o; order, OTU; operational taxonomic unit, p; phylum s; species, Y; 
recovered in samples 
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1.7 Full Statistical Analyses for Microbiota Data 
Table 4S: Full statistical analyses for gastric biopsies from baseline to explant (FDR q assessed by linear 
regression modelling). 
Phylum FDR q Change from Baseline 
Fusobacteria 0.0048 Increase 
Synergistetes 0.04 Increase 
Firmicutes 0.7 Decrease 
Lentisphaerae 0.7 Increase 
Verrucomicrobia 0.7 Increase 
Actinobacteria 0.82 Decrease 
Bacteroidetes 0.82 Increase 
Proteobacteria 0.92 Decrease 
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Genus 
FDR q Change from 
Baseline 
Rothia 0.00024 Decrease 
Streptococcus 0.00035 Decrease 
Dialister 0.0039 Increase 
Fusobacterium 0.0039 Increase 
Unclassified Enterobacteriaceae 0.0039 Increase 
Unclassified Gammaproteobacteria 0.0039 Increase 
Lactobacillus 0.0041 Increase 
Klebsiella 0.0041 Increase 
Actinomyces 0.0048 Decrease 
Granulicatella 0.0048 Decrease 
Bifidobacterium 0.0072 Increase 
Helicobacter 0.012 Decrease 
Selenomonas 0.013 Increase 
Neisseria 0.021 Decrease 
Bulleidia 0.021 Decrease 
Erwinia 0.024 Increase 
Megasphaera 0.024 Increase 
TG5 0.024 Increase 
Unclassified Coriobacteriaceae 0.053 Increase 
Morganella 0.062 Increase 
Unclassified Aeromonadaceae 0.071 Increase 
Slackia 0.071 Increase 
Haemophilus 0.071 Decrease 
Gemella 0.13 Decrease 
Moryella 0.15 Decrease 
Unclassified Veillonellaceae 0.19 Increase 
Parvimonas 0.2 Increase 
Collinsella 0.22 Increase 
Bacteroides 0.22 Increase 
Acidaminococcus 0.22 Decrease 
Actinobacillus 0.23 Decrease 
Prevotella 0.33 Decrease 
Atopobium 0.35 Decrease 
Leptotrichia 0.4 Increase 
Enterococcus 0.47 Increase 
Cetobacterium 0.5 Increase 
Unclassified Victivallaceae 0.5 Increase 
Akkermansia 0.51 Increase 
Unclassified Lachnospiraceae 0.54 Increase 
Porphyromonas 0.54 Decrease 
Aggregatibacter 0.89 Decrease 
Veillonella 0.89 Increase 
Peptostreptococcus 1 Decrease 
Coprococcus 1 Unchanged 
Unclassified S247 NaN Unchanged 
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OTU FDR q 
Change from 
Baseline 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 0.00006 Decrease 
p__Fusobacteria__g__Fusobacterium_34791 0.000078 Increase 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU379777 0.00098 Decrease 
p__Firmicutes__g__Streptococcus__s__infantis_517754 0.00098 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.00098 Increase 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0.002 Decrease 
p__Actinobacteria__g__Actinomyces_4350499 0.002 Decrease 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 0.0022 Decrease 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.0028 Increase 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.0028 Increase 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.003 Increase 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.0037 Increase 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.0037 Increase 
p__Firmicutes__g__Lactobacillus_563654 0.0037 Increase 
p__Actinobacteria__g__Actinomyces_565136 0.0037 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.0066 Increase 
p__Firmicutes__g__Lactobacillus_574021 0.0074 Increase 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.0076 Increase 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.0076 Increase 
p__Actinobacteria__g__Bifidobacterium_4426298 0.0076 Increase 
p__Firmicutes__g__Lactobacillus_586093 0.0076 Increase 
p__Firmicutes__g__Lactobacillus_592160 0.011 Increase 
p__Proteobacteria__g__Klebsiella_786708 0.012 Increase 
p__Firmicutes__g__Lactobacillus_539647 0.015 Increase 
p__Proteobacteria__f__Enterobacteriaceae_510870 0.02 Increase 
p__Firmicutes__g__Lactobacillus_533133 0.02 Increase 
p__Firmicutes__g__Lactobacillus_331248 0.02 Increase 
p__Firmicutes__g__Lactobacillus_582884 0.021 Increase 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.021 Increase 
p__Firmicutes__g__Streptococcus_349024 0.025 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_797229 0.027 Increase 
p__Firmicutes__g__Selenomonas_4297955 0.027 Increase 
p__Proteobacteria__f__Enterobacteriaceae_1109844 0.029 Increase 
p__Firmicutes__g__Selenomonas_295019 0.029 Increase 
p__Firmicutes__g__Lactobacillus_590168 0.029 Increase 
p__Firmicutes__g__Lactobacillus_573010 0.036 Increase 
p__Proteobacteria__g__Haemophilus__s__parainfluenzae_New.Reference 
OTU100511 0.075 Decrease 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.075 Increase 
p__Firmicutes__g__Lactobacillus_340960 0.088 Increase 
p__Firmicutes__g__Lactobacillus_354225 0.11 Increase 
p__Firmicutes__g__Megasphaera_41128 0.11 Increase 
p__Actinobacteria__g__Collinsella__s__aerofaciens_1811927 0.12 Increase 
p__Actinobacteria__g__Collinsella_365181 0.12 Increase 
p__Firmicutes__g__Lactobacillus_823803 0.14 Increase 
p__Bacteroidetes__g__Prevotella__s__nigrescens_2195 0.18 Increase 
p__Fusobacteria__g__Fusobacterium_545299 0.2 Increase 
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p__Firmicutes__g__Veillonella_561537 0.26 Increase 
p__Bacteroidetes__g__Bacteroides_568118 0.31 Increase 
p__Firmicutes__g__Veillonella_518743 0.49 Decrease 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU13477 0.74 Increase 
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Table 5S: Full statistical analyses for duodenal biopsies from baseline to explant (FDR q assessed by 
linear regression modelling). 
Phylum FDR q Change from Baseline 
Fusobacteria 0.031 Increase 
Firmicutes 0.16 Decrease 
Synergistetes 0.16 Increase 
Lentisphaerae 0.34 Unchanged 
Bacteroidetes 0.45 Decrease 
Actinobacteria 0.45 Increase 
Proteobacteria 0.47 Increase 
Verrucomicrobia 1 Unchanged 
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Genus 
FDR q Change 
from 
Baseline 
Streptococcus 2.9E-07 Decrease 
Dialister 0.000031 Increase 
Haemophilus 0.0013 Decrease 
Helicobacter 0.0043 Decrease 
Lactobacillus 0.0056 Increase 
Klebsiella 0.0062 Increase 
Unclassified 
Gammaproteobacteria 0.0075 
Increase 
Gemella 0.0099 Decrease 
Bifidobacterium 0.011 Increase 
Selenomonas 0.011 Increase 
Neisseria 0.013 Decrease 
Megasphaera 0.019 Increase 
Unclassified 
Enterobacteriaceae 0.026 
Increase 
Fusobacterium 0.026 Increase 
Granulicatella 0.026 Decrease 
Bulleidia 0.033 Decrease 
Slackia 0.044 Increase 
Rothia 0.056 Decrease 
Prevotella 0.056 Decrease 
Leptotrichia 0.062 Increase 
Unclassified 
Aeromonadaceae 0.073 
Increase 
Unclassified 
Coriobacteriaceae 0.11 
Increase 
Morganella 0.11 Increase 
TG5 0.11 Increase 
Moryella 0.13 Decrease 
Actinomyces 0.13 Decrease 
Parvimonas 0.15 Increase 
Erwinia 0.15 Increase 
Collinsella 0.15 Increase 
Veillonella 0.16 Decrease 
Actinobacillus 0.17 Decrease 
Aggregatibacter 0.21 Decrease 
Unclassified 
Victivallaceae 0.22 
Unchanged 
Acidaminococcus 0.22 Decrease 
Coprococcus 0.28 Unchanged 
Porphyromonas 0.28 Decrease 
Enterococcus 0.29 Increase 
Bacteroides 0.32 Increase 
Unclassified 
Veillonellaceae 0.38 
Increase 
Cetobacterium 0.54 Increase 
Unclassified 
Lachnospiraceae 0.55 
Increase 
Atopobium 0.8 Decrease 
Genus 
FDR q Change 
from 
Baseline 
Peptostreptococcus 1 Decrease 
Akkermansia 1 Unchanged 
Unclassified S247 NaN Unchanged 
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Change from 
Baseline 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 2.8E-08 Decrease 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU379777 2.2E-06 Decrease 
p__Firmicutes__g__Streptococcus__s__infantis_517754 9.5E-06 Decrease 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 0.00014 Decrease 
p__Fusobacteria__g__Fusobacterium_34791 0.00061 Increase 
p__Firmicutes__g__Streptococcus_349024 0.00076 Decrease 
p__Proteobacteria__g__Haemophilus__s__parainfluenzae_New.Reference 
OTU100511 0.0023 Decrease 
p__Firmicutes__g__Lactobacillus_592160 0.0023 Increase 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0.0033 Decrease 
p__Proteobacteria__g__Klebsiella_786708 0.0035 Increase 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.0035 Increase 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.0035 Increase 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.0042 Increase 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.0043 Increase 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.0047 Increase 
p__Firmicutes__g__Lactobacillus_331248 0.0075 Increase 
p__Firmicutes__g__Lactobacillus_574021 0.0076 Increase 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.0079 Increase 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.0079 Increase 
p__Firmicutes__g__Lactobacillus_582884 0.012 Increase 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.012 Increase 
p__Firmicutes__g__Lactobacillus_590168 0.014 Increase 
p__Firmicutes__g__Lactobacillus_573010 0.016 Increase 
p__Firmicutes__g__Selenomonas_295019 0.017 Increase 
p__Actinobacteria__g__Bifidobacterium_4426298 0.019 Increase 
p__Proteobacteria__f__Enterobacteriaceae_510870 0.019 Increase 
p__Firmicutes__g__Selenomonas_4297955 0.022 Increase 
p__Firmicutes__g__Lactobacillus_563654 0.023 Increase 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.024 Increase 
p__Firmicutes__g__Lactobacillus_533133 0.037 Increase 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.042 Increase 
p__Firmicutes__g__Lactobacillus_340960 0.052 Increase 
p__Actinobacteria__g__Actinomyces_4350499 0.056 Decrease 
p__Firmicutes__g__Lactobacillus_539647 0.068 Increase 
p__Firmicutes__g__Megasphaera_41128 0.09 Increase 
p__Actinobacteria__g__Collinsella_365181 0.092 Increase 
p__Firmicutes__g__Lactobacillus_354225 0.092 Increase 
p__Actinobacteria__g__Collinsella__s__aerofaciens_1811927 0.11 Increase 
p__Firmicutes__g__Lactobacillus_586093 0.12 Increase 
p__Firmicutes__g__Veillonella_518743 0.12 Decrease 
p__Actinobacteria__g__Actinomyces_565136 0.17 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_797229 0.19 Increase 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.2 Increase 
p__Proteobacteria__f__Enterobacteriaceae_1109844 0.28 Increase 
p__Firmicutes__g__Lactobacillus_823803 0.29 Increase 
p__Bacteroidetes__g__Bacteroides_568118 0.48 Increase 
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OTU FDR q 
Change from 
Baseline 
p__Fusobacteria__g__Fusobacterium_545299 0.54 Increase 
p__Bacteroidetes__g__Prevotella__s__nigrescens_2195 0.6 Increase 
p__Firmicutes__g__Veillonella_561537 0.69 Increase 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU13477 0.99 Increase 
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Table 6S: Full statistical analyses for mucosal adjacent device surface compared to luminal adjacent 
device surface (FDR q assessed by linear regression modelling). 
Phylum FDR q 
Proteobacteria 0.00031 
Synergistetes 0.028 
Firmicutes 0.14 
Verrucomicrobia 0.48 
Bacteroidetes 0.75 
Actinobacteria 0.79 
Lentisphaerae 0.79 
Fusobacteria 0.9 
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Genus FDR q 
Klebsiella 0.00009 
Streptococcus 0.00009 
Atopobium 0.000097 
Unclassified.cGammaproteobacteria 0.00028 
Parvimonas 0.00031 
Unclassified.Coriobacteriaceae 0.00052 
Prevotella 0.0011 
Porphyromonas 0.0011 
Bacteroides 0.0032 
Slackia 0.0032 
Megasphaera 0.0047 
Veillonella 0.0047 
Bulleidia 0.0053 
Rothia 0.0071 
Gemella 0.0075 
Unclassified.Enterobacteriaceae 0.012 
Actinomyces 0.014 
TG5 0.016 
Peptostreptococcus 0.032 
Morganella 0.037 
Cetobacterium 0.092 
Unclassified.Lachnospiraceae 0.12 
Leptotrichia 0.12 
Lactobacillus 0.12 
Granulicatella 0.19 
Unclassified.Veillonellaceae 0.22 
Helicobacter 0.24 
Aggregatibacter 0.25 
Neisseria 0.28 
Akkermansia 0.34 
Bifidobacterium 0.4 
Dialister 0.64 
Moryella 0.64 
Unclassified.Victivallaceae 0.84 
Collinsella 0.84 
Unclassified.Aeromonadaceae 0.84 
Actinobacillus 0.84 
Selenomonas 0.84 
Erwinia 0.84 
Acidaminococcus 0.88 
Haemophilus 0.89 
Enterococcus 0.99 
Fusobacterium 0.99 
Unclassified.S247 NaN 
Coprococcus NaN 
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OTU FDR q 
p__Proteobacteria__g__Klebsiella_786708 4.1E-06 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.000048 
p__Firmicutes__g__Lactobacillus_331248 0.00017 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.00032 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.00037 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.00037 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.00037 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.00037 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 0.00089 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.0018 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.0023 
p__Firmicutes__g__Streptococcus_349024 0.0032 
p__Fusobacteria__g__Fusobacterium_545299 0.0032 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU13477 0.0032 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0.0043 
p__Firmicutes__g__Lactobacillus_582884 0.0066 
p__Firmicutes__g__Lactobacillus_354225 0.0066 
p__Bacteroidetes__g__Prevotella__s__nigrescens_2195 0.0066 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.0066 
p__Firmicutes__g__Veillonella_561537 0.008 
p__Firmicutes__g__Lactobacillus_533133 0.012 
p__Firmicutes__g__Lactobacillus_539647 0.013 
p__Firmicutes__g__Lactobacillus_573010 0.013 
p__Firmicutes__g__Lactobacillus_586093 0.013 
p__Firmicutes__g__Veillonella_518743 0.013 
p__Bacteroidetes__g__Bacteroides_568118 0.013 
p__Firmicutes__g__Lactobacillus_574021 0.014 
p__Firmicutes__g__Lactobacillus_340960 0.021 
p__Firmicutes__g__Lactobacillus_590168 0.022 
p__Actinobacteria__g__Actinomyces_4350499 0.03 
p__Firmicutes__g__Streptococcus__s__infantis_517754 0.034 
p__Firmicutes__g__Lactobacillus_823803 0.039 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 0.039 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU379777 0.084 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.11 
p__Firmicutes__g__Megasphaera_41128 0.12 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.13 
p__Actinobacteria__g__Actinomyces_565136 0.13 
p__Actinobacteria__g__Bifidobacterium_4426298 0.14 
p__Firmicutes__g__Selenomonas_295019 0.19 
p__Firmicutes__g__Lactobacillus_592160 0.22 
p__Actinobacteria__g__Collinsella_365181 0.33 
p__Proteobacteria__f__Enterobacteriaceae_797229 0.35 
p__Firmicutes__g__Selenomonas_4297955 0.38 
p__Proteobacteria__f__Enterobacteriaceae_1109844 0.4 
p__Proteobacteria__g__Haemophilus__s__parainfluenzae_New.ReferenceOTU100511 0.62 
p__Proteobacteria__f__Enterobacteriaceae_510870 0.69 
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OTU FDR q 
p__Actinobacteria__g__Collinsella__s__aerofaciens_1811927 0.79 
p__Firmicutes__g__Lactobacillus_563654 0.87 
p__Fusobacteria__g__Fusobacterium_34791 0.91 
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Table 7S: Full statistical analyses for top mucosal adjacent device surface compared to explant duodenal 
biopsy (FDR q assessed by linear regression modelling). 
Phylum FDR q Compared to Device 
Bacteroidetes 0.00025 Increase 
Fusobacteria 0.00025 Increase 
Synergistetes 0.0026 Increase 
Proteobacteria 0.028 Decrease 
Actinobacteria 0.35 Decrease 
Verrucomicrobia 0.35 Increase 
Lentisphaerae 0.35 Decrease 
Firmicutes 0.41 Increase 
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Genus 
FDR q Compared 
to Device 
Prevotella 4.4E-09 Increase 
Parvimonas 3.1E-08 Increase 
Streptococcus 1.4E-06 Increase 
Bulleidia 0.00002 Increase 
Porphyromonas 0.000038 Increase 
Veillonella 0.000043 Increase 
Dialister 0.000057 Increase 
Atopobium 0.00006 Increase 
Selenomonas 0.00011 Increase 
Actinomyces 0.00016 Increase 
Granulicatella 0.00024 Increase 
Fusobacterium 0.00032 Increase 
Peptostreptococcus 0.00081 Increase 
Haemophilus 0.0022 Increase 
TG5 0.0029 Increase 
Rothia 0.0061 Increase 
Gemella 0.0067 Increase 
Erwinia 0.0083 Decrease 
Slackia 0.016 Increase 
Leptotrichia 0.017 Increase 
Neisseria 0.021 Increase 
Unclassified 
Aeromonadaceae 0.024 
Increase 
Unclassified 
Enterobacteriaceae 0.024 
Decrease 
Moryella 0.024 Increase 
Klebsiella 0.026 Decrease 
Bifidobacterium 0.037 Decrease 
Actinobacillus 0.051 Increase 
Megasphaera 0.071 Increase 
Unclassified 
Coriobacteriaceae 0.2 
Increase 
Helicobacter 0.2 Decrease 
Coprococcus 0.2 Increase 
Enterococcus 0.2 Decrease 
Cetobacterium 0.2 Increase 
Unclassified 
Veillonellaceae 0.21 
Increase 
Bacteroides 0.25 Decrease 
Unclassified 
Gammaproteobacteria 0.29 
Decrease 
Unclassified 
Lachnospiraceae 0.29 
Decrease 
Morganella 0.29 Increase 
Akkermansia 0.29 Increase 
Lactobacillus 0.31 Decrease 
Unclassified 
Victivallaceae 0.32 
Decrease 
Genus 
FDR q Compared 
to Device 
Acidaminococcus 0.32 Decrease 
Collinsella 0.35 Decrease 
Aggregatibacter 0.4 Increase 
Unclassified S247 NaN Unchanged 
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OTU FDR Compared to Device 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 0.00006 Increased 
p__Actinobacteria__g__Actinomyces_4350499 0.00006 Increased 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU379777 0.00008 Increased 
p__Bacteroidetes__g__Prevotella__s__nigrescens_2195 0.00017 Increased 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 0.00017 Increased 
p__Firmicutes__g__Veillonella_561537 0.00017 Increased 
p__Firmicutes__g__Streptococcus_349024 0.00017 Increased 
p__Firmicutes__g__Streptococcus__s__infantis_517754 0.00017 Increased 
p__Actinobacteria__g__Actinomyces_565136 0.0002 Increased 
p__Firmicutes__g__Veillonella_518743 0.00024 Increased 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.00034 Increased 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0.00071 Increased 
p__Proteobacteria__g__Haemophilus__s__parainfluenzae_New.Reference 
OTU100511 0.00081 Increased 
p__Fusobacteria__g__Fusobacterium_34791 0.001 Increased 
p__Fusobacteria__g__Fusobacterium_545299 0.001 Increased 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU13477 0.001 Increased 
p__Firmicutes__g__Selenomonas_295019 0.0013 Increased 
p__Firmicutes__g__Selenomonas_4297955 0.0047 Increased 
p__Proteobacteria__g__Klebsiella_786708 0.0068 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.011 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.011 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.014 Decreased 
p__Actinobacteria__g__Bifidobacterium_4426298 0.022 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.023 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.026 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.029 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_510870 0.063 Decreased 
p__Firmicutes__g__Lactobacillus_340960 0.07 Decreased 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.1 Decreased 
p__Firmicutes__g__Lactobacillus_539647 0.11 Decreased 
p__Firmicutes__g__Lactobacillus_533133 0.16 Decreased 
p__Firmicutes__g__Lactobacillus_586093 0.23 Decreased 
p__Firmicutes__g__Lactobacillus_823803 0.26 Decreased 
p__Firmicutes__g__Lactobacillus_563654 0.29 Decreased 
p__Firmicutes__g__Lactobacillus_574021 0.3 Decreased 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.35 Decreased 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.35 Decreased 
p__Firmicutes__g__Lactobacillus_590168 0.38 Decreased 
p__Firmicutes__g__Lactobacillus_582884 0.49 Increased 
p__Firmicutes__g__Lactobacillus_331248 0.5 Decreased 
p__Firmicutes__g__Megasphaera_41128 0.5 Increased 
p__Firmicutes__g__Lactobacillus_592160 0.51 Increased 
p__Proteobacteria__f__Enterobacteriaceae_797229 0.51 Decreased 
p__Bacteroidetes__g__Bacteroides_568118 0.53 Decreased 
p__Actinobacteria__g__Collinsella__s__aerofaciens_1811927 0.61 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.75 Decreased 
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OTU FDR Compared to Device 
p__Firmicutes__g__Lactobacillus_354225 0.82 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_1109844 0.85 Increased 
p__Firmicutes__g__Lactobacillus_573010 0.98 Decreased 
p__Actinobacteria__g__Collinsella_365181 0.98 Decreased 
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Table 8S: Full statistical analyses for top mucosal adjacent device surface compared to baseline duodenal 
biopsy (FDR q assessed by linear regression modelling). 
Phylum FDR q 
Compared to 
Device 
Bacteroidetes 0.035 Increase 
Proteobacteria 0.24 Decrease 
Firmicutes 0.24 Increase 
Synergistetes 0.24 Increase 
Actinobacteria 0.36 Decrease 
Lentisphaerae 0.36 Decrease 
Fusobacteria 0.43 Decrease 
Verrucomicrobia 0.95 Unchanged 
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Genus FDR q 
Compared to 
Device 
Streptococcus 0 Increase 
Prevotella 1.7E-13 Increase 
Gemella 4.2E-11 Increase 
Haemophilus 3.5E-06 Increase 
Rothia 3.5E-06 Increase 
Granulicatella 3.5E-06 Increase 
Atopobium 9.8E-06 Increase 
Actinomyces 0.000011 Increase 
Neisseria 0.00012 Increase 
Porphyromonas 0.00023 Increase 
Bulleidia 0.00023 Increase 
Peptostreptococcus 0.0003 Increase 
Veillonella 0.00043 Increase 
Unclassified.Enterobacteriaceae 0.00043 Decrease 
Moryella 0.00086 Increase 
Klebsiella 0.00089 Decrease 
Helicobacter 0.0014 Increase 
Parvimonas 0.005 Increase 
Unclassified.cGammaproteobacteria 0.005 Decrease 
Lactobacillus 0.01 Decrease 
Erwinia 0.033 Decrease 
Actinobacillus 0.035 Increase 
Bifidobacterium 0.045 Decrease 
Dialister 0.091 Decrease 
Morganella 0.11 Decrease 
Unclassified.Aeromonadaceae 0.13 Decrease 
TG5 0.18 Increase 
Acidaminococcus 0.18 Increase 
Collinsella 0.21 Decrease 
Megasphaera 0.22 Decrease 
Aggregatibacter 0.25 Increase 
Enterococcus 0.26 Decrease 
Slackia 0.27 Decrease 
Bacteroides 0.29 Decrease 
Selenomonas 0.37 Decrease 
Unclassified.Coriobacteriaceae 0.41 Decrease 
Unclassified.Lachnospiraceae 0.56 Decrease 
Cetobacterium 0.6 Decrease 
Leptotrichia 0.64 Decrease 
Fusobacterium 0.64 Decrease 
Unclassified.Veillonellaceae 0.71 Increase 
Akkermansia 0.97 Unchanged 
Unclassified.Victivallaceae 1 Unchanged 
Unclassified.S247 NaN Unchanged 
Coprococcus NaN Unchanged 
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OTU FDR q 
Compared to 
Device 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU100710 0 Increase 
p__Firmicutes__g__Streptococcus_New.CleanUp.ReferenceOTU379777 0 Increase 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU32130 0 Increase 
p__Firmicutes__g__Streptococcus__s__infantis_517754 6.2E-14 Increase 
p__Bacteroidetes__g__Prevotella__s__melaninogenica_535359 2.3E-12 Increase 
p__Firmicutes__g__Streptococcus_349024 8.1E-09 Increase 
p__Actinobacteria__g__Actinomyces_565136 1E-07 Increase 
p__Actinobacteria__g__Actinomyces_4350499 1.1E-06 Increase 
p__Proteobacteria__g__Haemophilus__s__parainfluenzae_ 
New.ReferenceOTU100511 1.6E-06 Increase 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.000035 Decrease 
p__Bacteroidetes__g__Prevotella__s__nigrescens_2195 0.000095 Increase 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.00022 Decrease 
p__Firmicutes__g__Veillonella_518743 0.00046 Increase 
p__Firmicutes__g__Streptococcus_New.ReferenceOTU13477 0.00075 Increase 
p__Proteobacteria__f__Enterobacteriaceae_228556 0.00097 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_822899 0.00097 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_2016095 0.001 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_332958 0.0011 Decrease 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU102659 0.0013 Decrease 
p__Fusobacteria__g__Fusobacterium_545299 0.0018 Increase 
p__Proteobacteria__g__Klebsiella_786708 0.0029 Decrease 
p__Proteobacteria__g__Klebsiella_New.ReferenceOTU14298 0.0036 Decrease 
p__Proteobacteria__c__Gammaproteobacteria_808486 0.0048 Decrease 
p__Firmicutes__g__Lactobacillus_592160 0.013 Decrease 
p__Firmicutes__g__Lactobacillus_331248 0.024 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_510870 0.032 Decrease 
p__Firmicutes__g__Lactobacillus_590168 0.032 Decrease 
p__Firmicutes__g__Lactobacillus_533133 0.032 Decrease 
p__Firmicutes__g__Lactobacillus_539647 0.033 Decrease 
p__Firmicutes__g__Veillonella_561537 0.033 Increase 
p__Firmicutes__g__Lactobacillus_574021 0.034 Decrease 
p__Bacteroidetes__g__Prevotella__s__tannerae_38227 0.038 Increase 
p__Firmicutes__g__Lactobacillus_563654 0.038 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.038 Decrease 
p__Firmicutes__g__Lactobacillus_340960 0.043 Decrease 
p__Actinobacteria__g__Bifidobacterium_4426298 0.044 Decrease 
p__Firmicutes__g__Lactobacillus_582884 0.083 Decrease 
p__Firmicutes__g__Lactobacillus_573010 0.083 Decrease 
p__Fusobacteria__g__Fusobacterium_34791 0.083 Decrease 
p__Firmicutes__g__Selenomonas_4297955 0.12 Decrease 
p__Firmicutes__g__Megasphaera_41128 0.12 Decrease 
p__Actinobacteria__g__Collinsella_365181 0.14 Decrease 
p__Actinobacteria__g__Collinsella__s__aerofaciens_1811927 0.17 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_797229 0.18 Decrease 
p__Firmicutes__g__Lactobacillus_354225 0.19 Decrease 
p__Firmicutes__g__Lactobacillus_586093 0.24 Decrease 
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OTU FDR q 
Compared to 
Device 
p__Firmicutes__g__Lactobacillus_823803 0.32 Decrease 
p__Proteobacteria__f__Enterobacteriaceae_1109844 0.39 Decrease 
p__Firmicutes__g__Selenomonas_295019 0.45 Decrease 
p__Bacteroidetes__g__Bacteroides_568118 0.45 Decrease 
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Table 9S: Full statistical analyses for eight weeks post-implant stool samples compared to baseline (FDR 
q assessed by linear regression modelling). 
Phylum FDR q Change from Baseline 
Fusobacteria 0.0041 Increased 
Proteobacteria 0.0041 Increased 
Unclassified Bacteria 0.053 Increased 
Bacteroidetes 0.12 Decreased 
Verrucomicrobia 0.34 Increased 
Synergistetes 0.34 Increased 
Lentisphaerae 0.34 Increased 
Actinobacteria 0.68 Decreased 
Firmicutes 0.68 Increased 
Euryarchaeota 0.83 Decreased 
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Genus 
FDR q Compared to 
Baseline 
Citrobacter 
0.0000
24 
Increased 
Enterococcus 
0.0000
24 
Increased 
Bifidobacterium 0.0025 Increased 
Unclassified 
Clostridiaceae 0.0025 
Increased 
Fusobacterium 0.0025 Increased 
Lactobacillus 0.0025 Increased 
Clostridium 0.0025 Increased 
Serratia 0.0037 Increased 
Acinetobacter 0.0059 Increased 
Unclassified 
Lachnospiraceae 0.0086 
Decreased 
Unclassified 
Enterobacteriaceae 0.013 
Increased 
Klebsiella 0.013 Increased 
Veillonella 0.019 Increased 
Unclassified 
Gammaproteobacteria 0.025 
Increased 
Unclassified Bacteria 0.048 Increased 
Erwinia 0.048 Increased 
Streptococcus 0.059 Increased 
Unclassified 
Clostridiales 0.088 
Decreased 
Blautia 0.088 Decreased 
Sutterella 0.15 Decreased 
Coprococcus 0.16 Increased 
Selenomonas 0.16 Increased 
Unclassified 
Erysipelotrichaceae 0.16 
Decreased 
Unclassified 
Coriobacteriaceae 0.16 
Decreased 
Unclassified 
Aeromonadaceae 0.16 
Increased 
Parvimonas 0.16 Increased 
Bacteroides 0.2 Decreased 
Faecalibacterium 0.22 Decreased 
Proteus 0.22 Increased 
Collinsella 0.26 Decreased 
Parabacteroides 0.29 Decreased 
Akkermansia 0.29 Increased 
Unclassified 
Ruminococcaceae 0.32 
Decreased 
TG5 0.32 Increased 
Unclassified 
Victivallaceae 0.32 
Increased 
Dysgonomonas 0.32 Increased 
Eubacterium 0.39 Decreased 
Unclassified.S247 0.39 Decreased 
Prevotella 0.39 Decreased 
Leptotrichia 0.53 Unchanged 
Genus 
FDR q Compared to 
Baseline 
Adlercreutzia 0.54 Increased 
Dorea 0.54 Decreased 
Ruminococcus 0.57 Decreased 
Dialister 0.61 Increased 
Methanobrevibacter 0.89 Decreased 
Catenibacterium 0.9 Increased 
Megasphaera 0.91 Decreased 
Acidaminococcus 0.93 Increased 
Cetobacterium NaN Unchanged 
Aggregatibacter NaN Unchanged 
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OTU FDR q Compared to baseline 
p__Proteobacteria__g__Citrobacter_786708 0.00005 Increased 
p__Proteobacteria__f__Enterobacteriaceae_819636 0.0006 Increased 
p__Actinobacteria__g__Bifidobacterium_4426298 0.003 Increased 
p__Firmicutes__g__Lactobacillus_563654 0.0032 Increased 
p__Fusobacteria__g__Fusobacterium_545299 0.0033 Increased 
p__Firmicutes__g__Lactobacillus_582884 0.0036 Increased 
p__Firmicutes__g__Lactobacillus_329402 0.0036 Increased 
p__Firmicutes__g__Lactobacillus_549756 0.0036 Increased 
p__Firmicutes__f__Lachnospiraceae_New.CleanUp.ReferenceOTU93368 0.0041 Decreased 
p__Firmicutes__f__Lachnospiraceae_New.ReferenceOTU100192 0.0041 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_New.ReferenceOTU100973 0.0041 Increased 
p__Firmicutes__g__Lactobacillus_New.CleanUp.ReferenceOTU388917 0.0079 Increased 
p__Firmicutes__g__Lactobacillus_586093 0.0088 Increased 
p__Proteobacteria__f__Enterobacteriaceae_823118 0.0093 Increased 
p__Firmicutes__g__Veillonella__s__parvula_518743 0.0093 Increased 
p__Proteobacteria__g__Klebsiella_822899 0.011 Increased 
p__Firmicutes__g__Lactobacillus_539647 0.011 Increased 
p__Firmicutes__g__Lactobacillus_590168 0.014 Increased 
p__Firmicutes__f__Lachnospiraceae_369709 0.014 Decreased 
p__Firmicutes__o__Clostridiales_470382 0.016 Decreased 
p__Firmicutes__g__Lactobacillus_725198 0.017 Increased 
p__Proteobacteria__f__Enterobacteriaceae_812379 0.02 Increased 
p__Firmicutes__g__Streptococcus_516966 0.02 Increased 
p__Firmicutes__g__Lactobacillus_340960 0.02 Increased 
p__Firmicutes__g__Lactobacillus_New.ReferenceOTU100589 0.02 Increased 
p__Firmicutes__g__Veillonella__s__parvula_4352537 0.021 Increased 
p__Firmicutes__f__Lachnospiraceae_New.CleanUp.ReferenceOTU1164950 0.028 Decreased 
p__Firmicutes__g__Lactobacillus_823803 0.043 Increased 
p__Firmicutes__g__Lactobacillus_331248 0.043 Increased 
p__Firmicutes__g__Veillonella_2283862 0.052 Increased 
p__Bacteroidetes__g__Bacteroides_323231 0.069 Decreased 
p__Firmicutes__g__Megasphaera_41128 0.072 Increased 
p__Firmicutes__g__Lactobacillus_354225 0.073 Increased 
p__Firmicutes__f__Lachnospiraceae_New.ReferenceOTU100062 0.085 Decreased 
p__Firmicutes__f__Ruminococcaceae_New.CleanUp.ReferenceOTU926888 0.097 Decreased 
p__Bacteroidetes__g__Bacteroides_568118 0.099 Decreased 
p__Firmicutes__g__Lactobacillus_581474 0.099 Increased 
p__Actinobacteria__f__Coriobacteriaceae_196140 0.12 Decreased 
p__Actinobacteria__g__Collinsella_193575 0.13 Decreased 
p__Firmicutes__g__Lactobacillus_354971 0.21 Increased 
p__Firmicutes__g__Blautia_532203 0.22 Decreased 
p__Bacteroidetes__g__Parabacteroides__s__distasonis_577294 0.23 Decreased 
p__Firmicutes__g__Blautia_New.CleanUp.ReferenceOTU30692 0.23 Decreased 
p__Firmicutes__g__Blautia_367790 0.26 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_588216 0.27 Increased 
p__Actinobacteria__g__Collinsella_365181 0.27 Decreased 
p__Proteobacteria__f__Enterobacteriaceae_797229 0.47 Increased 
 314 
 
OTU FDR q Compared to baseline 
p__Bacteroidetes__g__Bacteroides_326626 0.62 Decreased 
p__Firmicutes__g__Ruminococcus_333096 0.68 Decreased 
p__Bacteroidetes__g__Bacteroides_364029 0.73 Decreased 
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Table 10S: Full statistical analyses for eight weeks post-implant stool samples compared to explant (FDR 
q assessed by linear regression modelling). 
Phylum FDR q Change from 8 weeks 
Fusobacteria 0.11 Decreased 
Unclassified Bacteria 0.11 Decreased 
Bacteroidetes 0.11 Decreased 
Proteobacteria 0.11 Decreased 
Verrucomicrobia 0.15 Decreased 
Euryarchaeota 0.34 Increased 
Firmicutes 0.34 Increased 
Lentisphaerae 0.42 Decreased 
Actinobacteria 0.42 Increased 
Synergistetes 0.42 Increased 
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Genus 
FDR q Compared 
to 8 weeks 
Enterococcus 0.0098 Decreased 
Lactobacillus 0.017 Decreased 
Bifidobacterium 0.018 Decreased 
Fusobacterium 0.031 Decreased 
Unclassified 
Enterobacteriaceae 0.044 
Decreased 
Citrobacter 0.072 Decreased 
Veillonella 0.084 Decreased 
Unclassified 
Gammaproteobacteria 0.085 
Decreased 
Erwinia 0.085 Decreased 
Unclassified 
Lachnospiraceae 0.085 
Increased 
Unclassified 
Ruminococcaceae 0.085 
Increased 
Unclassified Bacteria 0.13 Decreased 
Acinetobacter 0.14 Decreased 
Serratia 0.16 Decreased 
Unclassified 
Erysipelotrichaceae 0.21 
Increased 
Megasphaera 0.21 Decreased 
Akkermansia 0.21 Decreased 
Selenomonas 0.22 Decreased 
Unclassified Clostridiales 0.26 Increased 
Unclassified 
Aeromonadaceae 0.4 
Decreased 
Parvimonas 0.4 Decreased 
Ruminococcus 0.43 Increased 
Proteus 0.43 Decreased 
Blautia 0.43 Increased 
Genus 
FDR q Compared 
to 8 weeks 
Parabacteroides 0.43 Decreased 
Methanobrevibacter 0.43 Increased 
Acidaminococcus 0.44 Decreased 
Collinsella 0.44 Increased 
Klebsiella 0.51 Decreased 
Catenibacterium 0.52 Decreased 
Adlercreutzia 0.52 Increased 
Dialister 0.52 Decreased 
Unclassified 
Victivallaceae 0.52 
Decreased 
Clostridium 0.54 Decreased 
Leptotrichia 0.54 Increased 
Unclassified.S247 0.54 Decreased 
TG5 0.56 Increased 
Eubacterium 0.64 Decreased 
Bacteroides 0.64 Decreased 
Dorea 0.64 Decreased 
Unclassified 
Clostridiaceae 0.65 
Decreased 
Faecalibacterium 0.75 Increased 
Streptococcus 0.77 Increased 
Unclassified 
Coriobacteriaceae 0.77 
Increased 
Coprococcus 0.78 Decreased 
Sutterella 0.84 Increased 
Prevotella 0.87 Decreased 
Dysgonomonas 0.97 Increased 
Cetobacterium 1 Increased 
Aggregatibacter NaN Unchanged 
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Table 11S: KEGG ortholog pathways that were significantly different between the gastric biopsies of 
DJBS patients at explant, compared to control patients. 
Pathways that were significantly 
higher in DJBS at explant FDR q 
Other transporters 0.00057 
Pertussis 0.00057 
Biosynthesis of unsaturated fatty 
acids 0.00057 
Bile secretion 0.00057 
Phenylalanine metabolism 0.00057 
Transcription related proteins 0.00057 
Prion diseases 0.00057 
Geraniol degradation 0.00057 
Carotenoid biosynthesis 0.00067 
Shigellosis 0.00067 
Fluorobenzoate degradation 0.00067 
Other ion-coupled transporters 0.00067 
Lipid metabolism 0.00074 
Beta-alanine metabolism 0.00088 
Vibrio cholerae infection 0.00095 
Metabolism of cofactors and vitamins 0.001 
Caprolactam degradation 0.001 
Pores ion channels 0.0014 
Amino acid metabolism 0.0014 
Fatty acid metabolism 0.0014 
Pentose and glucoronate 
interconversions 0.0015 
Function unknown 0.0015 
Secondary bile acid biosynthesis 0.0015 
Primary bile acid biosynthesis 0.0015 
Phenylpropanoid biosynthesis 0.0015 
Chlorocyclohexane and 
chlorobenzene degradation 0.0015 
Ethylbenzene degradation 0.0024 
Bacterial invasion of epithelial cells 0.0024 
Tyrosine metabolism 0.0036 
Glycan biosynthesis and metabolism 0.0037 
Drug metabolism – cytochrome P450 0.0037 
Limonene and pinene degradation 0.0037 
Retinol metabolism 0.0037 
Metabolism of xenobiotics by 
cytochrome P450 0.0037 
Transcription factors 0.0037 
Nucleotide metabolism 0.0037 
Biosynthesis of siderophore group 
nonribosomal peptides 0.004 
Toluene degradation 0.0057 
Inorganic ion transport and 
metabolism 0.0057 
African trypanosomiasis 0.0063 
Aminobenzoate degradation 0.0064 
Pathways that were significantly 
higher in DJBS at explant FDR q 
Chagas disease American 
trypanosomiasis. 0.0069 
Signal transduction mechanisms 0.0077 
Butanoate metabolism 0.0079 
Glutathione metabolism 0.009 
Alpha-linolenic acid metabolism 0.0099 
Flagellar assembly 0.011 
Membrane and intracellular structural 
molecules 0.014 
Biosynthesis and biodegradation of 
secondary metabolites 0.017 
Two component system 0.018 
Chloroalkane and chloroalkene 
degradation 0.021 
Others 0.021 
Energy metabolism 0.022 
Ascorbate and aldarate metabolism 0.023 
Bacterial motility proteins 0.024 
Carbohydrate metabolism 0.024 
Starch and sucrose metabolism 0.026 
Styrene degradation 0.028 
Vibrio cholerae pathogenic cycle 0.029 
Tropane piperidine and pyridine 
alkaloid biosynthesis 0.029 
Lysine degradation 0.031 
Bacterial chemotaxis 0.031 
Electron transfer carriers 0.033 
Protein kinases 0.034 
Isoquinoline alkaloid biosynthesis 0.034 
Inositol phosphate metabolism 0.037 
Atrazine degradation 0.039 
Glyoxylate and dicarboxylate 
metabolism 0.043 
Valine leucine and isoleucine 
degradation 0.044 
Lipopolysaccharide biosynthesis 
proteins 0.044 
Tryptophan metabolism 0.047 
Cyanoamino acid metabolism 0.049 
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Pathways that were significantly lower 
in DJBS at explant FDR q 
Protein export 0.00057 
Bacterial toxins 0.00057 
Phenylalanine tyrosine and tryptophan 
biosynthesis 0.00057 
Polycyclic aromatic hydrocarbon 
degradation 0.00057 
Phosphatidylinositol signalling system 0.00067 
Aminoacyl tRNA biosynthesis 0.00067 
Ribosome biogenesis in eukaryotes 0.00067 
Pantothenate and CoA biosynthesis 0.00069 
Lysine biosynthesis 0.00093 
Photosynthesis 0.001 
Photosynthesis proteins 0.001 
Nucleotide excision repair 0.0011 
Type 1 diabetes mellitus 0.0012 
RNA polymerase 0.0012 
Folate biosynthesis 0.0012 
Restriction enzyme 0.0014 
Base excision repair 0.0016 
Ribosome 0.0019 
Thiamine metabolism 0.002 
Meiosis – yeast 0.0021 
DNA replication 0.0023 
Taurine and hypotaurine metabolism 0.0024 
Primary immunodeficiency 0.003 
Ribosome Biogenesis 0.003 
Mismatch repair 0.0032 
Amino acid related enzymes 0.0032 
Ether lipid metabolism 0.0037 
Terpenoid backbone biosynthesis 0.0037 
D-alanine metabolism 0.0037 
Homologous recombination 0.0037 
DNA replication proteins 0.0037 
Cysteine and methionine metabolism 0.0043 
D-glutamine and D-glutamate 
metabolism 0.0049 
Amoebiasis 0.0052 
Cell cycle – Caulobacter 0.0064 
Butirosin and neomycin biosynthesis 0.0064 
Pyrimidine metabolism 0.0074 
Translation factors 0.0092 
Apoptosis 0.011 
DNA repair and recombination proteins 0.011 
RNA degradation 0.011 
Tuberculosis 0.012 
Alzheimer’s disease 0.013 
Peptidoglycan biosynthesis 0.013 
Pathways that were significantly lower 
in DJBS at explant FDR q 
Purine metabolism 0.014 
Flavone and flavonol biosynthesis 0.023 
Penicillin and cephalosporin biosynthesis 0.024 
Selenocompound metabolism 0.029 
Prenyltransferases 0.029 
Basal transcription factors 0.031 
Sporulation 0.034 
Translation proteins 0.037 
Protein folding and associated processing 0.041 
Zeatin biosynthesis 0.045 
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Table 12S: KEGG ortholog pathways that were significantly different between the duodenal biopsies of 
DJBS patients at explant, compared to control patients. 
 
Pathways that were significantly 
higher in DJBS at explant FDR q 
Shigellosis 0.000074 
Bacterial motility proteins 0.0001 
Vibrio cholerae infection 0.0001 
Flagellar assembly 0.0001 
Bacterial chemotaxis 0.0002 
Alpha linolenic acid metabolism 0.00032 
Fluorobenzoate degradation 0.00033 
Tyrosine metabolism 0.00033 
Metabolism of cofactors and vitamins 0.00033 
Lipid metabolism 0.00033 
Styrene degradation 0.00035 
Other transporters 0.00043 
Transcription related proteins 0.00047 
Bile secretion 0.00047 
Secondary bile acid biosynthesis 0.00047 
Primary bile acid biosynthesis 0.00047 
Phenylalanine metabolism 0.00047 
Flavonoid biosynthesis 0.00067 
Caprolactam degradation 0.00067 
Chlorocyclohexane and chlorobenzene 
degradation 0.00067 
Fatty acid metabolism 0.00067 
Other ion-coupled transporters 0.00067 
Carotenoid biosynthesis 0.00067 
Atrazine degradation 0.00067 
Metabolism of xenobiotics by 
cytochrome P450 0.00067 
Biosynthesis and biodegradation of 
secondary metabolites 0.00067 
Phenylpropanoid biosynthesis 0.00069 
Drug metabolism – cytochrome P450 0.00073 
Replication, recombination and repair 
proteins 0.00077 
Pentose and glucoronate 
interconversions 0.0008 
Two component system 0.00082 
Propanoate metabolism 0.00082 
Transcription factors 0.0009 
Limonene and pinene degradation 0.001 
Electron transfer carriers 0.0012 
Secretion system 0.0013 
Chloroalkane and chloroalkene 
degradation 0.0013 
Function unknown 0.0013 
Pathways that were significantly 
higher in DJBS at explant FDR q 
Synthesis and degradation of ketone 
bodies 0.0014 
Pertussis 0.0014 
Prion diseases 0.0019 
Tryptophan metabolism 0.002 
Benzoate degradation 0.0027 
Ethylbenzene degradation 0.0032 
Butanoate metabolism 0.0037 
Cyanoamino acid metabolism 0.0039 
Signal transduction mechanisms 0.0041 
Biosynthesis of unsaturated fatty acids 0.0041 
Retinol metabolism 0.0042 
Bacterial secretion system 0.0042 
Bacterial invasion of epithelial cells 0.0048 
Glycan biosynthesis and metabolism 0.0049 
Geraniol degradation 0.0049 
Amino acid metabolism 0.0052 
Sulfur relay system 0.0071 
Nucleotide metabolism 0.0088 
Glyoxylate and dicarboxylate 
metabolism 0.009 
Inorganic ion transport and metabolism 0.0092 
Glutathione metabolism 0.0098 
Naphthalene degradation 0.01 
Vibrio cholerae pathogenic cycle 0.011 
X 1.1.1-trichloro-2-2-bis (4-
chlorophenyl) ethane (DDT) 
degradation 0.015 
Phosphotransferase system - PTS. 0.015 
Lysine degradation 0.016 
ABC transporters 0.019 
Others 0.022 
Nitrotoluene degradation 0.022 
Biosynthesis of siderophore group 
nonribosomal peptides 0.023 
Beta-alanine metabolism 0.028 
Ascorbate and aldarate metabolism 0.028 
Arginine and proline metabolism 0.03 
Parkinson’s disease 0.038 
Cardiac muscle contraction 0.038 
Aminobenzoate degradation 0.038 
Bisphenol degradation 0.043 
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Pathways that were significantly 
lower in DJBS at explant FDR q 
Folate biosynthesis 0.000048 
Pantothenate and CoA biosynthesis 0.000048 
Ribosome Biogenesis 0.000048 
Phenylalanine tyrosine and tryptophan 
biosynthesis 0.000048 
Protein export 0.0001 
Homologous recombination 0.00013 
Ribosome biogenesis in eukaryotes 0.00019 
DNA replication 0.00043 
Drug metabolism – other enzymes 0.00047 
Peptidoglycan biosynthesis 0.00052 
Primary immunodeficiency 0.00052 
One carbon pool by folate 0.00057 
Translation proteins 0.00067 
DNA replication proteins 0.00067 
Peroxisome 0.00067 
Meiosis - yeast 0.00067 
Ribosome 0.00067 
Glycine serine and threonine 
metabolism 0.00067 
Lysosome 0.00069 
DNA repair and recombination proteins 0.00075 
Adipocytokine signalling pathway 0.00075 
Amino acid related enzymes 0.00077 
RNA degradation 0.00085 
Bacterial toxins 0.00088 
Glycosphingolipid biosynthesis – globo 
series 0.00097 
Purine metabolism 0.001 
Base excision repair 0.0012 
Nucleotide excision repair 0.0012 
Lysine biosynthesis 0.0014 
N-glycan biosynthesis 0.0014 
Mismatch repair 0.0014 
PPAR signalling pathway 0.0016 
Pyrimidine metabolism 0.0017 
Glycosaminoglycan degradation 0.0018 
Polycyclic aromatic hydrocarbon 
degradation 0.0019 
Tuberculosis 0.0019 
Thiamine metabolism 0.0021 
Restriction enzyme 0.0032 
Pathways that were significantly 
lower in DJBS at explant FDR q 
Other glycan degradation 0.0032 
Zeatin biosynthesis 0.0037 
Lipid biosynthesis proteins 0.0037 
Cysteine and methionine metabolism 0.0041 
Prenyltransferases 0.0042 
Photosynthesis 0.0042 
Type 1 diabetes mellitus 0.0046 
Glycosphingolipid biosynthesis –
ganglio series 0.0048 
Proteasome 0.0049 
Cell cycle - Caulobacter 0.0049 
Photosynthesis proteins 0.005 
Phosphatidylinositol signalling system 0.0054 
Nicotinate and nicotinamide 
metabolism 0.0054 
Valine leucine and isoleucine 
biosynthesis 0.0064 
Translation factors 0.0064 
Terpenoid backbone biosynthesis 0.0067 
Selenocompound metabolism 0.0067 
RNA polymerase 0.0091 
Apoptosis 0.0099 
Streptomycin biosynthesis 0.01 
Polyketide sugar unit biosynthesis 0.013 
D-glutamine and D-glutamate 
metabolism 0.013 
MAPK signalling pathway - yeast 0.013 
Aminoacyl tRNA biosynthesis 0.013 
Vitamin B6 metabolism 0.013 
Amoebiasis 0.015 
Sphingolipid metabolism 0.016 
Protein folding and associated 
processing 0.016 
Citrate cycle TCA cycle. 0.016 
Ubiquitin system 0.02 
Penicillin and cephalosporin 
biosynthesis 0.02 
Alzheimer’s disease 0.028 
D-alanine metabolism 0.033 
Protein digestion and absorption 0.037 
Ether lipid metabolism 0.037 
Insulin signalling pathway 0.047 
Chromosome 0.047 
 
